Repository navigation
Expand file tree
/
Copy pathdata.csv
More file actions
We can make this file beautiful and searchable if this error is corrected: Illegal quoting in line 33.
408 lines (408 loc) · 419 KB
/
Copy pathdata.csv
File metadata and controls
408 lines (408 loc) · 419 KB
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
study;condition_arm1;condition_arm2;multi_arm1;multi_arm2;outcome_domain;outcome_type;instrument;time;time_weeks;rating;baseline_m_arm1;baseline_m_arm2;baseline_sd_arm1;baseline_sd_arm2;mean_arm1;mean_arm2;sd_arm1;sd_arm2;n_arm1;n_arm2;m_change_arm1;m_change_arm2;sd_change_arm1;sd_change_arm2;n_change_arm1;n_change_arm2;event_arm1;event_arm2;totaln_arm1;totaln_arm2;precalc_g;precalc_g_se;precalc_log_rr;precalc_log_rr_se;.id;.g;.g_se;.log_rr;.log_rr_se;outcome_hierachy;rob_domain1;rob_domain2;rob_domain3;rob_domain4;rob_domain5;rob_overall;protocol;country;recruitment;incentive;specify_incentive;target_group;manual;program_name;guidance;setting_arm1;setting_arm2;internet_based;no_sessions_arm1;no_sessions_arm2;time_total_arm1;time_total_arm2;duration_therapy_arm1;duration_therapy_arm2;sessions_weekly_arm1;sessions_weekly_arm2;duration_session_arm1;duration_session_arm2;ave_modules_completed_arm1;ave_modules_completed_arm2;sd_modules_completed_arm1;sd_modules_completed_arm2;prop_modules_completed_arm1;m_age_arm1;m_age_arm2;sd_age_arm1;sd_age_arm2;female_arm1;female_arm2;female_total;prop_female_total;n_allocation_arm1;n_allocation_arm2;n_total_allocation;n_start_arm1;n_start_arm2;n_total_start;n_comp_arm1;n_comp_arm2;n_total_comp;reasons_partref;reasons_treatref;reasons_preterm;diagnosis_how;diagnosis_which;m_no_symptoms_arm1;m_no_symptoms_arm2;sd_no_symptoms_arm1;sd_no_symptoms_arm2;m_duration_symptoms_arm1;m_duration_symptoms_arm2;sd_duration_symptoms_arm1;sd_duration_symptoms_arm2;comorbidities_ex;specify_comorbidities_ex;consumer_satis;specify_consumer_satis;neg_eff;specify_neg_eff
alda, 2011;cbt;tau;NA;NA;som;msd;vas;post;10;self-report;64,2;64,72;10,78;10,44;36,88;64,72;8,29;7,48;49;46;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;alda_2011_msd_vas_post_10.0_self-report_cbt_tau_NA_NA;-3,491827832;0,327674858;NA;NA;primary;low;low;low;high;some concerns;high;ISRCTN registry, ISRCTN10804772, https://www.isrctn.com/ISRCTN10804772, Effectiveness of the psychological and pharmacological treatment of catastrophization in patients with fibromyalgia: a randomized controlled trial, https://pubmed.ncbi.nlm.nih.gov/19389246/;es;clinical;no;NA;adults;yes;manual based protocol derived from Thorn'a model;psy;group;NA;no;10;NA;900;NA;11;NA;0,91;NA;90;NA;NA;NA;NA;NA;NA;46,35;47,04;6,71;6,53;54;53;107;0,95;57;56;113;57;55;112;43;53;96;NA;NA;NA;clinical interview;fm;NA;NA;NA;NA;154,92;140,28;85,8;48,24;yes;those excluded were patients with severe axis I psychiatric disorders (dementia, schizophrenia, paranoid disorder and alcohol and/or drug abuse), patients with severe axis II psychiatric disorders or other medical disorders that, from the clinician’s point of view, prevented the patient from following the treatment protocol, women who were pregnant or nursing, and those who declined to participate.;no;NA;no;NA
alda, 2011;cbt;tau;NA;NA;som;msd;vas;follow up;34;self-report;64,2;64,72;10,78;10,44;40,68;44,34;10,93;8,56;49;46;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;alda_2011_msd_vas_followup_34.0_self-report_cbt_tau_NA_NA;-0,36839478;0,207058627;NA;NA;primary;low;low;low;high;some concerns;high;ISRCTN registry, ISRCTN10804772, https://www.isrctn.com/ISRCTN10804772, Effectiveness of the psychological and pharmacological treatment of catastrophization in patients with fibromyalgia: a randomized controlled trial, https://pubmed.ncbi.nlm.nih.gov/19389246/;es;clinical;no;NA;adults;yes;manual based protocol derived from Thorn'a model;psy;group;NA;no;10;NA;900;NA;11;NA;0,91;NA;90;NA;NA;NA;NA;NA;NA;46,35;47,04;6,71;6,53;54;53;107;0,95;57;56;113;57;55;112;43;53;96;NA;NA;NA;clinical interview;fm;NA;NA;NA;NA;154,92;140,28;85,8;48,24;yes;those excluded were patients with severe axis I psychiatric disorders (dementia, schizophrenia, paranoid disorder and alcohol and/or drug abuse), patients with severe axis II psychiatric disorders or other medical disorders that, from the clinician’s point of view, prevented the patient from following the treatment protocol, women who were pregnant or nursing, and those who declined to participate.;no;NA;no;NA
alda, 2011;cbt;tau;NA;NA;depr;msd;hdrs;post;10;clinican;14,47;14,09;3,93;4,64;7,78;8,17;2,46;2,25;49;46;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;alda_2011_msd_hdrs_post_10.0_clinican_cbt_tau_NA_NA;-0,163867893;0,205647605;NA;NA;primary;low;low;low;high;some concerns;high;ISRCTN registry, ISRCTN10804772, https://www.isrctn.com/ISRCTN10804772, Effectiveness of the psychological and pharmacological treatment of catastrophization in patients with fibromyalgia: a randomized controlled trial, https://pubmed.ncbi.nlm.nih.gov/19389246/;es;clinical;no;NA;adults;yes;manual based protocol derived from Thorn'a model;psy;group;NA;no;10;NA;900;NA;11;NA;0,91;NA;90;NA;NA;NA;NA;NA;NA;46,35;47,04;6,71;6,53;54;53;107;0,95;57;56;113;57;55;112;43;53;96;NA;NA;NA;clinical interview;fm;NA;NA;NA;NA;154,92;140,28;85,8;48,24;yes;those excluded were patients with severe axis I psychiatric disorders (dementia, schizophrenia, paranoid disorder and alcohol and/or drug abuse), patients with severe axis II psychiatric disorders or other medical disorders that, from the clinician’s point of view, prevented the patient from following the treatment protocol, women who were pregnant or nursing, and those who declined to participate.;no;NA;no;NA
alda, 2011;cbt;tau;NA;NA;depr;msd;hdrs;follow up;34;clinican;14,47;14,09;3,93;4,64;7,91;8,57;2,5;2,47;49;46;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;alda_2011_msd_hdrs_followup_34.0_clinican_cbt_tau_NA_NA;-0,263389826;0,206199899;NA;NA;primary;low;low;low;high;some concerns;high;ISRCTN registry, ISRCTN10804772, https://www.isrctn.com/ISRCTN10804772, Effectiveness of the psychological and pharmacological treatment of catastrophization in patients with fibromyalgia: a randomized controlled trial, https://pubmed.ncbi.nlm.nih.gov/19389246/;es;clinical;no;NA;adults;yes;manual based protocol derived from Thorn'a model;psy;group;NA;no;10;NA;900;NA;11;NA;0,91;NA;90;NA;NA;NA;NA;NA;NA;46,35;47,04;6,71;6,53;54;53;107;0,95;57;56;113;57;55;112;43;53;96;NA;NA;NA;clinical interview;fm;NA;NA;NA;NA;154,92;140,28;85,8;48,24;yes;those excluded were patients with severe axis I psychiatric disorders (dementia, schizophrenia, paranoid disorder and alcohol and/or drug abuse), patients with severe axis II psychiatric disorders or other medical disorders that, from the clinician’s point of view, prevented the patient from following the treatment protocol, women who were pregnant or nursing, and those who declined to participate.;no;NA;no;NA
alda, 2011;cbt;tau;NA;NA;anx;msd;ham-a;post;10;clinican;10,84;9,5;4,27;2,98;7,09;7,4;2,96;2,18;49;46;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;alda_2011_msd_ham-a_post_10.0_clinican_cbt_tau_NA_NA;-0,117730889;0,205478559;NA;NA;primary;low;low;low;some concerns;some concerns;some concerns;ISRCTN registry, ISRCTN10804772, https://www.isrctn.com/ISRCTN10804772, Effectiveness of the psychological and pharmacological treatment of catastrophization in patients with fibromyalgia: a randomized controlled trial, https://pubmed.ncbi.nlm.nih.gov/19389246/;es;clinical;no;NA;adults;yes;manual based protocol derived from Thorn'a model;psy;group;NA;no;10;NA;900;NA;11;NA;0,91;NA;90;NA;NA;NA;NA;NA;NA;46,35;47,04;6,71;6,53;54;53;107;0,95;57;56;113;57;55;112;43;53;96;NA;NA;NA;clinical interview;fm;NA;NA;NA;NA;154,92;140,28;85,8;48,24;yes;those excluded were patients with severe axis I psychiatric disorders (dementia, schizophrenia, paranoid disorder and alcohol and/or drug abuse), patients with severe axis II psychiatric disorders or other medical disorders that, from the clinician’s point of view, prevented the patient from following the treatment protocol, women who were pregnant or nursing, and those who declined to participate.;no;NA;no;NA
alda, 2011;cbt;tau;NA;NA;anx;msd;ham-a;follow up;34;clinican;10,84;9,5;4,27;2,98;7,25;7,58;3,02;2,07;49;46;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;alda_2011_msd_ham-a_followup_34.0_clinican_cbt_tau_NA_NA;-0,125704968;0,205503825;NA;NA;primary;low;low;low;some concerns;some concerns;some concerns;ISRCTN registry, ISRCTN10804772, https://www.isrctn.com/ISRCTN10804772, Effectiveness of the psychological and pharmacological treatment of catastrophization in patients with fibromyalgia: a randomized controlled trial, https://pubmed.ncbi.nlm.nih.gov/19389246/;es;clinical;no;NA;adults;yes;manual based protocol derived from Thorn'a model;psy;group;NA;no;10;NA;900;NA;11;NA;0,91;NA;90;NA;NA;NA;NA;NA;NA;46,35;47,04;6,71;6,53;54;53;107;0,95;57;56;113;57;55;112;43;53;96;NA;NA;NA;clinical interview;fm;NA;NA;NA;NA;154,92;140,28;85,8;48,24;yes;those excluded were patients with severe axis I psychiatric disorders (dementia, schizophrenia, paranoid disorder and alcohol and/or drug abuse), patients with severe axis II psychiatric disorders or other medical disorders that, from the clinician’s point of view, prevented the patient from following the treatment protocol, women who were pregnant or nursing, and those who declined to participate.;no;NA;no;NA
alda, 2011;cbt;tau;NA;NA;phs;msd;fiq;post;10;self-report;-65,91;-64,48;10,85;10,5;-46,21;-48,64;9,18;6,77;49;46;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;alda_2011_msd_fiq_post_10.0_self-report_cbt_tau_NA_NA;0,297432169;0,206447393;NA;NA;primary;low;low;low;high;some concerns;high;ISRCTN registry, ISRCTN10804772, https://www.isrctn.com/ISRCTN10804772, Effectiveness of the psychological and pharmacological treatment of catastrophization in patients with fibromyalgia: a randomized controlled trial, https://pubmed.ncbi.nlm.nih.gov/19389246/;es;clinical;no;NA;adults;yes;manual based protocol derived from Thorn'a model;psy;group;NA;no;10;NA;900;NA;11;NA;0,91;NA;90;NA;NA;NA;NA;NA;NA;46,35;47,04;6,71;6,53;54;53;107;0,95;57;56;113;57;55;112;43;53;96;NA;NA;NA;clinical interview;fm;NA;NA;NA;NA;154,92;140,28;85,8;48,24;yes;those excluded were patients with severe axis I psychiatric disorders (dementia, schizophrenia, paranoid disorder and alcohol and/or drug abuse), patients with severe axis II psychiatric disorders or other medical disorders that, from the clinician’s point of view, prevented the patient from following the treatment protocol, women who were pregnant or nursing, and those who declined to participate.;no;NA;no;NA
alda, 2011;cbt;tau;NA;NA;phs;msd;fiq;follow up;34;self-report;-65,91;-64,48;10,85;10,5;-48,8;-53,26;9,11;7,54;49;46;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;alda_2011_msd_fiq_followup_34.0_self-report_cbt_tau_NA_NA;0,527468915;0,208891359;NA;NA;primary;low;low;low;high;some concerns;high;ISRCTN registry, ISRCTN10804772, https://www.isrctn.com/ISRCTN10804772, Effectiveness of the psychological and pharmacological treatment of catastrophization in patients with fibromyalgia: a randomized controlled trial, https://pubmed.ncbi.nlm.nih.gov/19389246/;es;clinical;no;NA;adults;yes;manual based protocol derived from Thorn'a model;psy;group;NA;no;10;NA;900;NA;11;NA;0,91;NA;90;NA;NA;NA;NA;NA;NA;46,35;47,04;6,71;6,53;54;53;107;0,95;57;56;113;57;55;112;43;53;96;NA;NA;NA;clinical interview;fm;NA;NA;NA;NA;154,92;140,28;85,8;48,24;yes;those excluded were patients with severe axis I psychiatric disorders (dementia, schizophrenia, paranoid disorder and alcohol and/or drug abuse), patients with severe axis II psychiatric disorders or other medical disorders that, from the clinician’s point of view, prevented the patient from following the treatment protocol, women who were pregnant or nursing, and those who declined to participate.;no;NA;no;NA
alda, 2011;cbt;tau;NA;NA;phs;msd;euroqol-vas;post;10;self-report;44,55;43,87;16,67;14,5;60,46;52,26;16,63;14,03;49;46;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;alda_2011_msd_euroqol-vas_post_10.0_self-report_cbt_tau_NA_NA;0,527246003;0,208888349;NA;NA;secondary;NA;NA;NA;NA;NA;NA;ISRCTN registry, ISRCTN10804772, https://www.isrctn.com/ISRCTN10804772, Effectiveness of the psychological and pharmacological treatment of catastrophization in patients with fibromyalgia: a randomized controlled trial, https://pubmed.ncbi.nlm.nih.gov/19389246/;es;clinical;no;NA;adults;yes;manual based protocol derived from Thorn'a model;psy;group;NA;no;10;NA;900;NA;11;NA;0,91;NA;90;NA;NA;NA;NA;NA;NA;46,35;47,04;6,71;6,53;54;53;107;0,95;57;56;113;57;55;112;43;53;96;NA;NA;NA;clinical interview;fm;NA;NA;NA;NA;154,92;140,28;85,8;48,24;yes;those excluded were patients with severe axis I psychiatric disorders (dementia, schizophrenia, paranoid disorder and alcohol and/or drug abuse), patients with severe axis II psychiatric disorders or other medical disorders that, from the clinician’s point of view, prevented the patient from following the treatment protocol, women who were pregnant or nursing, and those who declined to participate.;no;NA;no;NA
allen, 2006;cbt;tau;NA;NA;som;msd;sss;post;12;self-report;61,88;56,22;30,23;30,22;38,26;48,71;25,64;25,42;43;41;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;allen_2006_msd_sss_post_12.0_self-report_cbt_tau_NA_NA;-0,405520737;0,220551854;NA;NA;primary;some concerns;low;low;high;some concerns;high;NA;us;combined;no;NA;adults;yes;treating somatizazion: a cognitive-behavioral appraoch (woolfolk and allen);psy;individual;NA;no;10;NA;600;NA;12;NA;NA;NA;60;NA;NA;NA;NA;NA;NA;45,47;47,85;8,45;10,99;36;39;75;0,89;43;41;84;43;41;84;39;38;77;NA;NA;NA;clinical interview;sd (dsm-iv);NA;NA;NA;NA;299,4;300;138,48;181,44;yes;an unstable major medical condition, a medication regimen that had not been stable for at least 2 months prior to baseline, active suicidal ideation, a history of psychosis, or current psychoactive substance dependence;no;NA;no;NA
allen, 2006;cbt;tau;NA;NA;som;msd;sss;follow up;60;self-report;61,88;56,22;30,23;30,22;35,02;45,39;25,9;25,25;43;41;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;allen_2006_msd_sss_followup_60.0_self-report_cbt_tau_NA_NA;-0,401597282;0,220508322;NA;NA;primary;some concerns;low;low;high;some concerns;high;NA;us;combined;no;NA;adults;yes;treating somatizazion: a cognitive-behavioral appraoch (woolfolk and allen);psy;individual;NA;no;10;NA;600;NA;12;NA;NA;NA;60;NA;NA;NA;NA;NA;NA;45,47;47,85;8,45;10,99;36;39;75;0,89;43;41;84;43;41;84;39;38;77;NA;NA;NA;clinical interview;sd (dsm-iv);NA;NA;NA;NA;299,4;300;138,48;181,44;yes;an unstable major medical condition, a medication regimen that had not been stable for at least 2 months prior to baseline, active suicidal ideation, a history of psychosis, or current psychoactive substance dependence;no;NA;no;NA
allen, 2006;cbt;tau;NA;NA;phs;msd;sf-36 physical functioning;post;12;self-report;52,56;55,24;28,52;29,2;63,28;56,92;26,75;26,7;43;41;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;allen_2006_msd_sf-36physicalfunctioning_post_12.0_self-report_cbt_tau_NA_NA;0,23579064;0,219050566;NA;NA;primary;some concerns;low;low;high;some concerns;high;NA;us;combined;no;NA;adults;yes;treating somatizazion: a cognitive-behavioral appraoch (woolfolk and allen);psy;individual;NA;no;10;NA;600;NA;12;NA;NA;NA;60;NA;NA;NA;NA;NA;NA;45,47;47,85;8,45;10,99;36;39;75;0,89;43;41;84;43;41;84;39;38;77;NA;NA;NA;clinical interview;sd (dsm-iv);NA;NA;NA;NA;299,4;300;138,48;181,44;yes;an unstable major medical condition, a medication regimen that had not been stable for at least 2 months prior to baseline, active suicidal ideation, a history of psychosis, or current psychoactive substance dependence;no;NA;no;NA
allen, 2006;cbt;tau;NA;NA;phs;msd;sf-36 physical functioning;follow up;60;self-report;52,56;55,24;28,52;29,2;68,57;59,17;28,67;28,14;43;41;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;allen_2006_msd_sf-36physicalfunctioning_followup_60.0_self-report_cbt_tau_NA_NA;0,327802777;0,219767078;NA;NA;primary;some concerns;low;low;high;some concerns;high;NA;us;combined;no;NA;adults;yes;treating somatizazion: a cognitive-behavioral appraoch (woolfolk and allen);psy;individual;NA;no;10;NA;600;NA;12;NA;NA;NA;60;NA;NA;NA;NA;NA;NA;45,47;47,85;8,45;10,99;36;39;75;0,89;43;41;84;43;41;84;39;38;77;NA;NA;NA;clinical interview;sd (dsm-iv);NA;NA;NA;NA;299,4;300;138,48;181,44;yes;an unstable major medical condition, a medication regimen that had not been stable for at least 2 months prior to baseline, active suicidal ideation, a history of psychosis, or current psychoactive substance dependence;no;NA;no;NA
blanchard, 2007;cbt;att plac;cbt;att plac;som;msd;physician global ratings;post;12;clinican;5,8;6;1;1,2;4,4;4,9;1,4;1,5;109;39;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;blanchard_2007_msd_physicianglobalratings_post_12.0_clinican_cbt_attplac_cbt_attplac;-0,348655148;0,187697294;NA;NA;primary;some concerns;low;low;low;some concerns;some concerns;NA;us;combined;no;NA;adults;yes;NA;psy;group;NA;no;10;NA;900;NA;10;NA;1;NA;90;NA;NA;NA;NA;NA;NA;48,1;49,38;13,7;13;85;32;117;0,71;120;44;164;120;44;164;NA;NA;NA;NA;NA;NA;clinical interview;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;exclusionary criteria included organic GI disease (inflammatory bowel disease or lactose malabsorption syndrome), or very low baseline diary pain ratings (see above), or the presence of a psychotic disorder, or current severe major depression with moderate to severe suicidal ideation as determined by the SCID (see below). Additional exclusions were for current psychotherapy of any kind or lifetime exposure to CBT.;no;NA;no;NA
blanchard, 2007;cbt;psy plac;cbt;psy plac;som;msd;physician global ratings;post;12;clinican;5,8;6;1;1,2;4,4;5;1,4;1,8;109;46;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;blanchard_2007_msd_physicianglobalratings_post_12.0_clinican_cbt_psyplac_cbt_psyplac;-0,390601098;0,177229992;NA;NA;primary;some concerns;low;low;low;some concerns;some concerns;NA;us;combined;no;NA;adults;yes;NA;psy;group;NA;no;10;NA;900;NA;10;NA;1;NA;90;NA;NA;NA;NA;NA;NA;48,1;51,5;13,7;11,3;85;38;123;0,74;120;46;166;120;46;166;NA;NA;NA;NA;NA;NA;clinical interview;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;exclusionary criteria included organic GI disease (inflammatory bowel disease or lactose malabsorption syndrome), or very low baseline diary pain ratings (see above), or the presence of a psychotic disorder, or current severe major depression with moderate to severe suicidal ideation as determined by the SCID (see below). Additional exclusions were for current psychotherapy of any kind or lifetime exposure to CBT.;no;NA;no;NA
boyce, 2003;cbt;tau;NA;NA;som;msd;ibs-sss;post;8;self-report;21,5;21;4,3;4,6;16,1;17;4,8;4,6;21;24;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;boyce_2003_msd_ibs-sss_post_8.0_self-report_cbt_tau_NA_NA;-0,188367027;0,299489843;NA;NA;primary;low;some concerns;low;high;some concerns;high;NA;au;combined;no;NA;adults;yes;manual-based program based on the hypochondriasis model of Salkovskis and the CBT approach used for anxiety disorders as outlined by Andrews et al.;psy;individual;NA;no;8;NA;480;NA;8;NA;1;NA;60;NA;NA;NA;NA;NA;NA;41,2;41,6;12,2;11,6;28;28;56;0,81;35;34;69;35;34;69;NA;NA;NA;NA;NA;NA;combined;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;subjects were excluded if they answered positively to the interviewer’s questions regarding the presence of any major current medical or psychotic illness, a history of alcoholism, current psychological treatment and current use of antide- pressants or antipsychotic medications, or current use of medications that could affect bowel function (e.g., antispas- modics, prokinetics). Although approximately 50% of the subjects had previously been on medication for IBS, the vast majority of these people were not taking medication at the time of randomization into the study.;no;NA;no;NA
boyce, 2003;cbt;tau;NA;NA;som;msd;ibs-sss;follow up;52;self-report;21,5;21;4,3;4,6;13;11,4;4,7;4;18;21;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;boyce_2003_msd_ibs-sss_followup_52.0_self-report_cbt_tau_NA_NA;0,361499806;0,323914419;NA;NA;primary;low;some concerns;low;high;some concerns;high;NA;au;combined;no;NA;adults;yes;manual-based program based on the hypochondriasis model of Salkovskis and the CBT approach used for anxiety disorders as outlined by Andrews et al.;psy;individual;NA;no;8;NA;480;NA;8;NA;1;NA;60;NA;NA;NA;NA;NA;NA;41,2;41,6;12,2;11,6;28;28;56;0,81;35;34;69;35;34;69;NA;NA;NA;NA;NA;NA;combined;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;subjects were excluded if they answered positively to the interviewer’s questions regarding the presence of any major current medical or psychotic illness, a history of alcoholism, current psychological treatment and current use of antide- pressants or antipsychotic medications, or current use of medications that could affect bowel function (e.g., antispas- modics, prokinetics). Although approximately 50% of the subjects had previously been on medication for IBS, the vast majority of these people were not taking medication at the time of randomization into the study.;no;NA;no;NA
boyce, 2003;cbt;tau;NA;NA;depr;msd;hads-d;post;8;self-report;5,3;5,6;4;3,8;4,1;4,1;3,5;3,4;21;24;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;boyce_2003_msd_hads-d_post_8.0_self-report_cbt_tau_NA_NA;0;0,298807152;NA;NA;primary;low;some concerns;low;high;some concerns;high;NA;au;combined;no;NA;adults;yes;manual-based program based on the hypochondriasis model of Salkovskis and the CBT approach used for anxiety disorders as outlined by Andrews et al.;psy;individual;NA;no;8;NA;480;NA;8;NA;1;NA;60;NA;NA;NA;NA;NA;NA;41,2;41,6;12,2;11,6;28;28;56;0,81;35;34;69;35;34;69;NA;NA;NA;NA;NA;NA;combined;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;subjects were excluded if they answered positively to the interviewer’s questions regarding the presence of any major current medical or psychotic illness, a history of alcoholism, current psychological treatment and current use of antide- pressants or antipsychotic medications, or current use of medications that could affect bowel function (e.g., antispas- modics, prokinetics). Although approximately 50% of the subjects had previously been on medication for IBS, the vast majority of these people were not taking medication at the time of randomization into the study.;no;NA;no;NA
boyce, 2003;cbt;tau;NA;NA;depr;msd;hads-d;follow up;52;self-report;5,3;5,6;4;3,8;3,6;4,4;4,1;4,5;18;21;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;boyce_2003_msd_hads-d_followup_52.0_self-report_cbt_tau_NA_NA;-0,181371595;0,321891438;NA;NA;primary;low;some concerns;low;high;some concerns;high;NA;au;combined;no;NA;adults;yes;manual-based program based on the hypochondriasis model of Salkovskis and the CBT approach used for anxiety disorders as outlined by Andrews et al.;psy;individual;NA;no;8;NA;480;NA;8;NA;1;NA;60;NA;NA;NA;NA;NA;NA;41,2;41,6;12,2;11,6;28;28;56;0,81;35;34;69;35;34;69;NA;NA;NA;NA;NA;NA;combined;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;subjects were excluded if they answered positively to the interviewer’s questions regarding the presence of any major current medical or psychotic illness, a history of alcoholism, current psychological treatment and current use of antide- pressants or antipsychotic medications, or current use of medications that could affect bowel function (e.g., antispas- modics, prokinetics). Although approximately 50% of the subjects had previously been on medication for IBS, the vast majority of these people were not taking medication at the time of randomization into the study.;no;NA;no;NA
boyce, 2003;cbt;tau;NA;NA;anx;msd;hads-a;post;8;self-report;9,1;8,5;3,7;8,2;8,2;6,9;3,5;4,4;21;24;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;boyce_2003_msd_hads-a_post_8.0_self-report_cbt_tau_NA_NA;0,318770487;0,300758124;NA;NA;primary;low;some concerns;low;high;some concerns;high;NA;au;combined;no;NA;adults;yes;manual-based program based on the hypochondriasis model of Salkovskis and the CBT approach used for anxiety disorders as outlined by Andrews et al.;psy;individual;NA;no;8;NA;480;NA;8;NA;1;NA;60;NA;NA;NA;NA;NA;NA;41,2;41,6;12,2;11,6;28;28;56;0,81;35;34;69;35;34;69;NA;NA;NA;NA;NA;NA;combined;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;subjects were excluded if they answered positively to the interviewer’s questions regarding the presence of any major current medical or psychotic illness, a history of alcoholism, current psychological treatment and current use of antide- pressants or antipsychotic medications, or current use of medications that could affect bowel function (e.g., antispas- modics, prokinetics). Although approximately 50% of the subjects had previously been on medication for IBS, the vast majority of these people were not taking medication at the time of randomization into the study.;no;NA;no;NA
boyce, 2003;cbt;tau;NA;NA;anx;msd;hads-a;follow up;52;self-report;9,1;8,5;3,7;8,2;7,6;6,5;5;4;18;21;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;boyce_2003_msd_hads-a_followup_52.0_self-report_cbt_tau_NA_NA;0,240137822;0,322405085;NA;NA;primary;low;some concerns;low;high;some concerns;high;NA;au;combined;no;NA;adults;yes;manual-based program based on the hypochondriasis model of Salkovskis and the CBT approach used for anxiety disorders as outlined by Andrews et al.;psy;individual;NA;no;8;NA;480;NA;8;NA;1;NA;60;NA;NA;NA;NA;NA;NA;41,2;41,6;12,2;11,6;28;28;56;0,81;35;34;69;35;34;69;NA;NA;NA;NA;NA;NA;combined;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;subjects were excluded if they answered positively to the interviewer’s questions regarding the presence of any major current medical or psychotic illness, a history of alcoholism, current psychological treatment and current use of antide- pressants or antipsychotic medications, or current use of medications that could affect bowel function (e.g., antispas- modics, prokinetics). Although approximately 50% of the subjects had previously been on medication for IBS, the vast majority of these people were not taking medication at the time of randomization into the study.;no;NA;no;NA
boyce, 2003;cbt;tau;NA;NA;phs;msd;sf-36;post;8;self-report;77,8;86,5;19,9;16,7;87,3;88,6;14,9;15,2;21;24;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;boyce_2003_msd_sf-36_post_8.0_self-report_cbt_tau_NA_NA;-0,084800166;0,298945637;NA;NA;primary;low;some concerns;low;high;some concerns;high;NA;au;combined;no;NA;adults;yes;manual-based program based on the hypochondriasis model of Salkovskis and the CBT approach used for anxiety disorders as outlined by Andrews et al.;psy;individual;NA;no;8;NA;480;NA;8;NA;1;NA;60;NA;NA;NA;NA;NA;NA;41,2;41,6;12,2;11,6;28;28;56;0,81;35;34;69;35;34;69;NA;NA;NA;NA;NA;NA;combined;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;subjects were excluded if they answered positively to the interviewer’s questions regarding the presence of any major current medical or psychotic illness, a history of alcoholism, current psychological treatment and current use of antide- pressants or antipsychotic medications, or current use of medications that could affect bowel function (e.g., antispas- modics, prokinetics). Although approximately 50% of the subjects had previously been on medication for IBS, the vast majority of these people were not taking medication at the time of randomization into the study.;no;NA;no;NA
boyce, 2003;cbt;tau;NA;NA;phs;msd;sf-36;follow up;52;self-report;77,8;86,5;19,9;16,7;80;88,8;25,7;18;18;21;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;boyce_2003_msd_sf-36_followup_52.0_self-report_cbt_tau_NA_NA;-0,394039617;0,324421045;NA;NA;primary;low;some concerns;low;high;some concerns;high;NA;au;combined;no;NA;adults;yes;manual-based program based on the hypochondriasis model of Salkovskis and the CBT approach used for anxiety disorders as outlined by Andrews et al.;psy;individual;NA;no;8;NA;480;NA;8;NA;1;NA;60;NA;NA;NA;NA;NA;NA;41,2;41,6;12,2;11,6;28;28;56;0,81;35;34;69;35;34;69;NA;NA;NA;NA;NA;NA;combined;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;subjects were excluded if they answered positively to the interviewer’s questions regarding the presence of any major current medical or psychotic illness, a history of alcoholism, current psychological treatment and current use of antide- pressants or antipsychotic medications, or current use of medications that could affect bowel function (e.g., antispas- modics, prokinetics). Although approximately 50% of the subjects had previously been on medication for IBS, the vast majority of these people were not taking medication at the time of randomization into the study.;no;NA;no;NA
castel, 2012;cbt;tau;NA;NA;som;msd;nrs;post;15;self-report;6,1;6,9;0,3;0,3;5,6;6,5;0,3;0,3;34;30;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;castel_2012_msd_nrs_post_15.0_self-report_cbt_tau_NA_NA;-2,963562753;0,36477061;NA;NA;primary;some concerns;low;low;high;some concerns;high;NA;es;clinical;no;NA;adults;yes;cbt program;NA;mixed;NA;no;14;NA;1680;NA;14;NA;1;NA;120;NA;12,3;NA;1,7;NA;0,88;50;48,7;7,5;6,5;32;30;62;0,97;34;30;64;NA;NA;NA;31;29;60;NA;NA;NA;clinical interview;fm;NA;NA;NA;NA;NA;NA;NA;NA;yes;exclusion criteria were 1 or more additional severe chronic medical pain conditions (eg, sciatica and complex regional pain syndrome), significant suicidal ideation, severe psycho-pathology (eg, psychosis), or moderate-to-severe cognitive impairment;no;NA;no;NA
castel, 2012;cbt;tau;NA;NA;som;msd;nrs;follow up;39;self-report;6,1;6,9;0,3;0,3;5,7;6,8;0,4;0,3;34;30;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;castel_2012_msd_nrs_followup_39.0_self-report_cbt_tau_NA_NA;-3,046091196;0,370173216;NA;NA;primary;some concerns;low;low;high;some concerns;high;NA;es;clinical;no;NA;adults;yes;cbt program;NA;mixed;NA;no;14;NA;1680;NA;14;NA;1;NA;120;NA;12,3;NA;1,7;NA;0,88;50;48,7;7,5;6,5;32;30;62;0,97;34;30;64;NA;NA;NA;31;29;60;NA;NA;NA;clinical interview;fm;NA;NA;NA;NA;NA;NA;NA;NA;yes;exclusion criteria were 1 or more additional severe chronic medical pain conditions (eg, sciatica and complex regional pain syndrome), significant suicidal ideation, severe psycho-pathology (eg, psychosis), or moderate-to-severe cognitive impairment;no;NA;no;NA
castel, 2012;cbt;tau;NA;NA;phs;msd;fiq;post;15;self-report;-62,7;-66,1;2,8;3;-52,2;-64,6;3,3;3,5;34;30;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;castel_2012_msd_fiq_post_15.0_self-report_cbt_tau_NA_NA;3,608052263;0,408613293;NA;NA;primary;some concerns;low;low;high;some concerns;high;NA;es;clinical;no;NA;adults;yes;cbt program;NA;mixed;NA;no;14;NA;1680;NA;14;NA;1;NA;120;NA;12,3;NA;1,7;NA;0,88;50;48,7;7,5;6,5;32;30;62;0,97;34;30;64;NA;NA;NA;31;29;60;NA;NA;NA;clinical interview;fm;NA;NA;NA;NA;NA;NA;NA;NA;yes;exclusion criteria were 1 or more additional severe chronic medical pain conditions (eg, sciatica and complex regional pain syndrome), significant suicidal ideation, severe psycho-pathology (eg, psychosis), or moderate-to-severe cognitive impairment;no;NA;no;NA
castel, 2012;cbt;tau;NA;NA;phs;msd;fiq;follow up;39;self-report;-62,7;-66,1;2,8;3;-50,5;-68,5;3,5;3,7;34;30;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;castel_2012_msd_fiq_followup_39.0_self-report_cbt_tau_NA_NA;4,9462321;0,508535631;NA;NA;primary;some concerns;low;low;high;some concerns;high;NA;es;clinical;no;NA;adults;yes;cbt program;NA;mixed;NA;no;14;NA;1680;NA;14;NA;1;NA;120;NA;12,3;NA;1,7;NA;0,88;50;48,7;7,5;6,5;32;30;62;0,97;34;30;64;NA;NA;NA;31;29;60;NA;NA;NA;clinical interview;fm;NA;NA;NA;NA;NA;NA;NA;NA;yes;exclusion criteria were 1 or more additional severe chronic medical pain conditions (eg, sciatica and complex regional pain syndrome), significant suicidal ideation, severe psycho-pathology (eg, psychosis), or moderate-to-severe cognitive impairment;no;NA;no;NA
castel, 2013;cbt;tau;NA;NA;som;msd;nrs;post;12;self-report;6,8;7,1;1,4;1,6;5,7;6,9;1,9;1,8;81;74;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;castel_2013_msd_nrs_post_12.0_self-report_cbt_tau_NA_NA;-0,644432393;0,164960906;NA;NA;primary;some concerns;low;low;high;some concerns;high;NA;es;clinical;no;NA;adults;yes;adapted from bradley (1996), espie (2006), thorn (2004), waters (2004);mixed;group;NA;no;24;NA;2880;NA;12;NA;2;NA;120;NA;21,95;NA;2;NA;0,91;49;48,8;6,8;7,2;81;74;155;1;81;74;155;NA;NA;NA;NA;NA;NA;NA;NA;NA;clinical interview;fm;NA;NA;NA;NA;150;129,6;118,8;94,8;yes;another severe chronic pain pathology (e.g., sciatica or complex regional pain syndrome), having been diagnosed with inflammatory rheumatic disease, being physically unable to perform the exercises, an open wound, a skin disease, being under psychiatric and/or psychological treatment within the past 3 years, significant suicidal ideation, cognitive or sensorial deterioration that impedes an adequate followup to the treatment, or a pending legal resolution for disability;no;NA;no;NA
castel, 2013;cbt;tau;NA;NA;som;msd;nrs;follow up;60;self-report;6,8;7,1;1,4;1,6;6,7;7,1;1,6;1,8;81;74;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;castel_2013_msd_nrs_followup_60.0_self-report_cbt_tau_NA_NA;-0,234364199;0,161363341;NA;NA;primary;some concerns;low;low;high;some concerns;high;NA;es;clinical;no;NA;adults;yes;adapted from bradley (1996), espie (2006), thorn (2004), waters (2004);mixed;group;NA;no;24;NA;2880;NA;12;NA;2;NA;120;NA;21,95;NA;2;NA;0,91;49;48,8;6,8;7,2;81;74;155;1;81;74;155;NA;NA;NA;NA;NA;NA;NA;NA;NA;clinical interview;fm;NA;NA;NA;NA;150;129,6;118,8;94,8;yes;another severe chronic pain pathology (e.g., sciatica or complex regional pain syndrome), having been diagnosed with inflammatory rheumatic disease, being physically unable to perform the exercises, an open wound, a skin disease, being under psychiatric and/or psychological treatment within the past 3 years, significant suicidal ideation, cognitive or sensorial deterioration that impedes an adequate followup to the treatment, or a pending legal resolution for disability;no;NA;no;NA
castel, 2013;cbt;tau;NA;NA;phs;msd;fiq;post;12;self-report;-64,6;-66,6;16;17,4;-47,7;-65,9;20,2;16,1;81;74;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;castel_2013_msd_fiq_post_12.0_self-report_cbt_tau_NA_NA;0,986505997;0,170380706;NA;NA;primary;some concerns;low;low;high;some concerns;high;NA;es;clinical;no;NA;adults;yes;adapted from bradley (1996), espie (2006), thorn (2004), waters (2004);mixed;group;NA;no;24;NA;2880;NA;12;NA;2;NA;120;NA;21,95;NA;2;NA;0,91;49;48,8;6,8;7,2;81;74;155;1;81;74;155;NA;NA;NA;NA;NA;NA;NA;NA;NA;clinical interview;fm;NA;NA;NA;NA;150;129,6;118,8;94,8;yes;another severe chronic pain pathology (e.g., sciatica or complex regional pain syndrome), having been diagnosed with inflammatory rheumatic disease, being physically unable to perform the exercises, an open wound, a skin disease, being under psychiatric and/or psychological treatment within the past 3 years, significant suicidal ideation, cognitive or sensorial deterioration that impedes an adequate followup to the treatment, or a pending legal resolution for disability;no;NA;no;NA
castel, 2013;cbt;tau;NA;NA;phs;msd;fiq;follow up;60;self-report;-64,6;-66,6;16;17,4;-58,8;-20,5;69,6;17,2;81;74;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;castel_2013_msd_fiq_followup_60.0_self-report_cbt_tau_NA_NA;-0,73701557;0,166219009;NA;NA;primary;some concerns;low;low;high;some concerns;high;NA;es;clinical;no;NA;adults;yes;adapted from bradley (1996), espie (2006), thorn (2004), waters (2004);mixed;group;NA;no;24;NA;2880;NA;12;NA;2;NA;120;NA;21,95;NA;2;NA;0,91;49;48,8;6,8;7,2;81;74;155;1;81;74;155;NA;NA;NA;NA;NA;NA;NA;NA;NA;clinical interview;fm;NA;NA;NA;NA;150;129,6;118,8;94,8;yes;another severe chronic pain pathology (e.g., sciatica or complex regional pain syndrome), having been diagnosed with inflammatory rheumatic disease, being physically unable to perform the exercises, an open wound, a skin disease, being under psychiatric and/or psychological treatment within the past 3 years, significant suicidal ideation, cognitive or sensorial deterioration that impedes an adequate followup to the treatment, or a pending legal resolution for disability;no;NA;no;NA
chalder, 2021;cbt;tau;NA;NA;som;msd;phq-15;post;20;self-report;16,2;15,7;5,5;5,4;14,2;15,3;5,8;6;127;131;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;chalder_2021_msd_phq-15_post_20.0_self-report_cbt_tau_NA_NA;-0,185818046;0,124799492;NA;NA;primary;low;low;low;high;low;high;clinicaltrials.gov nct02426788;gb;clinical;no;NA;adults;yes;change and evaluation in secondary care (prince secondary);mixed;group;NA;no;8;NA;480;NA;22;NA;0,36;NA;60;NA;NA;NA;NA;NA;NA;43,7;42,5;12,3;12,9;136;133;269;0,83;161;163;324;NA;NA;NA;NA;NA;NA;NA;NA;NA;combined;mus;NA;NA;NA;NA;NA;NA;NA;NA;yes;"patients were excluded if they had active psychosis and/or factitious disorder; headaches as their main and only pps symptom (given the clinical complexity of differentiating headaches and migraine, headaches were excluded); non-epileptic seizures as their main and only pps symptom (due to an ongoing RCT at the time of recruitment that was evaluating a specific cognitive behavioural approach for Dissociative Seizures, now published (goldstein 2020))";no;NA;yes;there were 324 adverse events recorded in the intervention arm and 348 in the control arm with majority of adverse events being gastro-intestinal (52 in tdt-cbt plus smc, 42 in smc), musculoskeletal (33 in tdt-cbt plus smc, 49 in smc), psychiatric (34 in tdt-cbt +smc, 46 in smc) and immunological (48 in tdt-cbt plus smc, 40 in smc). an adverse event was defined as any medical occurrence, this included symptoms such as swollen eye, hip pain, flu symptoms, etc. there were 57 withdrawals from the trial, 30 from the tdt-cbt plus smc arm and 27 from the smc arm with the majority being due to the participant no longer wanting to take part in the trial (26 from tdt-cbt plus smc and 26 from smc). no adverse events were reported as being related to the intervention received.
chalder, 2021;cbt;tau;NA;NA;som;msd;phq-15;follow up;52;self-report;16,2;15,7;5,5;5,4;14,5;15,6;6,1;5,8;120;123;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;chalder_2021_msd_phq-15_followup_52.0_self-report_cbt_tau_NA_NA;-0,184297289;0,128583591;NA;NA;primary;low;low;low;high;low;high;clinicaltrials.gov nct02426788;gb;clinical;no;NA;adults;yes;change and evaluation in secondary care (prince secondary);mixed;group;NA;no;8;NA;480;NA;22;NA;0,36;NA;60;NA;NA;NA;NA;NA;NA;43,7;42,5;12,3;12,9;136;133;269;0,83;161;163;324;NA;NA;NA;NA;NA;NA;NA;NA;NA;combined;mus;NA;NA;NA;NA;NA;NA;NA;NA;yes;"patients were excluded if they had active psychosis and/or factitious disorder; headaches as their main and only pps symptom (given the clinical complexity of differentiating headaches and migraine, headaches were excluded); non-epileptic seizures as their main and only pps symptom (due to an ongoing RCT at the time of recruitment that was evaluating a specific cognitive behavioural approach for Dissociative Seizures, now published (goldstein 2020))";no;NA;yes;there were 324 adverse events recorded in the intervention arm and 348 in the control arm with majority of adverse events being gastro-intestinal (52 in tdt-cbt plus smc, 42 in smc), musculoskeletal (33 in tdt-cbt plus smc, 49 in smc), psychiatric (34 in tdt-cbt +smc, 46 in smc) and immunological (48 in tdt-cbt plus smc, 40 in smc). an adverse event was defined as any medical occurrence, this included symptoms such as swollen eye, hip pain, flu symptoms, etc. there were 57 withdrawals from the trial, 30 from the tdt-cbt plus smc arm and 27 from the smc arm with the majority being due to the participant no longer wanting to take part in the trial (26 from tdt-cbt plus smc and 26 from smc). no adverse events were reported as being related to the intervention received.
chalder, 2021;cbt;tau;NA;NA;depr;msd;phq-9;post;20;self-report;13,5;14;6,6;6,4;8,4;10,5;6,3;6,2;127;131;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;chalder_2021_msd_phq-9_post_20.0_self-report_cbt_tau_NA_NA;-0,335045823;0,125405083;NA;NA;primary;low;low;low;high;low;high;clinicaltrials.gov nct02426788;gb;clinical;no;NA;adults;yes;change and evaluation in secondary care (prince secondary);mixed;group;NA;no;8;NA;480;NA;22;NA;0,36;NA;60;NA;NA;NA;NA;NA;NA;43,7;42,5;12,3;12,9;136;133;269;0,83;161;163;324;NA;NA;NA;NA;NA;NA;NA;NA;NA;combined;mus;NA;NA;NA;NA;NA;NA;NA;NA;yes;"patients were excluded if they had active psychosis and/or factitious disorder; headaches as their main and only pps symptom (given the clinical complexity of differentiating headaches and migraine, headaches were excluded); non-epileptic seizures as their main and only pps symptom (due to an ongoing RCT at the time of recruitment that was evaluating a specific cognitive behavioural approach for Dissociative Seizures, now published (goldstein 2020))";no;NA;yes;there were 324 adverse events recorded in the intervention arm and 348 in the control arm with majority of adverse events being gastro-intestinal (52 in tdt-cbt plus smc, 42 in smc), musculoskeletal (33 in tdt-cbt plus smc, 49 in smc), psychiatric (34 in tdt-cbt +smc, 46 in smc) and immunological (48 in tdt-cbt plus smc, 40 in smc). an adverse event was defined as any medical occurrence, this included symptoms such as swollen eye, hip pain, flu symptoms, etc. there were 57 withdrawals from the trial, 30 from the tdt-cbt plus smc arm and 27 from the smc arm with the majority being due to the participant no longer wanting to take part in the trial (26 from tdt-cbt plus smc and 26 from smc). no adverse events were reported as being related to the intervention received.
chalder, 2021;cbt;tau;NA;NA;depr;msd;phq-9;follow up;52;self-report;13,5;14;6,6;6,4;8,5;10,3;6;6,5;120;123;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;chalder_2021_msd_phq-9_followup_52.0_self-report_cbt_tau_NA_NA;-0,28673089;0,128971467;NA;NA;primary;low;low;low;high;low;high;clinicaltrials.gov nct02426788;gb;clinical;no;NA;adults;yes;change and evaluation in secondary care (prince secondary);mixed;group;NA;no;8;NA;480;NA;22;NA;0,36;NA;60;NA;NA;NA;NA;NA;NA;43,7;42,5;12,3;12,9;136;133;269;0,83;161;163;324;NA;NA;NA;NA;NA;NA;NA;NA;NA;combined;mus;NA;NA;NA;NA;NA;NA;NA;NA;yes;"patients were excluded if they had active psychosis and/or factitious disorder; headaches as their main and only pps symptom (given the clinical complexity of differentiating headaches and migraine, headaches were excluded); non-epileptic seizures as their main and only pps symptom (due to an ongoing RCT at the time of recruitment that was evaluating a specific cognitive behavioural approach for Dissociative Seizures, now published (goldstein 2020))";no;NA;yes;there were 324 adverse events recorded in the intervention arm and 348 in the control arm with majority of adverse events being gastro-intestinal (52 in tdt-cbt plus smc, 42 in smc), musculoskeletal (33 in tdt-cbt plus smc, 49 in smc), psychiatric (34 in tdt-cbt +smc, 46 in smc) and immunological (48 in tdt-cbt plus smc, 40 in smc). an adverse event was defined as any medical occurrence, this included symptoms such as swollen eye, hip pain, flu symptoms, etc. there were 57 withdrawals from the trial, 30 from the tdt-cbt plus smc arm and 27 from the smc arm with the majority being due to the participant no longer wanting to take part in the trial (26 from tdt-cbt plus smc and 26 from smc). no adverse events were reported as being related to the intervention received.
chalder, 2021;cbt;tau;NA;NA;anx;msd;gad-7;post;20;self-report;10;11,2;6;6,1;8,4;10,5;6,3;6,2;128;132;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;chalder_2021_msd_gad-7_post_20.0_self-report_cbt_tau_NA_NA;-0,335053145;0,124921596;NA;NA;primary;low;low;low;high;low;high;clinicaltrials.gov nct02426788;gb;clinical;no;NA;adults;yes;change and evaluation in secondary care (prince secondary);mixed;group;NA;no;8;NA;480;NA;22;NA;0,36;NA;60;NA;NA;NA;NA;NA;NA;43,7;42,5;12,3;12,9;136;133;269;0,83;161;163;324;NA;NA;NA;NA;NA;NA;NA;NA;NA;combined;mus;NA;NA;NA;NA;NA;NA;NA;NA;yes;"patients were excluded if they had active psychosis and/or factitious disorder; headaches as their main and only pps symptom (given the clinical complexity of differentiating headaches and migraine, headaches were excluded); non-epileptic seizures as their main and only pps symptom (due to an ongoing RCT at the time of recruitment that was evaluating a specific cognitive behavioural approach for Dissociative Seizures, now published (goldstein 2020))";no;NA;yes;there were 324 adverse events recorded in the intervention arm and 348 in the control arm with majority of adverse events being gastro-intestinal (52 in tdt-cbt plus smc, 42 in smc), musculoskeletal (33 in tdt-cbt plus smc, 49 in smc), psychiatric (34 in tdt-cbt +smc, 46 in smc) and immunological (48 in tdt-cbt plus smc, 40 in smc). an adverse event was defined as any medical occurrence, this included symptoms such as swollen eye, hip pain, flu symptoms, etc. there were 57 withdrawals from the trial, 30 from the tdt-cbt plus smc arm and 27 from the smc arm with the majority being due to the participant no longer wanting to take part in the trial (26 from tdt-cbt plus smc and 26 from smc). no adverse events were reported as being related to the intervention received.
chalder, 2021;cbt;tau;NA;NA;anx;msd;gad-7;follow up;52;self-report;10;11,2;6;6,1;8,5;10,3;6;6,5;119;123;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;chalder_2021_msd_gad-7_followup_52.0_self-report_cbt_tau_NA_NA;-0,286678907;0,129245168;NA;NA;primary;low;low;low;high;low;high;clinicaltrials.gov nct02426788;gb;clinical;no;NA;adults;yes;change and evaluation in secondary care (prince secondary);mixed;group;NA;no;8;NA;480;NA;22;NA;0,36;NA;60;NA;NA;NA;NA;NA;NA;43,7;42,5;12,3;12,9;136;133;269;0,83;161;163;324;NA;NA;NA;NA;NA;NA;NA;NA;NA;combined;mus;NA;NA;NA;NA;NA;NA;NA;NA;yes;"patients were excluded if they had active psychosis and/or factitious disorder; headaches as their main and only pps symptom (given the clinical complexity of differentiating headaches and migraine, headaches were excluded); non-epileptic seizures as their main and only pps symptom (due to an ongoing RCT at the time of recruitment that was evaluating a specific cognitive behavioural approach for Dissociative Seizures, now published (goldstein 2020))";no;NA;yes;there were 324 adverse events recorded in the intervention arm and 348 in the control arm with majority of adverse events being gastro-intestinal (52 in tdt-cbt plus smc, 42 in smc), musculoskeletal (33 in tdt-cbt plus smc, 49 in smc), psychiatric (34 in tdt-cbt +smc, 46 in smc) and immunological (48 in tdt-cbt plus smc, 40 in smc). an adverse event was defined as any medical occurrence, this included symptoms such as swollen eye, hip pain, flu symptoms, etc. there were 57 withdrawals from the trial, 30 from the tdt-cbt plus smc arm and 27 from the smc arm with the majority being due to the participant no longer wanting to take part in the trial (26 from tdt-cbt plus smc and 26 from smc). no adverse events were reported as being related to the intervention received.
chalder, 2021;cbt;tau;NA;NA;phs;msd;wsas;post;20;self-report;-36,4;-26,6;8,8;8,1;-21,4;-23,8;10,6;10;127;132;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;chalder_2021_msd_wsas_post_20.0_self-report_cbt_tau_NA_NA;0,232362169;0,12471815;NA;NA;primary;low;low;low;high;low;high;clinicaltrials.gov nct02426788;gb;clinical;no;NA;adults;yes;change and evaluation in secondary care (prince secondary);mixed;group;NA;no;8;NA;480;NA;22;NA;0,36;NA;60;NA;NA;NA;NA;NA;NA;43,7;42,5;12,3;12,9;136;133;269;0,83;161;163;324;NA;NA;NA;NA;NA;NA;NA;NA;NA;combined;mus;NA;NA;NA;NA;NA;NA;NA;NA;yes;"patients were excluded if they had active psychosis and/or factitious disorder; headaches as their main and only pps symptom (given the clinical complexity of differentiating headaches and migraine, headaches were excluded); non-epileptic seizures as their main and only pps symptom (due to an ongoing RCT at the time of recruitment that was evaluating a specific cognitive behavioural approach for Dissociative Seizures, now published (goldstein 2020))";no;NA;yes;there were 324 adverse events recorded in the intervention arm and 348 in the control arm with majority of adverse events being gastro-intestinal (52 in tdt-cbt plus smc, 42 in smc), musculoskeletal (33 in tdt-cbt plus smc, 49 in smc), psychiatric (34 in tdt-cbt +smc, 46 in smc) and immunological (48 in tdt-cbt plus smc, 40 in smc). an adverse event was defined as any medical occurrence, this included symptoms such as swollen eye, hip pain, flu symptoms, etc. there were 57 withdrawals from the trial, 30 from the tdt-cbt plus smc arm and 27 from the smc arm with the majority being due to the participant no longer wanting to take part in the trial (26 from tdt-cbt plus smc and 26 from smc). no adverse events were reported as being related to the intervention received.
chalder, 2021;cbt;tau;NA;NA;phs;msd;wsas;follow up;52;self-report;-36,4;-26,3;8,8;8,1;-21,4;-23;10,8;10,8;120;123;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;chalder_2021_msd_wsas_followup_52.0_self-report_cbt_tau_NA_NA;0,147686627;0,128485699;NA;NA;primary;low;low;low;high;low;high;clinicaltrials.gov nct02426788;gb;clinical;no;NA;adults;yes;change and evaluation in secondary care (prince secondary);mixed;group;NA;no;8;NA;480;NA;22;NA;0,36;NA;60;NA;NA;NA;NA;NA;NA;43,7;42,5;12,3;12,9;136;133;269;0,83;161;163;324;NA;NA;NA;NA;NA;NA;NA;NA;NA;combined;mus;NA;NA;NA;NA;NA;NA;NA;NA;yes;"patients were excluded if they had active psychosis and/or factitious disorder; headaches as their main and only pps symptom (given the clinical complexity of differentiating headaches and migraine, headaches were excluded); non-epileptic seizures as their main and only pps symptom (due to an ongoing RCT at the time of recruitment that was evaluating a specific cognitive behavioural approach for Dissociative Seizures, now published (goldstein 2020))";no;NA;yes;there were 324 adverse events recorded in the intervention arm and 348 in the control arm with majority of adverse events being gastro-intestinal (52 in tdt-cbt plus smc, 42 in smc), musculoskeletal (33 in tdt-cbt plus smc, 49 in smc), psychiatric (34 in tdt-cbt +smc, 46 in smc) and immunological (48 in tdt-cbt plus smc, 40 in smc). an adverse event was defined as any medical occurrence, this included symptoms such as swollen eye, hip pain, flu symptoms, etc. there were 57 withdrawals from the trial, 30 from the tdt-cbt plus smc arm and 27 from the smc arm with the majority being due to the participant no longer wanting to take part in the trial (26 from tdt-cbt plus smc and 26 from smc). no adverse events were reported as being related to the intervention received.
edinger, 2005;cbt;tau;NA;NA;som;msd;mpq;post;6;self-report;30,6;27,5;12,39;17,7;27,6;34,4;14,71;12,3;15;9;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;edinger_2005_msd_mpq_post_6.0_self-report_cbt_tau_NA_NA;-0,472947415;0,427523756;NA;NA;primary;low;low;low;high;some concerns;high;NA;us;community;no;NA;adults;yes;NA;psy;individual;NA;no;6;NA;165;NA;6;NA;1;NA;27,5;NA;NA;NA;NA;NA;NA;50,1;48,3;6,9;9,1;17;11;28;0,97;18;11;29;16;11;27;NA;NA;NA;NA;NA;NA;combined;fm;NA;NA;NA;NA;NA;NA;NA;NA;yes;"currently pregnant, breastfeeding, or not practicing contraception; (2) having a comorbid sleep-disruptive medical condition; (3) meeting structured interview criteria for an axis I depressive (other than dysthymia), anxiety, or substance abuse disorder; (4) having a severe hypnotic dependence, suggested by the use of a hypnotic agent in a higher than recommended dosage or repeated episodes of rebound insomnia on withdrawal; (5) having symptoms of sleep apnea, restless legs syndrome, or circadian rhythm disorder; and (6) having an apnea-hypopnea index or periodic limb movement (plm)-related arousal index of 15 or more per hour on a screening polysomnogram (psg).";yes;therapy evaluation questionnaire;no;NA
edinger, 2005;cbt;tau;NA;NA;som;msd;mpq;follow up;30;self-report;30,6;27,5;12,39;17,7;28,8;34,1;13,95;14,7;15;9;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;edinger_2005_msd_mpq_followup_30.0_self-report_cbt_tau_NA_NA;-0,359677555;0,425051635;NA;NA;primary;low;low;low;high;some concerns;high;NA;us;community;no;NA;adults;yes;NA;psy;individual;NA;no;6;NA;165;NA;6;NA;1;NA;27,5;NA;NA;NA;NA;NA;NA;50,1;48,3;6,9;9,1;17;11;28;0,97;18;11;29;16;11;27;NA;NA;NA;NA;NA;NA;combined;fm;NA;NA;NA;NA;NA;NA;NA;NA;yes;"currently pregnant, breastfeeding, or not practicing contraception; (2) having a comorbid sleep-disruptive medical condition; (3) meeting structured interview criteria for an axis I depressive (other than dysthymia), anxiety, or substance abuse disorder; (4) having a severe hypnotic dependence, suggested by the use of a hypnotic agent in a higher than recommended dosage or repeated episodes of rebound insomnia on withdrawal; (5) having symptoms of sleep apnea, restless legs syndrome, or circadian rhythm disorder; and (6) having an apnea-hypopnea index or periodic limb movement (plm)-related arousal index of 15 or more per hour on a screening polysomnogram (psg).";yes;therapy evaluation questionnaire;no;NA
edinger, 2005;cbt;tau;NA;NA;som;msd;bpi;post;6;self-report;5;4,7;1,4;1,9;4,6;5,3;1,9;2;15;9;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;edinger_2005_msd_bpi_post_6.0_self-report_cbt_tau_NA_NA;-0,348929093;0,424851363;NA;NA;secondary;NA;NA;NA;NA;NA;NA;NA;us;community;no;NA;adults;yes;NA;psy;individual;NA;no;6;NA;165;NA;6;NA;1;NA;27,5;NA;NA;NA;NA;NA;NA;50,1;48,3;6,9;9,1;17;11;28;0,97;18;11;29;16;11;27;NA;NA;NA;NA;NA;NA;combined;fm;NA;NA;NA;NA;NA;NA;NA;NA;yes;"currently pregnant, breastfeeding, or not practicing contraception; (2) having a comorbid sleep-disruptive medical condition; (3) meeting structured interview criteria for an axis I depressive (other than dysthymia), anxiety, or substance abuse disorder; (4) having a severe hypnotic dependence, suggested by the use of a hypnotic agent in a higher than recommended dosage or repeated episodes of rebound insomnia on withdrawal; (5) having symptoms of sleep apnea, restless legs syndrome, or circadian rhythm disorder; and (6) having an apnea-hypopnea index or periodic limb movement (plm)-related arousal index of 15 or more per hour on a screening polysomnogram (psg).";yes;therapy evaluation questionnaire;no;NA
edinger, 2005;cbt;tau;NA;NA;phs;msd;sf-36;post;6;self-report;47,9;51,3;13,47;9,26;50,7;45,5;9,73;9,52;14;7;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;edinger_2005_msd_sf-36_post_6.0_self-report_cbt_tau_NA_NA;0,51654682;0,470296738;NA;NA;primary;low;low;low;high;some concerns;high;NA;us;community;no;NA;adults;yes;NA;psy;individual;NA;no;6;NA;165;NA;6;NA;1;NA;27,5;NA;NA;NA;NA;NA;NA;50,1;48,3;6,9;9,1;17;11;28;0,97;18;11;29;16;11;27;NA;NA;NA;NA;NA;NA;combined;fm;NA;NA;NA;NA;NA;NA;NA;NA;yes;"currently pregnant, breastfeeding, or not practicing contraception; (2) having a comorbid sleep-disruptive medical condition; (3) meeting structured interview criteria for an axis I depressive (other than dysthymia), anxiety, or substance abuse disorder; (4) having a severe hypnotic dependence, suggested by the use of a hypnotic agent in a higher than recommended dosage or repeated episodes of rebound insomnia on withdrawal; (5) having symptoms of sleep apnea, restless legs syndrome, or circadian rhythm disorder; and (6) having an apnea-hypopnea index or periodic limb movement (plm)-related arousal index of 15 or more per hour on a screening polysomnogram (psg).";yes;therapy evaluation questionnaire;no;NA
edinger, 2005;cbt;tau;NA;NA;phs;msd;sf-36;follow up;30;self-report;47,9;51,3;13,47;9,26;51,3;40;9,73;7,41;14;7;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;edinger_2005_msd_sf-36_followup_30.0_self-report_cbt_tau_NA_NA;1,197117708;0,501307886;NA;NA;primary;low;low;low;high;some concerns;high;NA;us;community;no;NA;adults;yes;NA;psy;individual;NA;no;6;NA;165;NA;6;NA;1;NA;27,5;NA;NA;NA;NA;NA;NA;50,1;48,3;6,9;9,1;17;11;28;0,97;18;11;29;16;11;27;NA;NA;NA;NA;NA;NA;combined;fm;NA;NA;NA;NA;NA;NA;NA;NA;yes;"currently pregnant, breastfeeding, or not practicing contraception; (2) having a comorbid sleep-disruptive medical condition; (3) meeting structured interview criteria for an axis I depressive (other than dysthymia), anxiety, or substance abuse disorder; (4) having a severe hypnotic dependence, suggested by the use of a hypnotic agent in a higher than recommended dosage or repeated episodes of rebound insomnia on withdrawal; (5) having symptoms of sleep apnea, restless legs syndrome, or circadian rhythm disorder; and (6) having an apnea-hypopnea index or periodic limb movement (plm)-related arousal index of 15 or more per hour on a screening polysomnogram (psg).";yes;therapy evaluation questionnaire;no;NA
escobar, 2007;cbt;tau;NA;NA;som;msd;phq-15;post;12;self-report;14,17;13,98;5,4;5,44;9,32;11,5;5,32;5,28;63;64;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;escobar_2007_msd_phq-15_post_12.0_self-report_cbt_tau_NA_NA;-0,408857316;0,179343604;NA;NA;primary;low;high;low;high;some concerns;high;NA;us;clinical;no;NA;adults;yes;treating somatization;psy;individual;NA;no;10;NA;540;NA;12;NA;0,83;NA;54;NA;NA;NA;NA;NA;NA;40,97;39,58;12,72;13,37;75;76;151;0,88;87;85;172;NA;NA;NA;NA;NA;NA;NA;NA;NA;clinical interview;ssi;NA;NA;NA;NA;NA;NA;NA;NA;yes;severe psychiatric problems, such as psychotic symptoms or suicidal ideas, or medical disorders that may have explained the symptoms;no;NA;no;NA
escobar, 2007;cbt;tau;NA;NA;som;msd;phq-15;follow up;36;self-report;14,17;13,98;5,4;5,44;9,11;10,91;4,17;6,17;50;44;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;escobar_2007_msd_phq-15_followup_36.0_self-report_cbt_tau_NA_NA;-0,343231904;0,208240927;NA;NA;primary;low;high;low;high;some concerns;high;NA;us;clinical;no;NA;adults;yes;treating somatization;psy;individual;NA;no;10;NA;540;NA;12;NA;0,83;NA;54;NA;NA;NA;NA;NA;NA;40,97;39,58;12,72;13,37;75;76;151;0,88;87;85;172;NA;NA;NA;NA;NA;NA;NA;NA;NA;clinical interview;ssi;NA;NA;NA;NA;NA;NA;NA;NA;yes;severe psychiatric problems, such as psychotic symptoms or suicidal ideas, or medical disorders that may have explained the symptoms;no;NA;no;NA
escobar, 2007;cbt;tau;NA;NA;depr;msd;hdrs;post;12;clinican;18,25;17,41;5,97;5,99;12,82;14,6;6,75;6,77;63;65;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;escobar_2007_msd_hdrs_post_12.0_clinican_cbt_tau_NA_NA;-0,261736718;0,177562536;NA;NA;primary;low;high;low;low;some concerns;high;NA;us;clinical;no;NA;adults;yes;treating somatization;psy;individual;NA;no;10;NA;540;NA;12;NA;0,83;NA;54;NA;NA;NA;NA;NA;NA;40,97;39,58;12,72;13,37;75;76;151;0,88;87;85;172;NA;NA;NA;NA;NA;NA;NA;NA;NA;clinical interview;ssi;NA;NA;NA;NA;NA;NA;NA;NA;yes;severe psychiatric problems, such as psychotic symptoms or suicidal ideas, or medical disorders that may have explained the symptoms;no;NA;no;NA
escobar, 2007;cbt;tau;NA;NA;depr;msd;hdrs;follow up;36;clinican;18,25;17,41;5,97;5,99;12,88;14,29;6,28;6,17;51;44;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;escobar_2007_msd_hdrs_followup_36.0_clinican_cbt_tau_NA_NA;-0,224516422;0,206409211;NA;NA;primary;low;high;low;low;some concerns;high;NA;us;clinical;no;NA;adults;yes;treating somatization;psy;individual;NA;no;10;NA;540;NA;12;NA;0,83;NA;54;NA;NA;NA;NA;NA;NA;40,97;39,58;12,72;13,37;75;76;151;0,88;87;85;172;NA;NA;NA;NA;NA;NA;NA;NA;NA;clinical interview;ssi;NA;NA;NA;NA;NA;NA;NA;NA;yes;severe psychiatric problems, such as psychotic symptoms or suicidal ideas, or medical disorders that may have explained the symptoms;no;NA;no;NA
escobar, 2007;cbt;tau;NA;NA;anx;msd;ham-a;post;12;clinican;20,46;20,99;7;7,01;15,89;18,47;8,57;8,63;63;65;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;escobar_2007_msd_ham-a_post_12.0_clinican_cbt_tau_NA_NA;-0,298192411;0,177789624;NA;NA;primary;low;high;low;low;some concerns;high;NA;us;clinical;no;NA;adults;yes;treating somatization;psy;individual;NA;no;10;NA;540;NA;12;NA;0,83;NA;54;NA;NA;NA;NA;NA;NA;40,97;39,58;12,72;13,37;75;76;151;0,88;87;85;172;NA;NA;NA;NA;NA;NA;NA;NA;NA;clinical interview;ssi;NA;NA;NA;NA;NA;NA;NA;NA;yes;severe psychiatric problems, such as psychotic symptoms or suicidal ideas, or medical disorders that may have explained the symptoms;no;NA;no;NA
escobar, 2007;cbt;tau;NA;NA;anx;msd;ham-a;follow up;36;clinican;20,46;20,99;7;7,01;14,85;17,58;6,71;6,63;51;44;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;escobar_2007_msd_ham-a_followup_36.0_clinican_cbt_tau_NA_NA;-0,405795263;0,207884553;NA;NA;primary;low;high;low;low;some concerns;high;NA;us;clinical;no;NA;adults;yes;treating somatization;psy;individual;NA;no;10;NA;540;NA;12;NA;0,83;NA;54;NA;NA;NA;NA;NA;NA;40,97;39,58;12,72;13,37;75;76;151;0,88;87;85;172;NA;NA;NA;NA;NA;NA;NA;NA;NA;clinical interview;ssi;NA;NA;NA;NA;NA;NA;NA;NA;yes;severe psychiatric problems, such as psychotic symptoms or suicidal ideas, or medical disorders that may have explained the symptoms;no;NA;no;NA
escobar, 2007;cbt;tau;NA;NA;phs;msd;sf-36 physical functioning;post;12;self-report;63,28;61,41;24,9;24,98;72,19;69,71;23,41;23,41;63;63;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;escobar_2007_msd_sf-36physicalfunctioning_post_12.0_self-report_cbt_tau_NA_NA;0,105295587;0,178299093;NA;NA;primary;low;high;low;high;some concerns;high;NA;us;clinical;no;NA;adults;yes;treating somatization;psy;individual;NA;no;10;NA;540;NA;12;NA;0,83;NA;54;NA;NA;NA;NA;NA;NA;40,97;39,58;12,72;13,37;75;76;151;0,88;87;85;172;NA;NA;NA;NA;NA;NA;NA;NA;NA;clinical interview;ssi;NA;NA;NA;NA;NA;NA;NA;NA;yes;severe psychiatric problems, such as psychotic symptoms or suicidal ideas, or medical disorders that may have explained the symptoms;no;NA;no;NA
escobar, 2007;cbt;tau;NA;NA;phs;msd;sf-36 physical functioning;follow up;36;self-report;63,28;61,41;24,9;24,98;73,22;69,41;23,28;22,88;48;44;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;escobar_2007_msd_sf-36physicalfunctioning_followup_36.0_self-report_cbt_tau_NA_NA;0,16362936;0,209065977;NA;NA;primary;low;high;low;high;some concerns;high;NA;us;clinical;no;NA;adults;yes;treating somatization;psy;individual;NA;no;10;NA;540;NA;12;NA;0,83;NA;54;NA;NA;NA;NA;NA;NA;40,97;39,58;12,72;13,37;75;76;151;0,88;87;85;172;NA;NA;NA;NA;NA;NA;NA;NA;NA;clinical interview;ssi;NA;NA;NA;NA;NA;NA;NA;NA;yes;severe psychiatric problems, such as psychotic symptoms or suicidal ideas, or medical disorders that may have explained the symptoms;no;NA;no;NA
everitt, 2019;cbt;tau;telephone;tau;som;msd;ibs-sss;post;12;self-report;272,3;258,5;95,5;91,6;174;236,5;98,6;97,1;138;141;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;everitt_2019_msd_ibs-sss_post_12.0_self-report_cbt_tau_telephone_tau;-0,637035941;0,122759114;NA;NA;primary;low;low;low;high;low;high;ISRCTN registry, ISRCTN44427879, https://www.isrctn.com/ISRCTN44427879, Assessing Cognitive behavioural Therapy in Irritable Bowel (ACTIB): protocol for a randomised controlled trial of clinical-effectiveness and cost-effectiveness of therapist delivered cognitive behavioural therapy and web-based self-management in irritable bowel syndrome in adults, https://pubmed.ncbi.nlm.nih.gov/26179651/;gb;combined;yes;"10 £ voucher ""Love2shop""";adults;yes;regul8;psy;individual;NA;no;6;NA;360;NA;9;NA;0,67;NA;60;NA;NA;NA;NA;NA;NA;43,4;42;12,5;13,5;139;139;278;0,75;186;187;373;177;187;364;NA;NA;NA;NA;NA;NA;clinical interview;ibs;NA;NA;NA;NA;237;138;141,72;88,44;yes;unexplained rectal bleeding or weight loss or a diagnosis of inflammatory bowel disease (ibd), coeliac disease, peptic ulcer disease or colorectal carcinoma.;no;NA;yes;there were 77 recorded AEs in the TCBT arm, 61 in the WCBT arm and 55 in the TAU arm. Of these, 18.1% were gastrointestinal related. Fourteen of these events were seen in the TCBT arm, 10 in the WCBT arm and 11 in the TAU arm. Of the AEs, 23.3% were psychological events, of which 18 were seen in the TCBT arm, with 17 and 10 events seen in the WCBT and TAU arms, respectively. The other 14 body system codes made up 58.6% of AEs, most individual system codes accounting for < 10% of events. [see Tables 30 & 31 in extended report for more information]
everitt, 2019;cbt;tau;website;tau;som;msd;ibs-sss;post;12;self-report;264,2;258,5;99,3;91,6;179,1;236,5;104,2;97,1;148;141;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;everitt_2019_msd_ibs-sss_post_12.0_self-report_cbt_tau_website_tau;-0,567960233;0,120041581;NA;NA;primary;low;low;low;high;low;high;ISRCTN registry, ISRCTN44427879, https://www.isrctn.com/ISRCTN44427879, Assessing Cognitive behavioural Therapy in Irritable Bowel (ACTIB): protocol for a randomised controlled trial of clinical-effectiveness and cost-effectiveness of therapist delivered cognitive behavioural therapy and web-based self-management in irritable bowel syndrome in adults, https://pubmed.ncbi.nlm.nih.gov/26179651/;gb;combined;yes;"10 £ voucher ""Love2shop""";adults;yes;regul8;psy;individual;NA;no;3;NA;90;NA;9;NA;0,33;NA;30;NA;NA;NA;NA;NA;NA;43,8;42;13,6;13,5;145;139;284;0,76;185;187;372;170;187;357;NA;NA;NA;NA;NA;NA;clinical interview;ibs;NA;NA;NA;NA;189,96;138;99;88,44;yes;unexplained rectal bleeding or weight loss or a diagnosis of inflammatory bowel disease (ibd), coeliac disease, peptic ulcer disease or colorectal carcinoma.;no;NA;yes;there were 77 recorded AEs in the TCBT arm, 61 in the WCBT arm and 55 in the TAU arm. Of these, 18.1% were gastrointestinal related. Fourteen of these events were seen in the TCBT arm, 10 in the WCBT arm and 11 in the TAU arm. Of the AEs, 23.3% were psychological events, of which 18 were seen in the TCBT arm, with 17 and 10 events seen in the WCBT and TAU arms, respectively. The other 14 body system codes made up 58.6% of AEs, most individual system codes accounting for < 10% of events. [see Tables 30 & 31 in extended report for more information]
everitt, 2019;cbt;tau;telephone;tau;som;msd;ibs-sss;follow up;48;self-report;272,3;258,5;95,5;91,6;139;205,6;94,8;100,5;124;131;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;everitt_2019_msd_ibs-sss_followup_48.0_self-report_cbt_tau_telephone_tau;-0,679166646;0,128871802;NA;NA;primary;low;low;low;high;low;high;ISRCTN registry, ISRCTN44427879, https://www.isrctn.com/ISRCTN44427879, Assessing Cognitive behavioural Therapy in Irritable Bowel (ACTIB): protocol for a randomised controlled trial of clinical-effectiveness and cost-effectiveness of therapist delivered cognitive behavioural therapy and web-based self-management in irritable bowel syndrome in adults, https://pubmed.ncbi.nlm.nih.gov/26179651/;gb;combined;yes;"10 £ voucher ""Love2shop""";adults;yes;regul8;psy;individual;NA;no;8;NA;480;NA;9;NA;0,89;NA;60;NA;NA;NA;NA;NA;NA;43,4;42;12,5;13,5;139;139;278;0,75;186;187;373;177;187;364;NA;NA;NA;NA;NA;NA;clinical interview;ibs;NA;NA;NA;NA;237;138;141,72;88,44;yes;unexplained rectal bleeding or weight loss or a diagnosis of inflammatory bowel disease (ibd), coeliac disease, peptic ulcer disease or colorectal carcinoma.;no;NA;yes;there were 77 recorded AEs in the TCBT arm, 61 in the WCBT arm and 55 in the TAU arm. Of these, 18.1% were gastrointestinal related. Fourteen of these events were seen in the TCBT arm, 10 in the WCBT arm and 11 in the TAU arm. Of the AEs, 23.3% were psychological events, of which 18 were seen in the TCBT arm, with 17 and 10 events seen in the WCBT and TAU arms, respectively. The other 14 body system codes made up 58.6% of AEs, most individual system codes accounting for < 10% of events. [see Tables 30 & 31 in extended report for more information]
everitt, 2019;cbt;tau;website;tau;som;msd;ibs-sss;follow up;48;self-report;264,2;258,5;99,3;91,6;163;205,6;100,5;108,8;136;131;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;everitt_2019_msd_ibs-sss_followup_48.0_self-report_cbt_tau_website_tau;-0,40590256;0,123680306;NA;NA;primary;low;low;low;high;low;high;ISRCTN registry, ISRCTN44427879, https://www.isrctn.com/ISRCTN44427879, Assessing Cognitive behavioural Therapy in Irritable Bowel (ACTIB): protocol for a randomised controlled trial of clinical-effectiveness and cost-effectiveness of therapist delivered cognitive behavioural therapy and web-based self-management in irritable bowel syndrome in adults, https://pubmed.ncbi.nlm.nih.gov/26179651/;gb;combined;yes;"10 £ voucher ""Love2shop""";adults;yes;regul8;psy;individual;NA;no;5;NA;150;NA;9;NA;0,56;NA;30;NA;NA;NA;NA;NA;NA;43,8;42;13,6;13,5;145;139;284;0,76;185;187;372;170;187;357;NA;NA;NA;NA;NA;NA;clinical interview;ibs;NA;NA;NA;NA;189,96;138;99;88,44;yes;unexplained rectal bleeding or weight loss or a diagnosis of inflammatory bowel disease (ibd), coeliac disease, peptic ulcer disease or colorectal carcinoma.;no;NA;yes;there were 77 recorded AEs in the TCBT arm, 61 in the WCBT arm and 55 in the TAU arm. Of these, 18.1% were gastrointestinal related. Fourteen of these events were seen in the TCBT arm, 10 in the WCBT arm and 11 in the TAU arm. Of the AEs, 23.3% were psychological events, of which 18 were seen in the TCBT arm, with 17 and 10 events seen in the WCBT and TAU arms, respectively. The other 14 body system codes made up 58.6% of AEs, most individual system codes accounting for < 10% of events. [see Tables 30 & 31 in extended report for more information]
everitt, 2019;cbt;tau;telephone;tau;phs;msd;wsas;post;12;self-report;-13;-12,4;9,3;7,4;-9,4;-12,1;8,2;8,2;138;140;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;everitt_2019_msd_wsas_post_12.0_self-report_cbt_tau_telephone_tau;0,328372731;0,120765184;NA;NA;primary;low;low;low;high;low;high;ISRCTN registry, ISRCTN44427879, https://www.isrctn.com/ISRCTN44427879, Assessing Cognitive behavioural Therapy in Irritable Bowel (ACTIB): protocol for a randomised controlled trial of clinical-effectiveness and cost-effectiveness of therapist delivered cognitive behavioural therapy and web-based self-management in irritable bowel syndrome in adults, https://pubmed.ncbi.nlm.nih.gov/26179651/;gb;combined;yes;"10 £ voucher ""Love2shop""";adults;yes;regul8;psy;individual;NA;no;6;NA;360;NA;9;NA;0,67;NA;60;NA;NA;NA;NA;NA;NA;43,4;42;12,5;13,5;139;139;278;0,75;186;187;373;177;187;364;NA;NA;NA;NA;NA;NA;clinical interview;ibs;NA;NA;NA;NA;237;138;141,72;88,44;yes;unexplained rectal bleeding or weight loss or a diagnosis of inflammatory bowel disease (ibd), coeliac disease, peptic ulcer disease or colorectal carcinoma.;no;NA;yes;there were 77 recorded AEs in the TCBT arm, 61 in the WCBT arm and 55 in the TAU arm. Of these, 18.1% were gastrointestinal related. Fourteen of these events were seen in the TCBT arm, 10 in the WCBT arm and 11 in the TAU arm. Of the AEs, 23.3% were psychological events, of which 18 were seen in the TCBT arm, with 17 and 10 events seen in the WCBT and TAU arms, respectively. The other 14 body system codes made up 58.6% of AEs, most individual system codes accounting for < 10% of events. [see Tables 30 & 31 in extended report for more information]
everitt, 2019;cbt;tau;website;tau;phs;msd;wsas;post;12;self-report;-12,3;-12,4;8,8;7,4;-8,4;-12,1;7,8;8,2;149;140;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;everitt_2019_msd_wsas_post_12.0_self-report_cbt_tau_website_tau;0,461507962;0,119267329;NA;NA;primary;low;low;low;high;low;high;ISRCTN registry, ISRCTN44427879, https://www.isrctn.com/ISRCTN44427879, Assessing Cognitive behavioural Therapy in Irritable Bowel (ACTIB): protocol for a randomised controlled trial of clinical-effectiveness and cost-effectiveness of therapist delivered cognitive behavioural therapy and web-based self-management in irritable bowel syndrome in adults, https://pubmed.ncbi.nlm.nih.gov/26179651/;gb;combined;yes;"10 £ voucher ""Love2shop""";adults;yes;regul8;psy;individual;NA;no;3;NA;90;NA;9;NA;0,33;NA;30;NA;NA;NA;NA;NA;NA;43,8;42;13,6;13,5;145;139;284;0,76;185;187;372;170;187;357;NA;NA;NA;NA;NA;NA;clinical interview;ibs;NA;NA;NA;NA;189,96;138;99;88,44;yes;unexplained rectal bleeding or weight loss or a diagnosis of inflammatory bowel disease (ibd), coeliac disease, peptic ulcer disease or colorectal carcinoma.;no;NA;yes;there were 77 recorded AEs in the TCBT arm, 61 in the WCBT arm and 55 in the TAU arm. Of these, 18.1% were gastrointestinal related. Fourteen of these events were seen in the TCBT arm, 10 in the WCBT arm and 11 in the TAU arm. Of the AEs, 23.3% were psychological events, of which 18 were seen in the TCBT arm, with 17 and 10 events seen in the WCBT and TAU arms, respectively. The other 14 body system codes made up 58.6% of AEs, most individual system codes accounting for < 10% of events. [see Tables 30 & 31 in extended report for more information]
everitt, 2019;cbt;tau;telephone;tau;phs;msd;wsas;follow up;48;self-report;-13;-12,4;9,3;7,4;-7,4;-10,8;7,7;9,3;124;132;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;everitt_2019_msd_wsas_followup_48.0_self-report_cbt_tau_telephone_tau;0,395901417;0,126286263;NA;NA;primary;low;low;low;high;low;high;ISRCTN registry, ISRCTN44427879, https://www.isrctn.com/ISRCTN44427879, Assessing Cognitive behavioural Therapy in Irritable Bowel (ACTIB): protocol for a randomised controlled trial of clinical-effectiveness and cost-effectiveness of therapist delivered cognitive behavioural therapy and web-based self-management in irritable bowel syndrome in adults, https://pubmed.ncbi.nlm.nih.gov/26179651/;gb;combined;yes;"12 £ voucher ""Love2shop""";adults;yes;regul10;psy;individual;NA;no;8;NA;480;NA;9;NA;0,89;NA;60;NA;NA;NA;NA;NA;NA;43,4;42;12,5;13,5;139;139;278;0,75;186;187;373;177;187;364;NA;NA;NA;NA;NA;NA;clinical interview;ibs;NA;NA;NA;NA;237;138;141,72;88,44;yes;unexplained rectal bleeding or weight loss or a diagnosis of inflammatory bowel disease (ibd), coeliac disease, peptic ulcer disease or colorectal carcinoma.;no;NA;yes;there were 77 recorded AEs in the TCBT arm, 61 in the WCBT arm and 55 in the TAU arm. Of these, 18.1% were gastrointestinal related. Fourteen of these events were seen in the TCBT arm, 10 in the WCBT arm and 11 in the TAU arm. Of the AEs, 23.3% were psychological events, of which 18 were seen in the TCBT arm, with 17 and 10 events seen in the WCBT and TAU arms, respectively. The other 14 body system codes made up 58.6% of AEs, most individual system codes accounting for < 10% of events. [see Tables 30 & 31 in extended report for more information]
everitt, 2019;cbt;tau;website;tau;phs;msd;wsas;follow up;48;self-report;-12,3;-12,4;8,8;7,4;-6;-10,8;7,5;9,3;138;132;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;everitt_2019_msd_wsas_followup_48.0_self-report_cbt_tau_website_tau;0,567933582;0,124188594;NA;NA;primary;low;low;low;high;low;high;ISRCTN registry, ISRCTN44427879, https://www.isrctn.com/ISRCTN44427879, Assessing Cognitive behavioural Therapy in Irritable Bowel (ACTIB): protocol for a randomised controlled trial of clinical-effectiveness and cost-effectiveness of therapist delivered cognitive behavioural therapy and web-based self-management in irritable bowel syndrome in adults, https://pubmed.ncbi.nlm.nih.gov/26179651/;gb;combined;yes;"13 £ voucher ""Love2shop""";adults;yes;regul11;psy;individual;NA;no;5;NA;150;NA;9;NA;0,56;NA;30;NA;NA;NA;NA;NA;NA;43,8;42;13,6;13,5;145;139;284;0,76;185;187;372;170;187;357;NA;NA;NA;NA;NA;NA;clinical interview;ibs;NA;NA;NA;NA;189,96;138;99;88,44;yes;unexplained rectal bleeding or weight loss or a diagnosis of inflammatory bowel disease (ibd), coeliac disease, peptic ulcer disease or colorectal carcinoma.;no;NA;yes;there were 77 recorded AEs in the TCBT arm, 61 in the WCBT arm and 55 in the TAU arm. Of these, 18.1% were gastrointestinal related. Fourteen of these events were seen in the TCBT arm, 10 in the WCBT arm and 11 in the TAU arm. Of the AEs, 23.3% were psychological events, of which 18 were seen in the TCBT arm, with 17 and 10 events seen in the WCBT and TAU arms, respectively. The other 14 body system codes made up 58.6% of AEs, most individual system codes accounting for < 10% of events. [see Tables 30 & 31 in extended report for more information]
falcao, 2008;cbt;tau;NA;NA;som;msd;vas;post;10;self-report;6,88;7,03;2,29;2,25;3,28;3,53;3,58;2,88;25;26;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;falcao_2008_msd_vas_post_10.0_self-report_cbt_tau_NA_NA;-0,075931262;0,280213925;NA;NA;primary;low;high;high;low;some concerns;high;NA;br;clinical;no;NA;adults;yes;pmr + cognitive restructuring + stress management;para;group;NA;no;10;NA;NA;NA;10;NA;1;0;0;0;NA;NA;NA;NA;NA;44,88;46,46;9,95;12,23;30;30;60;1;30;30;60;30;30;60;NA;NA;NA;NA;NA;NA;clinical interview;fm;NA;NA;NA;NA;41,64;44,76;28,56;57,6;yes;"patients with other rheumatic diseases; patients with known hypersensibility to amitriptyline, cyclobenzaprine, or paracetamol; those in use of psychotropic drugs or with psychiatric diseases [based on past his- tory]; and those with work related litigation were excluded.";yes;91% in both treatment arms evaluated the treatment as good or outstanding;no;NA
falcao, 2008;cbt;tau;NA;NA;som;msd;vas;follow up;22;self-report;6,88;7,03;2,29;2,25;4,44;5,07;3,65;3,94;25;26;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;falcao_2008_msd_vas_followup_22.0_self-report_cbt_tau_NA_NA;-0,16320773;0,280590284;NA;NA;primary;low;high;high;low;some concerns;high;NA;br;clinical;no;NA;adults;yes;pmr + cognitive restructuring + stress management;para;group;NA;no;10;NA;NA;NA;10;NA;1;0;0;0;NA;NA;NA;NA;NA;44,88;46,46;9,95;12,23;30;30;60;1;30;30;60;30;30;60;NA;NA;NA;NA;NA;NA;clinical interview;fm;NA;NA;NA;NA;41,64;44,76;28,56;57,6;yes;"patients with other rheumatic diseases; patients with known hypersensibility to amitriptyline, cyclobenzaprine, or paracetamol; those in use of psychotropic drugs or with psychiatric diseases [based on past his- tory]; and those with work related litigation were excluded.";yes;91% in both treatment arms evaluated the treatment as good or outstanding;no;NA
falcao, 2008;cbt;tau;NA;NA;depr;msd;bdi;post;10;self-report;20,6;25,76;9,96;8,46;7,56;13,96;7,71;11,37;25;26;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;falcao_2008_msd_bdi_post_10.0_self-report_cbt_tau_NA_NA;-0,646275676;0,287550565;NA;NA;primary;low;high;high;low;some concerns;high;NA;br;clinical;no;NA;adults;yes;pmr + cognitive restructuring + stress management;para;group;NA;no;10;NA;NA;NA;10;NA;1;0;0;0;NA;NA;NA;NA;NA;44,88;46,46;9,95;12,23;30;30;60;1;30;30;60;30;30;60;NA;NA;NA;NA;NA;NA;clinical interview;fm;NA;NA;NA;NA;41,64;44,76;28,56;57,6;yes;"patients with other rheumatic diseases; patients with known hypersensibility to amitriptyline, cyclobenzaprine, or paracetamol; those in use of psychotropic drugs or with psychiatric diseases [based on past his- tory]; and those with work related litigation were excluded.";yes;91% in both treatment arms evaluated the treatment as good or outstanding;no;NA
falcao, 2008;cbt;tau;NA;NA;depr;msd;bdi;follow up;22;self-report;20,6;25,76;9,96;8,46;10,56;15,61;9,28;12,15;25;26;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;falcao_2008_msd_bdi_followup_22.0_self-report_cbt_tau_NA_NA;-0,458714723;0,283882796;NA;NA;primary;low;high;high;low;some concerns;high;NA;br;clinical;no;NA;adults;yes;pmr + cognitive restructuring + stress management;para;group;NA;no;10;NA;NA;NA;10;NA;1;0;0;0;NA;NA;NA;NA;NA;44,88;46,46;9,95;12,23;30;30;60;1;30;30;60;30;30;60;NA;NA;NA;NA;NA;NA;clinical interview;fm;NA;NA;NA;NA;41,64;44,76;28,56;57,6;yes;"patients with other rheumatic diseases; patients with known hypersensibility to amitriptyline, cyclobenzaprine, or paracetamol; those in use of psychotropic drugs or with psychiatric diseases [based on past his- tory]; and those with work related litigation were excluded.";yes;91% in both treatment arms evaluated the treatment as good or outstanding;no;NA
falcao, 2008;cbt;tau;NA;NA;anx;msd;stai;post;10;self-report;47,44;48,26;3,21;2,7;46,6;46,65;3,06;3,35;25;26;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;falcao_2008_msd_stai_post_10.0_self-report_cbt_tau_NA_NA;-0,015330799;0,280114111;NA;NA;primary;low;high;high;low;some concerns;high;NA;br;clinical;no;NA;adults;yes;pmr + cognitive restructuring + stress management;para;group;NA;no;10;NA;NA;NA;10;NA;1;0;0;0;NA;NA;NA;NA;NA;44,88;46,46;9,95;12,23;30;30;60;1;30;30;60;30;30;60;NA;NA;NA;NA;NA;NA;clinical interview;fm;NA;NA;NA;NA;41,64;44,76;28,56;57,6;yes;"patients with other rheumatic diseases; patients with known hypersensibility to amitriptyline, cyclobenzaprine, or paracetamol; those in use of psychotropic drugs or with psychiatric diseases [based on past his- tory]; and those with work related litigation were excluded.";yes;91% in both treatment arms evaluated the treatment as good or outstanding;no;NA
falcao, 2008;cbt;tau;NA;NA;anx;msd;stai;follow up;22;self-report;47,44;48,26;3,21;2,7;45,8;46,76;2,48;2,33;25;26;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;falcao_2008_msd_stai_followup_22.0_self-report_cbt_tau_NA_NA;-0,393086383;0,282885347;NA;NA;primary;low;high;high;low;some concerns;high;NA;br;clinical;no;NA;adults;yes;pmr + cognitive restructuring + stress management;para;group;NA;no;10;NA;NA;NA;10;NA;1;0;0;0;NA;NA;NA;NA;NA;44,88;46,46;9,95;12,23;30;30;60;1;30;30;60;30;30;60;NA;NA;NA;NA;NA;NA;clinical interview;fm;NA;NA;NA;NA;41,64;44,76;28,56;57,6;yes;"patients with other rheumatic diseases; patients with known hypersensibility to amitriptyline, cyclobenzaprine, or paracetamol; those in use of psychotropic drugs or with psychiatric diseases [based on past his- tory]; and those with work related litigation were excluded.";yes;91% in both treatment arms evaluated the treatment as good or outstanding;no;NA
falcao, 2008;cbt;tau;NA;NA;phs;msd;fiq;post;10;self-report;-64,91;-69,56;15,47;11,44;-46,6;-46,65;3,06;3,35;25;26;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;falcao_2008_msd_fiq_post_10.0_self-report_cbt_tau_NA_NA;0,015330799;0,280114111;NA;NA;primary;low;high;high;low;some concerns;high;NA;br;clinical;no;NA;adults;yes;pmr + cognitive restructuring + stress management;para;group;NA;no;10;NA;NA;NA;10;NA;1;0;0;0;NA;NA;NA;NA;NA;44,88;46,46;9,95;12,23;30;30;60;1;30;30;60;30;30;60;NA;NA;NA;NA;NA;NA;clinical interview;fm;NA;NA;NA;NA;41,64;44,76;28,56;57,6;yes;"patients with other rheumatic diseases; patients with known hypersensibility to amitriptyline, cyclobenzaprine, or paracetamol; those in use of psychotropic drugs or with psychiatric diseases [based on past his- tory]; and those with work related litigation were excluded.";yes;91% in both treatment arms evaluated the treatment as good or outstanding;no;NA
falcao, 2008;cbt;tau;NA;NA;phs;msd;fiq;follow up;22;self-report;-64,91;-69,56;15,47;11,44;-38,68;-42,76;24,81;27,24;25;26;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;falcao_2008_msd_fiq_followup_22.0_self-report_cbt_tau_NA_NA;0,154046125;0,280537902;NA;NA;primary;low;high;high;low;some concerns;high;NA;br;clinical;no;NA;adults;yes;pmr + cognitive restructuring + stress management;para;group;NA;no;10;NA;NA;NA;10;NA;1;0;0;0;NA;NA;NA;NA;NA;44,88;46,46;9,95;12,23;30;30;60;1;30;30;60;30;30;60;NA;NA;NA;NA;NA;NA;clinical interview;fm;NA;NA;NA;NA;41,64;44,76;28,56;57,6;yes;"patients with other rheumatic diseases; patients with known hypersensibility to amitriptyline, cyclobenzaprine, or paracetamol; those in use of psychotropic drugs or with psychiatric diseases [based on past his- tory]; and those with work related litigation were excluded.";yes;91% in both treatment arms evaluated the treatment as good or outstanding;no;NA
fjorback, 2013;cbt+ambt;ec;NA;NA;phs;msd;sf-36;post;12;self-report;30,3;31,2;9,8;9,4;33,8;31,5;10,8;9,6;53;51;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;fjorback_2013_msd_sf-36_post_12.0_self-report_cbt+ambt_ec_NA_NA;0,223185475;0,196770976;NA;NA;primary;low;low;low;high;some concerns;high;NA;dk;clinical;no;NA;adults;yes;mbsr;psychiatrist;group;NA;no;9;NA;1890;NA;8;NA;1,13;0;210;0;NA;NA;NA;NA;NA;38;40;9;8;47;48;95;0,8;59;60;119;NA;NA;NA;NA;NA;NA;NA;NA;NA;combined;bds;NA;NA;NA;NA;144;180;127,2;151,2;yes;current alcohol or drug abuse;no;NA;no;NA
fjorback, 2013;cbt+ambt;ec;NA;NA;phs;msd;sf-36;follow up;60;self-report;30,3;31,2;9,8;9,4;34;35,3;10,6;9,5;45;45;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;fjorback_2013_msd_sf-36_followup_60.0_self-report_cbt+ambt_ec_NA_NA;-0,128056032;0,211038205;NA;NA;primary;low;low;low;high;some concerns;high;NA;dk;clinical;no;NA;adults;yes;mbsr;psychiatrist;group;NA;no;9;NA;1890;NA;8;NA;1,13;0;210;0;NA;NA;NA;NA;NA;38;40;9;8;47;48;95;0,8;59;60;119;NA;NA;NA;NA;NA;NA;NA;NA;NA;combined;bds;NA;NA;NA;NA;144;180;127,2;151,2;yes;current alcohol or drug abuse;no;NA;no;NA
friedberg, 2013;cbt;att plac;cbt;att plac;som;msd;fss;post;14;self-report;5,4;5,71;0,97;0,99;4,94;5,39;1,16;1,17;37;38;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;friedberg_2013_msd_fss_post_14.0_self-report_cbt_attplac_cbt_attplac;-0,382257976;0,233103749;NA;NA;primary;low;low;low;low;some concerns;some concerns;NA;us;clinical;yes;candidates were offered up to $420 as compensation for full participation in the study;adults;yes;fsm;para;individual;NA;no;2;NA;120;NA;14;NA;0,14;NA;60;NA;NA;NA;NA;NA;NA;42,47;42,49;15,45;12,1;29;29;58;0,77;37;38;75;NA;NA;NA;NA;NA;NA;NA;NA;too much work to do in study, didn't feel that the type of treatment was appropriate, no longer interested, and “unknown” for those who did not return phone calls (the largest category).;clinical interview;cfs/me;NA;NA;NA;NA;140,04;107,16;109,32;89,4;yes;psychiatric exclusions were as follows: any psychosis or dementia, alcohol or substance abuse in the 2 years before illness onset and at any time afterward, current or past depression with melancholic or psychotic features within 5 years of illness onset or within 5 years of evaluation, and present or past anorexia nervosa or bulimia nervosa;no;NA;no;NA
friedberg, 2013;cbt;tau;cbt;tau;som;msd;fss;post;14;self-report;5,4;5,72;0,97;0,96;4,94;5,45;1,16;1,14;37;36;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;friedberg_2013_msd_fss_post_14.0_self-report_cbt_tau_cbt_tau;-0,438706767;0,236962968;NA;NA;primary;low;low;low;high;some concerns;high;NA;us;clinical;yes;candidates were offered up to $420 as compensation for full participation in the study;adults;yes;fsm;para;individual;NA;no;2;NA;120;NA;14;NA;0,14;NA;60;NA;NA;NA;NA;NA;NA;42,47;43,64;15,45;13,34;29;28;57;0,76;37;38;75;NA;NA;NA;NA;NA;NA;NA;NA;too much work to do in study, didn't feel that the type of treatment was appropriate, no longer interested, and “unknown” for those who did not return phone calls (the largest category).;clinical interview;cfs/me;NA;NA;NA;NA;140,04;117,72;109,32;100,44;yes;psychiatric exclusions were as follows: any psychosis or dementia, alcohol or substance abuse in the 2 years before illness onset and at any time afterward, current or past depression with melancholic or psychotic features within 5 years of illness onset or within 5 years of evaluation, and present or past anorexia nervosa or bulimia nervosa;no;NA;no;NA
friedberg, 2013;cbt;att plac;cbt;att plac;som;msd;fss;follow up;50;self-report;5,4;5,71;0,97;0,99;4,19;5,16;1,59;1,79;37;38;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;friedberg_2013_msd_fss_followup_50.0_self-report_cbt_attplac_cbt_attplac;-0,566598015;0,235643499;NA;NA;primary;low;low;low;low;some concerns;some concerns;NA;us;clinical;yes;candidates were offered up to $420 as compensation for full participation in the study;adults;yes;fsm;para;individual;NA;no;2;NA;120;NA;14;NA;0,14;NA;60;NA;NA;NA;NA;NA;NA;42,47;42,49;15,45;12,1;29;29;58;0,77;37;38;75;NA;NA;NA;NA;NA;NA;NA;NA;too much work to do in study, didn't feel that the type of treatment was appropriate, no longer interested, and “unknown” for those who did not return phone calls (the largest category).;clinical interview;cfs/me;NA;NA;NA;NA;140,04;107,16;109,32;89,4;yes;psychiatric exclusions were as follows: any psychosis or dementia, alcohol or substance abuse in the 2 years before illness onset and at any time afterward, current or past depression with melancholic or psychotic features within 5 years of illness onset or within 5 years of evaluation, and present or past anorexia nervosa or bulimia nervosa;no;NA;no;NA
friedberg, 2013;cbt;tau;cbt;tau;som;msd;fss;follow up;50;self-report;5,4;5,72;0,97;0,96;4,19;5,31;1,59;1,92;37;36;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;friedberg_2013_msd_fss_followup_50.0_self-report_cbt_tau_cbt_tau;-0,629466058;0,239952408;NA;NA;primary;low;low;low;high;some concerns;high;NA;us;clinical;yes;candidates were offered up to $420 as compensation for full participation in the study;adults;yes;fsm;para;individual;NA;no;2;NA;120;NA;14;NA;0,14;NA;60;NA;NA;NA;NA;NA;NA;42,47;43,64;15,45;13,34;29;28;57;0,76;37;38;75;NA;NA;NA;NA;NA;NA;NA;NA;too much work to do in study, didn't feel that the type of treatment was appropriate, no longer interested, and “unknown” for those who did not return phone calls (the largest category).;clinical interview;cfs/me;NA;NA;NA;NA;140,04;117,72;109,32;100,44;yes;psychiatric exclusions were as follows: any psychosis or dementia, alcohol or substance abuse in the 2 years before illness onset and at any time afterward, current or past depression with melancholic or psychotic features within 5 years of illness onset or within 5 years of evaluation, and present or past anorexia nervosa or bulimia nervosa;no;NA;no;NA
friedberg, 2013;cbt;att plac;cbt;att plac;depr;msd;bdi;post;14;self-report;17,1;16,41;8,82;9,55;13,52;16,41;9,98;9,55;37;38;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;friedberg_2013_msd_bdi_post_14.0_self-report_cbt_attplac_cbt_attplac;-0,292921208;0,232221477;NA;NA;primary;low;low;low;low;some concerns;some concerns;NA;us;clinical;yes;candidates were offered up to $420 as compensation for full participation in the study;adults;yes;fsm;para;individual;NA;no;2;NA;120;NA;14;NA;0,14;NA;60;NA;NA;NA;NA;NA;NA;42,47;42,49;15,45;12,1;29;29;58;0,77;37;38;75;NA;NA;NA;NA;NA;NA;NA;NA;too much work to do in study, didn't feel that the type of treatment was appropriate, no longer interested, and “unknown” for those who did not return phone calls (the largest category).;clinical interview;cfs/me;NA;NA;NA;NA;140,04;107,16;109,32;89,4;yes;psychiatric exclusions were as follows: any psychosis or dementia, alcohol or substance abuse in the 2 years before illness onset and at any time afterward, current or past depression with melancholic or psychotic features within 5 years of illness onset or within 5 years of evaluation, and present or past anorexia nervosa or bulimia nervosa;no;NA;no;NA
friedberg, 2013;cbt;tau;cbt;tau;depr;msd;bdi;post;14;self-report;17,1;18,31;8,82;8,64;13,52;16,17;9,98;10,98;37;36;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;friedberg_2013_msd_bdi_post_14.0_self-report_cbt_tau_cbt_tau;-0,250065533;0,235036888;NA;NA;primary;low;low;low;high;some concerns;high;NA;us;clinical;yes;candidates were offered up to $420 as compensation for full participation in the study;adults;yes;fsm;para;individual;NA;no;2;NA;120;NA;14;NA;0,14;NA;60;NA;NA;NA;NA;NA;NA;42,47;43,64;15,45;13,34;29;28;57;0,76;37;38;75;NA;NA;NA;NA;NA;NA;NA;NA;too much work to do in study, didn't feel that the type of treatment was appropriate, no longer interested, and “unknown” for those who did not return phone calls (the largest category).;clinical interview;cfs/me;NA;NA;NA;NA;140,04;117,72;109,32;100,44;yes;psychiatric exclusions were as follows: any psychosis or dementia, alcohol or substance abuse in the 2 years before illness onset and at any time afterward, current or past depression with melancholic or psychotic features within 5 years of illness onset or within 5 years of evaluation, and present or past anorexia nervosa or bulimia nervosa;no;NA;no;NA
friedberg, 2013;cbt;att plac;cbt;att plac;depr;msd;bdi;follow up;50;self-report;17,1;16,41;8,82;9,55;14,89;14,56;11,31;11,71;37;38;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;friedberg_2013_msd_bdi_followup_50.0_self-report_cbt_attplac_cbt_attplac;0,028364115;0,230972493;NA;NA;primary;low;low;low;low;some concerns;some concerns;NA;us;clinical;yes;candidates were offered up to $420 as compensation for full participation in the study;adults;yes;fsm;para;individual;NA;no;2;NA;120;NA;14;NA;0,14;NA;60;NA;NA;NA;NA;NA;NA;42,47;42,49;15,45;12,1;29;29;58;0,77;37;38;75;NA;NA;NA;NA;NA;NA;NA;NA;too much work to do in study, didn't feel that the type of treatment was appropriate, no longer interested, and “unknown” for those who did not return phone calls (the largest category).;clinical interview;cfs/me;NA;NA;NA;NA;140,04;107,16;109,32;89,4;yes;psychiatric exclusions were as follows: any psychosis or dementia, alcohol or substance abuse in the 2 years before illness onset and at any time afterward, current or past depression with melancholic or psychotic features within 5 years of illness onset or within 5 years of evaluation, and present or past anorexia nervosa or bulimia nervosa;no;NA;no;NA
friedberg, 2013;cbt;tau;cbt;tau;depr;msd;bdi;follow up;50;self-report;17,1;18,31;8,82;8,64;14,89;14,03;11,31;11,16;37;36;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;friedberg_2013_msd_bdi_followup_50.0_self-report_cbt_tau_cbt_tau;0,075726253;0,23418994;NA;NA;primary;low;low;low;high;some concerns;high;NA;us;clinical;yes;candidates were offered up to $420 as compensation for full participation in the study;adults;yes;fsm;para;individual;NA;no;2;NA;120;NA;14;NA;0,14;NA;60;NA;NA;NA;NA;NA;NA;42,47;43,64;15,45;13,34;29;28;57;0,76;37;38;75;NA;NA;NA;NA;NA;NA;NA;NA;too much work to do in study, didn't feel that the type of treatment was appropriate, no longer interested, and “unknown” for those who did not return phone calls (the largest category).;clinical interview;cfs/me;NA;NA;NA;NA;140,04;117,72;109,32;100,44;yes;psychiatric exclusions were as follows: any psychosis or dementia, alcohol or substance abuse in the 2 years before illness onset and at any time afterward, current or past depression with melancholic or psychotic features within 5 years of illness onset or within 5 years of evaluation, and present or past anorexia nervosa or bulimia nervosa;no;NA;no;NA
friedberg, 2013;cbt;att plac;cbt;att plac;anx;msd;bai;post;14;self-report;11,97;14,91;8,94;9;10,98;14,49;9,73;10,49;37;38;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;friedberg_2013_msd_bai_post_14.0_self-report_cbt_attplac_cbt_attplac;-0,343182964;0,232689542;NA;NA;primary;low;low;low;low;some concerns;some concerns;NA;us;clinical;yes;candidates were offered up to $420 as compensation for full participation in the study;adults;yes;fsm;para;individual;NA;no;2;NA;120;NA;14;NA;0,14;NA;60;NA;NA;NA;NA;NA;NA;42,47;42,49;15,45;12,1;29;29;58;0,77;37;38;75;NA;NA;NA;NA;NA;NA;NA;NA;too much work to do in study, didn't feel that the type of treatment was appropriate, no longer interested, and “unknown” for those who did not return phone calls (the largest category).;clinical interview;cfs/me;NA;NA;NA;NA;140,04;107,16;109,32;89,4;yes;psychiatric exclusions were as follows: any psychosis or dementia, alcohol or substance abuse in the 2 years before illness onset and at any time afterward, current or past depression with melancholic or psychotic features within 5 years of illness onset or within 5 years of evaluation, and present or past anorexia nervosa or bulimia nervosa;no;NA;no;NA
friedberg, 2013;cbt;tau;cbt;tau;anx;msd;bai;post;14;self-report;11,97;14,99;8,94;8,76;10,98;14,5;9,73;9,9;37;36;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;friedberg_2013_msd_bai_post_14.0_self-report_cbt_tau_cbt_tau;-0,354862939;0,235978611;NA;NA;primary;low;low;low;high;some concerns;high;NA;us;clinical;yes;candidates were offered up to $420 as compensation for full participation in the study;adults;yes;fsm;para;individual;NA;no;2;NA;120;NA;14;NA;0,14;NA;60;NA;NA;NA;NA;NA;NA;42,47;43,64;15,45;13,34;29;28;57;0,76;37;38;75;NA;NA;NA;NA;NA;NA;NA;NA;too much work to do in study, didn't feel that the type of treatment was appropriate, no longer interested, and “unknown” for those who did not return phone calls (the largest category).;clinical interview;cfs/me;NA;NA;NA;NA;140,04;117,72;109,32;100,44;yes;psychiatric exclusions were as follows: any psychosis or dementia, alcohol or substance abuse in the 2 years before illness onset and at any time afterward, current or past depression with melancholic or psychotic features within 5 years of illness onset or within 5 years of evaluation, and present or past anorexia nervosa or bulimia nervosa;no;NA;no;NA
friedberg, 2013;cbt;att plac;cbt;att plac;anx;msd;bai;follow up;50;self-report;11,97;14,91;8,94;9;12,02;13,88;11,5;11,47;37;38;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;friedberg_2013_msd_bai_followup_50.0_self-report_cbt_attplac_cbt_attplac;-0,16028351;0,231338875;NA;NA;primary;low;low;low;low;some concerns;some concerns;NA;us;clinical;yes;candidates were offered up to $420 as compensation for full participation in the study;adults;yes;fsm;para;individual;NA;no;2;NA;120;NA;14;NA;0,14;NA;60;NA;NA;NA;NA;NA;NA;42,47;42,49;15,45;12,1;29;29;58;0,77;37;38;75;NA;NA;NA;NA;NA;NA;NA;NA;too much work to do in study, didn't feel that the type of treatment was appropriate, no longer interested, and “unknown” for those who did not return phone calls (the largest category).;clinical interview;cfs/me;NA;NA;NA;NA;140,04;107,16;109,32;89,4;yes;psychiatric exclusions were as follows: any psychosis or dementia, alcohol or substance abuse in the 2 years before illness onset and at any time afterward, current or past depression with melancholic or psychotic features within 5 years of illness onset or within 5 years of evaluation, and present or past anorexia nervosa or bulimia nervosa;no;NA;no;NA
friedberg, 2013;cbt;tau;cbt;tau;anx;msd;bai;follow up;50;self-report;11,97;14,99;8,94;8,76;12,02;14,39;11,5;13,38;37;36;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;friedberg_2013_msd_bai_followup_50.0_self-report_cbt_tau_cbt_tau;-0,188158267;0,234632732;NA;NA;primary;low;low;low;high;some concerns;high;NA;us;clinical;yes;candidates were offered up to $420 as compensation for full participation in the study;adults;yes;fsm;para;individual;NA;no;2;NA;120;NA;14;NA;0,14;NA;60;NA;NA;NA;NA;NA;NA;42,47;43,64;15,45;13,34;29;28;57;0,76;37;38;75;NA;NA;NA;NA;NA;NA;NA;NA;too much work to do in study, didn't feel that the type of treatment was appropriate, no longer interested, and “unknown” for those who did not return phone calls (the largest category).;clinical interview;cfs/me;NA;NA;NA;NA;140,04;117,72;109,32;100,44;yes;psychiatric exclusions were as follows: any psychosis or dementia, alcohol or substance abuse in the 2 years before illness onset and at any time afterward, current or past depression with melancholic or psychotic features within 5 years of illness onset or within 5 years of evaluation, and present or past anorexia nervosa or bulimia nervosa;no;NA;no;NA
friedberg, 2013;cbt;att plac;cbt;att plac;phs;msd;sf-36;post;14;self-report;68,49;67,07;24,7;22,93;74,82;67,07;24,39;22,93;37;38;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;friedberg_2013_msd_sf-36_post_14.0_self-report_cbt_attplac_cbt_attplac;0,324162897;0,23250383;NA;NA;primary;low;low;low;low;some concerns;some concerns;NA;us;clinical;yes;candidates were offered up to $420 as compensation for full participation in the study;adults;yes;fsm;para;individual;NA;no;2;NA;120;NA;14;NA;0,14;NA;60;NA;NA;NA;NA;NA;NA;42,47;42,49;15,45;12,1;29;29;58;0,77;37;38;75;NA;NA;NA;NA;NA;NA;NA;NA;too much work to do in study, didn't feel that the type of treatment was appropriate, no longer interested, and “unknown” for those who did not return phone calls (the largest category).;clinical interview;cfs/me;NA;NA;NA;NA;140,04;107,16;109,32;89,4;yes;psychiatric exclusions were as follows: any psychosis or dementia, alcohol or substance abuse in the 2 years before illness onset and at any time afterward, current or past depression with melancholic or psychotic features within 5 years of illness onset or within 5 years of evaluation, and present or past anorexia nervosa or bulimia nervosa;no;NA;no;NA
friedberg, 2013;cbt;tau;cbt;tau;phs;msd;sf-36;post;14;self-report;68,49;59,77;24,7;24,04;74,82;64,92;24,39;22,02;37;36;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;friedberg_2013_msd_sf-36_post_14.0_self-report_cbt_tau_cbt_tau;0,421258182;0,236741333;NA;NA;primary;low;low;low;high;some concerns;high;NA;us;clinical;yes;candidates were offered up to $420 as compensation for full participation in the study;adults;yes;fsm;para;individual;NA;no;2;NA;120;NA;14;NA;0,14;NA;60;NA;NA;NA;NA;NA;NA;42,47;43,64;15,45;13,34;29;28;57;0,76;37;38;75;NA;NA;NA;NA;NA;NA;NA;NA;too much work to do in study, didn't feel that the type of treatment was appropriate, no longer interested, and “unknown” for those who did not return phone calls (the largest category).;clinical interview;cfs/me;NA;NA;NA;NA;140,04;117,72;109,32;100,44;yes;psychiatric exclusions were as follows: any psychosis or dementia, alcohol or substance abuse in the 2 years before illness onset and at any time afterward, current or past depression with melancholic or psychotic features within 5 years of illness onset or within 5 years of evaluation, and present or past anorexia nervosa or bulimia nervosa;no;NA;no;NA
friedberg, 2013;cbt;att plac;cbt;att plac;phs;msd;sf-36;follow up;50;self-report;68,49;67,07;24,7;22,93;66,3;65,96;29,74;26,14;37;38;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;friedberg_2013_msd_sf-36_followup_50.0_self-report_cbt_attplac_cbt_attplac;0,012029142;0,230962771;NA;NA;primary;low;low;low;low;some concerns;some concerns;NA;us;clinical;yes;candidates were offered up to $420 as compensation for full participation in the study;adults;yes;fsm;para;individual;NA;no;2;NA;120;NA;14;NA;0,14;NA;60;NA;NA;NA;NA;NA;NA;42,47;42,49;15,45;12,1;29;29;58;0,77;37;38;75;NA;NA;NA;NA;NA;NA;NA;NA;too much work to do in study, didn't feel that the type of treatment was appropriate, no longer interested, and “unknown” for those who did not return phone calls (the largest category).;clinical interview;cfs/me;NA;NA;NA;NA;140,04;107,16;109,32;89,4;yes;psychiatric exclusions were as follows: any psychosis or dementia, alcohol or substance abuse in the 2 years before illness onset and at any time afterward, current or past depression with melancholic or psychotic features within 5 years of illness onset or within 5 years of evaluation, and present or past anorexia nervosa or bulimia nervosa;no;NA;no;NA
friedberg, 2013;cbt;tau;cbt;tau;phs;msd;sf-36;follow up;50;self-report;68,49;59,77;24,7;24,04;66,3;56,44;29,74;25,26;37;36;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;friedberg_2013_msd_sf-36_followup_50.0_self-report_cbt_tau_cbt_tau;0,353171331;0,235960854;NA;NA;primary;low;low;low;high;some concerns;high;NA;us;clinical;yes;candidates were offered up to $420 as compensation for full participation in the study;adults;yes;fsm;para;individual;NA;no;2;NA;120;NA;14;NA;0,14;NA;60;NA;NA;NA;NA;NA;NA;42,47;43,64;15,45;13,34;29;28;57;0,76;37;38;75;NA;NA;NA;NA;NA;NA;NA;NA;too much work to do in study, didn't feel that the type of treatment was appropriate, no longer interested, and “unknown” for those who did not return phone calls (the largest category).;clinical interview;cfs/me;NA;NA;NA;NA;140,04;117,72;109,32;100,44;yes;psychiatric exclusions were as follows: any psychosis or dementia, alcohol or substance abuse in the 2 years before illness onset and at any time afterward, current or past depression with melancholic or psychotic features within 5 years of illness onset or within 5 years of evaluation, and present or past anorexia nervosa or bulimia nervosa;no;NA;no;NA
friedberg, 2016;cbt;tau;digital;tau;depr;msd;bdi;post;12;self-report;16,65;20,38;10,63;10,6;14,4;19,36;10,44;10,4;40;45;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;friedberg_2016_msd_bdi_post_12.0_self-report_cbt_tau_digital_tau;-0,471747089;0,220352828;NA;NA;primary;low;low;low;high;some concerns;high;NA;us;clinical;yes;candidates were offered up to $678 as compensation for full participation in the study;adults;yes;"friedberg f. chronic fatigue syndrome, fibromyalgia, and related illnesses: a clinical model of assessment and intervention. j clin psychol. 2010;6:641–665.";self-guided;individual;NA;no;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;48,01;50,03;12,43;11,28;38;42;80;0,86;45;48;93;41;48;89;41;48;89;(e.g. unable to access web diary, inability to begin treatment in a timely manner), fear of energy drain from doing study activities, or unknown reasons;NA;NA;combined;cfs/me;NA;NA;NA;NA;150,84;207,12;101,88;127,8;yes;exclusionary psychiatric disorders included any self-reported psychosis, substance or alcohol abuse in the two years prior to illness onset or at any time afterward, or current or past depression with melancholic or psychotic features within the five years prior to illness onset or any time afterward;no;NA;no;NA
friedberg, 2016;cbt;tau;pnp;tau;depr;msd;bdi;post;12;self-report;20,4;20,38;10,63;10,6;14,98;19,36;10,44;10,4;40;45;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;friedberg_2016_msd_bdi_post_12.0_self-report_cbt_tau_pnp_tau;-0,416583115;0,219685716;NA;NA;primary;low;low;low;high;some concerns;high;NA;us;clinical;yes;candidates were offered up to $678 as compensation for full participation in the study;adults;yes;"friedberg f. chronic fatigue syndrome, fibromyalgia, and related illnesses: a clinical model of assessment and intervention. j clin psychol. 2010;6:641–665.";self-guided;individual;NA;no;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;46,99;50,03;10,79;11,28;41;42;83;0,9;44;48;92;41;48;89;41;48;89;(e.g. unable to access web diary, inability to begin treatment in a timely manner), fear of energy drain from doing study activities, or unknown reasons;NA;NA;combined;cfs/me;NA;NA;NA;NA;164,52;207,12;83,76;127,8;yes;exclusionary psychiatric disorders included any self-reported psychosis, substance or alcohol abuse in the two years prior to illness onset or at any time afterward, or current or past depression with melancholic or psychotic features within the five years prior to illness onset or any time afterward;no;NA;no;NA
friedberg, 2016;cbt;tau;digital;tau;depr;msd;bdi;follow up;48;self-report;16,65;20,38;10,63;10,6;13,08;18,64;9,36;9,32;40;45;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;friedberg_2016_msd_bdi_followup_48.0_self-report_cbt_tau_digital_tau;-0,589968465;0,222052414;NA;NA;primary;low;low;low;high;some concerns;high;NA;us;clinical;yes;candidates were offered up to $678 as compensation for full participation in the study;adults;yes;"friedberg f. chronic fatigue syndrome, fibromyalgia, and related illnesses: a clinical model of assessment and intervention. j clin psychol. 2010;6:641–665.";self-guided;individual;NA;no;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;48,01;50,03;12,43;11,28;38;42;80;0,86;45;48;93;41;48;89;41;48;89;(e.g. unable to access web diary, inability to begin treatment in a timely manner), fear of energy drain from doing study activities, or unknown reasons;NA;NA;combined;cfs/me;NA;NA;NA;NA;150,84;207,12;101,88;127,8;yes;exclusionary psychiatric disorders included any self-reported psychosis, substance or alcohol abuse in the two years prior to illness onset or at any time afterward, or current or past depression with melancholic or psychotic features within the five years prior to illness onset or any time afterward;no;NA;no;NA
friedberg, 2016;cbt;tau;pnp;tau;depr;msd;bdi;follow up;48;self-report;20,4;20,38;10,63;10,6;14,42;18,64;9,36;9,32;40;45;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;friedberg_2016_msd_bdi_followup_48.0_self-report_cbt_tau_pnp_tau;-0,447781821;0,220053081;NA;NA;primary;low;low;low;high;some concerns;high;NA;us;clinical;yes;candidates were offered up to $678 as compensation for full participation in the study;adults;yes;"friedberg f. chronic fatigue syndrome, fibromyalgia, and related illnesses: a clinical model of assessment and intervention. j clin psychol. 2010;6:641–665.";self-guided;individual;NA;no;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;46,99;50,03;10,79;11,28;41;42;83;0,9;44;48;92;41;48;89;41;48;89;(e.g. unable to access web diary, inability to begin treatment in a timely manner), fear of energy drain from doing study activities, or unknown reasons;NA;NA;combined;cfs/me;NA;NA;NA;NA;164,52;207,12;83,76;127,8;yes;exclusionary psychiatric disorders included any self-reported psychosis, substance or alcohol abuse in the two years prior to illness onset or at any time afterward, or current or past depression with melancholic or psychotic features within the five years prior to illness onset or any time afterward;no;NA;no;NA
friedberg, 2016;cbt;tau;digital;tau;anx;msd;bai;post;12;self-report;16,49;18,84;10,3;10,3;16;17,77;9,8;9,84;41;46;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;friedberg_2016_msd_bai_post_12.0_self-report_cbt_tau_digital_tau;-0,178627547;0,215211621;NA;NA;primary;low;low;low;high;some concerns;high;NA;us;clinical;yes;candidates were offered up to $678 as compensation for full participation in the study;adults;yes;"friedberg f. chronic fatigue syndrome, fibromyalgia, and related illnesses: a clinical model of assessment and intervention. j clin psychol. 2010;6:641–665.";self-guided;individual;NA;no;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;48,01;50,03;12,43;11,28;38;42;80;0,86;45;48;93;41;48;89;41;48;89;(e.g. unable to access web diary, inability to begin treatment in a timely manner), fear of energy drain from doing study activities, or unknown reasons;NA;NA;combined;cfs/me;NA;NA;NA;NA;150,84;207,12;101,88;127,8;yes;exclusionary psychiatric disorders included any self-reported psychosis, substance or alcohol abuse in the two years prior to illness onset or at any time afterward, or current or past depression with melancholic or psychotic features within the five years prior to illness onset or any time afterward;no;NA;no;NA
friedberg, 2016;cbt;tau;pnp;tau;anx;msd;bai;post;12;self-report;18,69;18,84;10,3;10,3;16,23;9,8;16,92;10,3;40;46;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;friedberg_2016_msd_bai_post_12.0_self-report_cbt_tau_pnp_tau;0,462605046;0,219102541;NA;NA;primary;low;low;low;high;some concerns;high;NA;us;clinical;yes;candidates were offered up to $678 as compensation for full participation in the study;adults;yes;"friedberg f. chronic fatigue syndrome, fibromyalgia, and related illnesses: a clinical model of assessment and intervention. j clin psychol. 2010;6:641–665.";self-guided;individual;NA;no;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;46,99;50,03;10,79;11,28;41;42;83;0,9;44;48;92;41;48;89;41;48;89;(e.g. unable to access web diary, inability to begin treatment in a timely manner), fear of energy drain from doing study activities, or unknown reasons;NA;NA;combined;cfs/me;NA;NA;NA;NA;164,52;207,12;83,76;127,8;yes;exclusionary psychiatric disorders included any self-reported psychosis, substance or alcohol abuse in the two years prior to illness onset or at any time afterward, or current or past depression with melancholic or psychotic features within the five years prior to illness onset or any time afterward;no;NA;no;NA
friedberg, 2016;cbt;tau;digital;tau;anx;msd;bai;follow up;48;self-report;16,49;18,84;10,3;10,3;14,67;18,3;10,3;10,3;41;46;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;friedberg_2016_msd_bai_followup_48.0_self-report_cbt_tau_digital_tau;-0,34930836;0,21643289;NA;NA;primary;low;low;low;high;some concerns;high;NA;us;clinical;yes;candidates were offered up to $678 as compensation for full participation in the study;adults;yes;"friedberg f. chronic fatigue syndrome, fibromyalgia, and related illnesses: a clinical model of assessment and intervention. j clin psychol. 2010;6:641–665.";self-guided;individual;NA;no;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;48,01;50,03;12,43;11,28;38;42;80;0,86;45;48;93;41;48;89;41;48;89;(e.g. unable to access web diary, inability to begin treatment in a timely manner), fear of energy drain from doing study activities, or unknown reasons;NA;NA;combined;cfs/me;NA;NA;NA;NA;150,84;207,12;101,88;127,8;yes;exclusionary psychiatric disorders included any self-reported psychosis, substance or alcohol abuse in the two years prior to illness onset or at any time afterward, or current or past depression with melancholic or psychotic features within the five years prior to illness onset or any time afterward;no;NA;no;NA
friedberg, 2016;cbt;tau;pnp;tau;anx;msd;bai;follow up;48;self-report;18,69;18,84;10,3;10,3;16,92;18,3;10,3;10,3;40;46;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;friedberg_2016_msd_bai_followup_48.0_self-report_cbt_tau_pnp_tau;-0,132780756;0,216433582;NA;NA;primary;low;low;low;high;some concerns;high;NA;us;clinical;yes;candidates were offered up to $678 as compensation for full participation in the study;adults;yes;"friedberg f. chronic fatigue syndrome, fibromyalgia, and related illnesses: a clinical model of assessment and intervention. j clin psychol. 2010;6:641–665.";self-guided;individual;NA;no;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;46,99;50,03;10,79;11,28;41;42;83;0,9;44;48;92;41;48;89;41;48;89;(e.g. unable to access web diary, inability to begin treatment in a timely manner), fear of energy drain from doing study activities, or unknown reasons;NA;NA;combined;cfs/me;NA;NA;NA;NA;164,52;207,12;83,76;127,8;yes;exclusionary psychiatric disorders included any self-reported psychosis, substance or alcohol abuse in the two years prior to illness onset or at any time afterward, or current or past depression with melancholic or psychotic features within the five years prior to illness onset or any time afterward;no;NA;no;NA
friedberg, 2016;cbt;tau;digital;tau;phs;msd;sf-36;post;12;self-report;37,75;45,77;20,24;20,26;43,25;37,62;21;21;41;46;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;friedberg_2016_msd_sf-36_post_12.0_self-report_cbt_tau_digital_tau;0,265722714;0,215736991;NA;NA;primary;low;low;low;high;some concerns;high;NA;us;clinical;yes;candidates were offered up to $678 as compensation for full participation in the study;adults;yes;"friedberg f. chronic fatigue syndrome, fibromyalgia, and related illnesses: a clinical model of assessment and intervention. j clin psychol. 2010;6:641–665.";self-guided;individual;NA;no;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;48,01;50,03;12,43;11,28;38;42;80;0,86;45;48;93;41;48;89;41;48;89;(e.g. unable to access web diary, inability to begin treatment in a timely manner), fear of energy drain from doing study activities, or unknown reasons;NA;NA;combined;cfs/me;NA;NA;NA;NA;150,84;207,12;101,88;127,8;yes;exclusionary psychiatric disorders included any self-reported psychosis, substance or alcohol abuse in the two years prior to illness onset or at any time afterward, or current or past depression with melancholic or psychotic features within the five years prior to illness onset or any time afterward;no;NA;no;NA
friedberg, 2016;cbt;tau;pnp;tau;phs;msd;sf-36;post;12;self-report;37,75;45,77;20,24;20,26;43,75;37,62;21;21;40;46;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;friedberg_2016_msd_sf-36_post_12.0_self-report_cbt_tau_pnp_tau;0,289290689;0,217335059;NA;NA;primary;low;low;low;high;some concerns;high;NA;us;clinical;yes;candidates were offered up to $678 as compensation for full participation in the study;adults;yes;"friedberg f. chronic fatigue syndrome, fibromyalgia, and related illnesses: a clinical model of assessment and intervention. j clin psychol. 2010;6:641–665.";self-guided;individual;NA;no;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;46,99;50,03;10,79;11,28;41;42;83;0,9;44;48;92;41;48;89;41;48;89;(e.g. unable to access web diary, inability to begin treatment in a timely manner), fear of energy drain from doing study activities, or unknown reasons;NA;NA;combined;cfs/me;NA;NA;NA;NA;164,52;207,12;83,76;127,8;yes;exclusionary psychiatric disorders included any self-reported psychosis, substance or alcohol abuse in the two years prior to illness onset or at any time afterward, or current or past depression with melancholic or psychotic features within the five years prior to illness onset or any time afterward;no;NA;no;NA
friedberg, 2016;cbt;tau;digital;tau;phs;msd;sf-36;follow up;48;self-report;37,75;45,77;20,24;20,26;46,5;44,07;23,27;23,28;41;46;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;friedberg_2016_msd_sf-36_followup_48.0_self-report_cbt_tau_digital_tau;0,103478629;0,214923283;NA;NA;primary;low;low;low;high;some concerns;high;NA;us;clinical;yes;candidates were offered up to $678 as compensation for full participation in the study;adults;yes;"friedberg f. chronic fatigue syndrome, fibromyalgia, and related illnesses: a clinical model of assessment and intervention. j clin psychol. 2010;6:641–665.";self-guided;individual;NA;no;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;48,01;50,03;12,43;11,28;38;42;80;0,86;45;48;93;41;48;89;41;48;89;(e.g. unable to access web diary, inability to begin treatment in a timely manner), fear of energy drain from doing study activities, or unknown reasons;NA;NA;combined;cfs/me;NA;NA;NA;NA;150,84;207,12;101,88;127,8;yes;exclusionary psychiatric disorders included any self-reported psychosis, substance or alcohol abuse in the two years prior to illness onset or at any time afterward, or current or past depression with melancholic or psychotic features within the five years prior to illness onset or any time afterward;no;NA;no;NA
friedberg, 2016;cbt;tau;pnp;tau;phs;msd;sf-36;follow up;48;self-report;37,75;45,77;20,24;20,26;45,75;44,07;23,27;23,28;40;46;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;friedberg_2016_msd_sf-36_followup_48.0_self-report_cbt_tau_pnp_tau;0,07153296;0,216262388;NA;NA;primary;low;low;low;high;some concerns;high;NA;us;clinical;yes;candidates were offered up to $678 as compensation for full participation in the study;adults;yes;"friedberg f. chronic fatigue syndrome, fibromyalgia, and related illnesses: a clinical model of assessment and intervention. j clin psychol. 2010;6:641–665.";self-guided;individual;NA;no;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;46,99;50,03;10,79;11,28;41;42;83;0,9;44;48;92;41;48;89;41;48;89;(e.g. unable to access web diary, inability to begin treatment in a timely manner), fear of energy drain from doing study activities, or unknown reasons;NA;NA;combined;cfs/me;NA;NA;NA;NA;164,52;207,12;83,76;127,8;yes;exclusionary psychiatric disorders included any self-reported psychosis, substance or alcohol abuse in the two years prior to illness onset or at any time afterward, or current or past depression with melancholic or psychotic features within the five years prior to illness onset or any time afterward;no;NA;no;NA
friesen, 2017;cbt;wl;NA;NA;som;msd;bpi;post;8;self-report;5,45;6,02;1,1;1,39;4,99;6,28;1,66;1,28;30;30;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;friesen_2017_msd_bpi_post_8.0_self-report_cbt_wl_NA_NA;-0,859008673;0,27014567;NA;NA;primary;low;low;low;high;some concerns;high;ISRCTN registry, ISRCTN85116527, https://www.isrctn.com/ISRCTN85116527, Evaluating a self-guided internet-based pain course for individuals with fibromyalgia and anxiety and/or depression, https://doi.org/10.1186/ISRCTN85116527;ca;combined;no;NA;adults;yes;pain course;para;individual;NA;internet;5;NA;NA;NA;8;NA;0,63;NA;NA;NA;NA;NA;NA;NA;NA;49;46;10;13;28;29;57;0,95;30;30;60;29;30;59;26;27;53;NA;NA;not a good time (n = 1);combined;fm;NA;NA;NA;NA;240;156;108;120;no;NA;yes;treatment satisfaction questionnaire (tsq);no;NA
friesen, 2017;cbt;wl;NA;NA;depr;msd;phq-9;post;8;self-report;14,07;14,07;4,66;4,93;10,13;14;5,3;5,44;30;30;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;friesen_2017_msd_phq-9_post_8.0_self-report_cbt_wl_NA_NA;-0,71125061;0,266446955;NA;NA;primary;low;low;low;high;some concerns;high;ISRCTN registry, ISRCTN85116527, https://www.isrctn.com/ISRCTN85116527, Evaluating a self-guided internet-based pain course for individuals with fibromyalgia and anxiety and/or depression, https://doi.org/10.1186/ISRCTN85116527;ca;combined;no;NA;adults;yes;pain course;para;individual;NA;internet;5;NA;NA;NA;8;NA;0,63;NA;NA;NA;NA;NA;NA;NA;NA;49;46;10;13;28;29;57;0,95;30;30;60;29;30;59;26;27;53;NA;NA;not a good time (n = 1);combined;fm;NA;NA;NA;NA;240;156;108;120;no;NA;yes;treatment satisfaction questionnaire (tsq);no;NA
friesen, 2017;cbt;wl;NA;NA;depr;msd;hads-d;post;8;self-report;9,9;9,97;3,77;3,82;7,97;10,17;3,55;3,42;30;30;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;friesen_2017_msd_hads-d_post_8.0_self-report_cbt_wl_NA_NA;-0,622970152;0,26454949;NA;NA;secondary;NA;NA;NA;NA;NA;NA;ISRCTN registry, ISRCTN85116527, https://www.isrctn.com/ISRCTN85116527, Evaluating a self-guided internet-based pain course for individuals with fibromyalgia and anxiety and/or depression, https://doi.org/10.1186/ISRCTN85116527;ca;combined;no;NA;adults;yes;pain course;para;individual;NA;internet;5;NA;NA;NA;8;NA;0,63;NA;NA;NA;NA;NA;NA;NA;NA;49;46;10;13;28;29;57;0,95;30;30;60;29;30;59;26;27;53;NA;NA;not a good time (n = 1);combined;fm;NA;NA;NA;NA;240;156;108;120;no;NA;yes;treatment satisfaction questionnaire (tsq);no;NA
friesen, 2017;cbt;wl;NA;NA;anx;msd;gad-7;post;8;self-report;10,87;9,93;4,65;4,88;7,83;9,98;5,7;5,15;30;30;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;friesen_2017_msd_gad-7_post_8.0_self-report_cbt_wl_NA_NA;-0,390664833;0,26071475;NA;NA;primary;low;low;low;high;some concerns;high;ISRCTN registry, ISRCTN85116527, https://www.isrctn.com/ISRCTN85116527, Evaluating a self-guided internet-based pain course for individuals with fibromyalgia and anxiety and/or depression, https://doi.org/10.1186/ISRCTN85116527;ca;combined;no;NA;adults;yes;pain course;para;individual;NA;internet;5;NA;NA;NA;8;NA;0,63;NA;NA;NA;NA;NA;NA;NA;NA;49;46;10;13;28;29;57;0,95;30;30;60;29;30;59;26;27;53;NA;NA;not a good time (n = 1);combined;fm;NA;NA;NA;NA;240;156;108;120;no;NA;yes;treatment satisfaction questionnaire (tsq);no;NA
friesen, 2017;cbt;wl;NA;NA;anx;msd;hads-a;post;8;self-report;11,6;10,17;4;3,98;9,22;10,43;4,33;4,69;30;30;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;friesen_2017_msd_hads-a_post_8.0_self-report_cbt_wl_NA_NA;-0,264597706;0,259356037;NA;NA;secondary;NA;NA;NA;NA;NA;NA;ISRCTN registry, ISRCTN85116527, https://www.isrctn.com/ISRCTN85116527, Evaluating a self-guided internet-based pain course for individuals with fibromyalgia and anxiety and/or depression, https://doi.org/10.1186/ISRCTN85116527;ca;combined;no;NA;adults;yes;pain course;para;individual;NA;internet;5;NA;NA;NA;8;NA;0,63;NA;NA;NA;NA;NA;NA;NA;NA;49;46;10;13;28;29;57;0,95;30;30;60;29;30;59;26;27;53;NA;NA;not a good time (n = 1);combined;fm;NA;NA;NA;NA;240;156;108;120;no;NA;yes;treatment satisfaction questionnaire (tsq);no;NA
friesen, 2017;cbt;wl;NA;NA;phs;msd;sf-12;post;8;self-report;30,81;32,17;7,82;7,35;34,7;32,82;7,94;8,2;30;30;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;friesen_2017_msd_sf-12_post_8.0_self-report_cbt_wl_NA_NA;0,229906282;0,259072979;NA;NA;primary;low;low;low;high;some concerns;high;ISRCTN registry, ISRCTN85116527, https://www.isrctn.com/ISRCTN85116527, Evaluating a self-guided internet-based pain course for individuals with fibromyalgia and anxiety and/or depression, https://doi.org/10.1186/ISRCTN85116527;ca;combined;no;NA;adults;yes;pain course;para;individual;NA;internet;5;NA;NA;NA;8;NA;0,63;NA;NA;NA;NA;NA;NA;NA;NA;49;46;10;13;28;29;57;0,95;30;30;60;29;30;59;26;27;53;NA;NA;not a good time (n = 1);combined;fm;NA;NA;NA;NA;240;156;108;120;no;NA;yes;treatment satisfaction questionnaire (tsq);no;NA
friesen, 2017;cbt;wl;NA;NA;phs;msd;fiq;post;8;self-report;-65,19;-67,75;13,07;13,51;-53,39;-64,59;18,94;12,75;30;30;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;friesen_2017_msd_fiq_post_8.0_self-report_cbt_wl_NA_NA;0,684727571;0,265851952;NA;NA;secondary;NA;NA;NA;NA;NA;NA;ISRCTN registry, ISRCTN85116527, https://www.isrctn.com/ISRCTN85116527, Evaluating a self-guided internet-based pain course for individuals with fibromyalgia and anxiety and/or depression, https://doi.org/10.1186/ISRCTN85116527;ca;combined;no;NA;adults;yes;pain course;para;individual;NA;internet;5;NA;NA;NA;8;NA;0,63;NA;NA;NA;NA;NA;NA;NA;NA;49;46;10;13;28;29;57;0,95;30;30;60;29;30;59;26;27;53;NA;NA;not a good time (n = 1);combined;fm;NA;NA;NA;NA;240;156;108;120;no;NA;yes;treatment satisfaction questionnaire (tsq);no;NA
gaylord, 2011;ambt;psy plac;NA;NA;som;msd;ibs-sss;post;8;self-report;284,06;287,54;84,34;109,9;204,03;250,74;110,95;117,09;33;31;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;gaylord_2011_msd_ibs-sss_post_8.0_self-report_ambt_psyplac_NA_NA;-0,40489424;0,252732188;NA;NA;primary;low;low;some concerns;high;low;high;NCT00680693 (Clinicaltrials.gov);us;combined;yes;"""study participants were remunerated for completing the assessments and for attending a minimum of six of the nine sessions.""";adults;yes;mbsr;para;group;NA;no;9;NA;1200;NA;8;NA;1,13;NA;133,33;NA;7,1;NA;2,05;NA;0,79;44,72;40,89;12,55;14,68;36;39;75;1;36;39;75;36;39;75;8;2;10;NA;NA;NA;combined;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;"diagnosis of mental illness with psychosis; (ii) a history of inpatient admission for psychiatric disorder within the past 2 years; (iii) a history or current diagnosis of inflammatory bowel disease or gastrointestinal malignancy; (iv) active liver or pancreatic disease; (v) uncontrolled lactose intolerance; (vi) celiac disease; (vii) a history of abdominal trauma or surgery involving gastrointestinal resection";no;NA;no;NA
gaylord, 2011;ambt;psy plac;NA;NA;som;msd;ibs-sss;follow up;56;self-report;284,06;287,54;84,34;109,9;201,5;252,32;109,13;107,13;24;22;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;gaylord_2011_msd_ibs-sss_followup_56.0_self-report_ambt_psyplac_NA_NA;-0,461719071;0,299198886;NA;NA;primary;low;low;some concerns;high;low;high;NCT00680693 (Clinicaltrials.gov);us;combined;yes;"""study participants were remunerated for completing the assessments and for attending a minimum of six of the nine sessions.""";adults;yes;mbsr;para;group;NA;no;9;NA;1200;NA;8;NA;1,13;NA;133,33;NA;7,1;NA;2,05;NA;0,79;44,72;40,89;12,55;14,68;36;39;75;1;36;39;75;36;39;75;8;2;10;NA;NA;NA;combined;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;"diagnosis of mental illness with psychosis; (ii) a history of inpatient admission for psychiatric disorder within the past 2 years; (iii) a history or current diagnosis of inflammatory bowel disease or gastrointestinal malignancy; (iv) active liver or pancreatic disease; (v) uncontrolled lactose intolerance; (vi) celiac disease; (vii) a history of abdominal trauma or surgery involving gastrointestinal resection";no;NA;no;NA
gaylord, 2011;ambt;psy plac;NA;NA;som;msd;bsi-18 somatization;post;8;self-report;57,37;56,71;8,94;8,86;55;56,42;7,86;9,49;33;31;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;gaylord_2011_msd_bsi-18somatization_post_8.0_self-report_ambt_psyplac_NA_NA;-0,161477543;0,25053911;NA;NA;secondary;NA;NA;NA;NA;NA;NA;NCT00680693 (Clinicaltrials.gov);us;combined;yes;"""study participants were remunerated for completing the assessments and for attending a minimum of six of the nine sessions.""";adults;yes;mbsr;para;group;NA;no;9;NA;1200;NA;8;NA;1,13;NA;133,33;NA;7,1;NA;2,05;NA;0,79;44,72;40,89;12,55;14,68;36;39;75;1;36;39;75;36;39;NA;8;2;NA;NA;NA;NA;combined;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;"diagnosis of mental illness with psychosis; (ii) a history of inpatient admission for psychiatric disorder within the past 2 years; (iii) a history or current diagnosis of inflammatory bowel disease or gastrointestinal malignancy; (iv) active liver or pancreatic disease; (v) uncontrolled lactose intolerance; (vi) celiac disease; (vii) a history of abdominal trauma or surgery involving gastrointestinal resection";no;NA;no;NA
gaylord, 2011;ambt;psy plac;NA;NA;depr;msd;bsi-18 depression;post;8;self-report;55,11;54,78;10,55;11,3;53,62;54;9,75;12,66;36;39;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;gaylord_2011_msd_bsi-18depression_post_8.0_self-report_ambt_psyplac_NA_NA;-0,033111055;0,231141224;NA;NA;primary;low;low;some concerns;high;low;high;NCT00680693 (Clinicaltrials.gov);us;combined;yes;"""study participants were remunerated for completing the assessments and for attending a minimum of six of the nine sessions.""";adults;yes;mbsr;para;group;NA;no;9;NA;1200;NA;8;NA;1,13;NA;133,33;NA;7,1;NA;2,05;NA;0,79;44,72;40,89;12,55;14,68;36;39;75;1;36;39;75;36;39;75;8;2;10;NA;NA;NA;combined;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;"diagnosis of mental illness with psychosis; (ii) a history of inpatient admission for psychiatric disorder within the past 2 years; (iii) a history or current diagnosis of inflammatory bowel disease or gastrointestinal malignancy; (iv) active liver or pancreatic disease; (v) uncontrolled lactose intolerance; (vi) celiac disease; (vii) a history of abdominal trauma or surgery involving gastrointestinal resection";no;NA;no;NA
gaylord, 2011;ambt;psy plac;NA;NA;anx;msd;bsi-18 anxiety;post;8;self-report;55;54,84;9,84;10,6;51,14;53,2;8,82;10,15;36;39;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;gaylord_2011_msd_bsi-18anxiety_post_8.0_self-report_ambt_psyplac_NA_NA;-0,213807517;0,231797203;NA;NA;primary;low;low;some concerns;high;low;high;NCT00680693 (Clinicaltrials.gov);us;combined;yes;"""study participants were remunerated for completing the assessments and for attending a minimum of six of the nine sessions.""";adults;yes;mbsr;para;group;NA;no;9;NA;1200;NA;8;NA;1,13;NA;133,33;NA;7,1;NA;2,05;NA;0,79;44,72;40,89;12,55;14,68;36;39;75;1;36;39;75;36;39;75;8;2;10;NA;NA;NA;combined;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;"diagnosis of mental illness with psychosis; (ii) a history of inpatient admission for psychiatric disorder within the past 2 years; (iii) a history or current diagnosis of inflammatory bowel disease or gastrointestinal malignancy; (iv) active liver or pancreatic disease; (v) uncontrolled lactose intolerance; (vi) celiac disease; (vii) a history of abdominal trauma or surgery involving gastrointestinal resection";no;NA;no;NA
gaylord, 2011;ambt;psy plac;NA;NA;phs;msd;ibs-qol;post;8;self-report;64,8;67,22;19,8;20,73;74,99;70,92;15,14;17,4;36;39;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;gaylord_2011_msd_ibs-qol_post_8.0_self-report_ambt_psyplac_NA_NA;0,246281211;0,232016453;NA;NA;primary;low;low;some concerns;high;some concerns;high;NCT00680693 (Clinicaltrials.gov);us;combined;yes;"""study participants were remunerated for completing the assessments and for attending a minimum of six of the nine sessions.""";adults;yes;mbsr;para;group;NA;no;9;NA;1200;NA;8;NA;1,13;NA;133,33;NA;7,1;NA;2,05;NA;0,79;44,72;40,89;12,55;14,68;36;39;75;1;36;39;75;36;39;75;8;2;10;NA;NA;NA;combined;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;"diagnosis of mental illness with psychosis; (ii) a history of inpatient admission for psychiatric disorder within the past 2 years; (iii) a history or current diagnosis of inflammatory bowel disease or gastrointestinal malignancy; (iv) active liver or pancreatic disease; (v) uncontrolled lactose intolerance; (vi) celiac disease; (vii) a history of abdominal trauma or surgery involving gastrointestinal resection";no;NA;no;NA
ghandi, 2018;ambt;tau;NA;NA;som;msd;ibs-sss;post;8;self-report;29,37;26,25;4,749;9,85;10,87;20,12;3,09;10,43;8;8;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;ghandi_2018_msd_ibs-sss_post_8.0_self-report_ambt_tau_NA_NA;-1,136958066;0,543315368;NA;NA;primary;some concerns;high;high;high;some concerns;high;NA;ir;clinical;no;NA;adults;yes;mbsr;psy;group;NA;no;8;NA;720;NA;8;NA;1;NA;90;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;15;19;34;NA;NA;NA;NA;10;NA;NA;NA;NA;clinical interview;ibs;NA;NA;NA;NA;NA;NA;NA;NA;no;NA;no;NA;no;NA
ghandi, 2018;ambt;tau;NA;NA;som;msd;ibs-sss;follow up;56;self-report;29,37;26,25;4,749;9,85;9,37;24,75;4,68;8,46;8;8;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;ghandi_2018_msd_ibs-sss_followup_56.0_self-report_ambt_tau_NA_NA;-2,126995512;0,638875493;NA;NA;primary;some concerns;high;high;high;some concerns;high;NA;ir;clinical;no;NA;adults;yes;mbsr;psy;group;NA;no;8;NA;720;NA;8;NA;1;NA;90;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;15;19;34;NA;NA;NA;NA;10;NA;NA;NA;NA;clinical interview;ibs;NA;NA;NA;NA;NA;NA;NA;NA;no;NA;no;NA;no;NA
ghandi, 2018;ambt;tau;NA;NA;phs;msd;ibs-qol;post;8;self-report;74,5;20,94;75,25;29,85;55,62;65;11,1;25,65;8;8;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;ghandi_2018_msd_ibs-qol_post_8.0_self-report_ambt_tau_NA_NA;-0,448741398;0,506990938;NA;NA;primary;some concerns;high;high;high;some concerns;high;NA;ir;clinical;no;NA;adults;yes;mbsr;psy;group;NA;no;8;NA;720;NA;8;NA;1;NA;90;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;15;19;34;NA;NA;NA;NA;10;NA;NA;NA;NA;clinical interview;ibs;NA;NA;NA;NA;NA;NA;NA;NA;no;NA;no;NA;no;NA
ghandi, 2018;ambt;tau;NA;NA;phs;msd;ibs-qol;follow up;56;self-report;74,5;20,94;75,25;29,85;52,87;74,5;16,14;32,09;8;8;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;ghandi_2018_msd_ibs-qol_followup_56.0_self-report_ambt_tau_NA_NA;-0,805141586;0,52217122;NA;NA;primary;some concerns;high;high;high;some concerns;high;NA;ir;clinical;no;NA;adults;yes;mbsr;psy;group;NA;no;8;NA;720;NA;8;NA;1;NA;90;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;15;19;34;NA;NA;NA;NA;10;NA;NA;NA;NA;clinical interview;ibs;NA;NA;NA;NA;NA;NA;NA;NA;no;NA;no;NA;no;NA
gotaas, 2021;cbt;wl;NA;NA;som;msd;cfq;post;8;self-report;25,3;25,8;5,15;5,25;18,7;24,1;7,39;7,07;76;80;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;gotaas_2021_msd_cfq_post_8.0_self-report_cbt_wl_NA_NA;-0,743489956;0,16567145;NA;NA;primary;low;low;low;high;some concerns;high;clinicaltrials.gov, identifier: nct00920777;no;combined;no;NA;adults;yes;cbt manual;psy;individual;NA;no;17;NA;NA;NA;17;NA;1;NA;NA;NA;NA;NA;NA;NA;NA;37;32;11;10;69;67;136;0,86;78;80;158;77;80;157;59;72;131;NA;NA;to fatigue (n = 3), poor economy (n = 2), psychosocial strain (n = 2), long distance to treatment centre (n = 2), lack of motivation for the treatment (n = 4), change of therapist (n = 1), current infection (n = 1), and need of further psychiatric evaluation (n = 1).;combined;cfs/me;NA;NA;NA;NA;63,6;55,2;NA;NA;yes;patients who did not meet the cdc 1994 criteria or were pregnant, younger than 18 years or older than 62 years were excluded. patients who were unable to attend hospital outpatient appointments or did not speak fluent norwegian were also excluded;no;NA;no;NA
gotaas, 2021;cbt;wl;NA;NA;phs;msd;sf-36;post;8;self-report;54;54,8;19,7;19,62;71,2;57,9;21,93;21,22;76;80;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;gotaas_2021_msd_sf-36_post_8.0_self-report_cbt_wl_NA_NA;0,613626348;0,163940861;NA;NA;primary;low;low;low;high;some concerns;high;clinicaltrials.gov, identifier: nct00920777;no;combined;no;NA;adults;yes;cbt manual;psy;individual;NA;no;17;NA;NA;NA;17;NA;1;NA;NA;NA;NA;NA;NA;NA;NA;37;32;11;10;69;67;136;0,86;78;80;158;77;80;157;59;72;131;NA;NA;to fatigue (n = 3), poor economy (n = 2), psychosocial strain (n = 2), long distance to treatment centre (n = 2), lack of motivation for the treatment (n = 4), change of therapist (n = 1), current infection (n = 1), and need of further psychiatric evaluation (n = 1).;combined;cfs/me;NA;NA;NA;NA;63,6;55,2;NA;NA;yes;patients who did not meet the cdc 1994 criteria or were pregnant, younger than 18 years or older than 62 years were excluded. patients who were unable to attend hospital outpatient appointments or did not speak fluent norwegian were also excluded;no;NA;no;NA
greene, 1994;cbt;att plac;NA;NA;som;msd;gi symptoms;post;16;self-report;126,7;89,9;65,1;84,9;52,8;76,1;38,1;61,1;10;10;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;greene_1994_msd_gisymptoms_post_16.0_self-report_cbt_attplac_NA_NA;-0,438283015;0,453029115;NA;NA;primary;low;high;low;high;some concerns;high;NA;us;combined;no;NA;adults;no;intensive cognitive therapy;psy;individual;NA;no;10;NA;600;NA;8;NA;1,25;0;60;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;10;10;20;10;10;20;NA;NA;NA;NA;NA;NA;clinical interview;IBS;NA;NA;NA;NA;NA;NA;NA;NA;yes;NA;no;NA;no;NA
greene, 1994;cbt;att plac;NA;NA;depr;msd;bdi;post;16;self-report;10,6;11,8;7,9;3,8;5,1;9,5;3,1;5,5;10;10;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;greene_1994_msd_bdi_post_16.0_self-report_cbt_attplac_NA_NA;-0,943951305;0,47358737;NA;NA;primary;low;high;low;high;some concerns;high;NA;us;combined;no;NA;adults;no;intensive cognitive therapy;psy;individual;NA;no;10;NA;600;NA;8;NA;1,25;0;60;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;10;10;20;10;10;20;NA;NA;NA;NA;NA;NA;clinical interview;IBS;NA;NA;NA;NA;NA;NA;NA;NA;yes;NA;no;NA;no;NA
greene, 1994;cbt;att plac;NA;NA;anx;msd;stai state;post;16;self-report;41,1;39,1;6,4;3,2;38,4;38,5;4,7;4,7;10;10;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;greene_1994_msd_staistate_post_16.0_self-report_cbt_attplac_NA_NA;-0,020377585;0,447226248;NA;NA;primary;low;high;low;high;some concerns;high;NA;us;combined;no;NA;adults;no;intensive cognitive therapy;psy;individual;NA;no;10;NA;600;NA;8;NA;1,25;0;60;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;10;10;20;10;10;20;NA;NA;NA;NA;NA;NA;clinical interview;IBS;NA;NA;NA;NA;NA;NA;NA;NA;yes;NA;no;NA;no;NA
haghayegh, 2011;cbt;wl;NA;NA;depr;msd;bdi;post;8;self-report;31,58;32,08;8,07;8,92;26,32;30,83;7,66;8,58;16;16;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;haghayegh_2011_msd_bdi_post_8.0_self-report_cbt_wl_NA_NA;-0,540549881;0,360284243;NA;NA;primary;some concerns;high;low;high;some concerns;high;NA;ir;clinical;no;NA;adults;yes;Albany Cognitive-Behavioral Treatment Manual;psy;group;NA;no;8;NA;NA;NA;8;NA;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;6;5;11;0,34;16;16;32;NA;16;NA;NA;NA;NA;NA;NA;NA;clinical interview;IBS;NA;NA;NA;NA;NA;NA;NA;NA;no;NA;no;NA;no;NA
haghayegh, 2011;cbt;wl;NA;NA;depr;msd;bdi;follow up;16;self-report;31,58;32,08;8,07;8,92;27,75;32,11;8,52;8,16;16;16;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;haghayegh_2011_msd_bdi_followup_16.0_self-report_cbt_wl_NA_NA;-0,509483753;0,359539061;NA;NA;primary;some concerns;high;low;high;some concerns;high;NA;ir;clinical;no;NA;adults;yes;Albany Cognitive-Behavioral Treatment Manual;psy;group;NA;no;8;NA;NA;NA;8;NA;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;6;5;11;0,34;16;16;32;NA;16;NA;NA;NA;NA;NA;NA;NA;clinical interview;IBS;NA;NA;NA;NA;NA;NA;NA;NA;no;NA;no;NA;no;NA
haghayegh, 2011;cbt;wl;NA;NA;ha;msd;ibs-qol health concern;post;8;self-report;9,66;10,08;1,87;2,6;7,58;9,58;1,37;2,15;16;16;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;haghayegh_2011_msd_ibs-qolhealthconcern_post_8.0_self-report_cbt_wl_NA_NA;-1,081482231;0,3797796;NA;NA;primary;some concerns;high;low;high;some concerns;high;NA;ir;clinical;no;NA;adults;yes;Albany Cognitive-Behavioral Treatment Manual;psy;group;NA;no;8;NA;NA;NA;8;NA;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;6;5;11;0,34;16;16;32;NA;16;NA;NA;NA;NA;NA;NA;NA;clinical interview;IBS;NA;NA;NA;NA;NA;NA;NA;NA;no;NA;no;NA;no;NA
haghayegh, 2011;cbt;wl;NA;NA;ha;msd;ibs-qol health concern;follow up;16;self-report;9,66;10,08;1,87;2,6;7,75;9,41;1,05;1,97;16;16;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;haghayegh_2011_msd_ibs-qolhealthconcern_followup_16.0_self-report_cbt_wl_NA_NA;-1,025111817;0,377200039;NA;NA;primary;some concerns;high;low;high;some concerns;high;NA;ir;clinical;no;NA;adults;yes;Albany Cognitive-Behavioral Treatment Manual;psy;group;NA;no;8;NA;NA;NA;8;NA;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;6;5;11;0,34;16;16;32;NA;16;NA;NA;NA;NA;NA;NA;NA;clinical interview;IBS;NA;NA;NA;NA;NA;NA;NA;NA;no;NA;no;NA;no;NA
haghayegh, 2011;cbt;wl;NA;NA;phs;msd;ibs-qol;post;8;self-report;102,91;105,41;14,39;18,57;90,58;103,33;14,8;16,89;16;16;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;haghayegh_2011_msd_ibs-qol_post_8.0_self-report_cbt_wl_NA_NA;-0,782684109;0,367523172;NA;NA;primary;some concerns;high;low;high;some concerns;high;NA;ir;clinical;no;NA;adults;yes;Albany Cognitive-Behavioral Treatment Manual;psy;group;NA;no;8;NA;NA;NA;8;NA;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;6;5;11;0,34;16;16;32;NA;16;NA;NA;NA;NA;NA;NA;NA;clinical interview;IBS;NA;NA;NA;NA;NA;NA;NA;NA;no;NA;no;NA;no;NA
haghayegh, 2011;cbt;wl;NA;NA;phs;msd;ibs-qol;follow up;16;self-report;102,91;105,41;14,39;18,57;94,75;101,16;11,97;12,3;16;16;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;haghayegh_2011_msd_ibs-qol_followup_16.0_self-report_cbt_wl_NA_NA;-0,514859979;0,359664974;NA;NA;primary;some concerns;high;low;high;some concerns;high;NA;ir;clinical;no;NA;adults;yes;Albany Cognitive-Behavioral Treatment Manual;psy;group;NA;no;8;NA;NA;NA;8;NA;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;6;5;11;0,34;16;16;32;NA;16;NA;NA;NA;NA;NA;NA;NA;clinical interview;IBS;NA;NA;NA;NA;NA;NA;NA;NA;no;NA;no;NA;no;NA
henrich, 2020;ambt;wl;NA;NA;som;msd;gsrs-ibs;post;7;self-report;45,65;43;11,3;12,6;39,52;43,95;12,02;14,36;36;31;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;henrich_2020_msd_gsrs-ibs_post_7.0_self-report_ambt_wl_NA_NA;-0,332933526;0,246743881;NA;NA;primary;low;low;low;high;low;high;NCT02794376 (ClinicalTrials.gov);GB;combined;no;NA;adults;yes;mbct-ibs;psy;group;NA;no;6;NA;720;NA;7;NA;0,86;NA;120;NA;NA;NA;NA;NA;0;35,58;35,48;13,73;14,71;36;31;67;1;36;31;67;NA;NA;NA;NA;25;NA;NA;NA;NA;combined;ibs;NA;NA;NA;NA;162,89;144,71;155,71;136,52;yes;"“severe DSM Axis I or II psychiatric disorder (diagnosis of dementia, amnesia, delirium, a dissociative disorder, a personality disorder, schizophrenia or any other psychotic disorder, a substance-related or induced disorder, attention deficit hyperactivity disorder, attention deficit disorder, a primary diagnosis of obsessive compulsive disorder, current suicidality, regular non-suicidal self-injury; […] GI diagnosis other than IBS (e.g. inflammatory bowel disease, coeliac disease, another functional GI disorder)”";no;NA;no;NA
henrich, 2020;ambt;wl;NA;NA;som;msd;gsrs-ibs;follow up;13;self-report;45,65;43;11,3;12,6;32,83;43,1;13,7;9,69;36;31;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;henrich_2020_msd_gsrs-ibs_followup_13.0_self-report_ambt_wl_NA_NA;-0,844746274;0,255903755;NA;NA;primary;low;low;low;high;low;high;NCT02794376 (ClinicalTrials.gov);GB;combined;no;NA;adults;yes;mbct-ibs;psy;group;NA;no;6;NA;720;NA;7;NA;0,86;NA;120;NA;NA;NA;NA;NA;0;35,58;35,48;13,73;14,71;36;31;67;1;36;31;67;NA;NA;NA;NA;25;NA;NA;NA;NA;combined;ibs;NA;NA;NA;NA;162,89;144,71;155,71;136,52;yes;"“severe DSM Axis I or II psychiatric disorder (diagnosis of dementia, amnesia, delirium, a dissociative disorder, a personality disorder, schizophrenia or any other psychotic disorder, a substance-related or induced disorder, attention deficit hyperactivity disorder, attention deficit disorder, a primary diagnosis of obsessive compulsive disorder, current suicidality, regular non-suicidal self-injury; […] GI diagnosis other than IBS (e.g. inflammatory bowel disease, coeliac disease, another functional GI disorder)”";no;NA;no;NA
henrich, 2020;ambt;wl;NA;NA;depr;msd;dass-21 depression subscale;post;7;self-report;16,35;12,48;11,11;11,08;9,22;11,9;9,1;12,97;36;31;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;henrich_2020_msd_dass-21depressionsubscale_post_7.0_self-report_ambt_wl_NA_NA;-0,239599193;0,245915348;NA;NA;primary;low;low;low;high;low;high;NCT02794376 (ClinicalTrials.gov);GB;combined;no;NA;adults;yes;mbct-ibs;psy;group;NA;no;6;NA;720;NA;7;NA;0,86;NA;120;NA;NA;NA;NA;NA;0;35,58;35,48;13,73;14,71;36;31;67;1;36;31;67;NA;NA;NA;NA;25;NA;NA;NA;NA;combined;ibs;NA;NA;NA;NA;162,89;144,71;155,71;136,52;yes;"“severe DSM Axis I or II psychiatric disorder (diagnosis of dementia, amnesia, delirium, a dissociative disorder, a personality disorder, schizophrenia or any other psychotic disorder, a substance-related or induced disorder, attention deficit hyperactivity disorder, attention deficit disorder, a primary diagnosis of obsessive compulsive disorder, current suicidality, regular non-suicidal self-injury; […] GI diagnosis other than IBS (e.g. inflammatory bowel disease, coeliac disease, another functional GI disorder)”";no;NA;no;NA
henrich, 2020;ambt;wl;NA;NA;depr;msd;dass-21 depression subscale;follow up;13;self-report;16,35;12,48;11,11;11,08;9,3;11,14;10,53;10,73;36;31;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;henrich_2020_msd_dass-21depressionsubscale_followup_13.0_self-report_ambt_wl_NA_NA;-0,171206408;0,245478599;NA;NA;primary;low;low;low;high;low;high;NCT02794376 (ClinicalTrials.gov);GB;combined;no;NA;adults;yes;mbct-ibs;psy;group;NA;no;6;NA;720;NA;7;NA;0,86;NA;120;NA;NA;NA;NA;NA;0;35,58;35,48;13,73;14,71;36;31;67;1;36;31;67;NA;NA;NA;NA;25;NA;NA;NA;NA;combined;ibs;NA;NA;NA;NA;162,89;144,71;155,71;136,52;yes;"“severe DSM Axis I or II psychiatric disorder (diagnosis of dementia, amnesia, delirium, a dissociative disorder, a personality disorder, schizophrenia or any other psychotic disorder, a substance-related or induced disorder, attention deficit hyperactivity disorder, attention deficit disorder, a primary diagnosis of obsessive compulsive disorder, current suicidality, regular non-suicidal self-injury; […] GI diagnosis other than IBS (e.g. inflammatory bowel disease, coeliac disease, another functional GI disorder)”";no;NA;no;NA
henrich, 2020;ambt;wl;NA;NA;anx;msd;dass-21 anxiety subscale;post;7;self-report;14,78;9,52;10,18;5,4;8,61;9,62;8,93;7,17;36;31;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;henrich_2020_msd_dass-21anxietysubscale_post_7.0_self-report_ambt_wl_NA_NA;-0,122266349;0,245255036;NA;NA;primary;low;low;low;high;low;high;NCT02794376 (ClinicalTrials.gov);GB;combined;no;NA;adults;yes;mbct-ibs;psy;group;NA;no;6;NA;720;NA;7;NA;0,86;NA;120;NA;NA;NA;NA;NA;0;35,58;35,48;13,73;14,71;36;31;67;1;36;31;67;NA;NA;NA;NA;25;NA;NA;NA;NA;combined;ibs;NA;NA;NA;NA;162,89;144,71;155,71;136,52;yes;"“severe DSM Axis I or II psychiatric disorder (diagnosis of dementia, amnesia, delirium, a dissociative disorder, a personality disorder, schizophrenia or any other psychotic disorder, a substance-related or induced disorder, attention deficit hyperactivity disorder, attention deficit disorder, a primary diagnosis of obsessive compulsive disorder, current suicidality, regular non-suicidal self-injury; […] GI diagnosis other than IBS (e.g. inflammatory bowel disease, coeliac disease, another functional GI disorder)”";no;NA;no;NA
henrich, 2020;ambt;wl;NA;NA;anx;msd;dass-21 anxiety subscale;follow up;13;self-report;14,78;9,52;10,18;5,4;9,04;9,05;8,5;7,03;36;31;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;henrich_2020_msd_dass-21anxietysubscale_followup_13.0_self-report_ambt_wl_NA_NA;-0,001258201;0,245022151;NA;NA;primary;low;low;low;high;low;high;NCT02794376 (ClinicalTrials.gov);GB;combined;no;NA;adults;yes;mbct-ibs;psy;group;NA;no;6;NA;720;NA;7;NA;0,86;NA;120;NA;NA;NA;NA;NA;0;35,58;35,48;13,73;14,71;36;31;67;1;36;31;67;NA;NA;NA;NA;25;NA;NA;NA;NA;combined;ibs;NA;NA;NA;NA;162,89;144,71;155,71;136,52;yes;"“severe DSM Axis I or II psychiatric disorder (diagnosis of dementia, amnesia, delirium, a dissociative disorder, a personality disorder, schizophrenia or any other psychotic disorder, a substance-related or induced disorder, attention deficit hyperactivity disorder, attention deficit disorder, a primary diagnosis of obsessive compulsive disorder, current suicidality, regular non-suicidal self-injury; […] GI diagnosis other than IBS (e.g. inflammatory bowel disease, coeliac disease, another functional GI disorder)”";no;NA;no;NA
henrich, 2020;ambt;wl;NA;NA;phs;msd;ibs-qol;post;7;self-report;51,31;61,83;20,55;16,9;67,42;63,41;20,31;21,48;36;31;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;henrich_2020_msd_ibs-qol_post_7.0_self-report_ambt_wl_NA_NA;0,190024084;0,245584336;NA;NA;primary;some concerns;low;low;high;low;high;NCT02794376 (ClinicalTrials.gov);GB;combined;no;NA;adults;yes;mbct-ibs;psy;group;NA;no;6;NA;720;NA;7;NA;0,86;NA;120;NA;NA;NA;NA;NA;0;35,58;35,48;13,73;14,71;36;31;67;1;36;31;67;NA;NA;NA;NA;25;NA;NA;NA;NA;combined;ibs;NA;NA;NA;NA;162,89;144,71;155,71;136,52;yes;"“severe DSM Axis I or II psychiatric disorder (diagnosis of dementia, amnesia, delirium, a dissociative disorder, a personality disorder, schizophrenia or any other psychotic disorder, a substance-related or induced disorder, attention deficit hyperactivity disorder, attention deficit disorder, a primary diagnosis of obsessive compulsive disorder, current suicidality, regular non-suicidal self-injury; […] GI diagnosis other than IBS (e.g. inflammatory bowel disease, coeliac disease, another functional GI disorder)”";no;NA;no;NA
henrich, 2020;ambt;wl;NA;NA;phs;msd;ibs-qol;follow up;13;self-report;51,31;61,83;20,55;16,9;71,52;60,96;19,38;22,1;36;31;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;henrich_2020_msd_ibs-qol_followup_13.0_self-report_ambt_wl_NA_NA;0,50472631;0,248961382;NA;NA;primary;some concerns;low;low;high;low;high;NCT02794376 (ClinicalTrials.gov);GB;combined;no;NA;adults;yes;mbct-ibs;psy;group;NA;no;6;NA;720;NA;7;NA;0,86;NA;120;NA;NA;NA;NA;NA;0;35,58;35,48;13,73;14,71;36;31;67;1;36;31;67;NA;NA;NA;NA;25;NA;NA;NA;NA;combined;ibs;NA;NA;NA;NA;162,89;144,71;155,71;136,52;yes;"“severe DSM Axis I or II psychiatric disorder (diagnosis of dementia, amnesia, delirium, a dissociative disorder, a personality disorder, schizophrenia or any other psychotic disorder, a substance-related or induced disorder, attention deficit hyperactivity disorder, attention deficit disorder, a primary diagnosis of obsessive compulsive disorder, current suicidality, regular non-suicidal self-injury; […] GI diagnosis other than IBS (e.g. inflammatory bowel disease, coeliac disease, another functional GI disorder)”";no;NA;no;NA
huibers, 2004;cbt;tau;NA;NA;som;msd;cis;post;16;self-report;48,8;48,5;5,3;7,1;38,2;39,8;12,7;13,7;74;72;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;huibers_2004_msd_cis_post_16.0_self-report_cbt_tau_NA_NA;-0,120556649;0,165688562;NA;NA;primary;low;low;low;high;some concerns;high;NA;nl;other;no;NA;workers;yes;NA;gp;individual;NA;no;6;NA;180;NA;16;NA;0,38;NA;30;NA;5,3;NA;1,9;NA;0,88;43,6;43,3;8,9;7,7;39;44;83;0,55;76;75;151;71;75;146;NA;NA;NA;NA;NA;"too busy/work resumption; not satisfied; psychiatric complications; unknown reason";cut-off;cfs/me;NA;NA;NA;NA;27,9;26,9;31,4;27,6;yes;perviously classified psychiatric disorder;no;NA;no;NA
huibers, 2004;cbt;tau;NA;NA;som;msd;cis;follow up;72;self-report;48,8;48,5;5,3;7,1;35,5;33,9;12,9;13,8;70;68;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;huibers_2004_msd_cis_followup_72.0_self-report_cbt_tau_NA_NA;0,119179403;0,170421926;NA;NA;primary;low;low;low;high;some concerns;high;NA;nl;other;no;NA;workers;yes;NA;gp;individual;NA;no;6;NA;180;NA;16;NA;0,38;NA;30;NA;5,3;NA;1,9;NA;0,88;43,6;43,3;8,9;7,7;39;44;83;0,55;76;75;151;71;75;146;NA;NA;NA;NA;NA;"too busy/work resumption; not satisfied; psychiatric complications; unknown reason";cut-off;cfs/me;NA;NA;NA;NA;27,9;26,9;31,4;27,6;yes;perviously classified psychiatric disorder;no;NA;no;NA
huibers, 2004;cbt;tau;NA;NA;phs;msd;sf-36;post;16;self-report;56,8;67,1;25;22;65,2;72,5;25,8;19,1;74;72;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;huibers_2004_msd_sf-36_post_16.0_self-report_cbt_tau_NA_NA;-0,319281597;0,166598878;NA;NA;primary;low;low;low;high;some concerns;high;NA;nl;other;no;NA;workers;yes;NA;gp;individual;NA;no;6;NA;180;NA;16;NA;0,38;NA;30;NA;5,3;NA;1,9;NA;0,88;43,6;43,3;8,9;7,7;39;44;83;0,55;76;75;151;71;75;146;NA;NA;NA;NA;NA;"too busy/work resumption; not satisfied; psychiatric complications; unknown reason";cut-off;cfs/me;NA;NA;NA;NA;27,9;26,9;31,4;27,6;yes;perviously classified psychiatric disorder;no;NA;no;NA
huibers, 2004;cbt;tau;NA;NA;phs;msd;sf-36;follow up;72;self-report;56,8;67,1;25;22;70,1;77,4;24,7;20,9;70;68;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;huibers_2004_msd_sf-36_followup_72.0_self-report_cbt_tau_NA_NA;-0,31692119;0,171346319;NA;NA;primary;low;low;low;high;some concerns;high;NA;nl;other;no;NA;workers;yes;NA;gp;individual;NA;no;6;NA;180;NA;16;NA;0,38;NA;30;NA;5,3;NA;1,9;NA;0,88;43,6;43,3;8,9;7,7;39;44;83;0,55;76;75;151;71;75;146;NA;NA;NA;NA;NA;"too busy/work resumption; not satisfied; psychiatric complications; unknown reason";cut-off;cfs/me;NA;NA;NA;NA;27,9;26,9;31,4;27,6;yes;perviously classified psychiatric disorder;no;NA;no;NA
hunt, 2021;cbt;wl;NA;NA;som;msd;gsrs-ibs;post;8;self-report;40,19;38,73;11,13;11,62;28,25;39,25;10,97;10,54;24;36;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;hunt_2021_msd_gsrs-ibs_post_8.0_self-report_cbt_wl_NA_NA;-1,013494436;0,279697947;NA;NA;primary;low;low;low;high;some concerns;high;ClinicalTrials.gov / NCT04170686;us;community;yes;upon completion of each round of questionnaires, participants received us $20 in amazon credit;adults;yes;"Zemedy :Hunt M. Reclaim your life from IBS: A scientifically proven plan for relief without restrictive diets. New York: Sterling; Apr 05, 2016.";no guidance;individual;NA;app;10;NA;NA;NA;8;NA;1,25;NA;0;0;3,3;NA;2;NA;0,33;NA;NA;NA;NA;36;34;70;0,77;43;48;91;42;48;90;NA;NA;NA;NA;NA;NA;cut-off;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;exclusion criteria consisted of reporting having received a diagnosis of another comorbid GI disorder such as celiac disease or an inflammatory bowel disease. Exclusion criteria also included severe depression and/or suicidal ideation, defined as a score of 20 or above on the Patient Health Questionnaire-9 (PHQ-9), and/or positive endorsement of active suicidal ideation or intent on a separate suicide question. Twenty-five individuals met this criterion. They were excluded from the trial, but were given immediate access to the app.;no;NA;no;NA
hunt, 2021;cbt;wl;NA;NA;depr;msd;dass-21 depression subscale;post;8;self-report;11,4;16,17;9,61;10,55;6,25;16,72;6,55;10,09;24;36;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;hunt_2021_msd_dass-21depressionsubscale_post_8.0_self-report_cbt_wl_NA_NA;-1,166744844;0,284761392;NA;NA;primary;low;low;low;high;some concerns;high;ClinicalTrials.gov / NCT04170686;us;community;yes;upon completion of each round of questionnaires, participants received us $20 in amazon credit;adults;yes;"Zemedy :Hunt M. Reclaim your life from IBS: A scientifically proven plan for relief without restrictive diets. New York: Sterling; Apr 05, 2016.";no guidance;individual;NA;app;10;NA;NA;NA;8;NA;1,25;NA;0;0;3,3;NA;2;NA;0,33;NA;NA;NA;NA;36;34;70;0,77;43;48;91;42;48;90;NA;NA;NA;NA;NA;NA;cut-off;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;exclusion criteria consisted of reporting having received a diagnosis of another comorbid GI disorder such as celiac disease or an inflammatory bowel disease. Exclusion criteria also included severe depression and/or suicidal ideation, defined as a score of 20 or above on the Patient Health Questionnaire-9 (PHQ-9), and/or positive endorsement of active suicidal ideation or intent on a separate suicide question. Twenty-five individuals met this criterion. They were excluded from the trial, but were given immediate access to the app.;no;NA;no;NA
hunt, 2021;cbt;wl;NA;NA;anx;msd;dass-21 anxiety subscale;post;8;self-report;12,84;13,33;7,08;8,29;7,75;12,39;5,29;9,14;24;36;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;hunt_2021_msd_dass-21anxietysubscale_post_8.0_self-report_cbt_wl_NA_NA;-0,583944561;0,269000574;NA;NA;primary;low;low;low;high;some concerns;high;ClinicalTrials.gov / NCT04170686;us;community;yes;upon completion of each round of questionnaires, participants received us $20 in amazon credit;adults;yes;"Zemedy :Hunt M. Reclaim your life from IBS: A scientifically proven plan for relief without restrictive diets. New York: Sterling; Apr 05, 2016.";no guidance;individual;NA;app;10;NA;NA;NA;8;NA;1,25;NA;0;0;3,3;NA;2;NA;0,33;NA;NA;NA;NA;36;34;70;0,77;43;48;91;42;48;90;NA;NA;NA;NA;NA;NA;cut-off;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;exclusion criteria consisted of reporting having received a diagnosis of another comorbid GI disorder such as celiac disease or an inflammatory bowel disease. Exclusion criteria also included severe depression and/or suicidal ideation, defined as a score of 20 or above on the Patient Health Questionnaire-9 (PHQ-9), and/or positive endorsement of active suicidal ideation or intent on a separate suicide question. Twenty-five individuals met this criterion. They were excluded from the trial, but were given immediate access to the app.;no;NA;no;NA
hunt, 2021;cbt;wl;NA;NA;phs;msd;ibs-qol;post;8;self-report;-53,49;-59,53;19,42;18,49;-28,74;-60,52;16,61;17,92;24;36;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;hunt_2021_msd_ibs-qol_post_8.0_self-report_cbt_wl_NA_NA;1,801441996;0,311775671;NA;NA;primary;low;low;low;high;some concerns;high;ClinicalTrials.gov / NCT04170686;us;community;yes;upon completion of each round of questionnaires, participants received us $20 in amazon credit;adults;yes;"Zemedy :Hunt M. Reclaim your life from IBS: A scientifically proven plan for relief without restrictive diets. New York: Sterling; Apr 05, 2016.";no guidance;individual;NA;app;10;NA;NA;NA;8;NA;1,25;NA;0;0;3,3;NA;2;NA;0,33;NA;NA;NA;NA;36;34;70;0,77;43;48;91;42;48;90;NA;NA;NA;NA;NA;NA;cut-off;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;exclusion criteria consisted of reporting having received a diagnosis of another comorbid GI disorder such as celiac disease or an inflammatory bowel disease. Exclusion criteria also included severe depression and/or suicidal ideation, defined as a score of 20 or above on the Patient Health Questionnaire-9 (PHQ-9), and/or positive endorsement of active suicidal ideation or intent on a separate suicide question. Twenty-five individuals met this criterion. They were excluded from the trial, but were given immediate access to the app.;no;NA;no;NA
ito, 2020;ambt;wl;NA;NA;som;msd;ibssi;post;9;self-report;194,07;207,92;53,46;102,01;130;187,5;89,91;95,55;14;12;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;ito_2020_msd_ibssi_post_9.0_self-report_ambt_wl_NA_NA;-0,601746344;0,402724325;NA;NA;primary;low;low;low;high;low;high;JPRN-UMIN000027728;jp;university;yes;At the end of the workshop, participants received a 6000-yen (about $57) book token in return for their participation.;students;yes;cf. https://doi.org/10.1111/cp.12123;psy;mixed;NA;no;1;NA;300;NA;8;NA;0,13;NA;300;NA;NA;NA;NA;NA;NA;19,86;20,08;1,21;1,04;9;7;16;0,62;14;12;26;14;12;26;10;8;18;NA;NA;NA;cut-off;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;"the presence of warning symptoms which suggested the presence of organic disease at the selfreported screening and assessment (e.g., anemia, inflammatory reactions, fecal occult blood, unexplained weight loss in the past six months, or a family history of colon cancer); (3) suicidal ideation";no;NA;no;NA
ito, 2020;ambt;wl;NA;NA;som;msd;ibssi;follow up;17;self-report;194,07;207,92;53,46;102,01;128,33;174,12;67,92;75,06;14;12;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;ito_2020_msd_ibssi_followup_17.0_self-report_ambt_wl_NA_NA;-0,622098354;0,403357936;NA;NA;primary;low;low;low;high;low;high;JPRN-UMIN000027728;jp;university;yes;At the end of the workshop, participants received a 6000-yen (about $57) book token in return for their participation.;students;yes;cf. https://doi.org/10.1111/cp.12123;psy;mixed;NA;no;1;NA;300;NA;8;NA;0,13;NA;300;NA;NA;NA;NA;NA;NA;19,86;20,08;1,21;1,04;9;7;16;0,62;14;12;26;14;12;26;10;8;18;NA;NA;NA;cut-off;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;"the presence of warning symptoms which suggested the presence of organic disease at the selfreported screening and assessment (e.g., anemia, inflammatory reactions, fecal occult blood, unexplained weight loss in the past six months, or a family history of colon cancer); (3) suicidal ideation";no;NA;no;NA
ito, 2020;ambt;wl;NA;NA;depr;msd;bdi-II;post;9;self-report;14,14;19,25;9,58;10,45;13,4;25,7;9,97;12,34;14;12;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;ito_2020_msd_bdi-II_post_9.0_self-report_ambt_wl_NA_NA;-1,0712686;0,422249022;NA;NA;primary;low;low;low;high;low;high;JPRN-UMIN000027728;jp;university;yes;At the end of the workshop, participants received a 6000-yen (about $57) book token in return for their participation.;students;yes;cf. https://doi.org/10.1111/cp.12123;psy;mixed;NA;no;1;NA;300;NA;8;NA;0,13;NA;300;NA;NA;NA;NA;NA;NA;19,86;20,08;1,21;1,04;9;7;16;0,62;14;12;26;14;12;26;10;8;18;NA;NA;NA;cut-off;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;"the presence of warning symptoms which suggested the presence of organic disease at the selfreported screening and assessment (e.g., anemia, inflammatory reactions, fecal occult blood, unexplained weight loss in the past six months, or a family history of colon cancer); (3) suicidal ideation";no;NA;no;NA
ito, 2020;ambt;wl;NA;NA;depr;msd;bdi-II;follow up;17;self-report;14,14;19,25;9,58;10,45;8;22,25;8,06;13,13;14;12;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;ito_2020_msd_bdi-II_followup_17.0_self-report_ambt_wl_NA_NA;-1,29133431;0,434690194;NA;NA;primary;low;low;low;high;low;high;JPRN-UMIN000027728;jp;university;yes;At the end of the workshop, participants received a 6000-yen (about $57) book token in return for their participation.;students;yes;cf. https://doi.org/10.1111/cp.12123;psy;mixed;NA;no;1;NA;300;NA;8;NA;0,13;NA;300;NA;NA;NA;NA;NA;NA;19,86;20,08;1,21;1,04;9;7;16;0,62;14;12;26;14;12;26;10;8;18;NA;NA;NA;cut-off;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;"the presence of warning symptoms which suggested the presence of organic disease at the selfreported screening and assessment (e.g., anemia, inflammatory reactions, fecal occult blood, unexplained weight loss in the past six months, or a family history of colon cancer); (3) suicidal ideation";no;NA;no;NA
ito, 2020;ambt;wl;NA;NA;anx;msd;stai state;post;9;self-report;47,71;49,17;10,85;11,6;48,6;53;9,56;11,03;14;12;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;ito_2020_msd_staistate_post_9.0_self-report_ambt_wl_NA_NA;-0,415310208;0,397867727;NA;NA;primary;low;low;low;high;low;high;JPRN-UMIN000027728;jp;university;yes;At the end of the workshop, participants received a 6000-yen (about $57) book token in return for their participation.;students;yes;cf. https://doi.org/10.1111/cp.12123;psy;mixed;NA;no;1;NA;300;NA;8;NA;0,13;NA;300;NA;NA;NA;NA;NA;NA;19,86;20,08;1,21;1,04;9;7;16;0,62;14;12;26;14;12;26;10;8;18;NA;NA;NA;cut-off;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;"the presence of warning symptoms which suggested the presence of organic disease at the selfreported screening and assessment (e.g., anemia, inflammatory reactions, fecal occult blood, unexplained weight loss in the past six months, or a family history of colon cancer); (3) suicidal ideation";no;NA;no;NA
ito, 2020;ambt;wl;NA;NA;anx;msd;stai state;follow up;17;self-report;47,71;49,17;10,85;11,6;43,22;50;13,09;7,78;14;12;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;ito_2020_msd_staistate_followup_17.0_self-report_ambt_wl_NA_NA;-0,597998334;0,402609831;NA;NA;primary;low;low;low;high;low;high;JPRN-UMIN000027728;jp;university;yes;At the end of the workshop, participants received a 6000-yen (about $57) book token in return for their participation.;students;yes;cf. https://doi.org/10.1111/cp.12123;psy;mixed;NA;no;1;NA;300;NA;8;NA;0,13;NA;300;NA;NA;NA;NA;NA;NA;19,86;20,08;1,21;1,04;9;7;16;0,62;14;12;26;14;12;26;10;8;18;NA;NA;NA;cut-off;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;"the presence of warning symptoms which suggested the presence of organic disease at the selfreported screening and assessment (e.g., anemia, inflammatory reactions, fecal occult blood, unexplained weight loss in the past six months, or a family history of colon cancer); (3) suicidal ideation";no;NA;no;NA
ito, 2020;ambt;wl;NA;NA;phs;msd;ibs-qol;post;9;self-report;59,16;57,87;8,12;5,8;62,01;60,03;6,5;9,77;14;12;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;ito_2020_msd_ibs-qol_post_9.0_self-report_ambt_wl_NA_NA;0,234897996;0,394833297;NA;NA;primary;low;low;low;high;low;high;JPRN-UMIN000027728;jp;university;yes;At the end of the workshop, participants received a 6000-yen (about $57) book token in return for their participation.;students;yes;cf. https://doi.org/10.1111/cp.12123;psy;mixed;NA;no;1;NA;300;NA;8;NA;0,13;NA;300;NA;NA;NA;NA;NA;NA;19,86;20,08;1,21;1,04;9;7;16;0,62;14;12;26;14;12;26;10;8;18;NA;NA;NA;cut-off;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;"the presence of warning symptoms which suggested the presence of organic disease at the selfreported screening and assessment (e.g., anemia, inflammatory reactions, fecal occult blood, unexplained weight loss in the past six months, or a family history of colon cancer); (3) suicidal ideation";no;NA;no;NA
ito, 2020;ambt;wl;NA;NA;phs;msd;ibs-qol;follow up;17;self-report;59,16;57,87;8,12;5,8;58,6;57,41;3,22;5,99;14;12;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;ito_2020_msd_ibs-qol_followup_17.0_self-report_ambt_wl_NA_NA;0,245355616;0,394963691;NA;NA;primary;low;low;low;high;low;high;JPRN-UMIN000027728;jp;university;yes;At the end of the workshop, participants received a 6000-yen (about $57) book token in return for their participation.;students;yes;cf. https://doi.org/10.1111/cp.12123;psy;mixed;NA;no;1;NA;300;NA;8;NA;0,13;NA;300;NA;NA;NA;NA;NA;NA;19,86;20,08;1,21;1,04;9;7;16;0,62;14;12;26;14;12;26;10;8;18;NA;NA;NA;cut-off;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;"the presence of warning symptoms which suggested the presence of organic disease at the selfreported screening and assessment (e.g., anemia, inflammatory reactions, fecal occult blood, unexplained weight loss in the past six months, or a family history of colon cancer); (3) suicidal ideation";no;NA;no;NA
ito, 2020;ambt;wl;NA;NA;phs;msd;sf-36 pcs;post;9;self-report;53,49;59,53;19,42;18,49;28,74;60,52;16,61;17,92;14;12;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;ito_2020_msd_sf-36pcs_post_9.0_self-report_ambt_wl_NA_NA;-1,786959108;0,469297573;NA;NA;secondary;NA;NA;NA;NA;NA;NA;JPRN-UMIN000027728;jp;university;yes;At the end of the workshop, participants received a 6000-yen (about $57) book token in return for their participation.;students;yes;cf. https://doi.org/10.1111/cp.12123;psy;mixed;NA;no;1;NA;300;NA;8;NA;0,13;NA;300;NA;NA;NA;NA;NA;NA;19,86;20,08;1,21;1,04;9;7;16;0,62;14;12;26;14;12;26;10;8;18;NA;NA;NA;cut-off;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;"the presence of warning symptoms which suggested the presence of organic disease at the selfreported screening and assessment (e.g., anemia, inflammatory reactions, fecal occult blood, unexplained weight loss in the past six months, or a family history of colon cancer); (3) suicidal ideation";no;NA;no;NA
jang, 2014;cbt;psy plac;NA;NA;som;msd;bsss-ibs;post;8;self-report;9,31;9,22;2,4;3,16;6,26;8,78;2,12;3,9;39;37;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;jang_2014_msd_bsss-ibs_post_8.0_self-report_cbt_psyplac_NA_NA;-0,800589767;0,238687829;NA;NA;primary;low;high;low;high;some concerns;high;Clinical Research Information Service, cris.nih.go.kr, KCT000768, The effects of cognitive behavior therapy for the korean college students with irritable bowel syndrome, https://cris.nih.go.kr/cris/search/detailSearch.do/2371;kr;other;no;NA;students;yes;cbt;mixed;group;NA;no;8;NA;640;NA;8;NA;1;NA;80;NA;NA;NA;NA;NA;NA;21,9;21,2;1,9;2,3;45;45;90;1;45;45;90;NA;NA;NA;NA;NA;NA;NA;NA;personal circumstances (n = 3), health problem (n = 4), loss of contact (n = 7);clinical interview;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;patients were excluded for the following reasons: (a) history of digestive or abdominal surgery, (b) accompanying organic digestive disease (e.g. inflammatory bowel dis- ease, lactose malabsorption, celiac disease, obstructive bowel disease, etc.), (c) severe combined immune defi- ciency or thyroid disease, (d) mental illness or use of psychiatric drugs, (e) use of drugs that can affect bowel movements [e.g. prokinetics (5-HT and dopamine antagonist), antispasmodics, digestive stimulant, anti- diarrheal, antibiotics, antihistamines, laxatives, etc.], and (f) smoking.;no;NA;no;NA
jang, 2014;cbt;psy plac;NA;NA;som;msd;bsss-ibs;follow up;24;self-report;9,31;9,22;2,4;3,16;4,62;8,41;2,79;3,9;39;37;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;jang_2014_msd_bsss-ibs_followup_24.0_self-report_cbt_psyplac_NA_NA;-1,111246708;0,246900758;NA;NA;primary;low;high;low;high;some concerns;high;Clinical Research Information Service, cris.nih.go.kr, KCT000768, The effects of cognitive behavior therapy for the korean college students with irritable bowel syndrome, https://cris.nih.go.kr/cris/search/detailSearch.do/2371;kr;other;no;NA;students;yes;cbt;mixed;group;NA;no;8;NA;640;NA;8;NA;1;NA;80;NA;NA;NA;NA;NA;NA;21,9;21,2;1,9;2,3;45;45;90;1;45;45;90;NA;NA;NA;NA;NA;NA;NA;NA;personal circumstances (n = 3), health problem (n = 4), loss of contact (n = 7);clinical interview;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;patients were excluded for the following reasons: (a) history of digestive or abdominal surgery, (b) accompanying organic digestive disease (e.g. inflammatory bowel dis- ease, lactose malabsorption, celiac disease, obstructive bowel disease, etc.), (c) severe combined immune defi- ciency or thyroid disease, (d) mental illness or use of psychiatric drugs, (e) use of drugs that can affect bowel movements [e.g. prokinetics (5-HT and dopamine antagonist), antispasmodics, digestive stimulant, anti- diarrheal, antibiotics, antihistamines, laxatives, etc.], and (f) smoking.;no;NA;no;NA
jang, 2014;cbt;psy plac;NA;NA;phs;msd;ibs-qol;post;8;self-report;80,61;82,91;9,48;10,37;89,59;83,86;6,71;14,44;39;37;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;jang_2014_msd_ibs-qol_post_8.0_self-report_cbt_psyplac_NA_NA;0,508191004;0,233242815;NA;NA;primary;low;high;low;high;high;high;Clinical Research Information Service, cris.nih.go.kr, KCT000768, The effects of cognitive behavior therapy for the korean college students with irritable bowel syndrome, https://cris.nih.go.kr/cris/search/detailSearch.do/2371;kr;other;no;NA;students;yes;cbt;mixed;group;NA;no;8;NA;640;NA;8;NA;1;NA;80;NA;NA;NA;NA;NA;NA;21,9;21,2;1,9;2,3;45;45;90;1;45;45;90;NA;NA;NA;NA;NA;NA;NA;NA;personal circumstances (n = 3), health problem (n = 4), loss of contact (n = 7);clinical interview;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;patients were excluded for the following reasons: (a) history of digestive or abdominal surgery, (b) accompanying organic digestive disease (e.g. inflammatory bowel dis- ease, lactose malabsorption, celiac disease, obstructive bowel disease, etc.), (c) severe combined immune defi- ciency or thyroid disease, (d) mental illness or use of psychiatric drugs, (e) use of drugs that can affect bowel movements [e.g. prokinetics (5-HT and dopamine antagonist), antispasmodics, digestive stimulant, anti- diarrheal, antibiotics, antihistamines, laxatives, etc.], and (f) smoking.;no;NA;no;NA
jang, 2014;cbt;psy plac;NA;NA;phs;msd;ibs-qol;follow up;24;self-report;80,61;82,91;9,48;10,37;94,14;83,03;5,39;13,07;39;37;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;jang_2014_msd_ibs-qol_followup_24.0_self-report_cbt_psyplac_NA_NA;1,110738107;0,24688539;NA;NA;primary;low;high;low;high;high;high;Clinical Research Information Service, cris.nih.go.kr, KCT000768, The effects of cognitive behavior therapy for the korean college students with irritable bowel syndrome, https://cris.nih.go.kr/cris/search/detailSearch.do/2371;kr;other;no;NA;students;yes;cbt;mixed;group;NA;no;8;NA;640;NA;8;NA;1;NA;80;NA;NA;NA;NA;NA;NA;21,9;21,2;1,9;2,3;45;45;90;1;45;45;90;NA;NA;NA;NA;NA;NA;NA;NA;personal circumstances (n = 3), health problem (n = 4), loss of contact (n = 7);clinical interview;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;patients were excluded for the following reasons: (a) history of digestive or abdominal surgery, (b) accompanying organic digestive disease (e.g. inflammatory bowel dis- ease, lactose malabsorption, celiac disease, obstructive bowel disease, etc.), (c) severe combined immune defi- ciency or thyroid disease, (d) mental illness or use of psychiatric drugs, (e) use of drugs that can affect bowel movements [e.g. prokinetics (5-HT and dopamine antagonist), antispasmodics, digestive stimulant, anti- diarrheal, antibiotics, antihistamines, laxatives, etc.], and (f) smoking.;no;NA;no;NA
jang, 2014;cbt;psy plac;NA;NA;phs;msd;ibs-sss daily life disability subscale;post;8;self-report;6,59;6,35;4,36;4,72;3,51;6,16;3,19;4,49;39;37;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;jang_2014_msd_ibs-sssdailylifedisabilitysubscale_post_8.0_self-report_cbt_psyplac_NA_NA;-0,676520973;0,236095951;NA;NA;secondary;NA;NA;NA;NA;NA;NA;Clinical Research Information Service, cris.nih.go.kr, KCT000768, The effects of cognitive behavior therapy for the korean college students with irritable bowel syndrome, https://cris.nih.go.kr/cris/search/detailSearch.do/2371;kr;other;no;NA;students;yes;cbt;mixed;group;NA;no;8;NA;640;NA;8;NA;1;NA;80;NA;NA;NA;NA;NA;NA;21,9;21,2;1,9;2,3;45;45;90;1;45;45;90;NA;NA;NA;NA;NA;NA;NA;NA;personal circumstances (n = 3), health problem (n = 4), loss of contact (n = 7);clinical interview;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;patients were excluded for the following reasons: (a) history of digestive or abdominal surgery, (b) accompanying organic digestive disease (e.g. inflammatory bowel dis- ease, lactose malabsorption, celiac disease, obstructive bowel disease, etc.), (c) severe combined immune defi- ciency or thyroid disease, (d) mental illness or use of psychiatric drugs, (e) use of drugs that can affect bowel movements [e.g. prokinetics (5-HT and dopamine antagonist), antispasmodics, digestive stimulant, anti- diarrheal, antibiotics, antihistamines, laxatives, etc.], and (f) smoking.;no;NA;no;NA
janse, 2018;cbt;wl;feedback on demand;wl;som;msd;cis;post;24;self-report;49,9;49,5;4,9;5,3;37;43,9;13,1;10,5;80;80;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;janse_2018_msd_cis_post_24.0_self-report_cbt_wl_feedbackondemand_wl;-0,578465749;0,161417813;NA;NA;primary;some concerns;low;low;high;some concerns;high;netherlands trial register: NTR4013;nl;clinical;no;NA;adults;yes;NA;psy;individual;NA;internet;7;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;36,4;39,9;12,4;12,9;58;45;103;0,64;80;80;160;74;80;154;NA;76;NA;NA;NA;NA;combined;cfs/me;NA;NA;NA;NA;NA;NA;NA;NA;yes;"exclusion criteria were: (a) being involved in legal procedures concerning disability benefit claims; (b) participating in other CFS research.";no;NA;yes;adverse events were assessed 6 months post-randomisation (T1). All participants were asked if they had experienced new symptoms or an increase of existing symptoms during therapy or the waiting period. Patients who received iCBT were asked if they had experi- enced negative side-effects of the therapy.
janse, 2018;cbt;wl;protocol driven feedback;wl;som;msd;cis;post;24;self-report;50,7;49,5;5,3;5,3;36,6;43,9;14,6;10,5;80;80;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;janse_2018_msd_cis_post_24.0_self-report_cbt_wl_protocoldrivenfeedback_wl;-0,571335777;0,161337677;NA;NA;primary;some concerns;low;low;high;some concerns;high;netherlands trial register: NTR4013;n;clinical;no;NA;adults;yes;NA;psy;individual;NA;internet;7;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;36,6;39,9;12,8;12,9;54;45;99;0,62;80;80;160;76;80;156;28;76;104;NA;NA;NA;combined;cfs/me;NA;NA;NA;NA;NA;NA;NA;NA;yes;"exclusion criteria were: (a) being involved in legal procedures concerning disability benefit claims; (b) participating in other CFS research.";no;NA;yes;adverse events were assessed 6 months post-randomisation (T1). All participants were asked if they had experienced new symptoms or an increase of existing symptoms during therapy or the waiting period. Patients who received iCBT were asked if they had experi- enced negative side-effects of the therapy.
janse, 2018;cbt;wl;feedback on demand;wl;phs;msd;sf-36;post;24;self-report;62,9;62,3;17,7;19,2;77;70,8;21,3;21;80;80;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;janse_2018_msd_sf-36_post_24.0_self-report_cbt_wl_feedbackondemand_wl;0,291743158;0,158960777;NA;NA;primary;some concerns;low;low;high;some concerns;high;netherlands trial register: NTR4013;n;clinical;no;NA;adults;yes;NA;psy;individual;NA;internet;7;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;36,4;39,9;12,4;12,9;58;45;103;0,64;80;80;160;74;80;154;NA;76;NA;NA;NA;NA;combined;cfs/me;NA;NA;NA;NA;NA;NA;NA;NA;yes;"exclusion criteria were: (a) being involved in legal procedures concerning disability benefit claims; (b) participating in other CFS research.";no;NA;yes;adverse events were assessed 6 months post-randomisation (T1). All participants were asked if they had experienced new symptoms or an increase of existing symptoms during therapy or the waiting period. Patients who received iCBT were asked if they had experi- enced negative side-effects of the therapy.
janse, 2018;cbt;wl;protocol driven feedback;wl;phs;msd;sf-36;post;24;self-report;62,4;62,3;21,1;19,2;73,3;70,8;25,9;21;80;80;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;janse_2018_msd_sf-36_post_24.0_self-report_cbt_wl_protocoldrivenfeedback_wl;0,105528558;0,158224948;NA;NA;primary;some concerns;low;low;high;some concerns;high;netherlands trial register: NTR4013;n;clinical;no;NA;adults;yes;NA;psy;individual;NA;internet;7;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;36,6;39,9;12,8;12,9;54;45;99;0,62;80;80;160;76;80;156;28;76;104;NA;NA;NA;combined;cfs/me;NA;NA;NA;NA;NA;NA;NA;NA;yes;"exclusion criteria were: (a) being involved in legal procedures concerning disability benefit claims; (b) participating in other CFS research.";no;NA;yes;adverse events were assessed 6 months post-randomisation (T1). All participants were asked if they had experienced new symptoms or an increase of existing symptoms during therapy or the waiting period. Patients who received iCBT were asked if they had experi- enced negative side-effects of the therapy.
jensen, 2012;ambt;wl;NA;NA;som;msd;vas;post;12;self-report;61;65;20;10;49;59;19;26;19;15;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;jensen_2012_msd_vas_post_12.0_self-report_ambt_wl_NA_NA;-0,437168942;0,349637561;NA;NA;primary;low;low;low;high;some concerns;high;NA;se;clinical;no;NA;adults;yes;act for chronic pain;psy;group;NA;no;12;NA;1080;NA;12;NA;1;NA;90;NA;NA;NA;NA;NA;NA;44,5;46,9;1,5;1,1;25;18;43;1;25;18;43;23;17;40;20;16;36;NA;NA;NA;combined;fm;NA;NA;NA;NA;126;141,6;14,4;24;yes;claustrophobia + severe psychiatric comorbidity (psychiatric symptoms or behaviors that may significantly interfere with treatment and that should be addressed separately, such as suicidality, psychotic symptoms, and severe depressive episode);no;NA;no;NA
jensen, 2012;ambt;wl;NA;NA;depr;msd;bdi;post;12;self-report;16;19;6;12;11;16;5;10;19;15;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;jensen_2012_msd_bdi_post_12.0_self-report_ambt_wl_NA_NA;-0,642062187;0,354482081;NA;NA;primary;low;low;low;high;some concerns;high;NA;se;clinical;no;NA;adults;yes;act for chronic pain;psy;group;NA;no;12;NA;1080;NA;12;NA;1;NA;90;NA;NA;NA;NA;NA;NA;44,5;46,9;1,5;1,1;25;18;43;1;25;18;43;23;17;40;20;16;36;NA;NA;NA;combined;fm;NA;NA;NA;NA;126;141,6;14,4;24;yes;claustrophobia + severe psychiatric comorbidity (psychiatric symptoms or behaviors that may significantly interfere with treatment and that should be addressed separately, such as suicidality, psychotic symptoms, and severe depressive episode);no;NA;no;NA
jensen, 2012;ambt;wl;NA;NA;depr;msd;bdi;follow up;24;self-report;16;19;6;12;10;18;4;12;19;15;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;jensen_2012_msd_bdi_followup_24.0_self-report_ambt_wl_NA_NA;-0,920537962;0,363827076;NA;NA;primary;low;low;low;high;some concerns;high;NA;se;clinical;no;NA;adults;yes;act for chronic pain;psy;group;NA;no;12;NA;1080;NA;12;NA;1;NA;90;NA;NA;NA;NA;NA;NA;44,5;46,9;1,5;1,1;25;18;43;1;25;18;43;23;17;40;20;16;36;NA;NA;NA;combined;fm;NA;NA;NA;NA;126;141,6;14,4;24;yes;claustrophobia + severe psychiatric comorbidity (psychiatric symptoms or behaviors that may significantly interfere with treatment and that should be addressed separately, such as suicidality, psychotic symptoms, and severe depressive episode);no;NA;no;NA
jensen, 2012;ambt;wl;NA;NA;anx;msd;stai state;post;12;self-report;47;45;12;12;40;47;12;13;19;15;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;jensen_2012_msd_staistate_post_12.0_self-report_ambt_wl_NA_NA;-0,549082664;0,352064024;NA;NA;primary;low;low;low;high;some concerns;high;NA;se;clinical;no;NA;adults;yes;act for chronic pain;psy;group;NA;no;12;NA;1080;NA;12;NA;1;NA;90;NA;NA;NA;NA;NA;NA;44,5;46,9;1,5;1,1;25;18;43;1;25;18;43;23;17;40;20;16;36;NA;NA;NA;combined;fm;NA;NA;NA;NA;126;141,6;14,4;24;yes;claustrophobia + severe psychiatric comorbidity (psychiatric symptoms or behaviors that may significantly interfere with treatment and that should be addressed separately, such as suicidality, psychotic symptoms, and severe depressive episode);no;NA;no;NA
jensen, 2012;ambt;wl;NA;NA;anx;msd;stai state;follow up;24;self-report;47;45;12;12;39;46;7;13;19;15;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;jensen_2012_msd_staistate_followup_24.0_self-report_ambt_wl_NA_NA;-0,678395538;0,355524454;NA;NA;primary;low;low;low;high;some concerns;high;NA;se;clinical;no;NA;adults;yes;act for chronic pain;psy;group;NA;no;12;NA;1080;NA;12;NA;1;NA;90;NA;NA;NA;NA;NA;NA;44,5;46,9;1,5;1,1;25;18;43;1;25;18;43;23;17;40;20;16;36;NA;NA;NA;combined;fm;NA;NA;NA;NA;126;141,6;14,4;24;yes;claustrophobia + severe psychiatric comorbidity (psychiatric symptoms or behaviors that may significantly interfere with treatment and that should be addressed separately, such as suicidality, psychotic symptoms, and severe depressive episode);no;NA;no;NA
jensen, 2012;ambt;wl;NA;NA;phs;msd;sf-36;post;12;self-report;25,2;25,2;6,6;6,6;28,4;30,1;8;9,9;19;15;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;jensen_2012_msd_sf-36_post_12.0_self-report_ambt_wl_NA_NA;-0,186889609;0,346174873;NA;NA;primary;low;low;low;high;some concerns;high;NA;se;clinical;no;NA;adults;yes;act for chronic pain;psy;group;NA;no;12;NA;1080;NA;12;NA;1;NA;90;NA;NA;NA;NA;NA;NA;44,5;46,9;1,5;1,1;25;18;43;1;25;18;43;23;17;40;20;16;36;NA;NA;NA;combined;fm;NA;NA;NA;NA;126;141,6;14,4;24;yes;claustrophobia + severe psychiatric comorbidity (psychiatric symptoms or behaviors that may significantly interfere with treatment and that should be addressed separately, such as suicidality, psychotic symptoms, and severe depressive episode);no;NA;no;NA
jensen, 2012;ambt;wl;NA;NA;phs;msd;sf-36;follow up;24;self-report;25,2;25,2;6,6;6,6;28,4;31,1;8,4;10,8;19;15;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;jensen_2012_msd_sf-36_followup_24.0_self-report_ambt_wl_NA_NA;-0,276777134;0,347102245;NA;NA;primary;low;low;low;high;some concerns;high;NA;se;clinical;no;NA;adults;yes;act for chronic pain;psy;group;NA;no;12;NA;1080;NA;12;NA;1;NA;90;NA;NA;NA;NA;NA;NA;44,5;46,9;1,5;1,1;25;18;43;1;25;18;43;23;17;40;20;16;36;NA;NA;NA;combined;fm;NA;NA;NA;NA;126;141,6;14,4;24;yes;claustrophobia + severe psychiatric comorbidity (psychiatric symptoms or behaviors that may significantly interfere with treatment and that should be addressed separately, such as suicidality, psychotic symptoms, and severe depressive episode);no;NA;no;NA
jensen, 2012;ambt;wl;NA;NA;phs;msd;fiq;post;12;self-report;-49,3;-48,7;9,7;12;-39;-43,8;12,5;10,5;19;15;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;jensen_2012_msd_fiq_post_12.0_self-report_ambt_wl_NA_NA;0,401689292;0,348980382;NA;NA;secondary;NA;NA;NA;NA;NA;NA;NA;se;clinical;no;NA;adults;yes;act for chronic pain;psy;group;NA;no;12;NA;1080;NA;12;NA;1;NA;90;NA;NA;NA;NA;NA;NA;44,5;46,9;1,5;1,1;25;18;43;1;25;18;43;23;17;40;20;16;36;NA;NA;NA;combined;fm;NA;NA;NA;NA;126;141,6;14,4;24;yes;claustrophobia + severe psychiatric comorbidity (psychiatric symptoms or behaviors that may significantly interfere with treatment and that should be addressed separately, such as suicidality, psychotic symptoms, and severe depressive episode);no;NA;no;NA
karlsson, 2015;cbt;wl;NA;NA;som;msd;mpi-1 pain intensity;post;24;self-report;3,85;3,38;0,8;0,92;3,88;3,67;1,05;0,75;23;24;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;karlsson_2015_msd_mpi-1painintensity_post_24.0_self-report_cbt_wl_NA_NA;0,22712111;0,292767076;NA;NA;primary;low;low;low;high;some concerns;high;ClinicalTrials.gov, NCT01004458, https://clinicaltrials.gov/ct2/show/NCT01004458, Cognitive Behavioral Therapy Trial in Fibromylagia (FIBCOG);se;community;no;NA;adults;yes;stress management programme;psy;group;NA;no;20;NA;3600;NA;24;NA;0,83;NA;180;NA;NA;NA;NA;NA;NA;48,3;48,8;11,5;6,5;24;24;48;1,02;23;24;47;NA;NA;NA;23;24;47;NA;NA;severe depression (n=1);combined;fm;NA;NA;NA;NA;128,2;144;77,52;84,72;yes;major psychiatric disease;no;NA;no;NA
karlsson, 2015;cbt;wl;NA;NA;depr;msd;madrs;post;24;clinican;17,38;13,04;8,25;7,64;14,75;14,79;7,96;6,37;23;24;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;karlsson_2015_msd_madrs_post_24.0_clinican_cbt_wl_NA_NA;-0,005468986;0,291796602;NA;NA;primary;low;low;low;high;some concerns;high;ClinicalTrials.gov, NCT01004458, https://clinicaltrials.gov/ct2/show/NCT01004458, Cognitive Behavioral Therapy Trial in Fibromylagia (FIBCOG);se;community;no;NA;adults;yes;stress management programme;psy;group;NA;no;20;NA;3600;NA;24;NA;0,83;NA;180;NA;NA;NA;NA;NA;NA;48,3;48,8;11,5;6,5;24;24;48;1,02;23;24;47;NA;NA;NA;23;24;47;NA;NA;severe depression (n=1);combined;fm;NA;NA;NA;NA;128,2;144;77,52;84,72;yes;major psychiatric disease;no;NA;no;NA
karlsson, 2015;cbt;wl;NA;NA;phs;msd;mpi-1 interference;post;24;self-report;-4,04;-3,37;0,57;1,09;-4,05;-3,43;0,85;0,82;23;24;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;karlsson_2015_msd_mpi-1interference_post_24.0_self-report_cbt_wl_NA_NA;-0,730244293;0,301683469;NA;NA;primary;low;low;low;high;some concerns;high;ClinicalTrials.gov, NCT01004458, https://clinicaltrials.gov/ct2/show/NCT01004458, Cognitive Behavioral Therapy Trial in Fibromylagia (FIBCOG);se;community;no;NA;adults;yes;stress management programme;psy;group;NA;no;20;NA;3600;NA;24;NA;0,83;NA;180;NA;NA;NA;NA;NA;NA;48,3;48,8;11,5;6,5;24;24;48;1,02;23;24;47;NA;NA;NA;23;24;47;NA;NA;severe depression (n=1);combined;fm;NA;NA;NA;NA;128,2;144;77,52;84,72;yes;major psychiatric disease;no;NA;no;NA
kikuchi, 2022;cbt;tau;NA;NA;som;msd;ibs-sss;post;13;self-report;302,7;301,8;70,6;66,3;187,6;273,5;85,1;96,8;49;58;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;kikuchi_2022_msd_ibs-sss_post_13.0_self-report_cbt_tau_NA_NA;-0,930682903;0,204342011;NA;NA;primary;low;low;low;high;some concerns;high;UMIN-CTR (UMIN000031710).;jp;combined;yes;1000 Yen giftcard (around 9 Dollars);adults;yes;GCBT-IE;mixed;group;NA;mixed;10;NA;900;NA;10;NA;1;NA;90;NA;NA;NA;NA;NA;NA;41,9;37,4;14,3;14,7;35;37;72;0,63;54;60;114;54;58;112;NA;NA;NA;NA;NA;anxiety for COVID, death, other adverse events;combined;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;they were excluded fi they had uncontrolled comorbid abdominal disease, abdominal surgery likely related to IBS, unremitted mental illness (e.g., severe depression or psychosis), suicidalideation withmore than 2 points on item Patient Health Questionnaire-9 (PHQ-9) (19), were unsuitable for group therapy, or were pregnant. We also excluded those who had everreceived structured psychotherapies to remove the influence of previous psychotherapeutic experiences as much aspossible.;no;NA;yes;adverse events were assessed 6 months post-randomisation (T1). All participants were asked if they had experienced new symptoms or an increase of existing symptoms during therapy or the waiting period. Patients who received iCBT were asked if they had experi- enced negative side-effects of the therapy.
kikuchi, 2022;cbt;tau;NA;NA;depr;msd;phq-9;post;13;self-report;9,2;9,8;5,1;6;5,8;10,6;4,9;7,2;49;58;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;kikuchi_2022_msd_phq-9_post_13.0_self-report_cbt_tau_NA_NA;-0,761962872;0,201002087;NA;NA;primary;low;low;low;high;some concerns;high;UMIN-CTR (UMIN000031710).;jp;combined;yes;1000 Yen giftcard (around 9 Dollars);adults;yes;GCBT-IE;mixed;group;NA;mixed;10;NA;900;NA;10;NA;1;NA;90;NA;NA;NA;NA;NA;NA;41,9;37,4;14,3;14,7;35;37;72;0,63;54;60;114;54;58;112;NA;NA;NA;NA;NA;anxiety for COVID, death, other adverse events;combined;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;they were excluded fi they had uncontrolled comorbid abdominal disease, abdominal surgery likely related to IBS, unremitted mental illness (e.g., severe depression or psychosis), suicidalideation withmore than 2 points on item Patient Health Questionnaire-9 (PHQ-9) (19), were unsuitable for group therapy, or were pregnant. We also excluded those who had everreceived structured psychotherapies to remove the influence of previous psychotherapeutic experiences as much aspossible.;no;NA;yes;adverse events were assessed 6 months post-randomisation (T1). All participants were asked if they had experienced new symptoms or an increase of existing symptoms during therapy or the waiting period. Patients who received iCBT were asked if they had experi- enced negative side-effects of the therapy.
kikuchi, 2022;cbt;tau;NA;NA;anx;msd;gad-7;post;13;self-report;8,5;9,4;4,8;5,6;5,1;9,6;3,8;6,1;49;58;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;kikuchi_2022_msd_gad-7_post_13.0_self-report_cbt_tau_NA_NA;-0,863013282;0,202929192;NA;NA;primary;low;low;low;high;some concerns;high;UMIN-CTR (UMIN000031710).;jp;combined;yes;1000 Yen giftcard (around 9 Dollars);adults;yes;GCBT-IE;mixed;group;NA;mixed;10;NA;900;NA;10;NA;1;NA;90;NA;NA;NA;NA;NA;NA;41,9;37,4;14,3;14,7;35;37;72;0,63;54;60;114;54;58;112;NA;NA;NA;NA;NA;anxiety for COVID, death, other adverse events;combined;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;they were excluded fi they had uncontrolled comorbid abdominal disease, abdominal surgery likely related to IBS, unremitted mental illness (e.g., severe depression or psychosis), suicidalideation withmore than 2 points on item Patient Health Questionnaire-9 (PHQ-9) (19), were unsuitable for group therapy, or were pregnant. We also excluded those who had everreceived structured psychotherapies to remove the influence of previous psychotherapeutic experiences as much aspossible.;no;NA;yes;adverse events were assessed 6 months post-randomisation (T1). All participants were asked if they had experienced new symptoms or an increase of existing symptoms during therapy or the waiting period. Patients who received iCBT were asked if they had experi- enced negative side-effects of the therapy.
kikuchi, 2022;cbt;tau;NA;NA;phs;msd;ibs-qol;post;13;self-report;56,5;53,9;18,6;20,3;76,6;54,5;16,4;23;49;58;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;kikuchi_2022_msd_ibs-qol_post_13.0_self-report_cbt_tau_NA_NA;1,083462006;0,207880764;NA;NA;primary;low;low;low;high;some concerns;high;UMIN-CTR (UMIN000031710).;jp;combined;yes;1000 Yen giftcard (around 9 Dollars);adults;yes;GCBT-IE;mixed;group;NA;mixed;10;NA;900;NA;10;NA;1;NA;90;NA;NA;NA;NA;NA;NA;41,9;37,4;14,3;14,7;35;37;72;0,63;54;60;114;54;58;112;NA;NA;NA;NA;NA;anxiety for COVID, death, other adverse events;combined;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;they were excluded fi they had uncontrolled comorbid abdominal disease, abdominal surgery likely related to IBS, unremitted mental illness (e.g., severe depression or psychosis), suicidalideation withmore than 2 points on item Patient Health Questionnaire-9 (PHQ-9) (19), were unsuitable for group therapy, or were pregnant. We also excluded those who had everreceived structured psychotherapies to remove the influence of previous psychotherapeutic experiences as much aspossible.;no;NA;yes;adverse events were assessed 6 months post-randomisation (T1). All participants were asked if they had experienced new symptoms or an increase of existing symptoms during therapy or the waiting period. Patients who received iCBT were asked if they had experi- enced negative side-effects of the therapy.
knoop, 2008;cbt;wl;NA;NA;som;msd;cis;post;42;self-report;49,1;49,9;5,2;5,6;38,9;46,4;12,1;8,7;84;85;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;knoop_2008_msd_cis_post_42.0_self-report_cbt_wl_NA_NA;-0,709183548;0,158653509;NA;NA;primary;low;low;low;high;some concerns;high;ISRCTN registry, ISRCTN27293439, The effectiveness of self-instructions in the treatment of patients with chronic fatigue syndrome (CFS): a randomised controlled study, https://www.isrctn.com/ISRCTN27293439;nl;clinical;no;NA;adults;yes;minimal intervention based on CBT;psy;individual;NA;no;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;37,6;38,5;10;10,6;69;65;134;0,78;85;86;171;71;86;157;NA;NA;NA;NA;NA;NA;cut-off;cfs/me;NA;NA;NA;NA;NA;NA;NA;NA;yes;medical explanation of fatigue;no;NA;no;NA
knoop, 2008;cbt;wl;NA;NA;phs;msd;sf-36;post;42;self-report;52,3;54,1;20,4;21,1;65,9;60,2;23,2;23,7;84;85;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;knoop_2008_msd_sf-36_post_42.0_self-report_cbt_wl_NA_NA;0,241947899;0,154415763;NA;NA;primary;low;low;low;high;some concerns;high;ISRCTN registry, ISRCTN27293439, The effectiveness of self-instructions in the treatment of patients with chronic fatigue syndrome (CFS): a randomised controlled study, https://www.isrctn.com/ISRCTN27293439;nl;clinical;no;NA;adults;yes;minimal intervention based on CBT;psy;individual;NA;no;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;37,6;38,5;10;10,6;69;65;134;0,78;85;86;171;71;86;157;NA;NA;NA;NA;NA;NA;cut-off;cfs/me;NA;NA;NA;NA;NA;NA;NA;NA;yes;medical explanation of fatigue;no;NA;no;NA
kristjansdottir, 2013;cbt+ambt;wl;NA;NA;som;msd;vas;post;4;self-report;53,07;52,99;22,2;21,27;54,14;50,56;24,06;23,37;47;40;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;kristjansdottir_2013_msd_vas_post_4.0_self-report_cbt+ambt_wl_NA_NA;0,149428677;0,215423362;NA;NA;primary;some concerns;low;low;high;some concerns;high;ClinicalTrials.gov, NCT01236209, Stimulating Self Management in Patients With Fibromyalgia Through Web-based Situational Feedback, https://clinicaltrials.gov/ct2/show/record/NCT01236209;no;clinical;no;NA;adults;NA;smartphone intervention;self-guided;individual;NA;app;1;NA;60;NA;4;NA;0,25;NA;60;NA;NA;NA;NA;NA;NA;44,59;43,8;11,13;11,2;69;66;135;1;69;66;135;62;65;127;NA;NA;NA;met exclusion criteria after randomization;NA;NA;medical;cwp;NA;NA;NA;NA;157,32;185,64;105,36;145,08;yes;being diagnosed with a profound psychiatric disorder;no;NA;no;NA
kristjansdottir, 2013;cbt+ambt;wl;NA;NA;som;msd;vas;follow up;24;self-report;53,07;52,99;22,2;21,27;51,96;58,45;23,76;22,46;37;40;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;kristjansdottir_2013_msd_vas_followup_24.0_self-report_cbt+ambt_wl_NA_NA;-0,278216144;0,229215819;NA;NA;primary;some concerns;low;low;high;some concerns;high;ClinicalTrials.gov, NCT01236209, Stimulating Self Management in Patients With Fibromyalgia Through Web-based Situational Feedback, https://clinicaltrials.gov/ct2/show/record/NCT01236209;no;clinical;no;NA;adults;NA;smartphone intervention;self-guided;individual;NA;app;1;NA;60;NA;4;NA;0,25;NA;60;NA;NA;NA;NA;NA;NA;44,59;43,8;11,13;11,2;69;66;135;1;69;66;135;62;65;127;NA;NA;NA;met exclusion criteria after randomization;NA;NA;medical;cwp;NA;NA;NA;NA;157,32;185,64;105,36;145,08;yes;being diagnosed with a profound psychiatric disorder;no;NA;no;NA
kristjansdottir, 2013;cbt+ambt;wl;NA;NA;phs;msd;sf-8 physical;post;4;self-report;36,68;35,86;8,42;8,24;35,24;36,55;8,74;8,17;46;37;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;kristjansdottir_2013_msd_sf-8physical_post_4.0_self-report_cbt+ambt_wl_NA_NA;-0,152841002;0,221154999;NA;NA;primary;some concerns;low;high;high;some concerns;high;ClinicalTrials.gov, NCT01236209, Stimulating Self Management in Patients With Fibromyalgia Through Web-based Situational Feedback, https://clinicaltrials.gov/ct2/show/record/NCT01236209;no;clinical;no;NA;adults;NA;smartphone intervention;self-guided;individual;NA;app;1;NA;60;NA;4;NA;0,25;NA;60;NA;NA;NA;NA;NA;NA;44,59;43,8;11,13;11,2;69;66;135;1;69;66;135;62;65;127;NA;NA;NA;met exclusion criteria after randomization;NA;NA;medical;cwp;NA;NA;NA;NA;157,32;185,64;105,36;145,08;yes;being diagnosed with a profound psychiatric disorder;no;NA;no;NA
kristjansdottir, 2013;cbt+ambt;wl;NA;NA;phs;msd;sf-8 physical;follow up;24;self-report;36,68;35,86;8,42;8,24;37,54;34,37;9,44;8,59;37;40;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;kristjansdottir_2013_msd_sf-8physical_followup_24.0_self-report_cbt+ambt_wl_NA_NA;0,348377958;0,229850346;NA;NA;primary;some concerns;low;high;high;some concerns;high;ClinicalTrials.gov, NCT01236209, Stimulating Self Management in Patients With Fibromyalgia Through Web-based Situational Feedback, https://clinicaltrials.gov/ct2/show/record/NCT01236209;no;clinical;no;NA;adults;NA;smartphone intervention;self-guided;individual;NA;app;1;NA;60;NA;4;NA;0,25;NA;60;NA;NA;NA;NA;NA;NA;44,59;43,8;11,13;11,2;69;66;135;1;69;66;135;62;65;127;NA;NA;NA;met exclusion criteria after randomization;NA;NA;medical;cwp;NA;NA;NA;NA;157,32;185,64;105,36;145,08;yes;being diagnosed with a profound psychiatric disorder;no;NA;no;NA
lami, 2018;cbt;tau;cbt pain;tau;som;msd;mpq-sf vas;post;10;self-report;7,58;7,16;1,75;1,27;7,35;6,62;2,08;1,47;28;36;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;lami_2018_msd_mpq-sfvas_post_10.0_self-report_cbt_tau_cbtpain_tau;0,409316311;0,254623943;NA;NA;primary;low;high;high;high;some concerns;high;NA;es;clinical;no;NA;adults;yes;cbt for pain;psy;group;NA;no;9;NA;810;NA;9;NA;1;NA;90;NA;NA;NA;NA;NA;NA;49,35;51,37;6,43;9,38;42;42;84;1;42;42;84;34;41;75;NA;NA;NA;NA;NA;NA;combined;fm;NA;NA;NA;NA;121,2;138,84;108,36;127,56;yes;"the exclusion criteria were: (1) having major concomitant medical conditions (e.g., inflammatory rheumatic disease, endocrine disturbances, neurological disorder, cancer, recent surgery) or pregnancy; (2) hav- ing mental disorders with severe symptoms (e.g., major depression with suicide ideation, schizophrenia, personal- ity disorder) or other organic sleep disorder (i.e., apnea); (3) having a severe dependence of hypnotic drugs; and (4) having irregularities in circadian rhythms at the time of the study (i.e., by rotating work shifts).";no;NA;no;NA
lami, 2018;cbt;tau;cbt insomnia;tau;som;msd;mpq-sf vas;post;10;self-report;7,44;7,16;1,33;1,27;7,29;6,62;1,46;1,47;27;36;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;lami_2018_msd_mpq-sfvas_post_10.0_self-report_cbt_tau_cbtinsomnia_tau;0,451461831;0,257823795;NA;NA;primary;low;high;high;high;some concerns;high;NA;es;clinical;no;NA;adults;yes;cbt for insomnia;psy;group;NA;no;9;NA;810;NA;9;NA;1;NA;90;NA;NA;NA;NA;NA;NA;49,66;51,37;8,44;9,38;42;42;84;1;42;42;84;38;41;79;NA;NA;NA;NA;NA;NA;combined;fm;NA;NA;NA;NA;101,64;138,84;83,88;127,56;yes;"the exclusion criteria were: (1) having major concomitant medical conditions (e.g., inflammatory rheumatic disease, endocrine disturbances, neurological disorder, cancer, recent surgery) or pregnancy; (2) hav- ing mental disorders with severe symptoms (e.g., major depression with suicide ideation, schizophrenia, personal- ity disorder) or other organic sleep disorder (i.e., apnea); (3) having a severe dependence of hypnotic drugs; and (4) having irregularities in circadian rhythms at the time of the study (i.e., by rotating work shifts).";no;NA;no;NA
lami, 2018;cbt;tau;cbt pain;tau;som;msd;mpq-sf vas;follow up;22;self-report;7,58;7,16;1,75;1,27;7,21;7,2;1,79;1,58;24;26;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;lami_2018_msd_mpq-sfvas_followup_22.0_self-report_cbt_tau_cbtpain_tau;0,005845332;0,283069881;NA;NA;primary;low;high;high;high;some concerns;high;NA;es;clinical;no;NA;adults;yes;cbt for pain;psy;group;NA;no;9;NA;810;NA;9;NA;1;NA;90;NA;NA;NA;NA;NA;NA;49,35;51,37;6,43;9,38;42;42;84;1;42;42;84;34;41;75;NA;NA;NA;NA;NA;NA;combined;fm;NA;NA;NA;NA;121,2;138,84;108,36;127,56;yes;"the exclusion criteria were: (1) having major concomitant medical conditions (e.g., inflammatory rheumatic disease, endocrine disturbances, neurological disorder, cancer, recent surgery) or pregnancy; (2) hav- ing mental disorders with severe symptoms (e.g., major depression with suicide ideation, schizophrenia, personal- ity disorder) or other organic sleep disorder (i.e., apnea); (3) having a severe dependence of hypnotic drugs; and (4) having irregularities in circadian rhythms at the time of the study (i.e., by rotating work shifts).";no;NA;no;NA
lami, 2018;cbt;tau;cbt insomnia;tau;som;msd;mpq-sf vas;follow up;22;self-report;7,44;7,16;1,33;1,27;6,62;7,2;1,47;1,58;22;26;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;lami_2018_msd_mpq-sfvas_followup_22.0_self-report_cbt_tau_cbtinsomnia_tau;-0,372684478;0,292252498;NA;NA;primary;low;high;high;high;some concerns;high;NA;es;clinical;no;NA;adults;yes;cbt for insomnia;psy;group;NA;no;9;NA;810;NA;9;NA;1;NA;90;NA;NA;NA;NA;NA;NA;49,66;51,37;8,44;9,38;42;42;84;1;42;42;84;38;41;79;NA;NA;NA;NA;NA;NA;combined;fm;NA;NA;NA;NA;101,64;138,84;83,88;127,56;yes;"the exclusion criteria were: (1) having major concomitant medical conditions (e.g., inflammatory rheumatic disease, endocrine disturbances, neurological disorder, cancer, recent surgery) or pregnancy; (2) hav- ing mental disorders with severe symptoms (e.g., major depression with suicide ideation, schizophrenia, personal- ity disorder) or other organic sleep disorder (i.e., apnea); (3) having a severe dependence of hypnotic drugs; and (4) having irregularities in circadian rhythms at the time of the study (i.e., by rotating work shifts).";no;NA;no;NA
lami, 2018;cbt;tau;cbt pain;tau;depr;msd;scl-90-r depression;post;10;self-report;2,15;1,77;0,88;0,95;2,15;1,68;0,78;0,98;28;36;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;lami_2018_msd_scl-90-rdepression_post_10.0_self-report_cbt_tau_cbtpain_tau;0,516802319;0,256184089;NA;NA;primary;low;high;high;high;some concerns;high;NA;es;clinical;no;NA;adults;yes;cbt for pain;psy;group;NA;no;9;NA;810;NA;9;NA;1;NA;90;NA;NA;NA;NA;NA;NA;49,35;51,37;6,43;9,38;42;42;84;1;42;42;84;34;41;75;NA;NA;NA;NA;NA;NA;combined;fm;NA;NA;NA;NA;121,2;138,84;108,36;127,56;yes;"the exclusion criteria were: (1) having major concomitant medical conditions (e.g., inflammatory rheumatic disease, endocrine disturbances, neurological disorder, cancer, recent surgery) or pregnancy; (2) hav- ing mental disorders with severe symptoms (e.g., major depression with suicide ideation, schizophrenia, personal- ity disorder) or other organic sleep disorder (i.e., apnea); (3) having a severe dependence of hypnotic drugs; and (4) having irregularities in circadian rhythms at the time of the study (i.e., by rotating work shifts).";no;NA;no;NA
lami, 2018;cbt;tau;cbt insomnia;tau;depr;msd;scl-90-r depression;post;10;self-report;2,2;1,77;0,79;0,95;2,03;1,68;0,79;0,98;27;36;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;lami_2018_msd_scl-90-rdepression_post_10.0_self-report_cbt_tau_cbtinsomnia_tau;0,382425021;0,256913836;NA;NA;primary;low;high;high;high;some concerns;high;NA;es;clinical;no;NA;adults;yes;cbt for insomnia;psy;group;NA;no;9;NA;810;NA;9;NA;1;NA;90;NA;NA;NA;NA;NA;NA;49,66;51,37;8,44;9,38;42;42;84;1;42;42;84;38;41;79;NA;NA;NA;NA;NA;NA;combined;fm;NA;NA;NA;NA;101,64;138,84;83,88;127,56;yes;"the exclusion criteria were: (1) having major concomitant medical conditions (e.g., inflammatory rheumatic disease, endocrine disturbances, neurological disorder, cancer, recent surgery) or pregnancy; (2) hav- ing mental disorders with severe symptoms (e.g., major depression with suicide ideation, schizophrenia, personal- ity disorder) or other organic sleep disorder (i.e., apnea); (3) having a severe dependence of hypnotic drugs; and (4) having irregularities in circadian rhythms at the time of the study (i.e., by rotating work shifts).";no;NA;no;NA
lami, 2018;cbt;tau;cbt pain;tau;depr;msd;scl-90-r depression;follow up;22;self-report;2,15;1,77;0,88;0,95;2,11;1,47;0,9;0,78;24;26;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;lami_2018_msd_scl-90-rdepression_followup_22.0_self-report_cbt_tau_cbtpain_tau;0,750256726;0,293152067;NA;NA;primary;low;high;high;high;some concerns;high;NA;es;clinical;no;NA;adults;yes;cbt for pain;psy;group;NA;no;9;NA;810;NA;9;NA;1;NA;90;NA;NA;NA;NA;NA;NA;49,35;51,37;6,43;9,38;42;42;84;1;42;42;84;34;41;75;NA;NA;NA;NA;NA;NA;combined;fm;NA;NA;NA;NA;121,2;138,84;108,36;127,56;yes;"the exclusion criteria were: (1) having major concomitant medical conditions (e.g., inflammatory rheumatic disease, endocrine disturbances, neurological disorder, cancer, recent surgery) or pregnancy; (2) hav- ing mental disorders with severe symptoms (e.g., major depression with suicide ideation, schizophrenia, personal- ity disorder) or other organic sleep disorder (i.e., apnea); (3) having a severe dependence of hypnotic drugs; and (4) having irregularities in circadian rhythms at the time of the study (i.e., by rotating work shifts).";no;NA;no;NA
lami, 2018;cbt;tau;cbt insomnia;tau;depr;msd;scl-90-r depression;follow up;22;self-report;2,2;1,77;0,79;0,95;2,02;1,47;1,01;0,78;22;26;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;lami_2018_msd_scl-90-rdepression_followup_22.0_self-report_cbt_tau_cbtinsomnia_tau;0,606222586;0,296433701;NA;NA;primary;low;high;high;high;some concerns;high;NA;es;clinical;no;NA;adults;yes;cbt for insomnia;psy;group;NA;no;9;NA;810;NA;9;NA;1;NA;90;NA;NA;NA;NA;NA;NA;49,66;51,37;8,44;9,38;42;42;84;1;42;42;84;38;41;79;NA;NA;NA;NA;NA;NA;combined;fm;NA;NA;NA;NA;101,64;138,84;83,88;127,56;yes;"the exclusion criteria were: (1) having major concomitant medical conditions (e.g., inflammatory rheumatic disease, endocrine disturbances, neurological disorder, cancer, recent surgery) or pregnancy; (2) hav- ing mental disorders with severe symptoms (e.g., major depression with suicide ideation, schizophrenia, personal- ity disorder) or other organic sleep disorder (i.e., apnea); (3) having a severe dependence of hypnotic drugs; and (4) having irregularities in circadian rhythms at the time of the study (i.e., by rotating work shifts).";no;NA;no;NA
lami, 2018;cbt;tau;cbt pain;tau;anx;msd;scl-90-r anxiety;post;10;self-report;1,63;1,5;0,81;0,93;1,71;1,37;0,94;0,91;28;36;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;lami_2018_msd_scl-90-ranxiety_post_10.0_self-report_cbt_tau_cbtpain_tau;0,363817306;0,254070333;NA;NA;primary;low;high;high;high;some concerns;high;NA;es;clinical;no;NA;adults;yes;cbt for pain;psy;group;NA;no;9;NA;810;NA;9;NA;1;NA;90;NA;NA;NA;NA;NA;NA;49,35;51,37;6,43;9,38;42;42;84;1;42;42;84;34;41;75;NA;NA;NA;NA;NA;NA;combined;fm;NA;NA;NA;NA;121,2;138,84;108,36;127,56;yes;"the exclusion criteria were: (1) having major concomitant medical conditions (e.g., inflammatory rheumatic disease, endocrine disturbances, neurological disorder, cancer, recent surgery) or pregnancy; (2) hav- ing mental disorders with severe symptoms (e.g., major depression with suicide ideation, schizophrenia, personal- ity disorder) or other organic sleep disorder (i.e., apnea); (3) having a severe dependence of hypnotic drugs; and (4) having irregularities in circadian rhythms at the time of the study (i.e., by rotating work shifts).";no;NA;no;NA
lami, 2018;cbt;tau;cbt insomnia;tau;anx;msd;scl-90-r anxiety;post;10;self-report;1,78;1,5;0,93;0,93;1,68;1,37;1,05;0,91;27;36;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;lami_2018_msd_scl-90-ranxiety_post_10.0_self-report_cbt_tau_cbtinsomnia_tau;0,314947071;0,256167629;NA;NA;primary;low;high;high;high;some concerns;high;NA;es;clinical;no;NA;adults;yes;cbt for insomnia;psy;group;NA;no;9;NA;810;NA;9;NA;1;NA;90;NA;NA;NA;NA;NA;NA;49,66;51,37;8,44;9,38;42;42;84;1;42;42;84;38;41;79;NA;NA;NA;NA;NA;NA;combined;fm;NA;NA;NA;NA;101,64;138,84;83,88;127,56;yes;"the exclusion criteria were: (1) having major concomitant medical conditions (e.g., inflammatory rheumatic disease, endocrine disturbances, neurological disorder, cancer, recent surgery) or pregnancy; (2) hav- ing mental disorders with severe symptoms (e.g., major depression with suicide ideation, schizophrenia, personal- ity disorder) or other organic sleep disorder (i.e., apnea); (3) having a severe dependence of hypnotic drugs; and (4) having irregularities in circadian rhythms at the time of the study (i.e., by rotating work shifts).";no;NA;no;NA
lami, 2018;cbt;tau;cbt pain;tau;anx;msd;scl-90-r anxiety;follow up;22;self-report;1,63;1,5;0,81;0,93;1,6;1,18;1,05;1,18;24;26;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;lami_2018_msd_scl-90-ranxiety_followup_22.0_self-report_cbt_tau_cbtpain_tau;0,369243967;0,285544176;NA;NA;primary;low;high;high;high;some concerns;high;NA;es;clinical;no;NA;adults;yes;cbt for pain;psy;group;NA;no;9;NA;810;NA;9;NA;1;NA;90;NA;NA;NA;NA;NA;NA;49,35;51,37;6,43;9,38;42;42;84;1;42;42;84;34;41;75;NA;NA;NA;NA;NA;NA;combined;fm;NA;NA;NA;NA;121,2;138,84;108,36;127,56;yes;"the exclusion criteria were: (1) having major concomitant medical conditions (e.g., inflammatory rheumatic disease, endocrine disturbances, neurological disorder, cancer, recent surgery) or pregnancy; (2) hav- ing mental disorders with severe symptoms (e.g., major depression with suicide ideation, schizophrenia, personal- ity disorder) or other organic sleep disorder (i.e., apnea); (3) having a severe dependence of hypnotic drugs; and (4) having irregularities in circadian rhythms at the time of the study (i.e., by rotating work shifts).";no;NA;no;NA
lami, 2018;cbt;tau;cbt insomnia;tau;anx;msd;scl-90-r anxiety;follow up;22;self-report;1,78;1,5;0,93;0,93;1,62;1,18;0,98;0,69;22;26;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;lami_2018_msd_scl-90-ranxiety_followup_22.0_self-report_cbt_tau_cbtinsomnia_tau;0,518319364;0,294633049;NA;NA;primary;low;high;high;high;some concerns;high;NA;es;clinical;no;NA;adults;yes;cbt for insomnia;psy;group;NA;no;9;NA;810;NA;9;NA;1;NA;90;NA;NA;NA;NA;NA;NA;49,66;51,37;8,44;9,38;42;42;84;1;42;42;84;38;41;79;NA;NA;NA;NA;NA;NA;combined;fm;NA;NA;NA;NA;101,64;138,84;83,88;127,56;yes;"the exclusion criteria were: (1) having major concomitant medical conditions (e.g., inflammatory rheumatic disease, endocrine disturbances, neurological disorder, cancer, recent surgery) or pregnancy; (2) hav- ing mental disorders with severe symptoms (e.g., major depression with suicide ideation, schizophrenia, personal- ity disorder) or other organic sleep disorder (i.e., apnea); (3) having a severe dependence of hypnotic drugs; and (4) having irregularities in circadian rhythms at the time of the study (i.e., by rotating work shifts).";no;NA;no;NA
lami, 2018;cbt;tau;cbt pain;tau;phs;msd;fiq;post;10;self-report;-65,53;-55,57;11,08;18,14;-57,93;-55,45;14,16;16,79;28;36;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;lami_2018_msd_fiq_post_10.0_self-report_cbt_tau_cbtpain_tau;-0,156053867;0,252362888;NA;NA;primary;low;high;high;high;some concerns;high;NA;es;clinical;no;NA;adults;yes;cbt for pain;psy;group;NA;no;9;NA;810;NA;9;NA;1;NA;90;NA;NA;NA;NA;NA;NA;49,35;51,37;6,43;9,38;42;42;84;1;42;42;84;34;41;75;NA;NA;NA;NA;NA;NA;combined;fm;NA;NA;NA;NA;121,2;138,84;108,36;127,56;yes;"the exclusion criteria were: (1) having major concomitant medical conditions (e.g., inflammatory rheumatic disease, endocrine disturbances, neurological disorder, cancer, recent surgery) or pregnancy; (2) hav- ing mental disorders with severe symptoms (e.g., major depression with suicide ideation, schizophrenia, personal- ity disorder) or other organic sleep disorder (i.e., apnea); (3) having a severe dependence of hypnotic drugs; and (4) having irregularities in circadian rhythms at the time of the study (i.e., by rotating work shifts).";no;NA;no;NA
lami, 2018;cbt;tau;cbt insomnia;tau;phs;msd;fiq;post;10;self-report;-61,98;-55,57;11,14;18,14;-55,82;-55,45;14,52;16,79;27;36;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;lami_2018_msd_fiq_post_10.0_self-report_cbt_tau_cbtinsomnia_tau;-0,023037874;0,254596019;NA;NA;primary;low;high;high;high;some concerns;high;NA;es;clinical;no;NA;adults;yes;cbt for insomnia;psy;group;NA;no;9;NA;810;NA;9;NA;1;NA;90;NA;NA;NA;NA;NA;NA;49,66;51,37;8,44;9,38;42;42;84;1;42;42;84;38;41;79;NA;NA;NA;NA;NA;NA;combined;fm;NA;NA;NA;NA;101,64;138,84;83,88;127,56;yes;"the exclusion criteria were: (1) having major concomitant medical conditions (e.g., inflammatory rheumatic disease, endocrine disturbances, neurological disorder, cancer, recent surgery) or pregnancy; (2) hav- ing mental disorders with severe symptoms (e.g., major depression with suicide ideation, schizophrenia, personal- ity disorder) or other organic sleep disorder (i.e., apnea); (3) having a severe dependence of hypnotic drugs; and (4) having irregularities in circadian rhythms at the time of the study (i.e., by rotating work shifts).";no;NA;no;NA
lami, 2018;cbt;tau;cbt pain;tau;phs;msd;fiq;follow up;22;self-report;-65,53;-55,57;11,08;18,14;-53,33;-53,22;14,85;16,59;24;26;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;lami_2018_msd_fiq_followup_22.0_self-report_cbt_tau_cbtpain_tau;-0,006861268;0,283070117;NA;NA;primary;low;high;high;high;some concerns;high;NA;es;clinical;no;NA;adults;yes;cbt for pain;psy;group;NA;no;9;NA;810;NA;9;NA;1;NA;90;NA;NA;NA;NA;NA;NA;49,35;51,37;6,43;9,38;42;42;84;1;42;42;84;34;41;75;NA;NA;NA;NA;NA;NA;combined;fm;NA;NA;NA;NA;121,2;138,84;108,36;127,56;yes;"the exclusion criteria were: (1) having major concomitant medical conditions (e.g., inflammatory rheumatic disease, endocrine disturbances, neurological disorder, cancer, recent surgery) or pregnancy; (2) hav- ing mental disorders with severe symptoms (e.g., major depression with suicide ideation, schizophrenia, personal- ity disorder) or other organic sleep disorder (i.e., apnea); (3) having a severe dependence of hypnotic drugs; and (4) having irregularities in circadian rhythms at the time of the study (i.e., by rotating work shifts).";no;NA;no;NA
lami, 2018;cbt;tau;cbt insomnia;tau;phs;msd;fiq;follow up;22;self-report;-61,98;-55,57;11,14;18,14;-56,53;-53,22;13,97;16,59;22;26;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;lami_2018_msd_fiq_followup_22.0_self-report_cbt_tau_cbtinsomnia_tau;-0,210739198;0,29050688;NA;NA;primary;low;high;high;high;some concerns;high;NA;es;clinical;no;NA;adults;yes;cbt for insomnia;psy;group;NA;no;9;NA;810;NA;9;NA;1;NA;90;NA;NA;NA;NA;NA;NA;49,66;51,37;8,44;9,38;42;42;84;1;42;42;84;38;41;79;NA;NA;NA;NA;NA;NA;combined;fm;NA;NA;NA;NA;101,64;138,84;83,88;127,56;yes;"the exclusion criteria were: (1) having major concomitant medical conditions (e.g., inflammatory rheumatic disease, endocrine disturbances, neurological disorder, cancer, recent surgery) or pregnancy; (2) hav- ing mental disorders with severe symptoms (e.g., major depression with suicide ideation, schizophrenia, personal- ity disorder) or other organic sleep disorder (i.e., apnea); (3) having a severe dependence of hypnotic drugs; and (4) having irregularities in circadian rhythms at the time of the study (i.e., by rotating work shifts).";no;NA;no;NA
ljotsson, 2010;cbt+ambt;att plac;NA;NA;som;msd;gsrs-ibs;post;10;self-report;48,5;49,6;8,8;11,8;32,4;47,3;12,1;12,6;42;43;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;ljotsson_2010_msd_gsrs-ibs_post_10.0_self-report_cbt+ambt_attplac_NA_NA;-1,195006716;0,235838811;NA;NA;primary;low;low;low;high;some concerns;high;NA;se;community;no;NA;adults;yes;Internet-delivered exposure and mindfulness based therapy;para;individual;NA;internet;5;NA;NA;NA;10;NA;0,5;NA;0;0;NA;NA;NA;NA;NA;36,4;32,8;10,1;8,6;35;37;72;0,84;43;43;86;38;43;81;29;43;72;medical circumstances (n = 1);NA;NA;cut-off;ibs;NA;NA;NA;NA;86,4;66;NA;NA;yes;"the following alarm symptoms were cause for exclusion: a) symptom debut after age 50, b) blood in stool without satisfactory medical explanation (such as known hemorrhoids), c) diarrhea predominant IBS with no colonoscopy performed, d) rapid weight loss that could not be linked to change in diet, e) and night symptoms that persistently caused sleeplessness, and f) less than 2 years of IBS-symptoms (regardless of when diagnosis had been given). Besides being an alarm symptom, the last criterion was also applied because we hypothesized that it takes some time to develop GSA and avoidance behaviors in response to symptoms. Additionally, g) any presence of current or previous inflammatory bowel disease was cause for exclusion as well as h) lactose or gluten intolerance where proper adjustments in diet had not been made. The Montgomery √Ösberg Depression Rating Scale-Self report (MADRS-S; Svanborg & √Ösberg, 1994) was used to exclude participants fulfilling criteria for i) suicide ideation (item 9 ! 4), and j) severe depressive symptoms (total score ! 30). Participants fulfilling criteria for k) substance dependence according to Alcohol Use Disorders Identification Test (AUDIT; Saunders, Aasland, Babor, de la Fuente, & Grant, 1993) or Drug Use Disorders Identification Test (DUDIT; Berman, Bergman, Palmstierna, & Schlyter, 2005) and participants suffering from l) psychosis, m) manic episode, or n) anorexia according to the Mini- International Neuropsychiatric Interview (MINI; Sheehan et al., 1998) were also excluded.";yes;the treatment credibility questionnaire was completed by 40 of the 42 participants in the treatment condition with a mean score of 31.4 (SD 1‚ÅÑ4 10.7). There were no significant correlations between the treatment credibility and any change scores on the outcome measures or the number of completed steps. However, when comparing the 29 participants that reached step 5 and the 11 that did not reach step five (but completed the credibility question- naire) a significant difference was revealed, (M 1‚ÅÑ4 33.5, SD 1‚ÅÑ4 9.2 vs. M 1‚ÅÑ4 24.2, SD 1‚ÅÑ4 11.0) with a large between group effect size (t38 1‚ÅÑ4 2.34, p 1‚ÅÑ4 .02, d 1‚ÅÑ4 0.92).;no;NA
ljotsson, 2010;cbt+ambt;att plac;NA;NA;depr;msd;madrs;post;10;clinican;11,9;12,5;8,1;7,6;6,9;10,5;8,1;8,6;42;43;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;ljotsson_2010_msd_madrs_post_10.0_clinican_cbt+ambt_attplac_NA_NA;-0,426884952;0,219446991;NA;NA;primary;low;low;low;high;some concerns;high;NA;se;community;no;NA;adults;yes;Internet-delivered exposure and mindfulness based therapy;para;individual;NA;internet;5;NA;NA;NA;10;NA;0,5;NA;0;0;NA;NA;NA;NA;NA;36,4;32,8;10,1;8,6;35;37;72;0,84;43;43;86;38;43;81;29;43;72;medical circumstances (n = 1);NA;NA;cut-off;ibs;NA;NA;NA;NA;86,4;66;NA;NA;yes;"the following alarm symptoms were cause for exclusion: a) symptom debut after age 50, b) blood in stool without satisfactory medical explanation (such as known hemorrhoids), c) diarrhea predominant IBS with no colonoscopy performed, d) rapid weight loss that could not be linked to change in diet, e) and night symptoms that persistently caused sleeplessness, and f) less than 2 years of IBS-symptoms (regardless of when diagnosis had been given). Besides being an alarm symptom, the last criterion was also applied because we hypothesized that it takes some time to develop GSA and avoidance behaviors in response to symptoms. Additionally, g) any presence of current or previous inflammatory bowel disease was cause for exclusion as well as h) lactose or gluten intolerance where proper adjustments in diet had not been made. The Montgomery √Ösberg Depression Rating Scale-Self report (MADRS-S; Svanborg & √Ösberg, 1994) was used to exclude participants fulfilling criteria for i) suicide ideation (item 9 ! 4), and j) severe depressive symptoms (total score ! 30). Participants fulfilling criteria for k) substance dependence according to Alcohol Use Disorders Identification Test (AUDIT; Saunders, Aasland, Babor, de la Fuente, & Grant, 1993) or Drug Use Disorders Identification Test (DUDIT; Berman, Bergman, Palmstierna, & Schlyter, 2005) and participants suffering from l) psychosis, m) manic episode, or n) anorexia according to the Mini- International Neuropsychiatric Interview (MINI; Sheehan et al., 1998) were also excluded.";yes;the treatment credibility questionnaire was completed by 40 of the 42 participants in the treatment condition with a mean score of 31.4 (SD 1‚ÅÑ4 10.7). There were no significant correlations between the treatment credibility and any change scores on the outcome measures or the number of completed steps. However, when comparing the 29 participants that reached step 5 and the 11 that did not reach step five (but completed the credibility question- naire) a significant difference was revealed, (M 1‚ÅÑ4 33.5, SD 1‚ÅÑ4 9.2 vs. M 1‚ÅÑ4 24.2, SD 1‚ÅÑ4 11.0) with a large between group effect size (t38 1‚ÅÑ4 2.34, p 1‚ÅÑ4 .02, d 1‚ÅÑ4 0.92).;no;NA
ljotsson, 2010;cbt+ambt;att plac;NA;NA;phs;msd;ibs-qol;post;10;self-report;52,2;53,8;19,9;18,9;72,8;52,9;19,9;21,3;42;43;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;ljotsson_2010_msd_ibs-qol_post_10.0_self-report_cbt+ambt_attplac_NA_NA;0,956320775;0,229224561;NA;NA;primary;low;low;low;high;some concerns;high;NA;se;community;no;NA;adults;yes;Internet-delivered exposure and mindfulness based therapy;para;individual;NA;internet;5;NA;NA;NA;10;NA;0,5;NA;0;0;NA;NA;NA;NA;NA;36,4;32,8;10,1;8,6;35;37;72;0,84;43;43;86;38;43;81;29;43;72;medical circumstances (n = 1);NA;NA;cut-off;ibs;NA;NA;NA;NA;86,4;66;NA;NA;yes;"the following alarm symptoms were cause for exclusion: a) symptom debut after age 50, b) blood in stool without satisfactory medical explanation (such as known hemorrhoids), c) diarrhea predominant IBS with no colonoscopy performed, d) rapid weight loss that could not be linked to change in diet, e) and night symptoms that persistently caused sleeplessness, and f) less than 2 years of IBS-symptoms (regardless of when diagnosis had been given). Besides being an alarm symptom, the last criterion was also applied because we hypothesized that it takes some time to develop GSA and avoidance behaviors in response to symptoms. Additionally, g) any presence of current or previous inflammatory bowel disease was cause for exclusion as well as h) lactose or gluten intolerance where proper adjustments in diet had not been made. The Montgomery √Ösberg Depression Rating Scale-Self report (MADRS-S; Svanborg & √Ösberg, 1994) was used to exclude participants fulfilling criteria for i) suicide ideation (item 9 ! 4), and j) severe depressive symptoms (total score ! 30). Participants fulfilling criteria for k) substance dependence according to Alcohol Use Disorders Identification Test (AUDIT; Saunders, Aasland, Babor, de la Fuente, & Grant, 1993) or Drug Use Disorders Identification Test (DUDIT; Berman, Bergman, Palmstierna, & Schlyter, 2005) and participants suffering from l) psychosis, m) manic episode, or n) anorexia according to the Mini- International Neuropsychiatric Interview (MINI; Sheehan et al., 1998) were also excluded.";yes;the treatment credibility questionnaire was completed by 40 of the 42 participants in the treatment condition with a mean score of 31.4 (SD 1‚ÅÑ4 10.7). There were no significant correlations between the treatment credibility and any change scores on the outcome measures or the number of completed steps. However, when comparing the 29 participants that reached step 5 and the 11 that did not reach step five (but completed the credibility question- naire) a significant difference was revealed, (M 1‚ÅÑ4 33.5, SD 1‚ÅÑ4 9.2 vs. M 1‚ÅÑ4 24.2, SD 1‚ÅÑ4 11.0) with a large between group effect size (t38 1‚ÅÑ4 2.34, p 1‚ÅÑ4 .02, d 1‚ÅÑ4 0.92).;no;NA
ljotsson, 2011;cbt+ambt;att plac;NA;NA;som;msd;gsrs-ibs;post;10;self-report;44,6;39,8;11,1;12;31;40,9;10,2;14,5;30;31;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;ljotsson_2011_msd_gsrs-ibs_post_10.0_self-report_cbt+ambt_attplac_NA_NA;-0,77743631;0,265846776;NA;NA;primary;low;low;low;high;some concerns;high;ClinicalTrials.gov: NCT00844961;se;clinical;yes;NA;adults;yes;Internet-delivered exposure and mindfulness based therapy;para;individual;NA;internet;5;NA;NA;NA;10;NA;0,5;NA;NA;NA;NA;NA;NA;NA;NA;33,5;36,3;11,2;11,3;23;22;45;0,74;30;31;61;30;31;61;13;27;40;Symptom Improvement (n = 3), ICBT not suitable (n = 3), practical reasons (n = 3);NA;NA;medical;ibs;NA;NA;NA;NA;140,4;135,6;152,4;133,2;yes;Eligible patients were excluded if they g) reported debut of IBS symptoms after 50 years of age and were judged to require continued monitoring at the clinic, h) suffered from such severe diarrhea that IBS-symptom modifying drugs with psychotropic effects, such as tricyclic antidepressants or selective serotonin reuptake inhibitors, were judged to be the treatment of choice, i) could not read or write Swedish j) did not have access to the internet, k) were judged to be highly unsuitable for ICBT for somatic or psychological reasons as assessed by the gastroenterologist, or l) were not willing to participate in the study.;no;NA;yes;NA
ljotsson, 2011;cbt+ambt;att plac;NA;NA;phs;msd;ibs-qol;post;10;self-report;67,4;76,1;20,9;18,8;82,6;67,4;13,4;23,1;30;31;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;ljotsson_2011_msd_ibs-qol_post_10.0_self-report_cbt+ambt_attplac_NA_NA;0,791339185;0,266191541;NA;NA;primary;low;low;low;high;some concerns;high;ClinicalTrials.gov: NCT00844961;se;clinical;yes;NA;adults;yes;Internet-delivered exposure and mindfulness based therapy;para;individual;NA;internet;5;NA;NA;NA;10;NA;0,5;NA;NA;NA;NA;NA;NA;NA;NA;33,5;36,3;11,2;11,3;23;22;45;0,74;30;31;61;30;31;61;13;27;40;Symptom Improvement (n = 3), ICBT not suitable (n = 3), practical reasons (n = 3);NA;NA;medical;ibs;NA;NA;NA;NA;140,4;135,6;152,4;133,2;yes;Eligible patients were excluded if they g) reported debut of IBS symptoms after 50 years of age and were judged to require continued monitoring at the clinic, h) suffered from such severe diarrhea that IBS-symptom modifying drugs with psychotropic effects, such as tricyclic antidepressants or selective serotonin reuptake inhibitors, were judged to be the treatment of choice, i) could not read or write Swedish j) did not have access to the internet, k) were judged to be highly unsuitable for ICBT for somatic or psychological reasons as assessed by the gastroenterologist, or l) were not willing to participate in the study.;no;NA;yes;NA
luciano, 2014;ambt;wl;NA;NA;som;msd;vas pain;post;8;self-report;65,43;64,04;18,34;18,72;48,07;64,28;10,5;15,76;51;53;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;luciano_2014_msd_vaspain_post_8.0_self-report_ambt_wl_NA_NA;-1,197097053;0,21323248;NA;NA;primary;low;low;low;high;some concerns;high;NA;es;clinical;no;NA;adults;yes;original program (adapted to FM);psy;group;NA;no;8;NA;1200;NA;8;NA;1;NA;150;NA;6,8;NA;1,7;NA;0,85;48,88;48,28;5,94;5,71;49;50;99;0,95;51;53;104;51;53;104;22;50;72;NA;NA;"Lack of efficacy, n= 3; Patient decision, n= 2";combined;fm;NA;NA;NA;NA;168,96;155,76;107,52;104,88;yes;severe axis I psychiatric disorders (dementia, schizophrenia, paranoid disorder, alcohol and/or drug use disorders) and with severe somatic disorders that, from the clinician’s point of view, prevented patients from carrying out a psychological assessment or participating in other clinical trials;no;NA;no;NA
luciano, 2014;ambt;wl;NA;NA;som;msd;vas pain;follow up;24;self-report;65,43;64,04;18,34;18,72;49,58;64,36;10,98;15,34;51;53;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;luciano_2014_msd_vaspain_followup_24.0_self-report_ambt_wl_NA_NA;-1,096373172;0,210572846;NA;NA;primary;low;low;low;high;some concerns;high;NA;es;clinical;no;NA;adults;yes;original program (adapted to FM);psy;group;NA;no;8;NA;1200;NA;8;NA;1;NA;150;NA;6,8;NA;1,7;NA;0,85;48,88;48,28;5,94;5,71;49;50;99;0,95;51;53;104;51;53;104;22;50;72;NA;NA;"Lack of efficacy, n= 3; Patient decision, n= 2";combined;fm;NA;NA;NA;NA;168,96;155,76;107,52;104,88;yes;severe axis I psychiatric disorders (dementia, schizophrenia, paranoid disorder, alcohol and/or drug use disorders) and with severe somatic disorders that, from the clinician’s point of view, prevented patients from carrying out a psychological assessment or participating in other clinical trials;no;NA;no;NA
luciano, 2014;ambt;wl;NA;NA;depr;msd;hads-d;post;8;self-report;8;9,23;2,88;3,56;5,41;9,34;1,36;2,63;51;53;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;luciano_2014_msd_hads-d_post_8.0_self-report_ambt_wl_NA_NA;-1,852823705;0,235002958;NA;NA;primary;low;low;low;high;some concerns;high;NA;es;clinical;no;NA;adults;yes;original program (adapted to FM);psy;group;NA;no;8;NA;1200;NA;8;NA;1;NA;150;NA;6,8;NA;1,7;NA;0,85;48,88;48,28;5,94;5,71;49;50;99;0,95;51;53;104;51;53;104;22;50;72;NA;NA;"Lack of efficacy, n= 3; Patient decision, n= 2";combined;fm;NA;NA;NA;NA;168,96;155,76;107,52;104,88;yes;severe axis I psychiatric disorders (dementia, schizophrenia, paranoid disorder, alcohol and/or drug use disorders) and with severe somatic disorders that, from the clinician’s point of view, prevented patients from carrying out a psychological assessment or participating in other clinical trials;no;NA;no;NA
luciano, 2014;ambt;wl;NA;NA;depr;msd;hads-d;follow up;24;self-report;8;9,23;2,88;3,56;5,84;9,32;1,6;3,04;51;53;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;luciano_2014_msd_hads-d_followup_24.0_self-report_ambt_wl_NA_NA;-1,414208497;0,219623349;NA;NA;primary;low;low;low;high;some concerns;high;NA;es;clinical;no;NA;adults;yes;original program (adapted to FM);psy;group;NA;no;8;NA;1200;NA;8;NA;1;NA;150;NA;6,8;NA;1,7;NA;0,85;48,88;48,28;5,94;5,71;49;50;99;0,95;51;53;104;51;53;104;22;50;72;NA;NA;"Lack of efficacy, n= 3; Patient decision, n= 2";combined;fm;NA;NA;NA;NA;168,96;155,76;107,52;104,88;yes;severe axis I psychiatric disorders (dementia, schizophrenia, paranoid disorder, alcohol and/or drug use disorders) and with severe somatic disorders that, from the clinician’s point of view, prevented patients from carrying out a psychological assessment or participating in other clinical trials;no;NA;no;NA
luciano, 2014;ambt;wl;NA;NA;anx;msd;hads-a;post;8;self-report;12,67;12,4;4,36;4,31;8,28;11,36;2,38;3,8;51;53;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;luciano_2014_msd_hads-a_post_8.0_self-report_ambt_wl_NA_NA;-0,960188476;0,207302558;NA;NA;primary;low;low;low;high;some concerns;high;NA;es;clinical;no;NA;adults;yes;original program (adapted to FM);psy;group;NA;no;8;NA;1200;NA;8;NA;1;NA;150;NA;6,8;NA;1,7;NA;0,85;48,88;48,28;5,94;5,71;49;50;99;0,95;51;53;104;51;53;104;22;50;72;NA;NA;"Lack of efficacy, n= 3; Patient decision, n= 2";combined;fm;NA;NA;NA;NA;168,96;155,76;107,52;104,88;yes;severe axis I psychiatric disorders (dementia, schizophrenia, paranoid disorder, alcohol and/or drug use disorders) and with severe somatic disorders that, from the clinician’s point of view, prevented patients from carrying out a psychological assessment or participating in other clinical trials;no;NA;no;NA
luciano, 2014;ambt;wl;NA;NA;anx;msd;hads-a;follow up;24;self-report;12,67;12,4;4,36;4,31;8,73;12,15;2,04;4,2;51;53;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;luciano_2014_msd_hads-a_followup_24.0_self-report_ambt_wl_NA_NA;-1,022038864;0,208740431;NA;NA;primary;low;low;low;high;some concerns;high;NA;es;clinical;no;NA;adults;yes;original program (adapted to FM);psy;group;NA;no;8;NA;1200;NA;8;NA;1;NA;150;NA;6,8;NA;1,7;NA;0,85;48,88;48,28;5,94;5,71;49;50;99;0,95;51;53;104;51;53;104;22;50;72;NA;NA;"Lack of efficacy, n= 3; Patient decision, n= 2";combined;fm;NA;NA;NA;NA;168,96;155,76;107,52;104,88;yes;severe axis I psychiatric disorders (dementia, schizophrenia, paranoid disorder, alcohol and/or drug use disorders) and with severe somatic disorders that, from the clinician’s point of view, prevented patients from carrying out a psychological assessment or participating in other clinical trials;no;NA;no;NA
luciano, 2014;ambt;wl;NA;NA;phs;msd;fiq;post;8;self-report;-68,2;-65,87;8,96;7,63;-48,7;-67,68;6,91;9,23;51;53;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;luciano_2014_msd_fiq_post_8.0_self-report_ambt_wl_NA_NA;2,304478822;0,253748302;NA;NA;primary;low;low;low;high;some concerns;high;NA;es;clinical;no;NA;adults;yes;original program (adapted to FM);psy;group;NA;no;8;NA;1200;NA;8;NA;1;NA;150;NA;6,8;NA;1,7;NA;0,85;48,88;48,28;5,94;5,71;49;50;99;0,95;51;53;104;51;53;104;22;50;72;NA;NA;"Lack of efficacy, n= 3; Patient decision, n= 2";combined;fm;NA;NA;NA;NA;168,96;155,76;107,52;104,88;yes;severe axis I psychiatric disorders (dementia, schizophrenia, paranoid disorder, alcohol and/or drug use disorders) and with severe somatic disorders that, from the clinician’s point of view, prevented patients from carrying out a psychological assessment or participating in other clinical trials;no;NA;no;NA
luciano, 2014;ambt;wl;NA;NA;phs;msd;fiq;follow up;24;self-report;-68,2;-65,87;8,96;7,63;-49,49;-67,45;8,77;9,15;51;53;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;luciano_2014_msd_fiq_followup_24.0_self-report_ambt_wl_NA_NA;1,988415944;0,240349259;NA;NA;primary;low;low;low;high;some concerns;high;NA;es;clinical;no;NA;adults;yes;original program (adapted to FM);psy;group;NA;no;8;NA;1200;NA;8;NA;1;NA;150;NA;6,8;NA;1,7;NA;0,85;48,88;48,28;5,94;5,71;49;50;99;0,95;51;53;104;51;53;104;22;50;72;NA;NA;"Lack of efficacy, n= 3; Patient decision, n= 2";combined;fm;NA;NA;NA;NA;168,96;155,76;107,52;104,88;yes;severe axis I psychiatric disorders (dementia, schizophrenia, paranoid disorder, alcohol and/or drug use disorders) and with severe somatic disorders that, from the clinician’s point of view, prevented patients from carrying out a psychological assessment or participating in other clinical trials;no;NA;no;NA
luciano, 2014;ambt;wl;NA;NA;phs;msd;eq-5d;post;8;self-report;50,88;48,78;15,48;16,76;66,2;51;8,64;10,69;51;53;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;luciano_2014_msd_eq-5d_post_8.0_self-report_ambt_wl_NA_NA;1,549204668;0,224023213;NA;NA;secondary;NA;NA;NA;NA;NA;NA;NA;es;clinical;no;NA;adults;yes;original program (adapted to FM);psy;group;NA;no;8;NA;1200;NA;8;NA;1;NA;150;NA;6,8;NA;1,7;NA;0,85;48,88;48,28;5,94;5,71;49;50;99;0,95;51;53;104;51;53;104;22;50;72;NA;NA;"Lack of efficacy, n= 3; Patient decision, n= 2";combined;fm;NA;NA;NA;NA;168,96;155,76;107,52;104,88;yes;severe axis I psychiatric disorders (dementia, schizophrenia, paranoid disorder, alcohol and/or drug use disorders) and with severe somatic disorders that, from the clinician’s point of view, prevented patients from carrying out a psychological assessment or participating in other clinical trials;no;NA;no;NA
martin, 2007;cbt;tau;NA;NA;som;msd;bsi-6;post;4;self-report;0,76;0,6;0,75;0,51;0,59;0,5;0,55;0,5;70;70;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;martin_2007_msd_bsi-6_post_4.0_self-report_cbt_tau_NA_NA;0,170302226;0,16934033;NA;NA;primary;low;low;low;high;some concerns;high;NA;de;combined;no;NA;adults;yes;one sessions cbt;mixed;group;NA;no;1;NA;210;NA;1;NA;1;NA;210;NA;5;NA;0;NA;5;45,7;51,7;13,6;15,9;48;57;105;0,75;70;70;140;60;62;122;NA;NA;NA;NA;NA;NA;combined;mus;7,6;6,6;3,9;3,6;110,4;141,6;134,4;153,6;yes;severe current medical condition,chronic medical disease, psychotic symptoms, substance dependence;yes;"96% felt that it should be offered more often; 94% felt understood by the therapist; and 92% rated the strategies as promising for the management of their complaints.";yes;the negative ratings, as follows, were very low (between 0% and 4%). Although side effects were not assessed systematically, no adverse events were spontaneously reported.
martin, 2007;cbt;tau;NA;NA;som;msd;bsi-6;follow up;28;self-report;0,76;0,6;0,75;0,51;0,59;0,61;0,59;0,63;70;70;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;martin_2007_msd_bsi-6_followup_28.0_self-report_cbt_tau_NA_NA;-0,03259086;0,169042195;NA;NA;primary;low;low;low;high;some concerns;high;NA;de;combined;no;NA;adults;yes;one sessions cbt;mixed;group;NA;no;1;NA;210;NA;1;NA;1;NA;210;NA;5;NA;0;NA;5;45,7;51,7;13,6;15,9;48;57;105;0,75;70;70;140;60;62;122;NA;NA;NA;NA;NA;NA;combined;mus;7,6;6,6;3,9;3,6;110,4;141,6;134,4;153,6;yes;severe current medical condition,chronic medical disease, psychotic symptoms, substance dependence;yes;"96% felt that it should be offered more often; 94% felt understood by the therapist; and 92% rated the strategies as promising for the management of their complaints.";yes;the negative ratings, as follows, were very low (between 0% and 4%). Although side effects were not assessed systematically, no adverse events were spontaneously reported.
martin, 2007;cbt;tau;NA;NA;phs;msd;bdi;post;4;self-report;15,9;13,2;9,6;6,4;13,7;12,5;9,1;7,4;70;70;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;martin_2007_msd_bdi_post_4.0_self-report_cbt_tau_NA_NA;0,143900842;0,169251871;NA;NA;primary;low;low;low;high;some concerns;high;NA;de;combined;no;NA;adults;yes;one sessions cbt;mixed;group;NA;no;1;NA;210;NA;1;NA;1;NA;210;NA;5;NA;0;NA;5;45,7;51,7;13,6;15,9;48;57;105;0,75;70;70;140;60;62;122;NA;NA;NA;NA;NA;NA;combined;mus;7,6;6,6;3,9;3,6;110,4;141,6;134,4;153,6;yes;severe current medical condition,chronic medical disease, psychotic symptoms, substance dependence;yes;"96% felt that it should be offered more often; 94% felt understood by the therapist; and 92% rated the strategies as promising for the management of their complaints.";yes;the negative ratings, as follows, were very low (between 0% and 4%). Although side effects were not assessed systematically, no adverse events were spontaneously reported.
martin, 2007;cbt;tau;NA;NA;phs;msd;bdi;follow up;28;self-report;15,9;13,2;9,6;6,4;14,2;11,9;9,5;7,5;70;70;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;martin_2007_msd_bdi_followup_28.0_self-report_cbt_tau_NA_NA;0,267271703;0,169792083;NA;NA;primary;low;low;low;high;some concerns;high;NA;de;combined;no;NA;adults;yes;one sessions cbt;mixed;group;NA;no;1;NA;210;NA;1;NA;1;NA;210;NA;5;NA;0;NA;5;45,7;51,7;13,6;15,9;48;57;105;0,75;70;70;140;60;62;122;NA;NA;NA;NA;NA;NA;combined;mus;7,6;6,6;3,9;3,6;110,4;141,6;134,4;153,6;yes;severe current medical condition,chronic medical disease, psychotic symptoms, substance dependence;yes;"96% felt that it should be offered more often; 94% felt understood by the therapist; and 92% rated the strategies as promising for the management of their complaints.";yes;the negative ratings, as follows, were very low (between 0% and 4%). Although side effects were not assessed systematically, no adverse events were spontaneously reported.
martin, 2007;cbt;tau;NA;NA;ha;msd;wi;post;4;self-report;6,5;5,7;3,8;3,2;5,9;5,5;4,1;3,6;70;70;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;martin_2007_msd_wi_post_4.0_self-report_cbt_tau_NA_NA;0,103113263;0,169144371;NA;NA;primary;low;low;low;high;some concerns;high;NA;de;combined;no;NA;adults;yes;one sessions cbt;mixed;group;NA;no;1;NA;210;NA;1;NA;1;NA;210;NA;5;NA;0;NA;5;45,7;51,7;13,6;15,9;48;57;105;0,75;70;70;140;60;62;122;NA;NA;NA;NA;NA;NA;combined;mus;7,6;6,6;3,9;3,6;110,4;141,6;134,4;153,6;yes;severe current medical condition,chronic medical disease, psychotic symptoms, substance dependence;yes;"96% felt that it should be offered more often; 94% felt understood by the therapist; and 92% rated the strategies as promising for the management of their complaints.";yes;the negative ratings, as follows, were very low (between 0% and 4%). Although side effects were not assessed systematically, no adverse events were spontaneously reported.
martin, 2007;cbt;tau;NA;NA;ha;msd;wi;follow up;28;self-report;6,5;5,7;3,8;3,2;5,4;5,5;3,3;3,2;70;70;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;martin_2007_msd_wi_followup_28.0_self-report_cbt_tau_NA_NA;-0,030598082;0,16904085;NA;NA;primary;low;low;low;high;some concerns;high;NA;de;combined;no;NA;adults;yes;one sessions cbt;mixed;group;NA;no;1;NA;210;NA;1;NA;1;NA;210;NA;5;NA;0;NA;5;45,7;51,7;13,6;15,9;48;57;105;0,75;70;70;140;60;62;122;NA;NA;NA;NA;NA;NA;combined;mus;7,6;6,6;3,9;3,6;110,4;141,6;134,4;153,6;yes;severe current medical condition,chronic medical disease, psychotic symptoms, substance dependence;yes;"96% felt that it should be offered more often; 94% felt understood by the therapist; and 92% rated the strategies as promising for the management of their complaints.";yes;the negative ratings, as follows, were very low (between 0% and 4%). Although side effects were not assessed systematically, no adverse events were spontaneously reported.
mcbeth, 2012;cbt;tau;NA;NA;phs;msd;sf-36;post;24;self-report;38,9;37,4;8,4;8,2;41,5;39,9;11;10,1;87;88;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;mcbeth_2012_msd_sf-36_post_24.0_self-report_cbt_tau_NA_NA;0,150900303;0,151405144;NA;NA;primary;low;low;low;high;some concerns;high;ISRCTN registry, ISRCTN67013851, Managing Unexplained Symptoms (chronic widespread pain) In primary Care: Involving traditional and Accessible New approaches, https://www.isrctn.com/ISRCTN67013851;gb;clinical;no;NA;adults;yes;managing chronic widespread pain;psy;individual;NA;no;9;NA;337,5;NA;24;NA;0,38;NA;37,5;NA;5,93;NA;3,25;NA;0,66;56,5;56,3;13,7;12,5;80;76;156;0,71;112;109;221;NA;NA;NA;NA;NA;NA;NA;NA;NA;cut-off;cwp;NA;NA;NA;NA;NA;NA;NA;NA;yes;patient exclusions were a severe psychiatric disorder (currently sui- cidal or psychotic) impairing ability to engage with interven- tions, contraindications for exercise (eg, forbidden by family phy- sician, chest pain on exercise, syncope, uncontrolled epilepsy, current fracture), or a condition for which the interventions were not indicated (eg, metastatic cancer).;no;NA;yes;for safety outcomes, adverse events (serious and nonserious) were recorded. One of us (G.J.M., who was blind to treatment allocation) was notified of adverse events and determined whether the event was serious or nonserious. He was then unmasked to treatment allocation to determine whether adverse events were adverse reactions to treatment. Adverse events were rare. Two deaths were recorded: 1 in the exercise group and 1 in the TCBT group (respectively, the deaths occurred 14 and 2 months after randomization, and the causes of death were metastatic cancer and pancreatic cancer). None of the adverse events were adverse reactions.
mcbeth, 2012;cbt;tau;NA;NA;phs;msd;sf-36;follow up;36;self-report;38,9;37,4;8,4;8,2;40,8;39,6;11,2;10,5;91;98;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;mcbeth_2012_msd_sf-36_followup_36.0_self-report_cbt_tau_NA_NA;0,110230685;0,14568973;NA;NA;primary;low;low;low;high;some concerns;high;ISRCTN registry, ISRCTN67013851, Managing Unexplained Symptoms (chronic widespread pain) In primary Care: Involving traditional and Accessible New approaches, https://www.isrctn.com/ISRCTN67013851;gb;clinical;no;NA;adults;yes;managing chronic widespread pain;psy;individual;NA;no;9;NA;337,5;NA;24;NA;0,38;NA;37,5;NA;5,93;NA;3,25;NA;0,66;56,5;56,3;13,7;12,5;80;76;156;0,71;112;109;221;NA;NA;NA;NA;NA;NA;NA;NA;NA;cut-off;cwp;NA;NA;NA;NA;NA;NA;NA;NA;yes;patient exclusions were a severe psychiatric disorder (currently sui- cidal or psychotic) impairing ability to engage with interven- tions, contraindications for exercise (eg, forbidden by family phy- sician, chest pain on exercise, syncope, uncontrolled epilepsy, current fracture), or a condition for which the interventions were not indicated (eg, metastatic cancer).;no;NA;yes;for safety outcomes, adverse events (serious and nonserious) were recorded. One of us (G.J.M., who was blind to treatment allocation) was notified of adverse events and determined whether the event was serious or nonserious. He was then unmasked to treatment allocation to determine whether adverse events were adverse reactions to treatment. Adverse events were rare. Two deaths were recorded: 1 in the exercise group and 1 in the TCBT group (respectively, the deaths occurred 14 and 2 months after randomization, and the causes of death were metastatic cancer and pancreatic cancer). None of the adverse events were adverse reactions.
mccrae, 2019;cbt;tau;cbt pain;tau;som;msd;mpq;post;8;self-report;29,95;28,53;13,27;13,4;28,01;29,84;14,15;14,53;37;37;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;mccrae_2019_msd_mpq_post_8.0_self-report_cbt_tau_cbtpain_tau;-0,126270024;0,232731761;NA;NA;primary;low;low;low;high;some concerns;high;ClinicalTrials.gov, NCT02001077, Sleep and Pain Interventions in Fibromyalgia (SPIN), https://clinicaltrials.gov/ct2/show/NCT02001077;us;combined;yes;participants were compensated US$100 following each assessment period. They received the treatment and parking on the UF campus at no charge.;adults;yes;cbt for pain;para;individual;NA;no;8;NA;400;NA;8;NA;1;NA;50;NA;7,08;NA;2,02;NA;0,89;51,54;52,27;10,62;11,19;34;37;71;0,95;37;37;74;30;37;67;30;28;58;NA;NA;NA;combined;fm;NA;NA;NA;NA;94,64;109,46;76,16;88,62;yes;"exclusion criteria were sleep disorders other than insomnia, specifically sleep apnea (apnea–hypopnea index greater than 15 per hr or between 10 and 15 per hr with oxygen saturation below 88%) or periodic limb movements (PLMS index greater than 15 per hr); bipolar or seizure disorders (due to contraindication for the sleep restriction component of CBT-I); significant medical (e.g. cancer) or neurological disorder (e.g. dementia); severe untreated psychiatric comorbidity (e.g. schizophrenia and substance abuse); cognitive impairment based on Mini-Mental State Examination (MMSE) score below 26 [21]; and concurrent participation in CBT or other nonpharmacological treatment outside of the study.";yes;Average total credibility scores for CBT-I (M = 8.93, SD = 1.21) and CBT-P (M = 8.38, SD = 1.37) did not significantly differ.;no;NA
mccrae, 2019;cbt;tau;cbt insomnia;tau;som;msd;mpq;post;8;self-report;22,85;28,53;13,15;13,4;26,26;29,84;15,01;14,53;39;37;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;mccrae_2019_msd_mpq_post_8.0_self-report_cbt_tau_cbtinsomnia_tau;-0,239781375;0,230334805;NA;NA;primary;low;low;low;high;some concerns;high;ClinicalTrials.gov, NCT02001077, Sleep and Pain Interventions in Fibromyalgia (SPIN), https://clinicaltrials.gov/ct2/show/NCT02001077;us;combined;yes;participants were compensated US$100 following each assessment period. They received the treatment and parking on the UF campus at no charge.;adults;yes;cbt for insomnia;para;individual;NA;no;8;NA;400;NA;8;NA;1;NA;50;NA;6,95;NA;2,16;NA;0,87;54,13;52,27;11,03;11,19;39;37;76;0,95;39;37;76;30;37;67;27;28;55;NA;NA;NA;combined;fm;NA;NA;NA;NA;114,52;109,46;91,1;88,62;yes;"exclusion criteria were sleep disorders other than insomnia, specifically sleep apnea (apnea–hypopnea index greater than 15 per hr or between 10 and 15 per hr with oxygen saturation below 88%) or periodic limb movements (PLMS index greater than 15 per hr); bipolar or seizure disorders (due to contraindication for the sleep restriction component of CBT-I); significant medical (e.g. cancer) or neurological disorder (e.g. dementia); severe untreated psychiatric comorbidity (e.g. schizophrenia and substance abuse); cognitive impairment based on Mini-Mental State Examination (MMSE) score below 26 [21]; and concurrent participation in CBT or other nonpharmacological treatment outside of the study.";yes;Average total credibility scores for CBT-I (M = 8.93, SD = 1.21) and CBT-P (M = 8.38, SD = 1.37) did not significantly differ.;no;NA
mccrae, 2019;cbt;tau;cbt pain;tau;som;msd;mpq;follow up;32;self-report;29,95;28,53;13,27;13,4;28,99;23,3;15,01;16,02;37;37;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;mccrae_2019_msd_mpq_followup_32.0_self-report_cbt_tau_cbtpain_tau;0,362716236;0,234439488;NA;NA;primary;low;low;low;high;some concerns;high;ClinicalTrials.gov, NCT02001077, Sleep and Pain Interventions in Fibromyalgia (SPIN), https://clinicaltrials.gov/ct2/show/NCT02001077;us;combined;yes;participants were compensated US$100 following each assessment period. They received the treatment and parking on the UF campus at no charge.;adults;yes;cbt for pain;para;individual;NA;no;8;NA;400;NA;8;NA;1;NA;50;NA;7,08;NA;2,02;NA;0,89;51,54;52,27;10,62;11,19;34;37;71;0,95;37;37;74;30;37;67;30;28;58;NA;NA;NA;combined;fm;NA;NA;NA;NA;94,64;109,46;76,16;88,62;yes;"exclusion criteria were sleep disorders other than insomnia, specifically sleep apnea (apnea–hypopnea index greater than 15 per hr or between 10 and 15 per hr with oxygen saturation below 88%) or periodic limb movements (PLMS index greater than 15 per hr); bipolar or seizure disorders (due to contraindication for the sleep restriction component of CBT-I); significant medical (e.g. cancer) or neurological disorder (e.g. dementia); severe untreated psychiatric comorbidity (e.g. schizophrenia and substance abuse); cognitive impairment based on Mini-Mental State Examination (MMSE) score below 26 [21]; and concurrent participation in CBT or other nonpharmacological treatment outside of the study.";yes;Average total credibility scores for CBT-I (M = 8.93, SD = 1.21) and CBT-P (M = 8.38, SD = 1.37) did not significantly differ.;no;NA
mccrae, 2019;cbt;tau;cbt insomnia;tau;som;msd;mpq;follow up;32;self-report;22,85;28,53;13,15;13,4;23,62;23,3;16,22;16,02;39;37;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;mccrae_2019_msd_mpq_followup_32.0_self-report_cbt_tau_cbtinsomnia_tau;0,019645569;0,229500859;NA;NA;primary;low;low;low;high;some concerns;high;ClinicalTrials.gov, NCT02001077, Sleep and Pain Interventions in Fibromyalgia (SPIN), https://clinicaltrials.gov/ct2/show/NCT02001077;us;combined;yes;participants were compensated US$100 following each assessment period. They received the treatment and parking on the UF campus at no charge.;adults;yes;cbt for insomnia;para;individual;NA;no;8;NA;400;NA;8;NA;1;NA;50;NA;6,95;NA;2,16;NA;0,87;54,13;52,27;11,03;11,19;39;37;76;0,95;39;37;76;30;37;67;27;28;55;NA;NA;NA;combined;fm;NA;NA;NA;NA;114,52;109,46;91,1;88,62;yes;"exclusion criteria were sleep disorders other than insomnia, specifically sleep apnea (apnea–hypopnea index greater than 15 per hr or between 10 and 15 per hr with oxygen saturation below 88%) or periodic limb movements (PLMS index greater than 15 per hr); bipolar or seizure disorders (due to contraindication for the sleep restriction component of CBT-I); significant medical (e.g. cancer) or neurological disorder (e.g. dementia); severe untreated psychiatric comorbidity (e.g. schizophrenia and substance abuse); cognitive impairment based on Mini-Mental State Examination (MMSE) score below 26 [21]; and concurrent participation in CBT or other nonpharmacological treatment outside of the study.";yes;Average total credibility scores for CBT-I (M = 8.93, SD = 1.21) and CBT-P (M = 8.38, SD = 1.37) did not significantly differ.;no;NA
mccrae, 2019;cbt;tau;cbt pain;tau;depr;msd;bdi-II;post;8;self-report;16,87;19,12;10,26;10,53;15,58;16,94;10,68;10,94;37;37;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;mccrae_2019_msd_bdi-II_post_8.0_self-report_cbt_tau_cbtpain_tau;-0,124485353;0,232725127;NA;NA;primary;low;low;low;high;some concerns;high;ClinicalTrials.gov, NCT02001077, Sleep and Pain Interventions in Fibromyalgia (SPIN), https://clinicaltrials.gov/ct2/show/NCT02001077;us;combined;yes;participants were compensated US$100 following each assessment period. They received the treatment and parking on the UF campus at no charge.;adults;yes;cbt for pain;para;individual;NA;no;8;NA;400;NA;8;NA;1;NA;50;NA;7,08;NA;2,02;NA;0,89;51,54;52,27;10,62;11,19;34;37;71;0,95;37;37;74;30;37;67;30;28;58;NA;NA;NA;combined;fm;NA;NA;NA;NA;94,64;109,46;76,16;88,62;yes;"exclusion criteria were sleep disorders other than insomnia, specifically sleep apnea (apnea–hypopnea index greater than 15 per hr or between 10 and 15 per hr with oxygen saturation below 88%) or periodic limb movements (PLMS index greater than 15 per hr); bipolar or seizure disorders (due to contraindication for the sleep restriction component of CBT-I); significant medical (e.g. cancer) or neurological disorder (e.g. dementia); severe untreated psychiatric comorbidity (e.g. schizophrenia and substance abuse); cognitive impairment based on Mini-Mental State Examination (MMSE) score below 26 [21]; and concurrent participation in CBT or other nonpharmacological treatment outside of the study.";yes;Average total credibility scores for CBT-I (M = 8.93, SD = 1.21) and CBT-P (M = 8.38, SD = 1.37) did not significantly differ.;no;NA
mccrae, 2019;cbt;tau;cbt insomnia;tau;depr;msd;bdi-II;post;8;self-report;14,08;19,12;10,37;10,53;8,52;16,94;11,12;10,94;39;37;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;mccrae_2019_msd_bdi-II_post_8.0_self-report_cbt_tau_cbtinsomnia_tau;-0,755417794;0,237697094;NA;NA;primary;low;low;low;high;some concerns;high;ClinicalTrials.gov, NCT02001077, Sleep and Pain Interventions in Fibromyalgia (SPIN), https://clinicaltrials.gov/ct2/show/NCT02001077;us;combined;yes;participants were compensated US$100 following each assessment period. They received the treatment and parking on the UF campus at no charge.;adults;yes;cbt for insomnia;para;individual;NA;no;8;NA;400;NA;8;NA;1;NA;50;NA;6,95;NA;2,16;NA;0,87;54,13;52,27;11,03;11,19;39;37;76;0,95;39;37;76;30;37;67;27;28;55;NA;NA;NA;combined;fm;NA;NA;NA;NA;114,52;109,46;91,1;88,62;yes;"exclusion criteria were sleep disorders other than insomnia, specifically sleep apnea (apnea–hypopnea index greater than 15 per hr or between 10 and 15 per hr with oxygen saturation below 88%) or periodic limb movements (PLMS index greater than 15 per hr); bipolar or seizure disorders (due to contraindication for the sleep restriction component of CBT-I); significant medical (e.g. cancer) or neurological disorder (e.g. dementia); severe untreated psychiatric comorbidity (e.g. schizophrenia and substance abuse); cognitive impairment based on Mini-Mental State Examination (MMSE) score below 26 [21]; and concurrent participation in CBT or other nonpharmacological treatment outside of the study.";yes;Average total credibility scores for CBT-I (M = 8.93, SD = 1.21) and CBT-P (M = 8.38, SD = 1.37) did not significantly differ.;no;NA
mccrae, 2019;cbt;tau;cbt pain;tau;depr;msd;bdi-II;follow up;32;self-report;16,87;19,12;10,26;10,53;14,38;15,01;11,22;11,68;37;37;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;mccrae_2019_msd_bdi-II_followup_32.0_self-report_cbt_tau_cbtpain_tau;-0,054435712;0,232539247;NA;NA;primary;low;low;low;high;some concerns;high;ClinicalTrials.gov, NCT02001077, Sleep and Pain Interventions in Fibromyalgia (SPIN), https://clinicaltrials.gov/ct2/show/NCT02001077;us;combined;yes;participants were compensated US$100 following each assessment period. They received the treatment and parking on the UF campus at no charge.;adults;yes;cbt for pain;para;individual;NA;no;8;NA;400;NA;8;NA;1;NA;50;NA;7,08;NA;2,02;NA;0,89;51,54;52,27;10,62;11,19;34;37;71;0,89;37;37;74;30;37;67;30;28;58;NA;NA;NA;combined;fm;NA;NA;NA;NA;94,64;109,46;76,16;88,62;yes;"exclusion criteria were sleep disorders other than insomnia, specifically sleep apnea (apnea–hypopnea index greater than 15 per hr or between 10 and 15 per hr with oxygen saturation below 88%) or periodic limb movements (PLMS index greater than 15 per hr); bipolar or seizure disorders (due to contraindication for the sleep restriction component of CBT-I); significant medical (e.g. cancer) or neurological disorder (e.g. dementia); severe untreated psychiatric comorbidity (e.g. schizophrenia and substance abuse); cognitive impairment based on Mini-Mental State Examination (MMSE) score below 26 [21]; and concurrent participation in CBT or other nonpharmacological treatment outside of the study.";yes;Average total credibility scores for CBT-I (M = 8.93, SD = 1.21) and CBT-P (M = 8.38, SD = 1.37) did not significantly differ.;no;NA
mccrae, 2019;cbt;tau;cbt insomnia;tau;depr;msd;bdi-II;follow up;32;self-report;14,08;19,12;10,37;10,53;8,22;15,01;11,93;11,68;39;37;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;mccrae_2019_msd_bdi-II_followup_32.0_self-report_cbt_tau_cbtinsomnia_tau;-0,569135971;0,234186017;NA;NA;primary;low;low;low;high;some concerns;high;ClinicalTrials.gov, NCT02001077, Sleep and Pain Interventions in Fibromyalgia (SPIN), https://clinicaltrials.gov/ct2/show/NCT02001077;us;combined;yes;participants were compensated US$100 following each assessment period. They received the treatment and parking on the UF campus at no charge.;adults;yes;cbt for insomnia;para;individual;NA;no;8;NA;400;NA;8;NA;1;NA;50;NA;6,95;NA;2,16;NA;0,87;54,13;52,27;11,03;11,19;39;37;76;0,89;39;37;76;30;37;67;27;28;55;NA;NA;NA;combined;fm;NA;NA;NA;NA;114,52;109,46;91,1;88,62;yes;"exclusion criteria were sleep disorders other than insomnia, specifically sleep apnea (apnea–hypopnea index greater than 15 per hr or between 10 and 15 per hr with oxygen saturation below 88%) or periodic limb movements (PLMS index greater than 15 per hr); bipolar or seizure disorders (due to contraindication for the sleep restriction component of CBT-I); significant medical (e.g. cancer) or neurological disorder (e.g. dementia); severe untreated psychiatric comorbidity (e.g. schizophrenia and substance abuse); cognitive impairment based on Mini-Mental State Examination (MMSE) score below 26 [21]; and concurrent participation in CBT or other nonpharmacological treatment outside of the study.";yes;Average total credibility scores for CBT-I (M = 8.93, SD = 1.21) and CBT-P (M = 8.38, SD = 1.37) did not significantly differ.;no;NA
mccrae, 2019;cbt;tau;cbt pain;tau;anx;msd;staiy1;post;8;self-report;45,55;48,29;11,76;12,63;45,22;47,72;12,12;12,87;37;37;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;mccrae_2019_msd_staiy1_post_8.0_self-report_cbt_tau_cbtpain_tau;-0,197899497;0,233075733;NA;NA;primary;low;low;low;high;some concerns;high;ClinicalTrials.gov, NCT02001077, Sleep and Pain Interventions in Fibromyalgia (SPIN), https://clinicaltrials.gov/ct2/show/NCT02001077;us;combined;yes;participants were compensated US$100 following each assessment period. They received the treatment and parking on the UF campus at no charge.;adults;yes;cbt for pain;para;individual;NA;no;8;NA;400;NA;8;NA;1;NA;50;NA;7,08;NA;2,02;NA;0,89;51,54;52,27;10,62;11,19;34;37;71;0,89;37;37;74;30;37;67;30;28;58;NA;NA;NA;combined;fm;NA;NA;NA;NA;94,64;109,46;76,16;88,62;yes;"exclusion criteria were sleep disorders other than insomnia, specifically sleep apnea (apnea–hypopnea index greater than 15 per hr or between 10 and 15 per hr with oxygen saturation below 88%) or periodic limb movements (PLMS index greater than 15 per hr); bipolar or seizure disorders (due to contraindication for the sleep restriction component of CBT-I); significant medical (e.g. cancer) or neurological disorder (e.g. dementia); severe untreated psychiatric comorbidity (e.g. schizophrenia and substance abuse); cognitive impairment based on Mini-Mental State Examination (MMSE) score below 26 [21]; and concurrent participation in CBT or other nonpharmacological treatment outside of the study.";yes;Average total credibility scores for CBT-I (M = 8.93, SD = 1.21) and CBT-P (M = 8.38, SD = 1.37) did not significantly differ.;no;NA
mccrae, 2019;cbt;tau;cbt insomnia;tau;anx;msd;staiy1;post;8;self-report;43,35;48,29;11,64;12,63;38,95;47,72;12,72;12,87;39;37;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;mccrae_2019_msd_staiy1_post_8.0_self-report_cbt_tau_cbtinsomnia_tau;-0,678549428;0,236135036;NA;NA;primary;low;low;low;high;some concerns;high;ClinicalTrials.gov, NCT02001077, Sleep and Pain Interventions in Fibromyalgia (SPIN), https://clinicaltrials.gov/ct2/show/NCT02001077;us;combined;yes;participants were compensated US$100 following each assessment period. They received the treatment and parking on the UF campus at no charge.;adults;yes;cbt for insomnia;para;individual;NA;no;8;NA;400;NA;8;NA;1;NA;50;NA;6,95;NA;2,16;NA;0,87;54,13;52,27;11,03;11,19;39;37;76;0,71;39;37;76;30;37;67;27;28;55;NA;NA;NA;combined;fm;NA;NA;NA;NA;114,52;109,46;91,1;88,62;yes;"exclusion criteria were sleep disorders other than insomnia, specifically sleep apnea (apnea–hypopnea index greater than 15 per hr or between 10 and 15 per hr with oxygen saturation below 88%) or periodic limb movements (PLMS index greater than 15 per hr); bipolar or seizure disorders (due to contraindication for the sleep restriction component of CBT-I); significant medical (e.g. cancer) or neurological disorder (e.g. dementia); severe untreated psychiatric comorbidity (e.g. schizophrenia and substance abuse); cognitive impairment based on Mini-Mental State Examination (MMSE) score below 26 [21]; and concurrent participation in CBT or other nonpharmacological treatment outside of the study.";yes;Average total credibility scores for CBT-I (M = 8.93, SD = 1.21) and CBT-P (M = 8.38, SD = 1.37) did not significantly differ.;no;NA
mccrae, 2019;cbt;tau;cbt pain;tau;anx;msd;staiy1;follow up;32;self-report;45,55;48,29;11,76;12,63;43,86;43,87;12,78;13,7;37;37;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;mccrae_2019_msd_staiy1_followup_32.0_self-report_cbt_tau_cbtpain_tau;-0,000746941;0,232495286;NA;NA;primary;low;low;low;high;some concerns;high;ClinicalTrials.gov, NCT02001077, Sleep and Pain Interventions in Fibromyalgia (SPIN), https://clinicaltrials.gov/ct2/show/NCT02001077;us;combined;yes;participants were compensated US$100 following each assessment period. They received the treatment and parking on the UF campus at no charge.;adults;yes;cbt for pain;para;individual;NA;no;8;NA;400;NA;8;NA;1;NA;50;NA;7,08;NA;2,02;NA;0,89;51,54;52,27;10,62;11,19;34;37;71;0,81;37;37;74;30;37;67;30;28;58;NA;NA;NA;combined;fm;NA;NA;NA;NA;94,64;109,46;76,16;88,62;yes;"exclusion criteria were sleep disorders other than insomnia, specifically sleep apnea (apnea–hypopnea index greater than 15 per hr or between 10 and 15 per hr with oxygen saturation below 88%) or periodic limb movements (PLMS index greater than 15 per hr); bipolar or seizure disorders (due to contraindication for the sleep restriction component of CBT-I); significant medical (e.g. cancer) or neurological disorder (e.g. dementia); severe untreated psychiatric comorbidity (e.g. schizophrenia and substance abuse); cognitive impairment based on Mini-Mental State Examination (MMSE) score below 26 [21]; and concurrent participation in CBT or other nonpharmacological treatment outside of the study.";yes;Average total credibility scores for CBT-I (M = 8.93, SD = 1.21) and CBT-P (M = 8.38, SD = 1.37) did not significantly differ.;no;NA
mccrae, 2019;cbt;tau;cbt insomnia;tau;anx;msd;staiy1;follow up;32;self-report;43,35;48,29;11,64;12,63;38,07;43,87;13,73;13,7;39;37;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;mccrae_2019_msd_staiy1_followup_32.0_self-report_cbt_tau_cbtinsomnia_tau;-0,418581394;0,232044306;NA;NA;primary;low;low;low;high;some concerns;high;ClinicalTrials.gov, NCT02001077, Sleep and Pain Interventions in Fibromyalgia (SPIN), https://clinicaltrials.gov/ct2/show/NCT02001077;us;combined;yes;participants were compensated US$100 following each assessment period. They received the treatment and parking on the UF campus at no charge.;adults;yes;cbt for insomnia;para;individual;NA;no;8;NA;400;NA;8;NA;1;NA;50;NA;6,95;NA;2,16;NA;0,87;54,13;52,27;11,03;11,19;39;37;76;0,81;39;37;76;30;37;67;27;28;55;NA;NA;NA;combined;fm;NA;NA;NA;NA;114,52;109,46;91,1;88,62;yes;"exclusion criteria were sleep disorders other than insomnia, specifically sleep apnea (apnea–hypopnea index greater than 15 per hr or between 10 and 15 per hr with oxygen saturation below 88%) or periodic limb movements (PLMS index greater than 15 per hr); bipolar or seizure disorders (due to contraindication for the sleep restriction component of CBT-I); significant medical (e.g. cancer) or neurological disorder (e.g. dementia); severe untreated psychiatric comorbidity (e.g. schizophrenia and substance abuse); cognitive impairment based on Mini-Mental State Examination (MMSE) score below 26 [21]; and concurrent participation in CBT or other nonpharmacological treatment outside of the study.";yes;Average total credibility scores for CBT-I (M = 8.93, SD = 1.21) and CBT-P (M = 8.38, SD = 1.37) did not significantly differ.;no;NA
mccrae, 2019;cbt;tau;cbt pain;tau;phs;msd;pdi;post;8;self-report;-37,27;-37,59;15,28;15,62;38,03;35,68;15,95;16,79;37;37;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;mccrae_2019_msd_pdi_post_8.0_self-report_cbt_tau_cbtpain_tau;0,142007974;0,232794344;NA;NA;primary;low;low;low;high;some concerns;high;ClinicalTrials.gov, NCT02001077, Sleep and Pain Interventions in Fibromyalgia (SPIN), https://clinicaltrials.gov/ct2/show/NCT02001077;us;combined;yes;participants were compensated US$100 following each assessment period. They received the treatment and parking on the UF campus at no charge.;adults;yes;cbt for pain;para;individual;NA;no;8;NA;400;NA;8;NA;1;NA;50;NA;7,08;NA;2,02;NA;0,89;51,54;52,27;10,62;11,19;34;37;71;0,81;37;37;74;30;37;67;30;28;58;NA;NA;NA;combined;fm;NA;NA;NA;NA;94,64;109,46;76,16;88,62;yes;"exclusion criteria were sleep disorders other than insomnia, specifically sleep apnea (apnea–hypopnea index greater than 15 per hr or between 10 and 15 per hr with oxygen saturation below 88%) or periodic limb movements (PLMS index greater than 15 per hr); bipolar or seizure disorders (due to contraindication for the sleep restriction component of CBT-I); significant medical (e.g. cancer) or neurological disorder (e.g. dementia); severe untreated psychiatric comorbidity (e.g. schizophrenia and substance abuse); cognitive impairment based on Mini-Mental State Examination (MMSE) score below 26 [21]; and concurrent participation in CBT or other nonpharmacological treatment outside of the study.";yes;Average total credibility scores for CBT-I (M = 8.93, SD = 1.21) and CBT-P (M = 8.38, SD = 1.37) did not significantly differ.;no;NA
mccrae, 2019;cbt;tau;cbt insomnia;tau;phs;msd;pdi;post;8;self-report;-34,14;-37,59;15,6;15,62;27,85;35,68;16,86;16,79;39;37;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;mccrae_2019_msd_pdi_post_8.0_self-report_cbt_tau_cbtinsomnia_tau;-0,460619341;0,232578456;NA;NA;primary;low;low;low;high;some concerns;high;ClinicalTrials.gov, NCT02001077, Sleep and Pain Interventions in Fibromyalgia (SPIN), https://clinicaltrials.gov/ct2/show/NCT02001077;us;combined;yes;participants were compensated US$100 following each assessment period. They received the treatment and parking on the UF campus at no charge.;adults;yes;cbt for insomnia;para;individual;NA;no;8;NA;400;NA;8;NA;1;NA;50;NA;6,95;NA;2,16;NA;0,87;54,13;52,27;11,03;11,19;39;37;76;0,81;39;37;76;30;37;67;27;28;55;NA;NA;NA;combined;fm;NA;NA;NA;NA;114,52;109,46;91,1;88,62;yes;"exclusion criteria were sleep disorders other than insomnia, specifically sleep apnea (apnea–hypopnea index greater than 15 per hr or between 10 and 15 per hr with oxygen saturation below 88%) or periodic limb movements (PLMS index greater than 15 per hr); bipolar or seizure disorders (due to contraindication for the sleep restriction component of CBT-I); significant medical (e.g. cancer) or neurological disorder (e.g. dementia); severe untreated psychiatric comorbidity (e.g. schizophrenia and substance abuse); cognitive impairment based on Mini-Mental State Examination (MMSE) score below 26 [21]; and concurrent participation in CBT or other nonpharmacological treatment outside of the study.";yes;Average total credibility scores for CBT-I (M = 8.93, SD = 1.21) and CBT-P (M = 8.38, SD = 1.37) did not significantly differ.;no;NA
mccrae, 2019;cbt;tau;cbt pain;tau;phs;msd;pdi;follow up;32;self-report;-37,27;-37,59;15,28;15,62;36,37;34,87;17,2;18,07;37;37;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;mccrae_2019_msd_pdi_followup_32.0_self-report_cbt_tau_cbtpain_tau;0,084143419;0,23260032;NA;NA;primary;low;low;low;high;some concerns;high;ClinicalTrials.gov, NCT02001077, Sleep and Pain Interventions in Fibromyalgia (SPIN), https://clinicaltrials.gov/ct2/show/NCT02001077;us;combined;yes;participants were compensated US$100 following each assessment period. They received the treatment and parking on the UF campus at no charge.;adults;yes;cbt for pain;para;individual;NA;no;8;NA;400;NA;8;NA;1;NA;50;NA;7,08;NA;2,02;NA;0,89;51,54;52,27;10,62;11,19;34;37;71;0,81;37;37;74;30;37;67;30;28;58;NA;NA;NA;combined;fm;NA;NA;NA;NA;94,64;109,46;76,16;88,62;yes;"exclusion criteria were sleep disorders other than insomnia, specifically sleep apnea (apnea–hypopnea index greater than 15 per hr or between 10 and 15 per hr with oxygen saturation below 88%) or periodic limb movements (PLMS index greater than 15 per hr); bipolar or seizure disorders (due to contraindication for the sleep restriction component of CBT-I); significant medical (e.g. cancer) or neurological disorder (e.g. dementia); severe untreated psychiatric comorbidity (e.g. schizophrenia and substance abuse); cognitive impairment based on Mini-Mental State Examination (MMSE) score below 26 [21]; and concurrent participation in CBT or other nonpharmacological treatment outside of the study.";yes;Average total credibility scores for CBT-I (M = 8.93, SD = 1.21) and CBT-P (M = 8.38, SD = 1.37) did not significantly differ.;no;NA
mccrae, 2019;cbt;tau;cbt insomnia;tau;phs;msd;pdi;follow up;32;self-report;-34,14;-37,59;15,6;15,62;27,76;34,87;17,97;18,07;39;37;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;mccrae_2019_msd_pdi_followup_32.0_self-report_cbt_tau_cbtinsomnia_tau;-0,390576895;0,231716209;NA;NA;primary;low;low;low;high;some concerns;high;ClinicalTrials.gov, NCT02001077, Sleep and Pain Interventions in Fibromyalgia (SPIN), https://clinicaltrials.gov/ct2/show/NCT02001077;us;combined;yes;participants were compensated US$100 following each assessment period. They received the treatment and parking on the UF campus at no charge.;adults;yes;cbt for insomnia;para;individual;NA;no;8;NA;400;NA;8;NA;1;NA;50;NA;6,95;NA;2,16;NA;0,87;54,13;52,27;11,03;11,19;39;37;76;0,81;39;37;76;30;37;67;27;28;55;NA;NA;NA;combined;fm;NA;NA;NA;NA;114,52;109,46;91,1;88,62;yes;"exclusion criteria were sleep disorders other than insomnia, specifically sleep apnea (apnea–hypopnea index greater than 15 per hr or between 10 and 15 per hr with oxygen saturation below 88%) or periodic limb movements (PLMS index greater than 15 per hr); bipolar or seizure disorders (due to contraindication for the sleep restriction component of CBT-I); significant medical (e.g. cancer) or neurological disorder (e.g. dementia); severe untreated psychiatric comorbidity (e.g. schizophrenia and substance abuse); cognitive impairment based on Mini-Mental State Examination (MMSE) score below 26 [21]; and concurrent participation in CBT or other nonpharmacological treatment outside of the study.";yes;Average total credibility scores for CBT-I (M = 8.93, SD = 1.21) and CBT-P (M = 8.38, SD = 1.37) did not significantly differ.;no;NA
menga, 2014;cbt;tau;NA;NA;phs;msd;fiq;post;6;self-report;-49,7;-58,8;18,5;18,8;-43,9;-58,6;16,4;16,1;17;27;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;menga_2014_msd_fiq_post_6.0_self-report_cbt_tau_NA_NA;0,890285623;0,32434552;NA;NA;primary;low;high;high;high;some concerns;high;NA;us;clinical;no;NA;adults;yes;moodgym;self-guided;individual;NA;internet;5;NA;NA;NA;NA;6;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;28;28;56;NA;NA;NA;17;27;44;NA;noncompliance, medication changes, family illnesses, or other personal reasons (n = 11);NA;combined;fm;NA;NA;NA;NA;NA;NA;NA;NA;yes;patients having evidence of an inflammatory rheumatic disease or another disease process that could contribute to chronic pain or having significant, unstable medical or psychologic conditions that would compromise participation in the study or informed consent,Patients with signs or symptoms of severe depression or other severe psychologic disturbances, Patients currently undergoing CBT by any other system, Patient whose pharmacotherapy changed during the length of the study;no;NA;no;NA
menga, 2014;cbt;tau;NA;NA;phs;msd;fiq;follow up;12;self-report;-49,7;-58,8;18,5;18,8;-41;-57,7;19;19,6;17;27;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;menga_2014_msd_fiq_followup_12.0_self-report_cbt_tau_NA_NA;0,846511917;0,322961588;NA;NA;primary;low;high;high;high;some concerns;high;NA;us;clinical;no;NA;adults;yes;moodgym;self-guided;individual;NA;internet;5;NA;NA;NA;NA;6;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;28;28;56;NA;NA;NA;17;27;44;NA;noncompliance, medication changes, family illnesses, or other personal reasons (n = 11);NA;combined;fm;NA;NA;NA;NA;NA;NA;NA;NA;yes;patients having evidence of an inflammatory rheumatic disease or another disease process that could contribute to chronic pain or having significant, unstable medical or psychologic conditions that would compromise participation in the study or informed consent,Patients with signs or symptoms of severe depression or other severe psychologic disturbances, Patients currently undergoing CBT by any other system, Patient whose pharmacotherapy changed during the length of the study;no;NA;no;NA
menon, 2017;cbt;tau;NA;NA;som;msd;phq-15;post;4;self-report;7,4;7,2;4,1;5,6;5,3;6,9;3,2;3,5;41;35;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;menon_2017_msd_phq-15_post_4.0_self-report_cbt_tau_NA_NA;-0,47400221;0,233388832;NA;NA;primary;low;low;low;high;some concerns;high;Clinical Trials Registry of India (CTRI/2016/07/007082).;in;clinical;no;NA;adults;no;add-on single session counseling (SSC);psychiatrist;mixed;NA;no;1;NA;30;NA;1;NA;1;NA;30;0;NA;NA;NA;NA;NA;37,6;42,5;9,4;12,6;34;19;53;0,7;41;35;76;41;35;76;NA;NA;NA;NA;NA;NA;medical;mus;NA;NA;NA;NA;NA;NA;NA;NA;yes;DSM-IV diagnoses for schizophrenia, bipolar disorder, substance abuse, or if they were actively suicidal, as assessed by a brief screening measure adapted from the SCID-IV (First et al., 1997). Participants were also excluded if they showed markedly diminished cognitive capabilities, as evidenced by making four or more errors on the Short Portable Mental Status Questionnaire (Pfeiffer, 1975) or a score of less than 20 points on the Telephone Interview for Cognitive Status (TICS) (Brandt et al., 1988). Presence of another condition (e.g., AIDS, lupus, rheumatoid arthritis, untreated obstructive sleep apnea (OSA)) that might influence biological processes associated with CFS symptomatology or taking medications that would modulate immune or neuroendocrine functioning excluded patient participants from the study;no;NA;no;NA
menon, 2017;cbt;tau;NA;NA;depr;msd;phq-9;post;4;self-report;3,6;2,7;4,6;4,4;1,4;2,3;2,3;3,5;41;35;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;menon_2017_msd_phq-9_post_4.0_self-report_cbt_tau_NA_NA;-0,305776995;0,231494073;NA;NA;primary;low;low;low;high;some concerns;high;Clinical Trials Registry of India (CTRI/2016/07/007082).;in;clinical;no;NA;adults;no;add-on single session counseling (SSC);psychiatrist;mixed;NA;no;1;NA;30;NA;1;NA;1;NA;30;0;NA;NA;NA;NA;NA;37,6;42,5;9,4;12,6;34;19;53;0,7;41;35;76;41;35;76;NA;NA;NA;NA;NA;NA;medical;mus;NA;NA;NA;NA;NA;NA;NA;NA;yes;DSM-IV diagnoses for schizophrenia, bipolar disorder, substance abuse, or if they were actively suicidal, as assessed by a brief screening measure adapted from the SCID-IV (First et al., 1997). Participants were also excluded if they showed markedly diminished cognitive capabilities, as evidenced by making four or more errors on the Short Portable Mental Status Questionnaire (Pfeiffer, 1975) or a score of less than 20 points on the Telephone Interview for Cognitive Status (TICS) (Brandt et al., 1988). Presence of another condition (e.g., AIDS, lupus, rheumatoid arthritis, untreated obstructive sleep apnea (OSA)) that might influence biological processes associated with CFS symptomatology or taking medications that would modulate immune or neuroendocrine functioning excluded patient participants from the study;no;NA;no;NA
menon, 2017;cbt;tau;NA;NA;anx;msd;gad-7;post;4;self-report;3,2;3,3;3,7;3,9;2;1,6;2,2;2,6;41;35;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;menon_2017_msd_gad-7_post_4.0_self-report_cbt_tau_NA_NA;0,165516291;0,230533359;NA;NA;primary;low;low;low;high;some concerns;high;Clinical Trials Registry of India (CTRI/2016/07/007082).;in;clinical;no;NA;adults;no;add-on single session counseling (SSC);psychiatrist;mixed;NA;no;1;NA;30;NA;1;NA;1;NA;30;0;NA;NA;NA;NA;NA;37,6;42,5;9,4;12,6;34;19;53;0,7;41;35;76;41;35;76;NA;NA;NA;NA;NA;NA;medical;mus;NA;NA;NA;NA;NA;NA;NA;NA;yes;DSM-IV diagnoses for schizophrenia, bipolar disorder, substance abuse, or if they were actively suicidal, as assessed by a brief screening measure adapted from the SCID-IV (First et al., 1997). Participants were also excluded if they showed markedly diminished cognitive capabilities, as evidenced by making four or more errors on the Short Portable Mental Status Questionnaire (Pfeiffer, 1975) or a score of less than 20 points on the Telephone Interview for Cognitive Status (TICS) (Brandt et al., 1988). Presence of another condition (e.g., AIDS, lupus, rheumatoid arthritis, untreated obstructive sleep apnea (OSA)) that might influence biological processes associated with CFS symptomatology or taking medications that would modulate immune or neuroendocrine functioning excluded patient participants from the study;no;NA;no;NA
menon, 2017;cbt;tau;NA;NA;hcu;msd;doctor visits;post;4;self-report;4,4;5,2;3,3;5,7;2,1;1,9;1,8;1,1;41;35;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;menon_2017_msd_doctorvisits_post_4.0_self-report_cbt_tau_NA_NA;0,130328397;0,230381699;NA;NA;primary;NA;NA;NA;NA;NA;NA;Clinical Trials Registry of India (CTRI/2016/07/007082).;in;clinical;no;NA;adults;no;add-on single session counseling (SSC);psychiatrist;mixed;NA;no;1;NA;30;NA;1;NA;1;NA;30;0;NA;NA;NA;NA;NA;37,6;42,5;9,4;12,6;34;19;53;0,7;41;35;76;41;35;76;NA;NA;NA;NA;NA;NA;medical;mus;NA;NA;NA;NA;NA;NA;NA;NA;yes;DSM-IV diagnoses for schizophrenia, bipolar disorder, substance abuse, or if they were actively suicidal, as assessed by a brief screening measure adapted from the SCID-IV (First et al., 1997). Participants were also excluded if they showed markedly diminished cognitive capabilities, as evidenced by making four or more errors on the Short Portable Mental Status Questionnaire (Pfeiffer, 1975) or a score of less than 20 points on the Telephone Interview for Cognitive Status (TICS) (Brandt et al., 1988). Presence of another condition (e.g., AIDS, lupus, rheumatoid arthritis, untreated obstructive sleep apnea (OSA)) that might influence biological processes associated with CFS symptomatology or taking medications that would modulate immune or neuroendocrine functioning excluded patient participants from the study;no;NA;no;NA
milrad, 2019;cbt;psy plac;NA;NA;som;msd;fsi;post;20;self-report;2,32;2,78;0,92;0,77;2,65;2,92;0,74;0,59;75;75;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;milrad_2019_msd_fsi_post_20.0_self-report_cbt_psyplac_NA_NA;-0,401409198;0,164952293;NA;NA;primary;high;low;low;low;some concerns;high;ClinicalTrials.gov (NCT01650636).;us;combined;yes;after completing surveys participants were compensated $50 for their time.;adults;yes;cbsm;NA;individual;NA;internet;10;NA;600;NA;10;NA;1;NA;60;NA;9,31;NA;2,45;NA;0,93;48;47,9;11,4;10,5;67;64;131;0,87;75;75;150;NA;NA;NA;NA;NA;NA;NA;NA;NA;clinical interview;cfs/me;NA;NA;NA;NA;NA;NA;NA;NA;yes;based on this assessment, we excluded patients with DSM-IV diagnoses for schizophrenia, bipolar disorder, substance abuse, or if they were actively suicidal, as assessed by a brief screening measure adapted from the SCID-IV (First et al., 1997). Participants were also excluded if they showed markedly diminished cognitive capabilities, as evidenced by making four or more errors on the Short Portable Mental Status Questionnaire (Pfeiffer, 1975) or a score of less than 20 points on the Telephone Interview for Cognitive Status (TICS) (Brandt et al., 1988). Presence of another condition (e.g., AIDS, lupus, rheumatoid arthritis, untreated obstructive sleep apnea (OSA)) that might influence biological processes associated with CFS symptomatology or taking medications that would modulate immune or neuroendocrine functioning excluded patient participants from the study.;no;NA;no;NA
milrad, 2019;cbt;psy plac;NA;NA;depr;msd;ces-d;post;20;self-report;19,17;24,02;9,57;11,21;18,67;22,66;11,16;10,77;75;75;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;milrad_2019_msd_ces-d_post_20.0_self-report_cbt_psyplac_NA_NA;-0,36198072;0,164644774;NA;NA;primary;high;low;low;low;some concerns;high;ClinicalTrials.gov (NCT01650636).;us;combined;yes;after completing surveys participants were compensated $50 for their time.;adults;yes;cbsm;NA;individual;NA;internet;10;NA;600;NA;10;NA;1;NA;60;NA;9,31;NA;2,45;NA;0,93;48;47,9;11,4;10,5;67;64;131;0,87;75;75;150;NA;NA;NA;NA;NA;NA;NA;NA;NA;clinical interview;cfs/me;NA;NA;NA;NA;NA;NA;NA;NA;yes;based on this assessment, we excluded patients with DSM-IV diagnoses for schizophrenia, bipolar disorder, substance abuse, or if they were actively suicidal, as assessed by a brief screening measure adapted from the SCID-IV (First et al., 1997). Participants were also excluded if they showed markedly diminished cognitive capabilities, as evidenced by making four or more errors on the Short Portable Mental Status Questionnaire (Pfeiffer, 1975) or a score of less than 20 points on the Telephone Interview for Cognitive Status (TICS) (Brandt et al., 1988). Presence of another condition (e.g., AIDS, lupus, rheumatoid arthritis, untreated obstructive sleep apnea (OSA)) that might influence biological processes associated with CFS symptomatology or taking medications that would modulate immune or neuroendocrine functioning excluded patient participants from the study.;no;NA;no;NA
mohsenabadi, 2018;ambt;tau;NA;NA;som;msd;gsrs;post;12;self-report;54;56,6;7,2;6,5;46,25;54,88;8,21;6,48;32;32;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;mohsenabadi_2018_msd_gsrs_post_12.0_self-report_ambt_tau_NA_NA;-1,152712288;0,270439754;NA;NA;primary;some concerns;low;low;high;some concerns;high;irct.ir IRCT2017010431765N1;ir;clinical;no;NA;adults;yes;based on barlow;psy;individual;NA;no;12;NA;1440;NA;12;NA;1;NA;120;NA;10,8;NA;0,81;NA;0,9;31,2;30,6;4,7;5,7;20;18;38;0,59;32;32;64;NA;NA;NA;NA;NA;NA;NA;NA;not interested in doing homework exercises, too busy with work/school;combined;ibs;NA;NA;NA;NA;74,4;72;22,8;22,8;yes;receiving other psychological treatments since last year and during the research pro- cess, having bowel surgery, psychotic characteristics or suicidal thoughts, organic mental disorder, history of drug abuse or drug de- pendence.;no;NA;no;NA
mohsenabadi, 2018;ambt;tau;NA;NA;depr;msd;dass-42 depr;post;12;self-report;23,75;23,88;6,41;5,26;17,31;23,59;6,27;5,08;32;32;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;mohsenabadi_2018_msd_dass-42depr_post_12.0_self-report_ambt_tau_NA_NA;-1,087208034;0,268259233;NA;NA;primary;some concerns;low;low;high;some concerns;high;irct.ir IRCT2017010431765N1;ir;clinical;no;NA;adults;yes;based on barlow;psy;individual;NA;no;12;NA;1440;NA;12;NA;1;NA;120;NA;10,8;NA;0,81;NA;0,9;31,2;30,6;4,7;5,7;20;18;38;0,59;32;32;64;NA;NA;NA;NA;NA;NA;NA;NA;not interested in doing homework exercises, too busy with work/school;combined;ibs;NA;NA;NA;NA;74,4;72;22,8;22,8;yes;receiving other psychological treatments since last year and during the research pro- cess, having bowel surgery, psychotic characteristics or suicidal thoughts, organic mental disorder, history of drug abuse or drug de- pendence.;no;NA;no;NA
mohsenabadi, 2018;ambt;tau;NA;NA;anx;msd;dass-42 anx;post;12;self-report;21,5;22,06;6,32;6,55;14,44;21,28;5,55;7;32;32;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;mohsenabadi_2018_msd_dass-42anx_post_12.0_self-report_ambt_tau_NA_NA;-1,069684553;0,267694653;NA;NA;primary;some concerns;low;low;high;some concerns;high;irct.ir IRCT2017010431765N1;ir;clinical;no;NA;adults;yes;based on barlow;psy;individual;NA;no;12;NA;1440;NA;12;NA;1;NA;120;NA;10,8;NA;0,81;NA;0,9;31,2;30,6;4,7;5,7;20;18;38;0,59;32;32;64;NA;NA;NA;NA;NA;NA;NA;NA;not interested in doing homework exercises, too busy with work/school;combined;ibs;NA;NA;NA;NA;74,4;72;22,8;22,8;yes;receiving other psychological treatments since last year and during the research pro- cess, having bowel surgery, psychotic characteristics or suicidal thoughts, organic mental disorder, history of drug abuse or drug de- pendence.;no;NA;no;NA
moreno, 2013;cbt;tau;individual cbt;tau;som;msd;soms;post;10;self-report;18,55;21,26;10,62;11,49;11,63;19,47;8,15;8,52;50;48;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;moreno_2013_msd_soms_post_10.0_self-report_cbt_tau_individualcbt_tau;-0,933445887;0,212953796;NA;NA;primary;low;low;low;high;some concerns;high;ISRCTN69944771 (ClinicalTrials.gov);es;clinical;no;NA;adults;yes;treating somatization;gp;individual;NA;no;10;NA;600;NA;10;NA;1;NA;60;NA;NA;NA;NA;NA;NA;43,11;44,1;11,43;11,72;46;42;88;0,85;56;48;104;56;48;104;NA;NA;NA;Unable to contact (n=44), declined to participate (n=53);NA;During the treatment period, 16 of the 168 randomized patients were withdrawn from the study because of adverse events (6 in individual CBT, 6 in group CBT, and 4 in TAU);combined;ssi;NA;NA;NA;NA;NA;NA;NA;NA;yes;any primary psychiatric diagnosis other than somatization disorder, severe personality disorder that could prevent adequate implementation of the protocol for evaluation and/or intervention;no;NA;yes;patient reported (if they withdrew, but not more information provided)
moreno, 2013;cbt;tau;group cbt;tau;som;msd;soms;post;10;self-report;22,17;21,26;12,63;11,49;14,17;19,47;8,98;8,52;58;48;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;moreno_2013_msd_soms_post_10.0_self-report_cbt_tau_groupcbt_tau;-0,599615435;0,199487939;NA;NA;primary;low;low;low;high;some concerns;high;ISRCTN69944771 (ClinicalTrials.gov);es;clinical;no;NA;adults;yes;treating somatization;gp;group;NA;no;10;NA;1200;NA;10;NA;1;NA;120;NA;NA;NA;NA;NA;NA;49,23;44,1;8,64;11,72;57;42;99;0,88;64;48;112;64;48;112;NA;NA;NA;Unable to contact (n=44), declined to participate (n=53);NA;During the treatment period, 16 of the 168 randomized patients were withdrawn from the study because of adverse events (6 in individual CBT, 6 in group CBT, and 4 in TAU);combined;ssi;NA;NA;NA;NA;NA;NA;NA;NA;yes;any primary psychiatric diagnosis other than somatization disorder, severe personality disorder that could prevent adequate implementation of the protocol for evaluation and/or intervention;no;NA;yes;patient reported (if they withdrew, but not more information provided)
moreno, 2013;cbt;tau;individual cbt;tau;som;msd;soms;follow up;58;self-report;18,55;21,26;10,62;11,49;14,13;20,04;8,08;8,96;50;48;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;moreno_2013_msd_soms_followup_58.0_self-report_cbt_tau_individualcbt_tau;-0,688051362;0,208055287;NA;NA;primary;low;low;low;high;some concerns;high;ISRCTN69944771 (ClinicalTrials.gov);es;clinical;no;NA;adults;yes;treating somatization;gp;individual;NA;no;10;NA;600;NA;10;NA;1;NA;60;NA;NA;NA;NA;NA;NA;43,11;44,1;11,43;11,72;46;42;88;0,85;56;48;104;56;48;104;NA;NA;NA;Unable to contact (n=44), declined to participate (n=53);NA;During the treatment period, 16 of the 168 randomized patients were withdrawn from the study because of adverse events (6 in individual CBT, 6 in group CBT, and 4 in TAU);combined;ssi;NA;NA;NA;NA;NA;NA;NA;NA;yes;any primary psychiatric diagnosis other than somatization disorder, severe personality disorder that could prevent adequate implementation of the protocol for evaluation and/or intervention;no;NA;yes;patient reported (if they withdrew, but not more information provided)
moreno, 2013;cbt;tau;group cbt;tau;som;msd;soms;follow up;58;self-report;22,17;21,26;12,63;11,49;18,92;20,04;9;8,96;58;48;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;moreno_2013_msd_soms_followup_58.0_self-report_cbt_tau_groupcbt_tau;-0,123793187;0,195315273;NA;NA;primary;low;low;low;high;some concerns;high;ISRCTN69944771 (ClinicalTrials.gov);es;clinical;no;NA;adults;yes;treating somatization;gp;group;NA;no;10;NA;1200;NA;10;NA;1;NA;120;NA;NA;NA;NA;NA;NA;49,23;44,1;8,64;11,72;57;42;99;0,88;64;48;112;64;48;112;NA;NA;NA;Unable to contact (n=44), declined to participate (n=53);NA;During the treatment period, 16 of the 168 randomized patients were withdrawn from the study because of adverse events (6 in individual CBT, 6 in group CBT, and 4 in TAU);combined;ssi;NA;NA;NA;NA;NA;NA;NA;NA;yes;any primary psychiatric diagnosis other than somatization disorder, severe personality disorder that could prevent adequate implementation of the protocol for evaluation and/or intervention;no;NA;yes;patient reported (if they withdrew, but not more information provided)
moreno, 2013;cbt;tau;individual cbt;tau;depr;msd;hdrs;post;10;clinican;15,63;13,43;6,06;6,66;6,96;10,87;6,26;6,61;50;48;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;moreno_2013_msd_hdrs_post_10.0_clinican_cbt_tau_individualcbt_tau;-0,602973888;0,206682669;NA;NA;primary;low;low;low;high;some concerns;high;ISRCTN69944771 (ClinicalTrials.gov);es;clinical;no;NA;adults;yes;treating somatization;gp;individual;NA;no;10;NA;600;NA;10;NA;1;NA;60;NA;NA;NA;NA;NA;NA;43,11;44,1;11,43;11,72;46;42;88;0,85;56;48;104;56;48;104;NA;NA;NA;Unable to contact (n=44), declined to participate (n=53);NA;During the treatment period, 16 of the 168 randomized patients were withdrawn from the study because of adverse events (6 in individual CBT, 6 in group CBT, and 4 in TAU);combined;ssi;NA;NA;NA;NA;NA;NA;NA;NA;yes;any primary psychiatric diagnosis other than somatization disorder, severe personality disorder that could prevent adequate implementation of the protocol for evaluation and/or intervention;no;NA;yes;patient reported (if they withdrew, but not more information provided)
moreno, 2013;cbt;tau;group cbt;tau;depr;msd;hdrs;post;10;clinican;14,12;13,43;6,28;6,66;11,22;10,87;7,18;6,61;58;48;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;moreno_2013_msd_hdrs_post_10.0_clinican_cbt_tau_groupcbt_tau;0,050152879;0,195158271;NA;NA;primary;low;low;low;high;some concerns;high;ISRCTN69944771 (ClinicalTrials.gov);es;clinical;no;NA;adults;yes;treating somatization;gp;group;NA;no;10;NA;1200;NA;10;NA;1;NA;120;NA;NA;NA;NA;NA;NA;49,23;44,1;8,64;11,72;57;42;99;0,88;64;48;112;64;48;112;NA;NA;NA;Unable to contact (n=44), declined to participate (n=53);NA;During the treatment period, 16 of the 168 randomized patients were withdrawn from the study because of adverse events (6 in individual CBT, 6 in group CBT, and 4 in TAU);combined;ssi;NA;NA;NA;NA;NA;NA;NA;NA;yes;any primary psychiatric diagnosis other than somatization disorder, severe personality disorder that could prevent adequate implementation of the protocol for evaluation and/or intervention;no;NA;yes;patient reported (if they withdrew, but not more information provided)
moreno, 2013;cbt;tau;individual cbt;tau;depr;msd;hdrs;follow up;58;clinican;15,63;13,43;6,06;6,66;6,1;11,38;5,83;6,4;50;48;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;moreno_2013_msd_hdrs_followup_58.0_clinican_cbt_tau_individualcbt_tau;-0,856588607;0,21127297;NA;NA;primary;low;low;low;high;some concerns;high;ISRCTN69944771 (ClinicalTrials.gov);es;clinical;no;NA;adults;yes;treating somatization;gp;individual;NA;no;10;NA;600;NA;10;NA;1;NA;60;NA;NA;NA;NA;NA;NA;43,11;44,1;11,43;11,72;46;42;88;0,85;56;48;104;56;48;104;NA;NA;NA;Unable to contact (n=44), declined to participate (n=53);NA;During the treatment period, 16 of the 168 randomized patients were withdrawn from the study because of adverse events (6 in individual CBT, 6 in group CBT, and 4 in TAU);combined;ssi;NA;NA;NA;NA;NA;NA;NA;NA;yes;any primary psychiatric diagnosis other than somatization disorder, severe personality disorder that could prevent adequate implementation of the protocol for evaluation and/or intervention;no;NA;yes;patient reported (if they withdrew, but not more information provided)
moreno, 2013;cbt;tau;group cbt;tau;depr;msd;hdrs;follow up;58;clinican;14,12;13,43;6,28;6,66;5,97;11,38;6,47;6,4;58;48;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;moreno_2013_msd_hdrs_followup_58.0_clinican_cbt_tau_groupcbt_tau;-0,834188901;0,203482431;NA;NA;primary;low;low;low;high;some concerns;high;ISRCTN69944771 (ClinicalTrials.gov);es;clinical;no;NA;adults;yes;treating somatization;gp;group;NA;no;10;NA;1200;NA;10;NA;1;NA;120;NA;NA;NA;NA;NA;NA;49,23;44,1;8,64;11,72;57;42;99;0,88;64;48;112;64;48;112;NA;NA;NA;Unable to contact (n=44), declined to participate (n=53);NA;During the treatment period, 16 of the 168 randomized patients were withdrawn from the study because of adverse events (6 in individual CBT, 6 in group CBT, and 4 in TAU);combined;ssi;NA;NA;NA;NA;NA;NA;NA;NA;yes;any primary psychiatric diagnosis other than somatization disorder, severe personality disorder that could prevent adequate implementation of the protocol for evaluation and/or intervention;no;NA;yes;patient reported (if they withdrew, but not more information provided)
moreno, 2013;cbt;tau;individual cbt;tau;anx;msd;ham-a;post;10;clinican;17,71;17,84;8,95;9,9;7,33;13,07;7,18;7,58;50;48;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;moreno_2013_msd_ham-a_post_10.0_clinican_cbt_tau_individualcbt_tau;-0,771837881;0,209573309;NA;NA;primary;low;low;low;high;some concerns;high;ISRCTN69944771 (ClinicalTrials.gov);es;clinical;no;NA;adults;yes;treating somatization;gp;individual;NA;no;10;NA;600;NA;10;NA;1;NA;60;NA;NA;NA;NA;NA;NA;43,11;44,1;11,43;11,72;46;42;88;0,85;56;48;104;56;48;104;NA;NA;NA;Unable to contact (n=44), declined to participate (n=53);NA;During the treatment period, 16 of the 168 randomized patients were withdrawn from the study because of adverse events (6 in individual CBT, 6 in group CBT, and 4 in TAU);combined;ssi;NA;NA;NA;NA;NA;NA;NA;NA;yes;any primary psychiatric diagnosis other than somatization disorder, severe personality disorder that could prevent adequate implementation of the protocol for evaluation and/or intervention;no;NA;yes;patient reported (if they withdrew, but not more information provided)
moreno, 2013;cbt;tau;group cbt;tau;anx;msd;ham-a;post;10;clinican;20,18;17,84;10,18;9,9;11,47;13,07;8,24;7,58;58;48;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;moreno_2013_msd_ham-a_post_10.0_clinican_cbt_tau_groupcbt_tau;-0,199840172;0,195616573;NA;NA;primary;low;low;low;high;some concerns;high;ISRCTN69944771 (ClinicalTrials.gov);es;clinical;no;NA;adults;yes;treating somatization;gp;group;NA;no;10;NA;1200;NA;10;NA;1;NA;120;NA;NA;NA;NA;NA;NA;49,23;44,1;8,64;11,72;57;42;99;0,88;64;48;112;64;48;112;NA;NA;NA;Unable to contact (n=44), declined to participate (n=53);NA;During the treatment period, 16 of the 168 randomized patients were withdrawn from the study because of adverse events (6 in individual CBT, 6 in group CBT, and 4 in TAU);combined;ssi;NA;NA;NA;NA;NA;NA;NA;NA;yes;any primary psychiatric diagnosis other than somatization disorder, severe personality disorder that could prevent adequate implementation of the protocol for evaluation and/or intervention;no;NA;yes;patient reported (if they withdrew, but not more information provided)
moreno, 2013;cbt;tau;individual cbt;tau;anx;msd;ham-a;follow up;58;clinican;17,71;17,84;8,95;9,9;7,63;14,48;7,34;8,08;50;48;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;moreno_2013_msd_ham-a_followup_58.0_clinican_cbt_tau_individualcbt_tau;-0,881363652;0,211800456;NA;NA;primary;low;low;low;high;some concerns;high;ISRCTN69944771 (ClinicalTrials.gov);es;clinical;no;NA;adults;yes;treating somatization;gp;individual;NA;no;10;NA;600;NA;10;NA;1;NA;60;NA;NA;NA;NA;NA;NA;43,11;44,1;11,43;11,72;46;42;88;0,85;56;48;104;56;48;104;NA;NA;NA;Unable to contact (n=44), declined to participate (n=53);NA;During the treatment period, 16 of the 168 randomized patients were withdrawn from the study because of adverse events (6 in individual CBT, 6 in group CBT, and 4 in TAU);combined;ssi;NA;NA;NA;NA;NA;NA;NA;NA;yes;any primary psychiatric diagnosis other than somatization disorder, severe personality disorder that could prevent adequate implementation of the protocol for evaluation and/or intervention;no;NA;yes;patient reported (if they withdrew, but not more information provided)
moreno, 2013;cbt;tau;group cbt;tau;anx;msd;ham-a;follow up;58;clinican;20,18;17,84;10,18;9,9;7,53;14,48;6,47;8,08;58;48;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;moreno_2013_msd_ham-a_followup_58.0_clinican_cbt_tau_groupcbt_tau;-0,952734392;0,205958516;NA;NA;primary;low;low;low;high;some concerns;high;ISRCTN69944771 (ClinicalTrials.gov);es;clinical;no;NA;adults;yes;treating somatization;gp;group;NA;no;10;NA;1200;NA;10;NA;1;NA;120;NA;NA;NA;NA;NA;NA;49,23;44,1;8,64;11,72;57;42;99;0,88;64;48;112;64;48;112;NA;NA;NA;Unable to contact (n=44), declined to participate (n=53);NA;During the treatment period, 16 of the 168 randomized patients were withdrawn from the study because of adverse events (6 in individual CBT, 6 in group CBT, and 4 in TAU);combined;ssi;NA;NA;NA;NA;NA;NA;NA;NA;yes;any primary psychiatric diagnosis other than somatization disorder, severe personality disorder that could prevent adequate implementation of the protocol for evaluation and/or intervention;no;NA;yes;patient reported (if they withdrew, but not more information provided)
moss-morris, 2010;cbt;tau;NA;NA;som;msd;ibs-sss;post;8;self-report;228,5;222,8;83,8;80,7;156,7;195;81,98;82,9;30;33;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;moss-morris_2010_msd_ibs-sss_post_8.0_self-report_cbt_tau_NA_NA;-0,458711742;0,255633225;NA;NA;primary;low;low;low;high;some concerns;high;Australian clinical Trials Registry, ACTRN012605000286640;nz;clinical;no;NA;adults;yes;cognitive behavioral self management programme;psy;individual;NA;no;3;NA;180;NA;7,5;NA;0,4;NA;60;NA;NA;NA;NA;NA;NA;40;39;18;15,9;22;24;46;0,73;30;33;63;29;33;62;NA;NA;NA;NA;felt the program was not applicable;work commitments, moved overseas;clinical interview;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;participants were excluded if they : (a) suffered from another medical condition that had the potential to affect their symptoms (e.g. coeliac disease, obstructive bowel pathology, inflammatory bowel disease), (b) had had bowel surgery that may have caused similar symptoms, or (c) had a current serious mental dis- order such as a psychotic disorder or substance abuse problem.;yes;acceptability of the self-management treatment was assessed using three questions where patients were asked to rate the overall effectiveness of the pro- gramme, the efficacy of the programme compared to other treatments they had tried, and whether they enjoyed the programme.;no;NA
moss-morris, 2010;cbt;tau;NA;NA;som;msd;ibs-sss;follow up;32;self-report;228,5;222,8;83,8;80,7;119,4;193,3;81,7;92,3;30;33;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;moss-morris_2010_msd_ibs-sss_followup_32.0_self-report_cbt_tau_NA_NA;-0,834897713;0,263263572;NA;NA;primary;low;low;low;high;some concerns;high;Australian clinical Trials Registry, ACTRN012605000286640;nz;clinical;no;NA;adults;yes;cognitive behavioral self management programme;psy;individual;NA;no;3;NA;180;NA;7,5;NA;0,4;NA;60;NA;NA;NA;NA;NA;NA;40;39;18;15,9;22;24;46;0,73;30;33;63;29;33;62;NA;NA;NA;NA;felt the program was not applicable;work commitments, moved overseas;clinical interview;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;participants were excluded if they : (a) suffered from another medical condition that had the potential to affect their symptoms (e.g. coeliac disease, obstructive bowel pathology, inflammatory bowel disease), (b) had had bowel surgery that may have caused similar symptoms, or (c) had a current serious mental dis- order such as a psychotic disorder or substance abuse problem.;yes;acceptability of the self-management treatment was assessed using three questions where patients were asked to rate the overall effectiveness of the pro- gramme, the efficacy of the programme compared to other treatments they had tried, and whether they enjoyed the programme.;no;NA
moss-morris, 2010;cbt;tau;NA;NA;depr;msd;hads-d;post;8;self-report;3,9;4,1;3,4;3,1;3,9;3,8;3,42;3,2;30;33;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;moss-morris_2010_msd_hads-d_post_8.0_self-report_cbt_tau_NA_NA;0,029870842;0,252276878;NA;NA;primary;low;low;low;high;some concerns;high;Australian clinical Trials Registry, ACTRN012605000286640;nz;clinical;no;NA;adults;yes;cognitive behavioral self management programme;psy;individual;NA;no;3;NA;180;NA;7,5;NA;0,4;NA;60;NA;NA;NA;NA;NA;NA;40;39;18;15,9;22;24;46;0,73;30;33;63;29;33;62;NA;NA;NA;NA;felt the program was not applicable;work commitments, moved overseas;clinical interview;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;participants were excluded if they : (a) suffered from another medical condition that had the potential to affect their symptoms (e.g. coeliac disease, obstructive bowel pathology, inflammatory bowel disease), (b) had had bowel surgery that may have caused similar symptoms, or (c) had a current serious mental dis- order such as a psychotic disorder or substance abuse problem.;yes;acceptability of the self-management treatment was assessed using three questions where patients were asked to rate the overall effectiveness of the pro- gramme, the efficacy of the programme compared to other treatments they had tried, and whether they enjoyed the programme.;no;NA
moss-morris, 2010;cbt;tau;NA;NA;depr;msd;hads-d;follow up;32;self-report;3,9;4,1;3,4;3,1;2,9;4;2,4;3,7;30;33;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;moss-morris_2010_msd_hads-d_followup_32.0_self-report_cbt_tau_NA_NA;-0,344938617;0,254174007;NA;NA;primary;low;low;low;high;some concerns;high;Australian clinical Trials Registry, ACTRN012605000286640;nz;clinical;no;NA;adults;yes;cognitive behavioral self management programme;psy;individual;NA;no;3;NA;180;NA;7,5;NA;0,4;NA;60;NA;NA;NA;NA;NA;NA;40;39;18;15,9;22;24;46;0,73;30;33;63;29;33;62;NA;NA;NA;NA;felt the program was not applicable;work commitments, moved overseas;clinical interview;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;participants were excluded if they : (a) suffered from another medical condition that had the potential to affect their symptoms (e.g. coeliac disease, obstructive bowel pathology, inflammatory bowel disease), (b) had had bowel surgery that may have caused similar symptoms, or (c) had a current serious mental dis- order such as a psychotic disorder or substance abuse problem.;yes;acceptability of the self-management treatment was assessed using three questions where patients were asked to rate the overall effectiveness of the pro- gramme, the efficacy of the programme compared to other treatments they had tried, and whether they enjoyed the programme.;no;NA
moss-morris, 2010;cbt;tau;NA;NA;anx;msd;hads-a;post;8;self-report;9,1;6,9;3,8;4,3;8,7;6,6;4,4;4,7;30;33;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;moss-morris_2010_msd_hads-a_post_8.0_self-report_cbt_tau_NA_NA;0,454856871;0,255577176;NA;NA;primary;low;low;low;high;some concerns;high;Australian clinical Trials Registry, ACTRN012605000286640;nz;clinical;no;NA;adults;yes;cognitive behavioral self management programme;psy;individual;NA;no;3;NA;180;NA;7,5;NA;0,4;NA;60;NA;NA;NA;NA;NA;NA;40;39;18;15,9;22;24;46;0,73;30;33;63;29;33;62;NA;NA;NA;NA;felt the program was not applicable;work commitments, moved overseas;clinical interview;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;participants were excluded if they : (a) suffered from another medical condition that had the potential to affect their symptoms (e.g. coeliac disease, obstructive bowel pathology, inflammatory bowel disease), (b) had had bowel surgery that may have caused similar symptoms, or (c) had a current serious mental dis- order such as a psychotic disorder or substance abuse problem.;yes;acceptability of the self-management treatment was assessed using three questions where patients were asked to rate the overall effectiveness of the pro- gramme, the efficacy of the programme compared to other treatments they had tried, and whether they enjoyed the programme.;no;NA
moss-morris, 2010;cbt;tau;NA;NA;anx;msd;hads-a;follow up;32;self-report;9,1;6,9;3,8;4,3;7,5;6,4;3,8;4,1;30;33;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;moss-morris_2010_msd_hads-a_followup_32.0_self-report_cbt_tau_NA_NA;0,274333739;0,253473239;NA;NA;primary;low;low;low;high;some concerns;high;Australian clinical Trials Registry, ACTRN012605000286640;nz;clinical;no;NA;adults;yes;cognitive behavioral self management programme;psy;individual;NA;no;3;NA;180;NA;7,5;NA;0,4;NA;60;NA;NA;NA;NA;NA;NA;40;39;18;15,9;22;24;46;0,73;30;33;63;29;33;62;NA;NA;NA;NA;felt the program was not applicable;work commitments, moved overseas;clinical interview;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;participants were excluded if they : (a) suffered from another medical condition that had the potential to affect their symptoms (e.g. coeliac disease, obstructive bowel pathology, inflammatory bowel disease), (b) had had bowel surgery that may have caused similar symptoms, or (c) had a current serious mental dis- order such as a psychotic disorder or substance abuse problem.;yes;acceptability of the self-management treatment was assessed using three questions where patients were asked to rate the overall effectiveness of the pro- gramme, the efficacy of the programme compared to other treatments they had tried, and whether they enjoyed the programme.;no;NA
nhu, 2024;cbt;tau;NA;NA;som;msd;bpi-severity;post;8;self-report;5,6;5,25;1,62;1,7;5,41;5,11;1,41;1,55;17;18;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;nhu_2024_msd_bpi-severity_post_8.0_self-report_cbt_tau_NA_NA;0,197557177;0,339062061;NA;NA;primary;low;low;low;high;some concerns;high;NA;tw;clinical;no;NA;adults;yes;tele-cbt-i;psy;individual;NA;internet;6;NA;720;NA;6;NA;1;NA;120;NA;NA;NA;NA;NA;NA;49,35;47,06;9,23;10,43;14;18;32;0,8;20;20;40;18;19;37;17;19;36;NA;NA;medical condition (n =1);clinical interview;fm;NA;NA;NA;NA;NA;NA;NA;NA;yes;"(1) major neurological disorders, psychiatric disorders, substance related disorders, or cancers; (2) unstable medication doses for FM symptoms (3) major medical conditions or using medications that impacted sleep; (4) pregnancy; and (5) contraindications with MRI examination";no;NA;no;NA
nhu, 2024;cbt;tau;NA;NA;som;msd;nrs;post;8;self-report;6,12;5,5;1,96;2,3;5,59;5,28;1,97;2,11;17;18;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;nhu_2024_msd_nrs_post_8.0_self-report_cbt_tau_NA_NA;0,148239551;0,338685549;NA;NA;secondary;NA;NA;NA;NA;NA;NA;NA;tw;clinical;no;NA;adults;yes;tele-cbt-i;psy;individual;NA;internet;6;NA;720;NA;6;NA;1;NA;120;NA;NA;NA;NA;NA;NA;49,35;47,06;9,23;10,43;14;18;32;0,8;20;20;40;18;19;37;17;19;36;NA;NA;medical condition (n =1);clinical interview;fm;NA;NA;NA;NA;NA;NA;NA;NA;yes;"(1) major neurological disorders, psychiatric disorders, substance related disorders, or cancers; (2) unstable medication doses for FM symptoms (3) major medical conditions or using medications that impacted sleep; (4) pregnancy; and (5) contraindications with MRI examination";no;NA;no;NA
nhu, 2024;cbt;tau;NA;NA;depr;msd;bdi-II;post;8;self-report;22,88;23,06;13,11;11,62;20,24;20,11;12,18;10,81;17;18;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;nhu_2024_msd_bdi-II_post_8.0_self-report_cbt_tau_NA_NA;0,011050608;0,338202472;NA;NA;primary;low;low;low;high;some concerns;high;NA;tw;clinical;no;NA;adults;yes;tele-cbt-i;psy;individual;NA;internet;6;NA;720;NA;6;NA;1;NA;120;NA;NA;NA;NA;NA;NA;49,35;47,06;9,23;10,43;14;18;32;0,8;20;20;40;18;19;37;17;19;36;NA;NA;medical condition (n =1);clinical interview;fm;NA;NA;NA;NA;NA;NA;NA;NA;yes;"(1) major neurological disorders, psychiatric disorders, substance related disorders, or cancers; (2) unstable medication doses for FM symptoms (3) major medical conditions or using medications that impacted sleep; (4) pregnancy; and (5) contraindications with MRI examination";no;NA;no;NA
nhu, 2024;cbt;tau;NA;NA;anx;msd;bai;post;8;self-report;20,76;24,06;10,33;11,28;19,12;25,5;8,75;12,9;17;18;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;nhu_2024_msd_bai_post_8.0_self-report_cbt_tau_NA_NA;-0,562439816;0,345126822;NA;NA;primary;low;low;low;high;some concerns;high;NA;tw;clinical;no;NA;adults;yes;tele-cbt-i;psy;individual;NA;internet;6;NA;720;NA;6;NA;1;NA;120;NA;NA;NA;NA;NA;NA;49,35;47,06;9,23;10,43;14;18;32;0,8;20;20;40;18;19;37;17;19;36;NA;NA;medical condition (n =1);clinical interview;fm;NA;NA;NA;NA;NA;NA;NA;NA;yes;"(1) major neurological disorders, psychiatric disorders, substance related disorders, or cancers; (2) unstable medication doses for FM symptoms (3) major medical conditions or using medications that impacted sleep; (4) pregnancy; and (5) contraindications with MRI examination";no;NA;no;NA
nhu, 2024;cbt;tau;NA;NA;phs;msd;fiq;post;8;self-report;-59,12;-63,28;15,2;17,58;-56,65;-55,39;15,48;19,17;17;18;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;nhu_2024_msd_fiq_post_8.0_self-report_cbt_tau_NA_NA;-0,070437805;0,33830951;NA;NA;primary;low;low;low;high;some concerns;high;NA;tw;clinical;no;NA;adults;yes;tele-cbt-i;psy;individual;NA;internet;6;NA;720;NA;6;NA;1;NA;120;NA;NA;NA;NA;NA;NA;49,35;47,06;9,23;10,43;14;18;32;0,8;20;20;40;18;19;37;17;19;36;NA;NA;medical condition (n =1);clinical interview;fm;NA;NA;NA;NA;NA;NA;NA;NA;yes;"(1) major neurological disorders, psychiatric disorders, substance related disorders, or cancers; (2) unstable medication doses for FM symptoms (3) major medical conditions or using medications that impacted sleep; (4) pregnancy; and (5) contraindications with MRI examination";no;NA;no;NA
nhu, 2024;cbt;tau;NA;NA;phs;msd;bpi-inteference;post;8;self-report;5,12;5,39;1,32;1,91;5,12;4,78;1,73;1,8;53;49;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;nhu_2024_msd_bpi-inteference_post_8.0_self-report_cbt_tau_NA_NA;0,191300342;0,198640901;NA;NA;secondary;NA;NA;NA;NA;NA;NA;NA;tw;clinical;no;NA;adults;yes;tele-cbt-i;psy;individual;NA;internet;6;NA;720;NA;6;NA;1;NA;120;NA;NA;NA;NA;NA;NA;49,35;47,06;9,23;10,43;14;18;32;0,8;20;20;40;18;19;37;17;19;36;NA;NA;medical condition (n =1);clinical interview;fm;NA;NA;NA;NA;NA;NA;NA;NA;yes;"(1) major neurological disorders, psychiatric disorders, substance related disorders, or cancers; (2) unstable medication doses for FM symptoms (3) major medical conditions or using medications that impacted sleep; (4) pregnancy; and (5) contraindications with MRI examination";no;NA;no;NA
odowd, 2006;cbt;tau;NA;NA;depr;msd;hads-d;post;24;self-report;8,46;8,39;3,99;3,05;6,84;7,78;3,46;3,76;53;49;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;odowd_2006_msd_hads-d_post_24.0_self-report_cbt_tau_NA_NA;-0,258636689;0,199020053;NA;NA;primary;low;high;low;high;some concerns;high;NA;gb;clinical;no;NA;adults;NA;NA;mixed;group;NA;no;8;NA;960;NA;16;NA;0,5;NA;120;NA;NA;NA;NA;NA;NA;41,6;42,9;12;11,6;28;36;64;0,62;52;51;103;NA;NA;NA;NA;NA;NA;NA;N;moved away, work pressures, dropped out following an argument, transport problems, unable to attend owing to a bereavement, too ill to attend, could not see the point;clinical interview;cfs/me;NA;NA;NA;NA;NA;NA;NA;NA;yes;concurrent severe mental illness (i.e. psychosis and allied conditions), planned or concurrent rehabilitation, iinability to attend all treatment sessions, ongoing physical investigations;no;NA;no;NA
odowd, 2006;cbt;tau;NA;NA;depr;msd;hads-d;follow up;48;self-report;8,46;8,39;3,99;3,05;6,82;7,44;3,8;4,42;53;49;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;odowd_2006_msd_hads-d_followup_48.0_self-report_cbt_tau_NA_NA;-0,149743193;0,198463287;NA;NA;primary;low;high;low;high;some concerns;high;NA;gb;clinical;no;NA;adults;NA;NA;mixed;group;NA;no;8;NA;960;NA;16;NA;0,5;NA;120;NA;NA;NA;NA;NA;NA;41,6;42,9;12;11,6;28;36;64;0,62;52;51;103;NA;NA;NA;NA;NA;NA;NA;N;moved away, work pressures, dropped out following an argument, transport problems, unable to attend owing to a bereavement, too ill to attend, could not see the point;clinical interview;cfs/me;NA;NA;NA;NA;NA;NA;NA;NA;yes;concurrent severe mental illness (i.e. psychosis and allied conditions), planned or concurrent rehabilitation, iinability to attend all treatment sessions, ongoing physical investigations;no;NA;no;NA
odowd, 2006;cbt;tau;NA;NA;anx;msd;hads-a;post;24;self-report;9,94;9,74;3,83;4,27;8,14;9,61;3,86;4,69;53;49;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;odowd_2006_msd_hads-a_post_24.0_self-report_cbt_tau_NA_NA;-0,340991729;0,199636504;NA;NA;primary;low;high;low;high;some concerns;high;NA;gb;clinical;no;NA;adults;NA;NA;mixed;group;NA;no;8;NA;960;NA;16;NA;0,5;NA;120;NA;NA;NA;NA;NA;NA;41,6;42,9;12;11,6;28;36;64;0,62;52;51;103;NA;NA;NA;NA;NA;NA;NA;N;moved away, work pressures, dropped out following an argument, transport problems, unable to attend owing to a bereavement, too ill to attend, could not see the point;clinical interview;cfs/me;NA;NA;NA;NA;NA;NA;NA;NA;yes;concurrent severe mental illness (i.e. psychosis and allied conditions), planned or concurrent rehabilitation, iinability to attend all treatment sessions, ongoing physical investigations;no;NA;no;NA
odowd, 2006;cbt;tau;NA;NA;anx;msd;hads-a;follow up;48;self-report;9,94;9,74;3,83;4,27;8,33;9;4,46;5,17;53;49;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;odowd_2006_msd_hads-a_followup_48.0_self-report_cbt_tau_NA_NA;-0,138134207;0,198421382;NA;NA;primary;low;high;low;high;some concerns;high;NA;gb;clinical;no;NA;adults;NA;NA;mixed;group;NA;no;8;NA;960;NA;16;NA;0,5;NA;120;NA;NA;NA;NA;NA;NA;41,6;42,9;12;11,6;28;36;64;0,62;52;51;103;NA;NA;NA;NA;NA;NA;NA;N;moved away, work pressures, dropped out following an argument, transport problems, unable to attend owing to a bereavement, too ill to attend, could not see the point;clinical interview;cfs/me;NA;NA;NA;NA;NA;NA;NA;NA;yes;concurrent severe mental illness (i.e. psychosis and allied conditions), planned or concurrent rehabilitation, iinability to attend all treatment sessions, ongoing physical investigations;no;NA;no;NA
odowd, 2006;cbt;tau;NA;NA;phs;msd;sf-36;post;24;self-report;33,4;32,7;8,49;8,38;33,4;34,5;9,04;9,95;53;49;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;odowd_2006_msd_sf-36_post_24.0_self-report_cbt_tau_NA_NA;-0,115067871;0,198348128;NA;NA;primary;low;high;low;high;some concerns;high;NA;gb;clinical;no;NA;adults;NA;NA;mixed;group;NA;no;8;NA;960;NA;16;NA;0,5;NA;120;NA;NA;NA;NA;NA;NA;41,6;42,9;12;11,6;28;36;64;0,62;52;51;103;NA;NA;NA;NA;NA;NA;NA;N;moved away, work pressures, dropped out following an argument, transport problems, unable to attend owing to a bereavement, too ill to attend, could not see the point;clinical interview;cfs/me;NA;NA;NA;NA;NA;NA;NA;NA;yes;concurrent severe mental illness (i.e. psychosis and allied conditions), planned or concurrent rehabilitation, iinability to attend all treatment sessions, ongoing physical investigations;no;NA;no;NA
odowd, 2006;cbt;tau;NA;NA;phs;msd;sf-36;follow up;48;self-report;33,4;32,7;8,49;8,38;35,2;35;8,15;9,93;53;49;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;odowd_2006_msd_sf-36_followup_48.0_self-report_cbt_tau_NA_NA;0,021937632;0,198187999;NA;NA;primary;low;high;low;high;some concerns;high;NA;gb;clinical;no;NA;adults;NA;NA;mixed;group;NA;no;8;NA;960;NA;16;NA;0,5;NA;120;NA;NA;NA;NA;NA;NA;41,6;42,9;12;11,6;28;36;64;0,62;52;51;103;NA;NA;NA;NA;NA;NA;NA;N;moved away, work pressures, dropped out following an argument, transport problems, unable to attend owing to a bereavement, too ill to attend, could not see the point;clinical interview;cfs/me;NA;NA;NA;NA;NA;NA;NA;NA;yes;concurrent severe mental illness (i.e. psychosis and allied conditions), planned or concurrent rehabilitation, iinability to attend all treatment sessions, ongoing physical investigations;no;NA;no;NA
ong, 2023;ambt;att plac;NA;NA;som;msd;promis-si;post;5;self-report;63,64;62,79;5,29;5,71;61,47;61,29;7,24;5,66;43;43;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;ong_2023_msd_promis-si_post_5.0_self-report_ambt_attplac_NA_NA;0,02745192;0,215675889;NA;NA;primary;some concerns;low;low;high;low;high;NCT04869345.;us;combined;yes;"participants were compensated for their time and incentivized to remain in the study with gift cards: $75 for baseline, postinterven- tion, and follow-up assessments; $42 for the diary assess- ments ($2 each for 21 days); and $25 for postintervention feedback";older adults;yes;larkspur;self-guided;individual;NA;internet;5;NA;NA;NA;5;NA;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;42;39;81;0,85;49;46;95;NA;NA;NA;NA;NA;NA;NA;NA;NA;combined;fm;NA;NA;NA;NA;NA;NA;NA;NA;yes;moderate or severe cognitive impairment (2 or more errors on 6-item Mini-Mental State Examination);yes;participants were asked to provide feedback on perceived helpfulness, usability, and overall satisfaction with the pro- gram. participants were also asked to rate how much they would recommend the program to someone else with chronic pain using an 11-point Likert scale, ranging from 0 = defi- nitely not to 10 = definitely yes.;no;NA
ong, 2023;ambt;att plac;NA;NA;som;msd;promis-si;follow up;9;self-report;63,64;62,79;5,29;5,71;62,34;61,34;7,39;5,95;43;43;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;ong_2023_msd_promis-si_followup_9.0_self-report_ambt_attplac_NA_NA;0,147724251;0,215964826;NA;NA;primary;some concerns;low;low;high;low;high;NCT04869345.;us;combined;yes;"participants were compensated for their time and incentivized to remain in the study with gift cards: $75 for baseline, postinterven- tion, and follow-up assessments; $42 for the diary assess- ments ($2 each for 21 days); and $25 for postintervention feedback";older adults;yes;larkspur;self-guided;individual;NA;internet;5;NA;NA;NA;5;NA;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;42;39;81;0,85;49;46;95;NA;NA;NA;NA;NA;NA;NA;NA;NA;combined;fm;NA;NA;NA;NA;NA;NA;NA;NA;yes;moderate or severe cognitive impairment (2 or more errors on 6-item Mini-Mental State Examination);yes;participants were asked to provide feedback on perceived helpfulness, usability, and overall satisfaction with the pro- gram. participants were also asked to rate how much they would recommend the program to someone else with chronic pain using an 11-point Likert scale, ranging from 0 = defi- nitely not to 10 = definitely yes.;no;NA
ong, 2023;ambt;att plac;NA;NA;phs;msd;promis-pf;post;5;self-report;36,72;36,99;5,79;5,47;38,58;38,58;7,04;6,5;43;43;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;ong_2023_msd_promis-pf_post_5.0_self-report_ambt_attplac_NA_NA;0;0,215665546;NA;NA;primary;some concerns;low;low;high;low;high;NCT04869345.;us;combined;yes;"participants were compensated for their time and incentivized to remain in the study with gift cards: $75 for baseline, postinterven- tion, and follow-up assessments; $42 for the diary assess- ments ($2 each for 21 days); and $25 for postintervention feedback";older adults;yes;larkspur;self-guided;individual;NA;internet;5;NA;NA;NA;5;NA;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;42;39;81;0,85;49;46;95;NA;NA;NA;NA;NA;NA;NA;NA;NA;combined;fm;NA;NA;NA;NA;NA;NA;NA;NA;yes;moderate or severe cognitive impairment (2 or more errors on 6-item Mini-Mental State Examination);yes;participants were asked to provide feedback on perceived helpfulness, usability, and overall satisfaction with the pro- gram. participants were also asked to rate how much they would recommend the program to someone else with chronic pain using an 11-point Likert scale, ranging from 0 = defi- nitely not to 10 = definitely yes.;no;NA
ong, 2023;ambt;att plac;NA;NA;phs;msd;promis-pf;follow up;9;self-report;36,72;36,99;5,79;5,47;39,39;38,3;7,7;5,88;43;43;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;ong_2023_msd_promis-pf_followup_9.0_self-report_ambt_attplac_NA_NA;0,157682798;0,216006503;NA;NA;primary;some concerns;low;low;high;low;high;NCT04869345.;us;combined;yes;"participants were compensated for their time and incentivized to remain in the study with gift cards: $75 for baseline, postinterven- tion, and follow-up assessments; $42 for the diary assess- ments ($2 each for 21 days); and $25 for postintervention feedback";older adults;yes;larkspur;self-guided;individual;NA;internet;5;NA;NA;NA;5;NA;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;42;39;81;0,85;49;46;95;NA;NA;NA;NA;NA;NA;NA;NA;NA;combined;fm;NA;NA;NA;NA;NA;NA;NA;NA;yes;moderate or severe cognitive impairment (2 or more errors on 6-item Mini-Mental State Examination);yes;participants were asked to provide feedback on perceived helpfulness, usability, and overall satisfaction with the pro- gram. participants were also asked to rate how much they would recommend the program to someone else with chronic pain using an 11-point Likert scale, ranging from 0 = defi- nitely not to 10 = definitely yes.;no;NA
ong, 2023;ambt;att plac;NA;NA;phs;msd;promis-pi;post;5;self-report;63,63;62,78;5,19;4,95;62,12;62,27;5,86;6,34;43;43;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;ong_2023_msd_promis-pi_post_5.0_self-report_ambt_attplac_NA_NA;-0,024351113;0,215673684;NA;NA;secondary;NA;NA;NA;NA;NA;NA;NCT04869345.;us;combined;yes;"participants were compensated for their time and incentivized to remain in the study with gift cards: $75 for baseline, postinterven- tion, and follow-up assessments; $42 for the diary assess- ments ($2 each for 21 days); and $25 for postintervention feedback";older adults;yes;larkspur;self-guided;individual;NA;internet;5;NA;NA;NA;5;NA;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;42;39;81;0,85;49;46;95;NA;NA;NA;NA;NA;NA;NA;NA;NA;combined;fm;NA;NA;NA;NA;NA;NA;NA;NA;yes;moderate or severe cognitive impairment (2 or more errors on 6-item Mini-Mental State Examination);yes;participants were asked to provide feedback on perceived helpfulness, usability, and overall satisfaction with the pro- gram. participants were also asked to rate how much they would recommend the program to someone else with chronic pain using an 11-point Likert scale, ranging from 0 = defi- nitely not to 10 = definitely yes.;no;NA
owusu, 2021;cbt;tau;NA;NA;som;msd;ibs-sss;post;12;self-report;296,3;270,7;100,9;95,2;232,6;293,7;108,8;122,7;22;10;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;owusu_2021_msd_ibs-sss_post_12.0_self-report_cbt_tau_NA_NA;-0,526380561;0,387312137;NA;NA;primary;some concerns;some concerns;low;high;some concerns;high;NA;us;clinical;no;NA;adults;yes;parallel program;self-guided;individual;NA;internet;8;NA;NA;NA;12;NA;0,67;NA;NA;NA;5,58;NA;5,93;NA;0,7;38,6;40,5;10,8;14,5;18;10;28;0,78;25;11;36;20;11;31;7;10;17;NA;NA;NA;cut-off;ibs;NA;NA;NA;NA;138;80,4;127,2;96;yes;participants were excluded if they reported a diagnosis of inflammatory bowel disease or were deemed ineligible after a tel- ephone screening by a clinical psychologist after reporting severe depressive symptoms (ie, score of ≥20 on the 9-item Patient Health Questionnaire).3;no;NA;no;NA
parra-delgado, 2013;ambt;tau;NA;NA;som;msd;vas;post;8;self-report;1,88;1,83;0,33;0,31;1,86;1,92;0,3;0,28;15;16;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;parra-delgado_2013_msd_vas_post_8.0_self-report_ambt_tau_NA_NA;-0,201619155;0,360358032;NA;NA;primary;low;high;low;high;some concerns;high;NA;es;other;no;NA;adults;yes;mbct;psy;group;NA;no;8;NA;1200;NA;8;NA;1;NA;150;NA;NA;NA;NA;NA;NA;53,13;52,69;10,5;10,58;17;16;33;1,06;15;16;31;15;16;31;2;16;18;“do not complete assessment questionnaires (baseline) (n= 2), abandon (n= 1)”;NA;NA;clinical interview;fm;NA;NA;NA;NA;260,4;270;199,68;166,08;yes;“alcohol and/or substance dependence and/or abuse”;no;NA;no;NA
parra-delgado, 2013;ambt;tau;NA;NA;som;msd;vas;follow up;20;self-report;1,88;1,83;0,33;0,31;1,83;1,97;0,31;0,27;15;16;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;parra-delgado_2013_msd_vas_followup_20.0_self-report_ambt_tau_NA_NA;-0,470164918;0,364589677;NA;NA;primary;low;high;low;high;some concerns;high;NA;es;other;no;NA;adults;yes;mbct;psy;group;NA;no;8;NA;1200;NA;8;NA;1;NA;150;NA;NA;NA;NA;NA;NA;53,13;52,69;10,5;10,58;17;16;33;1,06;15;16;31;15;16;31;2;16;18;“do not complete assessment questionnaires (baseline) (n= 2), abandon (n= 1)”;NA;NA;clinical interview;fm;NA;NA;NA;NA;260,4;270;199,68;166,08;yes;“alcohol and/or substance dependence and/or abuse”;no;NA;no;NA
parra-delgado, 2013;ambt;tau;NA;NA;depr;msd;bdi;post;8;self-report;18,6;16,88;7,2;5,85;13;15,44;6,35;6,88;15;16;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;parra-delgado_2013_msd_bdi_post_8.0_self-report_ambt_tau_NA_NA;-0,358454309;0,362424595;NA;NA;primary;low;high;low;high;some concerns;high;NA;es;other;no;NA;adults;yes;mbct;psy;group;NA;no;8;NA;1200;NA;8;NA;1;NA;150;NA;NA;NA;NA;NA;NA;53,13;52,69;10,5;10,58;17;16;33;1,06;15;16;31;15;16;31;2;16;18;“do not complete assessment questionnaires (baseline) (n= 2), abandon (n= 1)”;NA;NA;clinical interview;fm;NA;NA;NA;NA;260,4;270;199,68;166,08;yes;“alcohol and/or substance dependence and/or abuse”;no;NA;no;NA
parra-delgado, 2013;ambt;tau;NA;NA;depr;msd;bdi;follow up;20;self-report;18,6;16,88;7,2;5,85;13,13;17,75;5,34;5,86;15;16;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;parra-delgado_2013_msd_bdi_followup_20.0_self-report_ambt_tau_NA_NA;-0,80133452;0,374280627;NA;NA;primary;low;high;low;high;some concerns;high;NA;es;other;no;NA;adults;yes;mbct;psy;group;NA;no;8;NA;1200;NA;8;NA;1;NA;150;NA;NA;NA;NA;NA;NA;53,13;52,69;10,5;10,58;17;16;33;1,06;15;16;31;15;16;31;2;16;18;“do not complete assessment questionnaires (baseline) (n= 2), abandon (n= 1)”;NA;NA;clinical interview;fm;NA;NA;NA;NA;260,4;270;199,68;166,08;yes;“alcohol and/or substance dependence and/or abuse”;no;NA;no;NA
parra-delgado, 2013;ambt;tau;NA;NA;phs;msd;fiq;post;8;self-report;-77,09;-64,74;13,45;14,06;-61,77;-66,2;13,65;17,22;15;16;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;parra-delgado_2013_msd_fiq_post_8.0_self-report_ambt_tau_NA_NA;0,276585909;0,361202878;NA;NA;primary;some concerns;high;low;high;some concerns;high;NA;es;other;no;NA;adults;yes;mbct;psy;group;NA;no;8;NA;1200;NA;8;NA;1;NA;150;NA;NA;NA;NA;NA;NA;53,13;52,69;10,5;10,58;17;16;33;1,06;15;16;31;15;16;31;2;16;18;“do not complete assessment questionnaires (baseline) (n= 2), abandon (n= 1)”;NA;NA;clinical interview;fm;NA;NA;NA;NA;260,4;270;199,68;166,08;yes;“alcohol and/or substance dependence and/or abuse”;no;NA;no;NA
parra-delgado, 2013;ambt;tau;NA;NA;phs;msd;fiq;follow up;20;self-report;-77,09;-64,74;13,45;14,06;-63,25;-70,77;15,8;10,54;15;16;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;parra-delgado_2013_msd_fiq_followup_20.0_self-report_ambt_tau_NA_NA;0,548979389;0,366458051;NA;NA;primary;some concerns;high;low;high;some concerns;high;NA;es;other;no;NA;adults;yes;mbct;psy;group;NA;no;8;NA;1200;NA;8;NA;1;NA;150;NA;NA;NA;NA;NA;NA;53,13;52,69;10,5;10,58;17;16;33;1,06;15;16;31;15;16;31;2;16;18;“do not complete assessment questionnaires (baseline) (n= 2), abandon (n= 1)”;NA;NA;clinical interview;fm;NA;NA;NA;NA;260,4;270;199,68;166,08;yes;“alcohol and/or substance dependence and/or abuse”;no;NA;no;NA
payne, 1995;cbt;psy plac;NA;NA;depr;msd;bdi;post;8;self-report;14,6;11,2;6,4;4,5;8,3;10,8;5,2;10,2;12;11;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;payne_1995_msd_bdi_post_8.0_self-report_cbt_psyplac_NA_NA;-0,301897462;0,419970429;NA;NA;primary;some concerns;high;low;high;some concerns;high;NA;us;clinical;no;NA;adults;yes;nach greene & blanchard (1994);psy;individual;NA;no;10;NA;600;NA;8;NA;1,25;NA;60;NA;NA;NA;NA;NA;NA;39,7;44;13,1;9,3;10;8;18;0,75;12;12;24;12;12;24;NA;NA;NA;NA;NA;NA;clinical interview;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;all patients were also diagnosed with ibs by their personal physician who had ordered appropriate tests to rule out other possible diseases such as inflammatory bowel disease, lactose intolerance, or parasites. all patients were requested to continue unchanged for the duration of treatment any current medication regimen.;yes;table 2: expectancy/credibility;no;NA
payne, 1995;cbt;psy plac;NA;NA;depr;msd;bdi;follow up;20;self-report;14,6;11,2;6,4;4,5;5,3;8,9;3,3;7,1;12;11;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;payne_1995_msd_bdi_followup_20.0_self-report_cbt_psyplac_NA_NA;-0,636604978;0,428632362;NA;NA;primary;some concerns;high;low;high;some concerns;high;NA;us;clinical;no;NA;adults;yes;nach greene & blanchard (1994);psy;individual;NA;no;10;NA;600;NA;8;NA;1,25;NA;60;NA;NA;NA;NA;NA;NA;39,7;44;13,1;9,3;10;8;18;0,75;12;12;24;12;12;24;NA;NA;NA;NA;NA;NA;clinical interview;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;all patients were also diagnosed with ibs by their personal physician who had ordered appropriate tests to rule out other possible diseases such as inflammatory bowel disease, lactose intolerance, or parasites. all patients were requested to continue unchanged for the duration of treatment any current medication regimen.;yes;table 2: expectancy/credibility;no;NA
payne, 1995;cbt;psy plac;NA;NA;anx;msd;stai state;post;8;self-report;49,1;41,5;10,1;8,7;43,8;41,6;9,9;12,9;12;11;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;payne_1995_msd_staistate_post_8.0_self-report_cbt_psyplac_NA_NA;0,185564061;0,418387601;NA;NA;primary;some concerns;high;low;high;some concerns;high;NA;us;clinical;no;NA;adults;yes;nach greene & blanchard (1994);psy;individual;NA;no;10;NA;600;NA;8;NA;1,25;NA;60;NA;NA;NA;NA;NA;NA;39,7;44;13,1;9,3;10;8;18;0,75;12;12;24;12;12;24;NA;NA;NA;NA;NA;NA;clinical interview;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;all patients were also diagnosed with ibs by their personal physician who had ordered appropriate tests to rule out other possible diseases such as inflammatory bowel disease, lactose intolerance, or parasites. all patients were requested to continue unchanged for the duration of treatment any current medication regimen.;yes;table 2: expectancy/credibility;no;NA
payne, 1995;cbt;psy plac;NA;NA;anx;msd;stai state;follow up;20;self-report;49,1;41,5;10,1;8,7;43,8;41,6;9,9;12,9;12;11;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;payne_1995_msd_staistate_followup_20.0_self-report_cbt_psyplac_NA_NA;0,185564061;0,418387601;NA;NA;primary;some concerns;high;low;high;some concerns;high;NA;us;clinical;no;NA;adults;yes;nach greene & blanchard (1994);psy;individual;NA;no;10;NA;600;NA;8;NA;1,25;NA;60;NA;NA;NA;NA;NA;NA;39,7;44;13,1;9,3;10;8;18;0,75;12;12;24;12;12;24;NA;NA;NA;NA;NA;NA;clinical interview;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;all patients were also diagnosed with ibs by their personal physician who had ordered appropriate tests to rule out other possible diseases such as inflammatory bowel disease, lactose intolerance, or parasites. all patients were requested to continue unchanged for the duration of treatment any current medication regimen.;yes;table 2: expectancy/credibility;no;NA
pedersen, 2019;ambt;ec;NA;NA;som;msd;bds checklist;post;24;self-report;36,16;34,03;6,36;6,15;35,77;35,03;7,33;6,48;53;54;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;pedersen_2019_msd_bdschecklist_post_24.0_self-report_ambt_ec_NA_NA;0,106262501;0,193494113;NA;NA;primary;low;low;low;high;some concerns;high;NCT01518647 (ClinicalTrials.gov);dk;clinical;no;NA;adults;yes;extended act;mixed;group;NA;no;9;NA;1695;NA;12;NA;0,75;NA;188,33;NA;NA;NA;NA;NA;NA;38,8;40,1;8;8,5;47;47;94;0,79;59;60;119;56;58;114;31;58;89;NA;NA;NA;combined;bds;36,2;35,5;8,7;8,7;NA;NA;NA;NA;yes;"diagnosis of psychosis, mania or depression with psychotic symptoms (icd-10: f2029, f3031, f32.3, f33.3), current abuse of alcohol or drugs; Patients with concurrent medical illness or psychiatric disorders were only excluded if the concurrent illness was the primary reason for health complaints or impairment for the patient";no;NA;no;NA
pedersen, 2019;ambt;ec;NA;NA;som;msd;bds checklist;follow up;80;self-report;36,16;34,03;6,36;6,15;37,52;35,69;7,81;6,52;53;54;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;pedersen_2019_msd_bdschecklist_followup_80.0_self-report_ambt_ec_NA_NA;0,252773327;0,194137417;NA;NA;primary;low;low;low;high;some concerns;high;NCT01518647 (ClinicalTrials.gov);dk;clinical;no;NA;adults;yes;extended act;mixed;group;NA;no;9;NA;1695;NA;12;NA;0,75;NA;188,33;NA;NA;NA;NA;NA;NA;38,8;40,1;8;8,5;47;47;94;0,79;59;60;119;56;58;114;31;58;89;NA;NA;NA;combined;bds;36,2;35,5;8,7;8,7;NA;NA;NA;NA;yes;"diagnosis of psychosis, mania or depression with psychotic symptoms (icd-10: f2029, f3031, f32.3, f33.3), current abuse of alcohol or drugs; Patients with concurrent medical illness or psychiatric disorders were only excluded if the concurrent illness was the primary reason for health complaints or impairment for the patient";no;NA;no;NA
pedersen, 2019;ambt;ec;NA;NA;som;msd;scl-92 som;post;24;self-report;1,74;1,87;0,62;0,7;1,78;1,73;0,73;0,67;53;54;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;pedersen_2019_msd_scl-92som_post_24.0_self-report_ambt_ec_NA_NA;0,070880995;0,193417321;NA;NA;secondary;NA;NA;NA;NA;NA;NA;NCT01518647 (ClinicalTrials.gov);dk;clinical;no;NA;adults;yes;extended act;mixed;group;NA;no;9;NA;1695;NA;12;NA;0,75;NA;188,33;NA;NA;NA;NA;NA;NA;38,8;40,1;8;8,5;47;47;94;0,79;59;60;119;56;58;114;31;58;89;NA;NA;NA;combined;bds;36,2;35,5;8,7;8,7;NA;NA;NA;NA;yes;"diagnosis of psychosis, mania or depression with psychotic symptoms (icd-10: f2029, f3031, f32.3, f33.3), current abuse of alcohol or drugs; Patients with concurrent medical illness or psychiatric disorders were only excluded if the concurrent illness was the primary reason for health complaints or impairment for the patient";no;NA;no;NA
pedersen, 2019;ambt;ec;NA;NA;depr;msd;scl-92 depr;post;24;self-report;1,32;1,58;0,87;0,78;1,3;1,37;0,87;0,9;53;54;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;pedersen_2019_msd_scl-92depr_post_24.0_self-report_ambt_ec_NA_NA;-0,07850578;0,193431279;NA;NA;primary;low;low;low;high;some concerns;high;NCT01518647 (ClinicalTrials.gov);dk;clinical;no;NA;adults;yes;extended act;mixed;group;NA;no;9;NA;1695;NA;12;NA;0,75;NA;188,33;NA;NA;NA;NA;NA;NA;38,8;40,1;8;8,5;47;47;94;0,79;59;60;119;56;58;114;31;58;89;NA;NA;NA;combined;bds;36,2;35,5;8,7;8,7;NA;NA;NA;NA;yes;"diagnosis of psychosis, mania or depression with psychotic symptoms (icd-10: f2029, f3031, f32.3, f33.3), current abuse of alcohol or drugs; Patients with concurrent medical illness or psychiatric disorders were only excluded if the concurrent illness was the primary reason for health complaints or impairment for the patient";no;NA;no;NA
pedersen, 2019;ambt;ec;NA;NA;depr;msd;scl-92 depr;follow up;80;self-report;1,34;1,58;0,87;0,78;1,22;1,31;0,85;0,82;53;54;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;pedersen_2019_msd_scl-92depr_followup_80.0_self-report_ambt_ec_NA_NA;-0,107013746;0,193496076;NA;NA;primary;low;low;low;high;some concerns;high;NCT01518647 (ClinicalTrials.gov);dk;clinical;no;NA;adults;yes;extended act;mixed;group;NA;no;9;NA;1695;NA;12;NA;0,75;NA;188,33;NA;NA;NA;NA;NA;NA;38,8;40,1;8;8,5;47;47;94;0,79;59;60;119;56;58;114;31;58;89;NA;NA;NA;combined;bds;36,2;35,5;8,7;8,7;NA;NA;NA;NA;yes;"diagnosis of psychosis, mania or depression with psychotic symptoms (icd-10: f2029, f3031, f32.3, f33.3), current abuse of alcohol or drugs; Patients with concurrent medical illness or psychiatric disorders were only excluded if the concurrent illness was the primary reason for health complaints or impairment for the patient";no;NA;no;NA
pedersen, 2019;ambt;ec;NA;NA;anx;msd;scl-92 anx;post;24;self-report;1,16;1,3;0,67;0,7;1,23;1,15;0,72;0,71;53;54;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;pedersen_2019_msd_scl-92anx_post_24.0_self-report_ambt_ec_NA_NA;0,111091686;0,193506971;NA;NA;primary;low;low;low;high;some concerns;high;NCT01518647 (ClinicalTrials.gov);dk;clinical;no;NA;adults;yes;extended act;mixed;group;NA;no;9;NA;1695;NA;12;NA;0,75;NA;188,33;NA;NA;NA;NA;NA;NA;38,8;40,1;8;8,5;47;47;94;0,79;59;60;119;56;58;114;31;58;89;NA;NA;NA;combined;bds;36,2;35,5;8,7;8,7;NA;NA;NA;NA;yes;"diagnosis of psychosis, mania or depression with psychotic symptoms (icd-10: f2029, f3031, f32.3, f33.3), current abuse of alcohol or drugs; Patients with concurrent medical illness or psychiatric disorders were only excluded if the concurrent illness was the primary reason for health complaints or impairment for the patient";no;NA;no;NA
pedersen, 2019;ambt;ec;NA;NA;anx;msd;scl-92 anx;follow up;80;self-report;1,16;1,3;0,67;0,7;1,1;1,19;0,76;0,7;53;54;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;pedersen_2019_msd_scl-92anx_followup_80.0_self-report_ambt_ec_NA_NA;-0,122349526;0,193539159;NA;NA;primary;low;low;low;high;some concerns;high;NCT01518647 (ClinicalTrials.gov);dk;clinical;no;NA;adults;yes;extended act;mixed;group;NA;no;9;NA;1695;NA;12;NA;0,75;NA;188,33;NA;NA;NA;NA;NA;NA;38,8;40,1;8;8,5;47;47;94;0,79;59;60;119;56;58;114;31;58;89;NA;NA;NA;combined;bds;36,2;35,5;8,7;8,7;NA;NA;NA;NA;yes;"diagnosis of psychosis, mania or depression with psychotic symptoms (icd-10: f2029, f3031, f32.3, f33.3), current abuse of alcohol or drugs; Patients with concurrent medical illness or psychiatric disorders were only excluded if the concurrent illness was the primary reason for health complaints or impairment for the patient";no;NA;no;NA
pedersen, 2019;ambt;ec;NA;NA;ha;msd;wi-7;post;24;self-report;1,23;1,42;0,81;0,84;1,01;0,95;0,85;0,65;53;54;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;pedersen_2019_msd_wi-7_post_24.0_self-report_ambt_ec_NA_NA;0,078828877;0,193431902;NA;NA;primary;low;low;low;high;some concerns;high;NCT01518647 (ClinicalTrials.gov);dk;clinical;no;NA;adults;yes;extended act;mixed;group;NA;no;9;NA;1695;NA;12;NA;0,75;NA;188,33;NA;NA;NA;NA;NA;NA;38,8;40,1;8;8,5;47;47;94;0,79;59;60;119;56;58;114;31;58;89;NA;NA;NA;combined;bds;36,2;35,5;8,7;8,7;NA;NA;NA;NA;yes;"diagnosis of psychosis, mania or depression with psychotic symptoms (icd-10: f2029, f3031, f32.3, f33.3), current abuse of alcohol or drugs; Patients with concurrent medical illness or psychiatric disorders were only excluded if the concurrent illness was the primary reason for health complaints or impairment for the patient";no;NA;no;NA
pedersen, 2019;ambt;ec;NA;NA;ha;msd;wi-7;follow up;80;self-report;1,23;1,42;0,81;0,84;1,01;0,91;0,9;0,65;53;54;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;pedersen_2019_msd_wi-7_followup_80.0_self-report_ambt_ec_NA_NA;0,126663657;0,193552315;NA;NA;primary;low;low;low;high;some concerns;high;NCT01518647 (ClinicalTrials.gov);dk;clinical;no;NA;adults;yes;extended act;mixed;group;NA;no;9;NA;1695;NA;12;NA;0,75;NA;188,33;NA;NA;NA;NA;NA;NA;38,8;40,1;8;8,5;47;47;94;0,79;59;60;119;56;58;114;31;58;89;NA;NA;NA;combined;bds;36,2;35,5;8,7;8,7;NA;NA;NA;NA;yes;"diagnosis of psychosis, mania or depression with psychotic symptoms (icd-10: f2029, f3031, f32.3, f33.3), current abuse of alcohol or drugs; Patients with concurrent medical illness or psychiatric disorders were only excluded if the concurrent illness was the primary reason for health complaints or impairment for the patient";no;NA;no;NA
pedersen, 2019;ambt;ec;NA;NA;phs;msd;sf-36;post;24;self-report;23,46;30,84;8,17;6,73;32,74;31,98;8,68;8,18;54;54;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;pedersen_2019_msd_sf-36_post_24.0_self-report_ambt_ec_NA_NA;0,089475482;0,192547741;NA;NA;primary;low;low;low;high;some concerns;high;NCT01518647 (ClinicalTrials.gov);dk;clinical;no;NA;adults;yes;extended act;mixed;group;NA;no;9;NA;1695;NA;12;NA;0,75;NA;188,33;NA;NA;NA;NA;NA;NA;38,8;40,1;8;8,5;47;47;94;0,79;59;60;119;56;58;114;31;58;89;NA;NA;NA;combined;bds;36,2;35,5;8,7;8,7;NA;NA;NA;NA;yes;"diagnosis of psychosis, mania or depression with psychotic symptoms (icd-10: f2029, f3031, f32.3, f33.3), current abuse of alcohol or drugs; Patients with concurrent medical illness or psychiatric disorders were only excluded if the concurrent illness was the primary reason for health complaints or impairment for the patient";no;NA;no;NA
pedersen, 2019;ambt;ec;NA;NA;phs;msd;sf-36;follow up;80;self-report;23,46;30,84;8,17;6,73;35,72;32,67;9,43;8,42;54;54;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;pedersen_2019_msd_sf-36_followup_80.0_self-report_ambt_ec_NA_NA;0,33877116;0,193845243;NA;NA;primary;low;low;low;high;some concerns;high;NCT01518647 (ClinicalTrials.gov);dk;clinical;no;NA;adults;yes;extended act;mixed;group;NA;no;9;NA;1695;NA;12;NA;0,75;NA;188,33;NA;NA;NA;NA;NA;NA;38,8;40,1;8;8,5;47;47;94;0,79;59;60;119;56;58;114;31;58;89;NA;NA;NA;combined;bds;36,2;35,5;8,7;8,7;NA;NA;NA;NA;yes;"diagnosis of psychosis, mania or depression with psychotic symptoms (icd-10: f2029, f3031, f32.3, f33.3), current abuse of alcohol or drugs; Patients with concurrent medical illness or psychiatric disorders were only excluded if the concurrent illness was the primary reason for health complaints or impairment for the patient";no;NA;no;NA
pedersen, 2019;ambt;ec;NA;NA;phs;msd;who-das II;post;24;self-report;42,64;44,92;14,38;15,46;43,36;43,7;16,17;15,31;54;54;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;pedersen_2019_msd_who-dasII_post_24.0_self-report_ambt_ec_NA_NA;-0,021439819;0,192455698;NA;NA;secondary;NA;NA;NA;NA;NA;NA;NCT01518647 (ClinicalTrials.gov);dk;clinical;no;NA;adults;yes;extended act;mixed;group;NA;no;9;NA;1695;NA;12;NA;0,75;NA;188,33;NA;NA;NA;NA;NA;NA;38,8;40,1;8;8,5;47;47;94;0,79;59;60;119;56;58;114;31;58;89;NA;NA;NA;combined;bds;36,2;35,5;8,7;8,7;NA;NA;NA;NA;yes;"diagnosis of psychosis, mania or depression with psychotic symptoms (icd-10: f2029, f3031, f32.3, f33.3), current abuse of alcohol or drugs; Patients with concurrent medical illness or psychiatric disorders were only excluded if the concurrent illness was the primary reason for health complaints or impairment for the patient";no;NA;no;NA
perez-aranda, 2019;ambt;tau;NA;NA;som;msd;fsdc;post;8;self-report;22,23;22,37;5,32;5,08;17,93;22,57;6,55;5,28;75;75;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;perez-aranda_2019_msd_fsdc_post_8.0_self-report_ambt_tau_NA_NA;-0,776005471;0,16939446;NA;NA;primary;low;low;low;high;some concerns;high;NCT02561416 (ClinicalTrials.gov);es;clinical;no;NA;adults;yes;manual by kabat-zinn (adapted for fm);NA;group;NA;no;8;NA;960;NA;8;NA;1;NA;120;NA;5;NA;2,72;NA;0,63;52,96;52,65;7,98;8,52;73;74;147;0,98;75;75;150;71;75;146;17;55;72;NA;NA;NA;clinical interview;fm;NA;NA;NA;NA;167,4;157,2;107,52;116,76;yes;"presence of cognitive impairment according to the Mini-Mental State Examination (score < 27); presence of comorbid severe mental or medical disorders which could interfere with treatment";no;NA;no;NA
perez-aranda, 2019;ambt;tau;NA;NA;som;msd;fsdc;follow up;48;self-report;22,23;22,37;5,32;5,08;18,18;22,71;7,21;4,43;75;75;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;perez-aranda_2019_msd_fsdc_followup_48.0_self-report_ambt_tau_NA_NA;-0,753215486;0,1690477;NA;NA;primary;low;low;low;high;some concerns;high;NCT02561416 (ClinicalTrials.gov);es;clinical;no;NA;adults;yes;manual by kabat-zinn (adapted for fm);NA;group;NA;no;8;NA;960;NA;8;NA;1;NA;120;NA;5;NA;2,72;NA;0,63;52,96;52,65;7,98;8,52;73;74;147;0,98;75;75;150;71;75;146;17;55;72;NA;NA;NA;clinical interview;fm;NA;NA;NA;NA;167,4;157,2;107,52;116,76;yes;"presence of cognitive impairment according to the Mini-Mental State Examination (score < 27); presence of comorbid severe mental or medical disorders which could interfere with treatment";no;NA;no;NA
perez-aranda, 2019;ambt;tau;NA;NA;depr;msd;hads-d;post;8;self-report;7,85;8,2;4,91;5,41;5,33;9,13;4,83;5,05;75;75;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;perez-aranda_2019_msd_hads-d_post_8.0_self-report_ambt_tau_NA_NA;-0,76513638;0,169227881;NA;NA;primary;low;low;low;high;some concerns;high;NCT02561416 (ClinicalTrials.gov);es;clinical;no;NA;adults;yes;manual by kabat-zinn (adapted for fm);NA;group;NA;no;8;NA;960;NA;8;NA;1;NA;120;NA;5;NA;2,72;NA;0,63;52,96;52,65;7,98;8,52;73;74;147;0,98;75;75;150;71;75;146;17;55;72;NA;NA;NA;clinical interview;fm;NA;NA;NA;NA;167,4;157,2;107,52;116,76;yes;"presence of cognitive impairment according to the Mini-Mental State Examination (score < 27); presence of comorbid severe mental or medical disorders which could interfere with treatment";no;NA;no;NA
perez-aranda, 2019;ambt;tau;NA;NA;depr;msd;hads-d;follow up;48;self-report;7,85;8,2;4,91;5,41;7,06;8,76;5,38;5,64;75;75;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;perez-aranda_2019_msd_hads-d_followup_48.0_self-report_ambt_tau_NA_NA;-0,306878403;0,164267442;NA;NA;primary;low;low;low;high;some concerns;high;NCT02561416 (ClinicalTrials.gov);es;clinical;no;NA;adults;yes;manual by kabat-zinn (adapted for fm);NA;group;NA;no;8;NA;960;NA;8;NA;1;NA;120;NA;5;NA;2,72;NA;0,63;52,96;52,65;7,98;8,52;73;74;147;0,98;75;75;150;71;75;146;17;55;72;NA;NA;NA;clinical interview;fm;NA;NA;NA;NA;167,4;157,2;107,52;116,76;yes;"presence of cognitive impairment according to the Mini-Mental State Examination (score < 27); presence of comorbid severe mental or medical disorders which could interfere with treatment";no;NA;no;NA
perez-aranda, 2019;ambt;tau;NA;NA;anx;msd;hads-a;post;8;self-report;10,65;11,48;4,11;5,52;7,92;4,82;11,7;4,5;75;75;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;perez-aranda_2019_msd_hads-a_post_8.0_self-report_ambt_tau_NA_NA;0,347955065;0,164542916;NA;NA;primary;low;low;low;high;some concerns;high;NCT02561416 (ClinicalTrials.gov);es;clinical;no;NA;adults;yes;manual by kabat-zinn (adapted for fm);NA;group;NA;no;8;NA;960;NA;8;NA;1;NA;120;NA;5;NA;2,72;NA;0,63;52,96;52,65;7,98;8,52;73;74;147;0,98;75;75;150;71;75;146;17;55;72;NA;NA;NA;clinical interview;fm;NA;NA;NA;NA;167,4;157,2;107,52;116,76;yes;"presence of cognitive impairment according to the Mini-Mental State Examination (score < 27); presence of comorbid severe mental or medical disorders which could interfere with treatment";no;NA;no;NA
perez-aranda, 2019;ambt;tau;NA;NA;anx;msd;hads-a;follow up;48;self-report;10,65;11,48;4,11;5,52;8,63;12,11;4,7;5,15;75;75;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;perez-aranda_2019_msd_hads-a_followup_48.0_self-report_ambt_tau_NA_NA;-0,70227969;0,168307677;NA;NA;primary;low;low;low;high;some concerns;high;NCT02561416 (ClinicalTrials.gov);es;clinical;no;NA;adults;yes;manual by kabat-zinn (adapted for fm);NA;group;NA;no;8;NA;960;NA;8;NA;1;NA;120;NA;5;NA;2,72;NA;0,63;52,96;52,65;7,98;8,52;73;74;147;0,98;75;75;150;71;75;146;17;55;72;NA;NA;NA;clinical interview;fm;NA;NA;NA;NA;167,4;157,2;107,52;116,76;yes;"presence of cognitive impairment according to the Mini-Mental State Examination (score < 27); presence of comorbid severe mental or medical disorders which could interfere with treatment";no;NA;no;NA
perez-aranda, 2019;ambt;tau;NA;NA;phs;msd;fiq-r;post;8;self-report;-63,51;-61,37;19,03;19,7;-47,99;-60,73;19,5;21,28;75;75;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;perez-aranda_2019_msd_fiq-r_post_8.0_self-report_ambt_tau_NA_NA;0,621053091;0,167228913;NA;NA;primary;low;low;low;high;some concerns;high;NCT02561416 (ClinicalTrials.gov);es;clinical;no;NA;adults;yes;manual by kabat-zinn (adapted for fm);NA;group;NA;no;8;NA;960;NA;8;NA;1;NA;120;NA;5;NA;2,72;NA;0,63;52,96;52,65;7,98;8,52;73;74;147;0,98;75;75;150;71;75;146;17;55;72;NA;NA;NA;clinical interview;fm;NA;NA;NA;NA;167,4;157,2;107,52;116,76;yes;"presence of cognitive impairment according to the Mini-Mental State Examination (score < 27); presence of comorbid severe mental or medical disorders which could interfere with treatment";no;NA;no;NA
perez-aranda, 2019;ambt;tau;NA;NA;phs;msd;fiq-r;follow up;48;self-report;-63,51;-61,37;19,03;19,7;-53,98;-63,75;22;18,88;75;75;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;perez-aranda_2019_msd_fiq-r_followup_48.0_self-report_ambt_tau_NA_NA;0,474179014;0,165601388;NA;NA;primary;low;low;low;high;some concerns;high;NCT02561416 (ClinicalTrials.gov);es;clinical;no;NA;adults;yes;manual by kabat-zinn (adapted for fm);NA;group;NA;no;8;NA;960;NA;8;NA;1;NA;120;NA;5;NA;2,72;NA;0,63;52,96;52,65;7,98;8,52;73;74;147;0,98;75;75;150;71;75;146;17;55;72;NA;NA;NA;clinical interview;fm;NA;NA;NA;NA;167,4;157,2;107,52;116,76;yes;"presence of cognitive impairment according to the Mini-Mental State Examination (score < 27); presence of comorbid severe mental or medical disorders which could interfere with treatment";no;NA;no;NA
prins, 2001;cbt;psy plac;cbt;psy plac;som;msd;cis;post;32;self-report;52,2;52,3;3,9;4;40,7;46,3;10,7;8,3;90;88;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;prins_2001_msd_cis_post_32.0_self-report_cbt_psyplac_cbt_psyplac;-0,581509779;0,153077681;NA;NA;primary;low;low;low;high;some concerns;high;NA;nl;clinical;no;NA;adults;yes;NA;mixed;individual;NA;no;16;NA;960;NA;32;NA;0,5;NA;60;NA;NA;NA;NA;NA;NA;36,2;37,1;9,4;10,6;70;71;141;0,77;93;90;183;83;86;169;NA;NA;NA;NA;NA;NA;combined;cfs/me;NA;NA;NA;NA;58,8;79,2;57,6;76,8;yes;additional exclusion criteria were previous or current participation in cfs research, pregnancy, and current treatment to achieve pregnancy;no;NA;no;NA
prins, 2001;cbt;tau;cbt;psy plac;som;msd;cis;post;32;self-report;52,2;51,9;3,9;4,1;40,7;46;10,7;9;90;88;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;prins_2001_msd_cis_post_32.0_self-report_cbt_tau_cbt_psyplac;-0,533272257;0,15257925;NA;NA;primary;low;low;low;high;some concerns;high;NA;nl;clinical;no;NA;adults;yes;NA;mixed;individual;NA;no;16;NA;960;NA;32;NA;0,5;NA;60;NA;NA;NA;NA;NA;NA;36,2;36,7;9,4;10,3;70;71;141;0,77;93;91;184;83;91;174;NA;NA;NA;NA;NA;NA;combined;cfs/me;NA;NA;NA;NA;58,8;63,6;57,6;64,8;yes;additional exclusion criteria were previous or current participation in cfs research, pregnancy, and current treatment to achieve pregnancy;no;NA;no;NA
prins, 2001;cbt;psy plac;cbt;psy plac;som;msd;cis;follow up;56;self-report;52,2;52,3;3,9;4;38,9;45,8;12;9,5;90;88;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;prins_2001_msd_cis_followup_56.0_self-report_cbt_psyplac_cbt_psyplac;-0,63401793;0,153667174;NA;NA;primary;low;low;low;high;some concerns;high;NA;nl;clinical;no;NA;adults;yes;NA;mixed;individual;NA;no;16;NA;960;NA;32;NA;0,5;NA;60;NA;NA;NA;NA;NA;NA;36,2;37,1;9,4;10,6;70;71;141;0,77;93;90;183;83;86;169;NA;NA;NA;NA;NA;NA;combined;cfs/me;NA;NA;NA;NA;58,8;79,2;57,6;76,8;yes;additional exclusion criteria were previous or current participation in cfs research, pregnancy, and current treatment to achieve pregnancy;no;NA;no;NA
prins, 2001;cbt;tau;cbt;psy plac;som;msd;cis;follow up;56;self-report;52,2;51,9;3,9;4,1;38,9;45,3;12;8,8;90;88;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;prins_2001_msd_cis_followup_56.0_self-report_cbt_tau_cbt_psyplac;-0,60460149;0,153330928;NA;NA;primary;low;low;low;high;some concerns;high;NA;nl;clinical;no;NA;adults;yes;NA;mixed;individual;NA;no;16;NA;960;NA;32;NA;0,5;NA;60;NA;NA;NA;NA;NA;NA;36,2;36,7;9,4;10,3;70;71;141;0,77;93;91;184;83;91;174;NA;NA;NA;NA;NA;NA;combined;cfs/me;NA;NA;NA;NA;58,8;63,6;57,6;64,8;yes;additional exclusion criteria were previous or current participation in cfs research, pregnancy, and current treatment to achieve pregnancy;no;NA;no;NA
prins, 2001;cbt;psy plac;cbt;psy plac;phs;msd;sip;post;32;self-report;-1755;-1842;613;560;-1209;-1500;677;692;90;88;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;prins_2001_msd_sip_post_32.0_self-report_cbt_psyplac_cbt_psyplac;0,423340929;0,151599775;NA;NA;primary;low;low;low;high;some concerns;high;NA;nl;clinical;no;NA;adults;yes;NA;mixed;individual;NA;no;16;NA;960;NA;32;NA;0,5;NA;60;NA;NA;NA;NA;NA;NA;36,2;37,1;9,4;10,6;70;71;141;0,77;93;90;183;83;86;169;NA;NA;NA;NA;NA;NA;combined;cfs/me;NA;NA;NA;NA;58,8;79,2;57,6;76,8;yes;additional exclusion criteria were previous or current participation in cfs research, pregnancy, and current treatment to achieve pregnancy;no;NA;no;NA
prins, 2001;cbt;tau;cbt;psy plac;phs;msd;sip;post;32;self-report;-1755;-1859;613;671;-1209;-1473;677;564;90;88;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;prins_2001_msd_sip_post_32.0_self-report_cbt_tau_cbt_psyplac;0,421469995;0,151585005;NA;NA;primary;low;low;low;high;some concerns;high;NA;nl;clinical;no;NA;adults;yes;NA;mixed;individual;NA;no;16;NA;960;NA;32;NA;0,5;NA;60;NA;NA;NA;NA;NA;NA;36,2;36,7;9,4;10,3;70;71;141;0,77;93;91;184;83;91;174;NA;NA;NA;NA;NA;NA;combined;cfs/me;NA;NA;NA;NA;58,8;63,6;57,6;64,8;yes;additional exclusion criteria were previous or current participation in cfs research, pregnancy, and current treatment to achieve pregnancy;no;NA;no;NA
prins, 2001;cbt;psy plac;cbt;psy plac;phs;msd;sip;follow up;56;self-report;-1755;-1842;613;560;-1117;-1553;730;713;90;88;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;prins_2001_msd_sip_followup_56.0_self-report_cbt_psyplac_cbt_psyplac;0,601595539;0,153297428;NA;NA;primary;low;low;low;high;some concerns;high;NA;nl;clinical;no;NA;adults;yes;NA;mixed;individual;NA;no;16;NA;960;NA;32;NA;0,5;NA;60;NA;NA;NA;NA;NA;NA;36,2;37,1;9,4;10,6;70;71;141;0,77;93;90;183;83;86;169;NA;NA;NA;NA;NA;NA;combined;cfs/me;NA;NA;NA;NA;58,8;79,2;57,6;76,8;yes;additional exclusion criteria were previous or current participation in cfs research, pregnancy, and current treatment to achieve pregnancy;no;NA;no;NA
prins, 2001;cbt;tau;cbt;psy plac;phs;msd;sip;follow up;56;self-report;-1755;-1859;613;671;-1117;-1460;730;571;90;88;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;prins_2001_msd_sip_followup_56.0_self-report_cbt_tau_cbt_psyplac;0,520447239;0,152453733;NA;NA;primary;low;low;low;high;some concerns;high;NA;nl;clinical;no;NA;adults;yes;NA;mixed;individual;NA;no;16;NA;960;NA;32;NA;0,5;NA;60;NA;NA;NA;NA;NA;NA;36,2;36,7;9,4;10,3;70;71;141;0,77;93;91;184;83;91;174;NA;NA;NA;NA;NA;NA;combined;cfs/me;NA;NA;NA;NA;58,8;63,6;57,6;64,8;yes;additional exclusion criteria were previous or current participation in cfs research, pregnancy, and current treatment to achieve pregnancy;no;NA;no;NA
rimes, 2013;ambt;wl;NA;NA;som;msd;cfq;post;8;self-report;25,4;23,4;5,1;3,9;21,3;25,2;6,2;4,7;16;19;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;rimes_2013_msd_cfq_post_8.0_self-report_ambt_wl_NA_NA;-0,701345041;0,349988218;NA;NA;primary;low;some concerns;low;high;some concerns;high;NA;gb;clinical;no;NA;adults;yes;segal et al. (2002) mbct manual;psy;group;NA;no;9;NA;1215;NA;8;NA;1,13;NA;135;NA;7,3;NA;0,95;NA;0,81;41,4;45,2;10,9;9,4;12;17;29;0,81;17;19;36;17;19;36;NA;19;NA;NA;NA;did not like group nature of mbct;combined;cfs/me;NA;NA;NA;NA;102;73,2;52,8;57,6;yes;current major depression;no;NA;no;NA
rimes, 2013;ambt;wl;NA;NA;som;msd;cfq;follow up;16;self-report;25,4;23,4;5,1;3,9;21,3;25;6,2;6,1;16;19;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;rimes_2013_msd_cfq_followup_16.0_self-report_ambt_wl_NA_NA;-0,588263811;0,34685683;NA;NA;primary;low;some concerns;low;high;some concerns;high;NA;gb;clinical;no;NA;adults;yes;segal et al. (2002) mbct manual;psy;group;NA;no;9;NA;1215;NA;8;NA;1,13;NA;135;NA;7,3;NA;0,95;NA;0,81;41,4;45,2;10,9;9,4;12;17;29;0,81;17;19;36;17;19;36;NA;19;NA;NA;NA;did not like group nature of mbct;combined;cfs/me;NA;NA;NA;NA;102;73,2;52,8;57,6;yes;current major depression;no;NA;no;NA
rimes, 2013;ambt;wl;NA;NA;depr;msd;hads-d;post;8;self-report;6,6;7,9;4,4;4,6;5,4;8;3,5;4,4;16;19;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;rimes_2013_msd_hads-d_post_8.0_self-report_ambt_wl_NA_NA;-0,632585622;0,348022015;NA;NA;primary;low;some concerns;low;high;some concerns;high;NA;gb;clinical;no;NA;adults;yes;segal et al. (2002) mbct manual;psy;group;NA;no;9;NA;1215;NA;8;NA;1,13;NA;135;NA;7,3;NA;0,95;NA;0,81;41,4;45,2;10,9;9,4;12;17;29;0,81;17;19;36;17;19;36;NA;19;NA;NA;NA;did not like group nature of mbct;combined;cfs/me;NA;NA;NA;NA;102;73,2;52,8;57,6;yes;current major depression;no;NA;no;NA
rimes, 2013;ambt;wl;NA;NA;depr;msd;hads-d;follow up;16;self-report;6,6;7,9;4,4;4,6;5,6;7,7;2,9;4,6;16;19;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;rimes_2013_msd_hads-d_followup_16.0_self-report_ambt_wl_NA_NA;-0,523477609;0,345299765;NA;NA;primary;low;some concerns;low;high;some concerns;high;NA;gb;clinical;no;NA;adults;yes;segal et al. (2002) mbct manual;psy;group;NA;no;9;NA;1215;NA;8;NA;1,13;NA;135;NA;7,3;NA;0,95;NA;0,81;41,4;45,2;10,9;9,4;12;17;29;0,81;17;19;36;17;19;36;NA;19;NA;NA;NA;did not like group nature of mbct;combined;cfs/me;NA;NA;NA;NA;102;73,2;52,8;57,6;yes;current major depression;no;NA;no;NA
rimes, 2013;ambt;wl;NA;NA;anx;msd;hads-a;post;8;self-report;8,1;8,3;4,7;5;7,7;9,3;3,2;5,1;16;19;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;rimes_2013_msd_hads-a_post_8.0_self-report_ambt_wl_NA_NA;-0,360161472;0,342158662;NA;NA;primary;low;some concerns;low;high;some concerns;high;NA;gb;clinical;no;NA;adults;yes;segal et al. (2002) mbct manual;psy;group;NA;no;9;NA;1215;NA;8;NA;1,13;NA;135;NA;7,3;NA;0,95;NA;0,81;41,4;45,2;10,9;9,4;12;17;29;0,81;17;19;36;17;19;36;NA;19;NA;NA;NA;did not like group nature of mbct;combined;cfs/me;NA;NA;NA;NA;102;73,2;52,8;57,6;yes;current major depression;no;NA;no;NA
rimes, 2013;ambt;wl;NA;NA;anx;msd;hads-a;follow up;16;self-report;8,1;8,3;4,7;5;7,8;8,9;3,6;5,2;16;19;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;rimes_2013_msd_hads-a_followup_16.0_self-report_ambt_wl_NA_NA;-0,236579175;0,34054231;NA;NA;primary;low;some concerns;low;high;some concerns;high;NA;gb;clinical;no;NA;adults;yes;segal et al. (2002) mbct manual;psy;group;NA;no;9;NA;1215;NA;8;NA;1,13;NA;135;NA;7,3;NA;0,95;NA;0,81;41,4;45,2;10,9;9,4;12;17;29;0,81;17;19;36;17;19;36;NA;19;NA;NA;NA;did not like group nature of mbct;combined;cfs/me;NA;NA;NA;NA;102;73,2;52,8;57,6;yes;current major depression;no;NA;no;NA
rimes, 2013;ambt;wl;NA;NA;phs;msd;pf-10;post;8;self-report;61,6;55,5;22,7;23,6;65,9;53,7;23,1;23,1;16;19;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;rimes_2013_msd_pf-10_post_8.0_self-report_ambt_wl_NA_NA;0,516043753;0,34513229;NA;NA;primary;low;some concerns;low;high;some concerns;high;NA;gb;clinical;no;NA;adults;yes;segal et al. (2002) mbct manual;psy;group;NA;no;9;NA;1215;NA;8;NA;1,13;NA;135;NA;7,3;NA;0,95;NA;0,81;41,4;45,2;10,9;9,4;12;17;29;0,81;17;19;36;17;19;36;NA;19;NA;NA;NA;did not like group nature of mbct;combined;cfs/me;NA;NA;NA;NA;102;73,2;52,8;57,6;yes;current major depression;no;NA;no;NA
rimes, 2013;ambt;wl;NA;NA;phs;msd;pf-10;follow up;16;self-report;61,6;55,5;22,7;23,6;65,6;55,9;26,3;23,3;16;19;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;rimes_2013_msd_pf-10_followup_16.0_self-report_ambt_wl_NA_NA;0,38358198;0,342539329;NA;NA;primary;low;some concerns;low;high;some concerns;high;NA;gb;clinical;no;NA;adults;yes;segal et al. (2002) mbct manual;psy;group;NA;no;9;NA;1215;NA;8;NA;1,13;NA;135;NA;7,3;NA;0,95;NA;0,81;41,4;45,2;10,9;9,4;12;17;29;0,81;17;19;36;17;19;36;NA;19;NA;NA;NA;did not like group nature of mbct;combined;cfs/me;NA;NA;NA;NA;102;73,2;52,8;57,6;yes;current major depression;no;NA;no;NA
sanders, 2007;cbt;wl;NA;NA;som;msd;pain diary;post;10;self-report;2,3;1,9;1,9;1,6;1,8;2;2,1;1,2;7;9;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;sanders_2007_msd_paindiary_post_10.0_self-report_cbt_wl_NA_NA;-0,114804044;0,504409578;NA;NA;primary;low;high;high;high;some concerns;high;NA;us;combined;no;NA;adults;yes;breaking the bonds of ibs;self-guided;individual;NA;no;5;NA;NA;NA;8;NA;0,63;NA;NA;NA;NA;NA;NA;NA;NA;56,9;41,8;14,6;10,3;17;9;26;0,93;17;11;28;NA;NA;NA;NA;NA;NA;NA;NA;NA;combined;ibs;NA;NA;NA;NA;195,6;180;180;152,4;yes;participants were excluded if it was discovered that they did not have ibs, they had inflammatory bowel disease, their physician noted a serious medical disease, they had a serious mental disorder (e.g., psychosis, mania, dementia), or if they were actively suicidal, under 18 years of age, or currently receiving psychological treatment of any kind;no;NA;no;NA
sanders, 2007;cbt;wl;NA;NA;phs;msd;ibs-qol;post;10;self-report;68;65,4;20,9;24,3;72,7;62,7;21,8;24,6;7;9;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;sanders_2007_msd_ibs-qol_post_10.0_self-report_cbt_wl_NA_NA;0,403333885;0,509563979;NA;NA;primary;low;high;high;high;some concerns;high;NA;us;combined;no;NA;adults;yes;breaking the bonds of ibs;self-guided;individual;NA;no;5;NA;NA;NA;8;NA;0,63;NA;NA;NA;NA;NA;NA;NA;NA;56,9;41,8;14,6;10,3;17;9;26;0,93;17;11;28;NA;NA;NA;NA;NA;NA;NA;NA;NA;combined;ibs;NA;NA;NA;NA;195,6;180;180;152,4;yes;participants were excluded if it was discovered that they did not have ibs, they had inflammatory bowel disease, their physician noted a serious medical disease, they had a serious mental disorder (e.g., psychosis, mania, dementia), or if they were actively suicidal, under 18 years of age, or currently receiving psychological treatment of any kind;no;NA;no;NA
schmidt, 2011;ambt;wl;ambt;wl;som;msd;gcq;post;8;self-report;48,43;48,36;13,53;14,79;42,01;47,41;10,63;14,3;53;59;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;schmidt_2011_msd_gcq_post_8.0_self-report_ambt_wl_ambt_wl;-0,422358329;0,191375136;NA;NA;primary;low;low;low;high;low;high;NCT00106275 (clinicaltrials.gov);de;combined;no;NA;adults;yes;mbsr;psy;group;NA;no;11;NA;1740;NA;8;NA;1,38;NA;158,18;NA;6,7;NA;NA;NA;0,61;53,4;52,3;8,7;10,9;58;59;117;1;58;59;117;53;59;112;NA;NA;NA;“refused to participate (n=3), other reasons (n=2)”;NA;NA;clinical interview;fm;NA;NA;NA;NA;154,5;173,9;117,2;119,1;yes;“life-threatening diseases, evidence of suppressed immune functioning”;no;NA;no;NA
schmidt, 2011;ambt;psy plac;ambt;psy plac;som;msd;gcq;post;8;self-report;48,43;47,02;13,53;14,65;42,01;43,41;10,63;15,76;53;59;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;schmidt_2011_msd_gcq_post_8.0_self-report_ambt_psyplac_ambt_psyplac;-0,102398536;0,189379338;NA;NA;primary;low;low;low;high;low;high;NCT00106275 (clinicaltrials.gov);de;combined;no;NA;adults;yes;mbsr;psy;group;NA;no;11;NA;1740;NA;8;NA;1,38;NA;158,18;NA;6,7;NA;NA;NA;0,61;53,4;51,9;8,7;9,2;58;59;117;1;58;59;117;53;56;109;NA;NA;NA;“refused to participate (n=3), other reasons (n=2)”;NA;NA;clinical interview;fm;NA;NA;NA;NA;154,5;188;117,2;132;yes;“life-threatening diseases, evidence of suppressed immune functioning”;no;NA;no;NA
schmidt, 2011;ambt;wl;ambt;wl;som;msd;gcq;follow up;16;self-report;48,43;48,36;13,53;14,79;42,63;45,29;12,2;15,04;53;59;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;schmidt_2011_msd_gcq_followup_16.0_self-report_ambt_wl_ambt_wl;-0,191844488;0,189693571;NA;NA;primary;low;low;low;high;low;high;NCT00106275 (clinicaltrials.gov);de;combined;no;NA;adults;yes;mbsr;psy;group;NA;no;11;NA;1740;NA;8;NA;1,38;NA;158,18;NA;6,7;NA;NA;NA;0,61;53,4;52,3;8,7;10,9;58;59;117;1;58;59;117;53;59;112;NA;NA;NA;“refused to participate (n=3), other reasons (n=2)”;NA;NA;clinical interview;fm;NA;NA;NA;NA;154,5;173,9;117,2;119,1;yes;“life-threatening diseases, evidence of suppressed immune functioning”;no;NA;no;NA
schmidt, 2011;ambt;psy plac;ambt;psy plac;som;msd;gcq;follow up;16;self-report;48,43;47,02;13,53;14,65;42,63;43,91;12,2;15,1;53;59;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;schmidt_2011_msd_gcq_followup_16.0_self-report_ambt_psyplac_ambt_psyplac;-0,092084919;0,189355368;NA;NA;primary;low;low;low;high;low;high;NCT00106275 (clinicaltrials.gov);de;combined;no;NA;adults;yes;mbsr;psy;group;NA;no;11;NA;1740;NA;8;NA;1,38;NA;158,18;NA;6,7;NA;NA;NA;0,61;53,4;51,9;8,7;9,2;58;59;117;1;58;59;117;53;56;109;NA;NA;NA;“refused to participate (n=3), other reasons (n=2)”;NA;NA;clinical interview;fm;NA;NA;NA;NA;154,5;188;117,2;132;yes;“life-threatening diseases, evidence of suppressed immune functioning”;no;NA;no;NA
schmidt, 2011;ambt;wl;ambt;wl;depr;msd;ces-d;post;8;self-report;25,19;25,43;9,6;9,26;23,2;24,22;9,04;10,28;53;59;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;schmidt_2011_msd_ces-d_post_8.0_self-report_ambt_wl_ambt_wl;-0,104290185;0,18938401;NA;NA;primary;low;low;low;high;low;high;NCT00106275 (clinicaltrials.gov);de;combined;no;NA;adults;yes;mbsr;psy;group;NA;no;11;NA;1740;NA;8;NA;1,38;NA;158,18;NA;6,7;NA;NA;NA;0,61;53,4;52,3;8,7;10,9;58;59;117;1;58;59;117;53;59;112;NA;NA;NA;“refused to participate (n=3), other reasons (n=2)”;NA;NA;clinical interview;fm;NA;NA;NA;NA;154,5;173,9;117,2;119,1;yes;“life-threatening diseases, evidence of suppressed immune functioning”;no;NA;no;NA
schmidt, 2011;ambt;psy plac;ambt;psy plac;depr;msd;ces-d;post;8;self-report;25,19;22,92;9,6;10,27;23,2;20,9;9,04;9,53;53;59;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;schmidt_2011_msd_ces-d_post_8.0_self-report_ambt_psyplac_ambt_psyplac;0,245580016;0,189973772;NA;NA;primary;low;low;low;high;low;high;NCT00106275 (clinicaltrials.gov);de;combined;no;NA;adults;yes;mbsr;psy;group;NA;no;11;NA;1740;NA;8;NA;1,38;NA;158,18;NA;6,7;NA;NA;NA;0,61;53,4;51,9;8,7;9,2;58;59;117;1;58;59;117;53;56;109;NA;NA;NA;“refused to participate (n=3), other reasons (n=2)”;NA;NA;clinical interview;fm;NA;NA;NA;NA;154,5;188;117,2;132;yes;“life-threatening diseases, evidence of suppressed immune functioning”;no;NA;no;NA
schmidt, 2011;ambt;wl;ambt;wl;depr;msd;ces-d;follow up;16;self-report;25,19;25,43;9,6;9,26;21,7;24;9,93;9,61;53;59;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;schmidt_2011_msd_ces-d_followup_16.0_self-report_ambt_wl_ambt_wl;-0,233983481;0,189907514;NA;NA;primary;low;low;low;high;low;high;NCT00106275 (clinicaltrials.gov);de;combined;no;NA;adults;yes;mbsr;psy;group;NA;no;11;NA;1740;NA;8;NA;1,38;NA;158,18;NA;6,7;NA;NA;NA;0,61;53,4;52,3;8,7;10,9;58;59;117;1;58;59;117;53;59;112;NA;NA;NA;“refused to participate (n=3), other reasons (n=2)”;NA;NA;clinical interview;fm;NA;NA;NA;NA;154,5;173,9;117,2;119,1;yes;“life-threatening diseases, evidence of suppressed immune functioning”;no;NA;no;NA
schmidt, 2011;ambt;psy plac;ambt;psy plac;depr;msd;ces-d;follow up;16;self-report;25,19;22,92;9,6;10,27;21,7;22,55;9,93;10,13;53;59;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;schmidt_2011_msd_ces-d_followup_16.0_self-report_ambt_psyplac_ambt_psyplac;-0,084116724;0,189338588;NA;NA;primary;low;low;low;high;low;high;NCT00106275 (clinicaltrials.gov);de;combined;no;NA;adults;yes;mbsr;psy;group;NA;no;11;NA;1740;NA;8;NA;1,38;NA;158,18;NA;6,7;NA;NA;NA;0,61;53,4;51,9;8,7;9,2;58;59;117;1;58;59;117;53;56;109;NA;NA;NA;“refused to participate (n=3), other reasons (n=2)”;NA;NA;clinical interview;fm;NA;NA;NA;NA;154,5;188;117,2;132;yes;“life-threatening diseases, evidence of suppressed immune functioning”;no;NA;no;NA
schmidt, 2011;ambt;wl;ambt;wl;anx;msd;stai state;post;8;self-report;51,6;46,68;9,18;10,68;47,65;48,39;8,43;9,92;53;59;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;schmidt_2011_msd_staistate_post_8.0_self-report_ambt_wl_ambt_wl;-0,079491018;0,189329542;NA;NA;primary;low;low;low;high;low;high;NCT00106275 (clinicaltrials.gov);de;combined;no;NA;adults;yes;mbsr;psy;group;NA;no;11;NA;1740;NA;8;NA;1,38;NA;158,18;NA;6,7;NA;NA;NA;0,61;53,4;52,3;8,7;10,9;58;59;117;1;58;59;117;53;59;112;NA;NA;NA;“refused to participate (n=3), other reasons (n=2)”;NA;NA;clinical interview;fm;NA;NA;NA;NA;154,5;173,9;117,2;119,1;yes;“life-threatening diseases, evidence of suppressed immune functioning”;no;NA;no;NA
schmidt, 2011;ambt;psy plac;ambt;psy plac;anx;msd;stai state;post;8;self-report;51,6;49,8;9,18;10,91;47,65;48;8,43;8,94;53;59;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;schmidt_2011_msd_staistate_post_8.0_self-report_ambt_psyplac_ambt_psyplac;-0,039942869;0,189273078;NA;NA;primary;low;low;low;high;low;high;NCT00106275 (clinicaltrials.gov);de;combined;no;NA;adults;yes;mbsr;psy;group;NA;no;11;NA;1740;NA;8;NA;1,38;NA;158,18;NA;6,7;NA;NA;NA;0,61;53,4;51,9;8,7;9,2;58;59;117;1;58;59;117;53;56;109;NA;NA;NA;“refused to participate (n=3), other reasons (n=2)”;NA;NA;clinical interview;fm;NA;NA;NA;NA;154,5;188;117,2;132;yes;“life-threatening diseases, evidence of suppressed immune functioning”;no;NA;no;NA
schmidt, 2011;ambt;wl;ambt;wl;anx;msd;stai state;follow up;16;self-report;51,6;46,68;9,18;10,68;47,86;49,18;9,12;10,47;53;59;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;schmidt_2011_msd_staistate_followup_16.0_self-report_ambt_wl_ambt_wl;-0,133028282;0,189465486;NA;NA;primary;low;low;low;high;low;high;NCT00106275 (clinicaltrials.gov);de;combined;no;NA;adults;yes;mbsr;psy;group;NA;no;11;NA;1740;NA;8;NA;1,38;NA;158,18;NA;6,7;NA;NA;NA;0,61;53,4;52,3;8,7;10,9;58;59;117;1;58;59;117;53;59;112;NA;NA;NA;“refused to participate (n=3), other reasons (n=2)”;NA;NA;clinical interview;fm;NA;NA;NA;NA;154,5;173,9;117,2;119,1;yes;“life-threatening diseases, evidence of suppressed immune functioning”;no;NA;no;NA
schmidt, 2011;ambt;psy plac;ambt;psy plac;anx;msd;stai state;follow up;16;self-report;51,6;49,8;9,18;10,91;47,86;48,44;9,12;10,94;53;59;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;schmidt_2011_msd_staistate_followup_16.0_self-report_ambt_psyplac_ambt_psyplac;-0,056917734;0,189292735;NA;NA;primary;low;low;low;high;low;high;NCT00106275 (clinicaltrials.gov);de;combined;no;NA;adults;yes;mbsr;psy;group;NA;no;11;NA;1740;NA;8;NA;1,38;NA;158,18;NA;6,7;NA;NA;NA;0,61;53,4;51,9;8,7;9,2;58;59;117;1;58;59;117;53;56;109;NA;NA;NA;“refused to participate (n=3), other reasons (n=2)”;NA;NA;clinical interview;fm;NA;NA;NA;NA;154,5;188;117,2;132;yes;“life-threatening diseases, evidence of suppressed immune functioning”;no;NA;no;NA
schmidt, 2011;ambt;wl;ambt;wl;phs;msd;plc;post;8;self-report;11,69;11,67;2,94;3,18;12,64;11,8;2,98;3,48;53;59;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;schmidt_2011_msd_plc_post_8.0_self-report_ambt_wl_ambt_wl;0,2564406;0,190038708;NA;NA;primary;low;low;low;high;low;high;NCT00106275 (clinicaltrials.gov);de;combined;no;NA;adults;yes;mbsr;psy;group;NA;no;11;NA;1740;NA;8;NA;1,38;NA;158,18;NA;6,7;NA;NA;NA;0,61;53,4;52,3;8,7;10,9;58;59;117;1;58;59;117;53;59;112;NA;NA;NA;“refused to participate (n=3), other reasons (n=2)”;NA;NA;clinical interview;fm;NA;NA;NA;NA;154,5;173,9;117,2;119,1;yes;“life-threatening diseases, evidence of suppressed immune functioning”;no;NA;no;NA
schmidt, 2011;ambt;psy plac;ambt;psy plac;phs;msd;plc;post;8;self-report;11,69;11,75;1,94;3,27;12,64;12,89;2,98;3,43;53;59;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;schmidt_2011_msd_plc_post_8.0_self-report_ambt_psyplac_ambt_psyplac;-0,076987069;0,189324859;NA;NA;primary;low;low;low;high;low;high;NCT00106275 (clinicaltrials.gov);de;combined;no;NA;adults;yes;mbsr;psy;group;NA;no;11;NA;1740;NA;8;NA;1,38;NA;158,18;NA;6,7;NA;NA;NA;0,61;53,4;51,9;8,7;9,2;58;59;117;1;58;59;117;53;56;109;NA;NA;NA;“refused to participate (n=3), other reasons (n=2)”;NA;NA;clinical interview;fm;NA;NA;NA;NA;154,5;188;117,2;132;yes;“life-threatening diseases, evidence of suppressed immune functioning”;no;NA;no;NA
schmidt, 2011;ambt;wl;ambt;wl;phs;msd;plc;follow up;16;self-report;11,69;11,67;2,94;3,18;12,83;12,29;3,06;3,28;53;59;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;schmidt_2011_msd_plc_followup_16.0_self-report_ambt_wl_ambt_wl;0,168762396;0,189594248;NA;NA;primary;low;low;low;high;low;high;NCT00106275 (clinicaltrials.gov);de;combined;no;NA;adults;yes;mbsr;psy;group;NA;no;11;NA;1740;NA;8;NA;1,38;NA;158,18;NA;6,7;NA;NA;NA;0,61;53,4;52,3;8,7;10,9;58;59;117;1;58;59;117;53;59;112;NA;NA;NA;“refused to participate (n=3), other reasons (n=2)”;NA;NA;clinical interview;fm;NA;NA;NA;NA;154,5;173,9;117,2;119,1;yes;“life-threatening diseases, evidence of suppressed immune functioning”;no;NA;no;NA
schmidt, 2011;ambt;psy plac;ambt;psy plac;phs;msd;plc;follow up;16;self-report;11,69;11,75;1,94;3,27;12,83;12,16;3,06;3,61;53;59;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;schmidt_2011_msd_plc_followup_16.0_self-report_ambt_psyplac_ambt_psyplac;0,197969328;0,189722051;NA;NA;primary;low;low;low;high;low;high;NCT00106275 (clinicaltrials.gov);de;combined;no;NA;adults;yes;mbsr;psy;group;NA;no;11;NA;1740;NA;8;NA;1,38;NA;158,18;NA;6,7;NA;NA;NA;0,61;53,4;51,9;8,7;9,2;58;59;117;1;58;59;117;53;56;109;NA;NA;NA;“refused to participate (n=3), other reasons (n=2)”;NA;NA;clinical interview;fm;NA;NA;NA;NA;154,5;188;117,2;132;yes;“life-threatening diseases, evidence of suppressed immune functioning”;no;NA;no;NA
schroeder, 2013;cbt;wl;NA;NA;som;msd;soms-7;post;8;self-report;41,27;34,39;23,95;23,69;32,24;36,43;25,5;26,56;49;44;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;schroeder_2013_msd_soms-7_post_8.0_self-report_cbt_wl_NA_NA;-0,159783501;0,20802643;NA;NA;primary;high;low;low;high;some concerns;high;NA;de;combined;no;NA;adults;yes;NA;psy;group;NA;no;8;NA;720;NA;8;NA;1;NA;90;NA;6,95;NA;1,02;NA;NA;49,1;45,4;13,06;12,58;38;32;70;0,75;49;44;93;NA;NA;NA;NA;44;NA;NA;NA;NA;combined;mus;NA;NA;NA;NA;NA;NA;NA;NA;yes;"psychotic symptoms; (suicidal tendencies; serious concentration or language problems)";no;NA;no;NA
schroeder, 2013;cbt;wl;NA;NA;depr;msd;hads-d;post;8;self-report;8,12;8,73;4,62;4,24;6,92;7,66;4,65;4,21;49;44;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;schroeder_2013_msd_hads-d_post_8.0_self-report_cbt_wl_NA_NA;-0,165009927;0,208048731;NA;NA;primary;some concerns;low;low;high;some concerns;high;NA;de;combined;no;NA;adults;yes;NA;psy;group;NA;no;8;NA;720;NA;8;NA;1;NA;90;NA;6,95;NA;1,02;NA;NA;49,1;45,4;13,06;12,58;38;32;70;0,75;49;44;93;NA;NA;NA;NA;44;NA;NA;NA;NA;combined;mus;NA;NA;NA;NA;NA;NA;NA;NA;yes;"psychotic symptoms; (suicidal tendencies; serious concentration or language problems)";no;NA;no;NA
schroeder, 2013;cbt;wl;NA;NA;anx;msd;hads-a;post;8;self-report;10,92;10,23;4,41;4,02;9,45;9,64;4,34;4,84;49;44;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;schroeder_2013_msd_hads-a_post_8.0_self-report_cbt_wl_NA_NA;-0,041114337;0,207712966;NA;NA;primary;some concerns;low;low;high;some concerns;high;NA;de;combined;no;NA;adults;yes;NA;psy;group;NA;no;8;NA;720;NA;8;NA;1;NA;90;NA;6,95;NA;1,02;NA;NA;49,1;45,4;13,06;12,58;38;32;70;0,75;49;44;93;NA;NA;NA;NA;44;NA;NA;NA;NA;combined;mus;NA;NA;NA;NA;NA;NA;NA;NA;yes;"psychotic symptoms; (suicidal tendencies; serious concentration or language problems)";no;NA;no;NA
schroeder, 2013;cbt;wl;NA;NA;phs;msd;sf-12;post;8;self-report;39,47;38,38;10,2;9,18;42,21;41,08;10,27;9,03;49;44;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;schroeder_2013_msd_sf-12_post_8.0_self-report_cbt_wl_NA_NA;0,115486444;0,207866161;NA;NA;primary;some concerns;low;low;high;some concerns;high;NA;de;combined;no;NA;adults;yes;NA;psy;group;NA;no;8;NA;720;NA;8;NA;1;NA;90;NA;6,95;NA;1,02;NA;NA;49,1;45,4;13,06;12,58;38;32;70;0,75;49;44;93;NA;NA;NA;NA;44;NA;NA;NA;NA;combined;mus;NA;NA;NA;NA;NA;NA;NA;NA;yes;"psychotic symptoms; (suicidal tendencies; serious concentration or language problems)";no;NA;no;NA
sephton, 2007;ambt;wl;NA;NA;som;msd;vas;post;8;self-report;68,1;69,2;25,4;19,6;60,4;68,5;26,4;23,5;51;40;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;sephton_2007_msd_vas_post_8.0_self-report_ambt_wl_NA_NA;-0,319087398;0,212548471;NA;NA;primary;low;low;some concerns;high;low;high;ISRCTN: 34628811;us;community;no;NA;adults;yes;8-week format of the parent program (university of massachusetts);psy;group;NA;no;9;NA;1650;NA;8;NA;1,13;NA;183,33;NA;5,5;NA;2,1;NA;0,61;48,4;47,6;8,9;11,5;51;40;91;1;51;40;91;NA;NA;NA;NA;NA;NA;NA;NA;NA;clinical interview;fm;NA;NA;NA;NA;54;58,8;43,6;62,4;yes;severe mental illness;no;NA;no;NA
sephton, 2007;ambt;wl;NA;NA;som;msd;vas;follow up;16;self-report;68,1;69,2;25,4;19,6;65,2;65,1;25;22,1;51;40;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;sephton_2007_msd_vas_followup_16.0_self-report_ambt_wl_NA_NA;0,004170941;0,211205919;NA;NA;primary;low;low;some concerns;high;low;high;ISRCTN: 34628811;us;community;no;NA;adults;yes;8-week format of the parent program (university of massachusetts);psy;group;NA;no;9;NA;1650;NA;8;NA;1,13;NA;183,33;NA;5,5;NA;2,1;NA;0,61;48,4;47,6;8,9;11,5;51;40;91;1;51;40;91;NA;NA;NA;NA;NA;NA;NA;NA;NA;clinical interview;fm;NA;NA;NA;NA;54;58,8;43,6;62,4;yes;severe mental illness;no;NA;no;NA
sephton, 2007;ambt;wl;NA;NA;depr;msd;bdi;post;8;self-report;15,7;14,7;7,1;6,9;12,4;15,1;7,4;8,1;51;39;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;sephton_2007_msd_bdi_post_8.0_self-report_ambt_wl_NA_NA;-0,347198145;0,214313248;NA;NA;primary;some concerns;low;some concerns;high;some concerns;high;ISRCTN: 34628811;us;community;no;NA;adults;yes;8-week format of the parent program (university of massachusetts);psy;group;NA;no;9;NA;1650;NA;8;NA;1,13;NA;183,33;NA;5,5;NA;2,1;NA;0,61;48,4;47,6;8,9;11,5;51;40;91;1;51;40;91;NA;NA;NA;NA;NA;NA;NA;NA;NA;clinical interview;fm;NA;NA;NA;NA;54;58,8;43,6;62,4;yes;severe mental illness;no;NA;no;NA
sephton, 2007;ambt;wl;NA;NA;depr;msd;bdi;follow up;16;self-report;15,7;14,7;7,1;6,9;13,3;14,8;7,5;8,1;51;30;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;sephton_2007_msd_bdi_followup_16.0_self-report_ambt_wl_NA_NA;-0,192308839;0,230594614;NA;NA;primary;some concerns;low;some concerns;high;some concerns;high;ISRCTN: 34628811;us;community;no;NA;adults;yes;8-week format of the parent program (university of massachusetts);psy;group;NA;no;9;NA;1650;NA;8;NA;1,13;NA;183,33;NA;5,5;NA;2,1;NA;0,61;48,4;47,6;8,9;11,5;51;40;91;1;51;40;91;NA;NA;NA;NA;NA;NA;NA;NA;NA;clinical interview;fm;NA;NA;NA;NA;54;58,8;43,6;62,4;yes;severe mental illness;no;NA;no;NA
sephton, 2007;ambt;wl;NA;NA;phs;msd;fiq;post;8;self-report;-1,3;-1,2;0,72;0,75;-1,2;-1,2;0,73;0,84;51;40;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;sephton_2007_msd_fiq_post_8.0_self-report_ambt_wl_NA_NA;0;0,211205689;NA;NA;primary;low;low;some concerns;high;low;high;ISRCTN: 34628811;us;community;no;NA;adults;yes;8-week format of the parent program (university of massachusetts);psy;group;NA;no;9;NA;1650;NA;8;NA;1,13;NA;183,33;NA;5,5;NA;2,1;NA;0,61;48,4;47,6;8,9;11,5;51;40;91;1;51;40;91;NA;NA;NA;NA;NA;NA;NA;NA;NA;clinical interview;fm;NA;NA;NA;NA;54;58,8;43,6;62,4;yes;severe mental illness;no;NA;no;NA
sephton, 2007;ambt;wl;NA;NA;phs;msd;fiq;follow up;16;self-report;-1,3;-1,2;0,72;0,75;-1,2;-1,2;0,74;0,76;51;40;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;sephton_2007_msd_fiq_followup_16.0_self-report_ambt_wl_NA_NA;0;0,211205689;NA;NA;primary;low;low;some concerns;high;low;high;ISRCTN: 34628811;us;community;no;NA;adults;yes;8-week format of the parent program (university of massachusetts);psy;group;NA;no;9;NA;1650;NA;8;NA;1,13;NA;183,33;NA;5,5;NA;2,1;NA;0,61;48,4;47,6;8,9;11,5;51;40;91;1;51;40;91;NA;NA;NA;NA;NA;NA;NA;NA;NA;clinical interview;fm;NA;NA;NA;NA;54;58,8;43,6;62,4;yes;severe mental illness;no;NA;no;NA
simister, 2018;ambt;tau;NA;NA;som;msd;sf-mpq;post;8;self-report;26,07;25,84;8,41;8,41;13,8;21;8,81;8,41;30;31;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;simister_2018_msd_sf-mpq_post_8.0_self-report_ambt_tau_NA_NA;-0,825663891;0,267066887;NA;NA;primary;low;low;low;high;low;high;NCT01642810 (ClinicalTrials.gov);ca;combined;yes;“an honorarium was provided after completion of the post-treatment and 3 month follow-up questionnaires”;adults;yes;online act protocol;psy;individual;NA;in;7;NA;NA;NA;8;NA;0,88;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33;34;67;30;31;61;NA;NA;NA;“not interested in participating (n=8), unable to travel to in-person visits (n=2), […], prefer in-person treatment (n=1), prefer alternative treatments (n=2)”;NA;NA;combined;fm;NA;NA;NA;NA;NA;NA;NA;NA;yes;“rheumatologic conditions, other conditions affecting the immune system (eg, chronic fatigue syndrome, multiple sclerosis, lupus), brain injury, cognitive impairment that would limit a participant’s ability to complete informed consent, active psychosis, substance abuse, untreated severe major depression or bipolar disorder, active suicidality, or current active injury claim”;no;NA;no;NA
simister, 2018;ambt;tau;NA;NA;som;msd;sf-mpq;follow up;20;self-report;26,07;25,84;8,41;8,41;21,46;22,49;9,1;9,21;30;31;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;simister_2018_msd_sf-mpq_followup_20.0_self-report_ambt_tau_NA_NA;-0,111057258;0,256310603;NA;NA;primary;low;low;low;high;low;high;NCT01642810 (ClinicalTrials.gov);ca;combined;yes;“an honorarium was provided after completion of the post-treatment and 3 month follow-up questionnaires”;adults;yes;online act protocol;psy;individual;NA;in;7;NA;NA;NA;8;NA;0,88;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33;34;67;30;31;61;NA;NA;NA;“not interested in participating (n=8), unable to travel to in-person visits (n=2), […], prefer in-person treatment (n=1), prefer alternative treatments (n=2)”;NA;NA;combined;fm;NA;NA;NA;NA;NA;NA;NA;NA;yes;“rheumatologic conditions, other conditions affecting the immune system (eg, chronic fatigue syndrome, multiple sclerosis, lupus), brain injury, cognitive impairment that would limit a participant’s ability to complete informed consent, active psychosis, substance abuse, untreated severe major depression or bipolar disorder, active suicidality, or current active injury claim”;no;NA;no;NA
simister, 2018;ambt;tau;NA;NA;depr;msd;ces-d;post;8;self-report;26,6;27,81;12,38;12,38;17,76;26,97;10,83;10,46;30;31;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;simister_2018_msd_ces-d_post_8.0_self-report_ambt_tau_NA_NA;-0,85427252;0,267822546;NA;NA;primary;low;low;low;high;low;high;NCT01642810 (ClinicalTrials.gov);ca;combined;yes;“an honorarium was provided after completion of the post-treatment and 3 month follow-up questionnaires”;adults;yes;online act protocol;psy;individual;NA;in;7;NA;NA;NA;8;NA;0,88;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33;34;67;30;31;61;NA;NA;NA;“not interested in participating (n=8), unable to travel to in-person visits (n=2), […], prefer in-person treatment (n=1), prefer alternative treatments (n=2)”;NA;NA;combined;fm;NA;NA;NA;NA;NA;NA;NA;NA;yes;“rheumatologic conditions, other conditions affecting the immune system (eg, chronic fatigue syndrome, multiple sclerosis, lupus), brain injury, cognitive impairment that would limit a participant’s ability to complete informed consent, active psychosis, substance abuse, untreated severe major depression or bipolar disorder, active suicidality, or current active injury claim”;no;NA;no;NA
simister, 2018;ambt;tau;NA;NA;depr;msd;ces-d;follow up;20;self-report;26,6;27,81;12,38;12,38;18,36;25,13;12,12;12,29;30;31;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;simister_2018_msd_ces-d_followup_20.0_self-report_ambt_tau_NA_NA;-0,547531639;0,260984027;NA;NA;primary;low;low;low;high;low;high;NCT01642810 (ClinicalTrials.gov);ca;combined;yes;“an honorarium was provided after completion of the post-treatment and 3 month follow-up questionnaires”;adults;yes;online act protocol;psy;individual;NA;in;7;NA;NA;NA;8;NA;0,88;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33;34;67;30;31;61;NA;NA;NA;“not interested in participating (n=8), unable to travel to in-person visits (n=2), […], prefer in-person treatment (n=1), prefer alternative treatments (n=2)”;NA;NA;combined;fm;NA;NA;NA;NA;NA;NA;NA;NA;yes;“rheumatologic conditions, other conditions affecting the immune system (eg, chronic fatigue syndrome, multiple sclerosis, lupus), brain injury, cognitive impairment that would limit a participant’s ability to complete informed consent, active psychosis, substance abuse, untreated severe major depression or bipolar disorder, active suicidality, or current active injury claim”;no;NA;no;NA
simister, 2018;ambt;tau;NA;NA;phs;msd;fiq;post;8;self-report;-55,83;-55,28;12,56;16,39;-39,07;-55,3;13,07;12,65;30;31;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;simister_2018_msd_fiq_post_8.0_self-report_ambt_tau_NA_NA;1,246120326;0,280447317;NA;NA;primary;low;low;low;high;low;high;NCT01642810 (ClinicalTrials.gov);ca;combined;yes;“an honorarium was provided after completion of the post-treatment and 3 month follow-up questionnaires”;adults;yes;online act protocol;psy;individual;NA;in;7;NA;NA;NA;8;NA;0,88;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33;34;67;30;31;61;NA;NA;NA;“not interested in participating (n=8), unable to travel to in-person visits (n=2), […], prefer in-person treatment (n=1), prefer alternative treatments (n=2)”;NA;NA;combined;fm;NA;NA;NA;NA;NA;NA;NA;NA;yes;“rheumatologic conditions, other conditions affecting the immune system (eg, chronic fatigue syndrome, multiple sclerosis, lupus), brain injury, cognitive impairment that would limit a participant’s ability to complete informed consent, active psychosis, substance abuse, untreated severe major depression or bipolar disorder, active suicidality, or current active injury claim”;no;NA;no;NA
simister, 2018;ambt;tau;NA;NA;phs;msd;fiq;follow up;20;self-report;-55,83;-55,28;12,56;16,39;-31,95;-53,82;13,8;13,92;30;31;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;simister_2018_msd_fiq_followup_20.0_self-report_ambt_tau_NA_NA;1,557649512;0,29325165;NA;NA;primary;low;low;low;high;low;high;NCT01642810 (ClinicalTrials.gov);ca;combined;yes;“an honorarium was provided after completion of the post-treatment and 3 month follow-up questionnaires”;adults;yes;online act protocol;psy;individual;NA;in;7;NA;NA;NA;8;NA;0,88;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33;34;67;30;31;61;NA;NA;NA;“not interested in participating (n=8), unable to travel to in-person visits (n=2), […], prefer in-person treatment (n=1), prefer alternative treatments (n=2)”;NA;NA;combined;fm;NA;NA;NA;NA;NA;NA;NA;NA;yes;“rheumatologic conditions, other conditions affecting the immune system (eg, chronic fatigue syndrome, multiple sclerosis, lupus), brain injury, cognitive impairment that would limit a participant’s ability to complete informed consent, active psychosis, substance abuse, untreated severe major depression or bipolar disorder, active suicidality, or current active injury claim”;no;NA;no;NA
thieme, 2006;cbt;att plac;NA;NA;som;msd;mpi pain intensity;post;15;self-report;4,15;3,8;0,84;0,99;3,45;3,79;1,03;1,07;42;40;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;thieme_2006_msd_mpipainintensity_post_15.0_self-report_cbt_attplac_NA_NA;-0,320858891;0,222371865;NA;NA;primary;some concerns;low;low;high;some concerns;high;NA;de;clinical;no;NA;adults;yes;after flor & birbaumer, 1994 and turk et al., 1983;mixed;group;NA;no;15;NA;1800;NA;15;NA;1;NA;120;NA;14,52;NA;NA;NA;NA;49,13;47,46;10,03;9,75;42;40;82;1;42;40;82;42;40;82;NA;NA;NA;NA;NA;depression;medical;fm;NA;NA;NA;NA;108,96;104,76;102;105,24;yes;the exclusion criteria consisted of inflammatory rheumatologic diseases and any concurrent major disease such as cancer, diabetes, or kidney failure.;no;NA;no;NA
thieme, 2006;cbt;att plac;NA;NA;som;msd;mpi pain intensity;follow up;63;self-report;4,15;3,8;0,84;0,99;3,18;4,14;1,42;1,46;42;40;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;thieme_2006_msd_mpipainintensity_followup_63.0_self-report_cbt_attplac_NA_NA;-0,660562745;0,226982182;NA;NA;primary;some concerns;low;low;high;some concerns;high;NA;de;clinical;no;NA;adults;yes;after flor & birbaumer, 1994 and turk et al., 1983;mixed;group;NA;no;15;NA;1800;NA;15;NA;1;NA;120;NA;14,52;NA;NA;NA;NA;49,13;47,46;10,03;9,75;42;40;82;1;42;40;82;42;40;82;NA;NA;NA;NA;NA;depression;medical;fm;NA;NA;NA;NA;108,96;104,76;102;105,24;yes;the exclusion criteria consisted of inflammatory rheumatologic diseases and any concurrent major disease such as cancer, diabetes, or kidney failure.;no;NA;no;NA
thieme, 2006;cbt;att plac;NA;NA;phs;msd;fiq;post;15;self-report;-4,35;-4,19;2,12;2,08;-3,64;-2,3;4,03;2,09;42;40;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;thieme_2006_msd_fiq_post_15.0_self-report_cbt_attplac_NA_NA;-0,410565632;0,223286727;NA;NA;primary;some concerns;low;low;high;some concerns;high;NA;de;clinical;no;NA;adults;yes;after flor & birbaumer, 1994 and turk et al., 1983;mixed;group;NA;no;15;NA;1800;NA;15;NA;1;NA;120;NA;14,52;NA;NA;NA;NA;49,13;47,46;10,03;9,75;42;40;82;1;42;40;82;42;40;82;NA;NA;NA;NA;NA;depression;medical;fm;NA;NA;NA;NA;108,96;104,76;102;105,24;yes;the exclusion criteria consisted of inflammatory rheumatologic diseases and any concurrent major disease such as cancer, diabetes, or kidney failure.;no;NA;no;NA
thieme, 2006;cbt;att plac;NA;NA;phs;msd;fiq;follow up;63;self-report;-4,35;-4,19;2,12;2,08;-3,42;-5,2;2,29;2,51;42;40;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;thieme_2006_msd_fiq_followup_63.0_self-report_cbt_attplac_NA_NA;0,734761908;0,228394935;NA;NA;primary;some concerns;low;low;high;some concerns;high;NA;de;clinical;no;NA;adults;yes;after flor & birbaumer, 1994 and turk et al., 1983;mixed;group;NA;no;15;NA;1800;NA;15;NA;1;NA;120;NA;14,52;NA;NA;NA;NA;49,13;47,46;10,03;9,75;42;40;82;1;42;40;82;42;40;82;NA;NA;NA;NA;NA;depression;medical;fm;NA;NA;NA;NA;108,96;104,76;102;105,24;yes;the exclusion criteria consisted of inflammatory rheumatologic diseases and any concurrent major disease such as cancer, diabetes, or kidney failure.;no;NA;no;NA
tkachuk, 2003;cbt;psy plac;NA;NA;som;msd;gi scale pain;post;9;self-report;0,97;1,21;0,65;0,73;1,07;1,08;0,86;0,91;14;13;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;tkachuk_2003_msd_giscalepain_post_9.0_self-report_cbt_psyplac_NA_NA;-0,010965046;0,385167517;NA;NA;primary;some concerns;high;high;high;some concerns;high;NA;ca;clinical;no;NA;adults;yes;cognitive behavioral group therapy;psy;group;NA;no;10;NA;900;NA;9;NA;1,11;NA;90;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;14;14;28;NA;NA;NA;NA;NA;NA;NA;NA;NA;clinical interview;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;patients diagnosed with severe mental disorders including schizophre- nia, bipolar disorder, severe major depression, current drug or alcohol abuse, or organic mental disorder were excluded at this stage and promptly referred for appropriate treatment.;no;NA;no;NA
tkachuk, 2003;cbt;psy plac;NA;NA;depr;msd;bdi-II;post;9;self-report;15,21;16,43;10,24;10,43;8,64;13,36;7,67;10,2;14;13;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;tkachuk_2003_msd_bdi-II_post_9.0_self-report_cbt_psyplac_NA_NA;-0,510033348;0,39175851;NA;NA;primary;some concerns;high;high;high;some concerns;high;NA;ca;clinical;no;NA;adults;yes;cognitive behavioral group therapy;psy;group;NA;no;10;NA;900;NA;9;NA;1,11;NA;90;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;14;14;28;NA;NA;NA;NA;NA;NA;NA;NA;NA;clinical interview;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;patients diagnosed with severe mental disorders including schizophre- nia, bipolar disorder, severe major depression, current drug or alcohol abuse, or organic mental disorder were excluded at this stage and promptly referred for appropriate treatment.;no;NA;no;NA
tkachuk, 2003;cbt;psy plac;NA;NA;anx;msd;stai trait;post;9;self-report;43,71;44,43;9,62;11,75;37,93;42,86;7,7;11,79;14;13;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;tkachuk_2003_msd_staitrait_post_9.0_self-report_cbt_psyplac_NA_NA;-0,484019835;0,391107999;NA;NA;primary;some concerns;high;high;high;some concerns;high;NA;ca;clinical;no;NA;adults;yes;cognitive behavioral group therapy;psy;group;NA;no;10;NA;900;NA;9;NA;1,11;NA;90;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;14;14;28;NA;NA;NA;NA;NA;NA;NA;NA;NA;clinical interview;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;patients diagnosed with severe mental disorders including schizophre- nia, bipolar disorder, severe major depression, current drug or alcohol abuse, or organic mental disorder were excluded at this stage and promptly referred for appropriate treatment.;no;NA;no;NA
tkachuk, 2003;cbt;psy plac;NA;NA;phs;msd;pcs;post;9;self-report;44,93;41,39;7,88;12,82;50,6;42,16;7,41;10,24;14;13;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;tkachuk_2003_msd_pcs_post_9.0_self-report_cbt_psyplac_NA_NA;0,921476806;0,406293264;NA;NA;primary;some concerns;high;high;high;some concerns;high;NA;ca;clinical;no;NA;adults;yes;cognitive behavioral group therapy;psy;group;NA;no;10;NA;900;NA;9;NA;1,11;NA;90;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;14;14;28;NA;NA;NA;NA;NA;NA;NA;NA;NA;clinical interview;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;patients diagnosed with severe mental disorders including schizophre- nia, bipolar disorder, severe major depression, current drug or alcohol abuse, or organic mental disorder were excluded at this stage and promptly referred for appropriate treatment.;no;NA;no;NA
vallejo, 2015;cbt;wl;NA;NA;depr;msd;bdi;post;10;self-report;21,49;18,55;6,95;7,75;16,38;18,83;4,15;7,41;20;20;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;vallejo_2015_msd_bdi_post_10.0_self-report_cbt_wl_NA_NA;-0,399858266;0,319500278;NA;NA;primary;low;low;low;high;some concerns;high;NA;es;clinical;no;NA;adults;yes;after mazumdar et al., 1999;psy;group;NA;no;10;NA;1200;10;NA;10;1;NA;120;NA;10;NA;0;NA;1;53,5;51,33;8,56;10,03;20;20;40;1;20;20;40;20;20;40;20;20;40;NA;NA;NA;clinical interview;fm;NA;NA;NA;NA;178,8;148,56;132,84;125,28;yes;"the exclusion criteria were as follows: (a) diag- nosed with any mental health disorder by a psychiatrist or clinical psychologist in a public mental health center or psychiatric service hospital; (b) the presence of suicidal ideation (score 1, 2 or 3 on item 9 of the Beck Depression Inventory (BDI)), (c) prior or present psychological treatment for fm or other chronic pain syndromes, or (d) scheduled for surgery in the next 3 months.";no;NA;no;NA
vallejo, 2015;cbt;wl;NA;NA;phs;msd;fiq;post;10;self-report;-68,43;-59,48;19,51;17,83;-58,2;-60,35;18,57;17,72;20;20;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;vallejo_2015_msd_fiq_post_10.0_self-report_cbt_wl_NA_NA;0,116103994;0,31650498;NA;NA;primary;low;low;low;high;some concerns;high;NA;es;clinical;no;NA;adults;yes;after mazumdar et al., 1999;psy;group;NA;no;10;NA;1200;10;NA;10;1;NA;120;NA;10;NA;0;NA;1;53,5;51,33;8,56;10,03;20;20;40;1;20;20;40;20;20;40;20;20;40;NA;NA;NA;clinical interview;fm;NA;NA;NA;NA;178,8;148,56;132,84;125,28;yes;"the exclusion criteria were as follows: (a) diag- nosed with any mental health disorder by a psychiatrist or clinical psychologist in a public mental health center or psychiatric service hospital; (b) the presence of suicidal ideation (score 1, 2 or 3 on item 9 of the Beck Depression Inventory (BDI)), (c) prior or present psychological treatment for fm or other chronic pain syndromes, or (d) scheduled for surgery in the next 3 months.";no;NA;no;NA
van ravesteijn, 2013;cbt+ambt;ec;NA;NA;som;msd;phq-15;post;12;self-report;12,6;12,7;4,68;5,15;10,9;12,6;4,9;6,1;58;53;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;vanravesteijn_2013_msd_phq-15_post_12.0_self-report_cbt+ambt_ec_NA_NA;-0,306669201;0,19115135;NA;NA;primary;low;some concerns;low;high;low;high;NTR2222 (Trialregister.nl);nl;clinical;no;NA;adults;yes;mbct + cognitive techniques (based on the original mbct manual for recurrent depression);para;group;NA;no;9;NA;1560;NA;8;NA;1,13;NA;173,33;NA;NA;NA;NA;NA;NA;47,6;46,5;11;12;49;38;87;0,73;61;58;119;53;55;108;NA;NA;NA;not interested (n = 3), withdrew and requested removal of all data (n=1);"eg: did not start (n=8); wl: received mindfulness training due to strong preference (n = 1)";eg: preferred other treatment (n=1), expectations not met (n=2);clinical interview;mus;NA;NA;NA;NA;NA;NA;NA;NA;yes;frequent attendance for other reasons than physical symptoms, physical symptoms fully explained by somatic diseases, no significant distress or functional impairment due to the symptoms, psychosis or bipolar disorder in medical history, current alcohol or drug abuse, cognitive impairment;no;NA;no;NA
van ravesteijn, 2013;cbt+ambt;ec;NA;NA;som;msd;phq-15;follow up;48;self-report;12,6;12,7;4,68;5,15;11;5,44;11,8;5,46;57;50;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;vanravesteijn_2013_msd_phq-15_followup_48.0_self-report_cbt+ambt_ec_NA_NA;0,58787538;0,197944885;NA;NA;primary;low;some concerns;low;high;low;high;NTR2222 (Trialregister.nl);nl;clinical;no;NA;adults;yes;mbct + cognitive techniques (based on the original mbct manual for recurrent depression);para;group;NA;no;9;NA;1560;NA;8;NA;1,13;NA;173,33;NA;NA;NA;NA;NA;NA;47,6;46,5;11;12;49;38;87;0,73;61;58;119;53;55;108;NA;NA;NA;not interested (n = 3), withdrew and requested removal of all data (n=1);"eg: did not start (n=8); wl: received mindfulness training due to strong preference (n = 1)";eg: preferred other treatment (n=1), expectations not met (n=2);clinical interview;mus;NA;NA;NA;NA;NA;NA;NA;NA;yes;frequent attendance for other reasons than physical symptoms, physical symptoms fully explained by somatic diseases, no significant distress or functional impairment due to the symptoms, psychosis or bipolar disorder in medical history, current alcohol or drug abuse, cognitive impairment;no;NA;no;NA
van ravesteijn, 2013;cbt+ambt;ec;NA;NA;depr;msd;phq-9;post;12;self-report;8,5;8,77;5,11;5,44;7,61;7,87;5,92;5,35;58;53;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;vanravesteijn_2013_msd_phq-9_post_12.0_self-report_cbt+ambt_ec_NA_NA;-0,045657957;0,190049533;NA;NA;primary;low;some concerns;low;high;low;high;NTR2222 (Trialregister.nl);nl;clinical;no;NA;adults;yes;mbct + cognitive techniques (based on the original mbct manual for recurrent depression);para;group;NA;no;9;NA;1560;NA;8;NA;1,13;NA;173,33;NA;NA;NA;NA;NA;NA;47,6;46,5;11;12;49;38;87;0,73;61;58;119;53;55;108;NA;NA;NA;not interested (n = 3), withdrew and requested removal of all data (n=1);"eg: did not start (n=8); wl: received mindfulness training due to strong preference (n = 1)";eg: preferred other treatment (n=1), expectations not met (n=2);clinical interview;mus;NA;NA;NA;NA;NA;NA;NA;NA;yes;frequent attendance for other reasons than physical symptoms, physical symptoms fully explained by somatic diseases, no significant distress or functional impairment due to the symptoms, psychosis or bipolar disorder in medical history, current alcohol or drug abuse, cognitive impairment;no;NA;no;NA
van ravesteijn, 2013;cbt+ambt;ec;NA;NA;depr;msd;phq-9;follow up;48;self-report;8,5;8,77;5,11;5,44;7,26;7,66;5,61;5,33;57;50;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;vanravesteijn_2013_msd_phq-9_followup_48.0_self-report_cbt+ambt_ec_NA_NA;-0,072455356;0,193826589;NA;NA;primary;low;some concerns;low;high;low;high;NTR2222 (Trialregister.nl);nl;clinical;no;NA;adults;yes;mbct + cognitive techniques (based on the original mbct manual for recurrent depression);para;group;NA;no;9;NA;1560;NA;8;NA;1,13;NA;173,33;NA;NA;NA;NA;NA;NA;47,6;46,5;11;12;49;38;87;0,73;61;58;119;53;55;108;NA;NA;NA;not interested (n = 3), withdrew and requested removal of all data (n=1);"eg: did not start (n=8); wl: received mindfulness training due to strong preference (n = 1)";eg: preferred other treatment (n=1), expectations not met (n=2);clinical interview;mus;NA;NA;NA;NA;NA;NA;NA;NA;yes;frequent attendance for other reasons than physical symptoms, physical symptoms fully explained by somatic diseases, no significant distress or functional impairment due to the symptoms, psychosis or bipolar disorder in medical history, current alcohol or drug abuse, cognitive impairment;no;NA;no;NA
van ravesteijn, 2013;cbt+ambt;ec;NA;NA;ha;msd;wi;post;12;self-report;23,1;23,3;8,61;10,3;20,6;21,9;9,16;9,26;58;53;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;vanravesteijn_2013_msd_wi_post_12.0_self-report_cbt+ambt_ec_NA_NA;-0,140210323;0,190260589;NA;NA;primary;low;some concerns;low;high;low;high;NTR2222 (Trialregister.nl);nl;clinical;no;NA;adults;yes;mbct + cognitive techniques (based on the original mbct manual for recurrent depression);para;group;NA;no;9;NA;1560;NA;8;NA;1,13;NA;173,33;NA;NA;NA;NA;NA;NA;47,6;46,5;11;12;49;38;87;0,73;61;58;119;53;55;108;NA;NA;NA;not interested (n = 3), withdrew and requested removal of all data (n=1);"eg: did not start (n=8); wl: received mindfulness training due to strong preference (n = 1)";eg: preferred other treatment (n=1), expectations not met (n=2);clinical interview;mus;NA;NA;NA;NA;NA;NA;NA;NA;yes;frequent attendance for other reasons than physical symptoms, physical symptoms fully explained by somatic diseases, no significant distress or functional impairment due to the symptoms, psychosis or bipolar disorder in medical history, current alcohol or drug abuse, cognitive impairment;no;NA;no;NA
van ravesteijn, 2013;cbt+ambt;ec;NA;NA;ha;msd;wi;follow up;48;self-report;23,1;23,3;8,61;10,3;20,6;22,6;9,19;10,1;57;50;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;vanravesteijn_2013_msd_wi_followup_48.0_self-report_cbt+ambt_ec_NA_NA;-0,206296313;0,19428229;NA;NA;primary;low;some concerns;low;high;low;high;NTR2222 (Trialregister.nl);nl;clinical;no;NA;adults;yes;mbct + cognitive techniques (based on the original mbct manual for recurrent depression);para;group;NA;no;9;NA;1560;NA;8;NA;1,13;NA;173,33;NA;NA;NA;NA;NA;NA;47,6;46,5;11;12;49;38;87;0,73;61;58;119;53;55;108;NA;NA;NA;not interested (n = 3), withdrew and requested removal of all data (n=1);"eg: did not start (n=8); wl: received mindfulness training due to strong preference (n = 1)";eg: preferred other treatment (n=1), expectations not met (n=2);clinical interview;mus;NA;NA;NA;NA;NA;NA;NA;NA;yes;frequent attendance for other reasons than physical symptoms, physical symptoms fully explained by somatic diseases, no significant distress or functional impairment due to the symptoms, psychosis or bipolar disorder in medical history, current alcohol or drug abuse, cognitive impairment;no;NA;no;NA
van ravesteijn, 2013;cbt+ambt;ec;NA;NA;phs;msd;sf-36 physical functioning;post;12;self-report;36,3;40,7;9,62;9,6;38,2;41,4;11;11,5;58;53;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;vanravesteijn_2013_msd_sf-36physicalfunctioning_post_12.0_self-report_cbt+ambt_ec_NA_NA;-0,282701217;0,190982515;NA;NA;primary;low;some concerns;low;high;low;high;NTR2222 (Trialregister.nl);nl;clinical;no;NA;adults;yes;mbct + cognitive techniques (based on the original mbct manual for recurrent depression);para;group;NA;no;9;NA;1560;NA;8;NA;1,13;NA;173,33;NA;NA;NA;NA;NA;NA;47,6;46,5;11;12;49;38;87;0,73;61;58;119;53;55;108;NA;NA;NA;not interested (n = 3), withdrew and requested removal of all data (n=1);"eg: did not start (n=8); wl: received mindfulness training due to strong preference (n = 1)";eg: preferred other treatment (n=1), expectations not met (n=2);clinical interview;mus;NA;NA;NA;NA;NA;NA;NA;NA;yes;frequent attendance for other reasons than physical symptoms, physical symptoms fully explained by somatic diseases, no significant distress or functional impairment due to the symptoms, psychosis or bipolar disorder in medical history, current alcohol or drug abuse, cognitive impairment;no;NA;no;NA
van ravesteijn, 2013;cbt+ambt;ec;NA;NA;phs;msd;sf-36 physical functioning;follow up;48;self-report;36,3;40,7;9,62;9,6;39,6;42,7;12,1;10,2;57;50;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;vanravesteijn_2013_msd_sf-36physicalfunctioning_followup_48.0_self-report_cbt+ambt_ec_NA_NA;-0,273501759;0,194675286;NA;NA;primary;low;some concerns;low;high;low;high;NTR2222 (Trialregister.nl);nl;clinical;no;NA;adults;yes;mbct + cognitive techniques (based on the original mbct manual for recurrent depression);para;group;NA;no;9;NA;1560;NA;8;NA;1,13;NA;173,33;NA;NA;NA;NA;NA;NA;47,6;46,5;11;12;49;38;87;0,73;61;58;119;53;55;108;NA;NA;NA;not interested (n = 3), withdrew and requested removal of all data (n=1);"eg: did not start (n=8); wl: received mindfulness training due to strong preference (n = 1)";eg: preferred other treatment (n=1), expectations not met (n=2);clinical interview;mus;NA;NA;NA;NA;NA;NA;NA;NA;yes;frequent attendance for other reasons than physical symptoms, physical symptoms fully explained by somatic diseases, no significant distress or functional impairment due to the symptoms, psychosis or bipolar disorder in medical history, current alcohol or drug abuse, cognitive impairment;no;NA;no;NA
vlaeyen, 1996;cbt;wl;NA;NA;depr;msd;bdi;post;6;self-report;12,8;15,5;6,6;8,3;13,4;13,2;5,8;5,8;46;40;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;vlaeyen_1996_msd_bdi_post_6.0_self-report_cbt_wl_NA_NA;0,034173958;0,216208334;NA;NA;primary;some concerns;high;high;high;some concerns;high;NA;nl;clinical;no;NA;adults;yes;cognitive-educational treatment;psy;group;NA;no;12;NA;1080;NA;6;NA;2;NA;90;NA;NA;NA;NA;NA;NA;44,6;42,8;9,3;9,6;46;35;81;0,88;49;43;92;46;40;86;NA;NA;NA;NA;NA;NA;clinical interview;fm;NA;NA;NA;NA;124,8;118,8;92,4;94,8;yes;severe psvchopathologv that would make the patient unable to participate in a group format.;no;NA;no;NA
vollmer, 1998;cbt;att plac;cbt individual;att plac;som;msd;gi symptom diary;post;12;self-report;3,14;4,14;1,89;2,38;1,4;3,09;1,15;1,45;11;10;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;vollmer_1998_msd_gisymptomdiary_post_12.0_self-report_cbt_attplac_cbtindividual_attplac;-1,247271893;0,480728872;NA;NA;primary;low;high;low;high;some concerns;high;NA;us;combined;no;NA;adults;yes;after greene and blanchard (1994);psy;individual;NA;no;10;NA;600;NA;10;NA;1;NA;60;NA;NA;NA;NA;NA;NA;40,6;47,7;13,4;7,9;8;8;16;0,76;11;10;21;NA;NA;NA;NA;NA;NA;NA;NA;NA;clinical interview;ibs;NA;NA;NA;NA;165,6;139,2;159,6;96;yes;"serious mental disorders based on the structured Anxiety Disorders Interview Schedule-Revised (ADIS-R; DiNardo, Brown, & Barlow, 1994).";no;NA;no;NA
vollmer, 1998;cbt;att plac;cbt group;NA;som;msd;gi symptom diary;post;12;self-report;3,97;4,14;2,22;2,38;2,13;3,09;1,53;1,45;11;10;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;vollmer_1998_msd_gisymptomdiary_post_12.0_self-report_cbt_attplac_cbtgroup_NA;-0,617429588;0,448060137;NA;NA;primary;low;high;low;high;some concerns;high;NA;us;combined;no;NA;adults;yes;after greene and blanchard (1994);psy;group;NA;no;10;NA;900;NA;10;NA;1;NA;90;NA;NA;NA;NA;NA;NA;42,5;14,1;47,7;7,9;9;8;17;0,81;11;10;21;NA;NA;NA;NA;NA;NA;NA;NA;NA;clinical interview;ibs;NA;NA;NA;NA;96;139,2;108;96;yes;"serious mental disorders based on the structured Anxiety Disorders Interview Schedule-Revised (ADIS-R; DiNardo, Brown, & Barlow, 1994).";no;NA;no;NA
white, 2011;cbt;tau;NA;NA;som;msd;cfq;post;24;self-report;27,7;28,3;3,7;3,6;21,5;24;7,8;6,9;155;157;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;white_2011_msd_cfq_post_24.0_self-report_cbt_tau_NA_NA;-0,338811673;0,114043402;NA;NA;primary;low;low;low;high;low;high;ISRCTN Registry, ISRCTN54285094, A randomised controlled trial of adaptive pacing, cognitive behaviour therapy, and graded exercise, as supplements to standardised specialist medical care versus standardised specialist medical care alone for patients with the chronic fatigue syndrome/myalgic encephalomyelitis or encephalopathy, https://www.isrctn.com/ISRCTN54285094;gb;clinical;no;NA;adults;yes;NA;mixed;individual;NA;no;15;NA;900;NA;36;NA;0,42;NA;60;NA;NA;NA;NA;NA;NA;39;37;12;11;NA;NA;NA;NA;161;160;321;158;159;317;NA;NA;NA;NA;NA;NA;combined;cfs/me;4,6;4,7;1,8;1,7;NA;NA;NA;NA;yes;we excluded patients who were younger than 18 years or at significant risk of self-harm, unable to attend hospital appointments, unable to speak and read English, had medical needs that made participation inappropriate, had previously received a trial treatment for their present illness at a pace trial clinic (we initially excluded anyone whohadreceivedatrialtreatment,butfoundthenatureof treatment given elsewhere hard to establish).10;yes;at 52 weeks, participants rated satisfaction with treatment received on a 7-point scale, condensed into three categories to aid interpretation (satisfied, neutral, or dissatisfied).;yes;table 4, measured serious deterioation, physical functioning reduction, pcgi worse,withdrwan due to worsening, serious adverse reactions
white, 2011;cbt;tau;NA;NA;som;msd;cfq;follow up;120;self-report;27,7;28,3;3,7;3,6;18,4;20,2;8,5;8,6;118;115;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;white_2011_msd_cfq_followup_120.0_self-report_cbt_tau_NA_NA;-0,209854398;0,131397678;NA;NA;primary;low;low;low;high;low;high;ISRCTN Registry, ISRCTN54285094, A randomised controlled trial of adaptive pacing, cognitive behaviour therapy, and graded exercise, as supplements to standardised specialist medical care versus standardised specialist medical care alone for patients with the chronic fatigue syndrome/myalgic encephalomyelitis or encephalopathy, https://www.isrctn.com/ISRCTN54285094;gb;clinical;no;NA;adults;yes;NA;mixed;individual;NA;no;15;NA;900;NA;36;NA;0,42;NA;60;NA;NA;NA;NA;NA;NA;39;37;12;11;NA;NA;NA;NA;161;160;321;158;159;317;NA;NA;NA;NA;NA;NA;combined;cfs/me;4,6;4,7;1,8;1,7;NA;NA;NA;NA;yes;we excluded patients who were younger than 18 years or at significant risk of self-harm, unable to attend hospital appointments, unable to speak and read English, had medical needs that made participation inappropriate, had previously received a trial treatment for their present illness at a pace trial clinic (we initially excluded anyone whohadreceivedatrialtreatment,butfoundthenatureof treatment given elsewhere hard to establish).10;yes;at 52 weeks, participants rated satisfaction with treatment received on a 7-point scale, condensed into three categories to aid interpretation (satisfied, neutral, or dissatisfied).;yes;table 4, measured serious deterioation, physical functioning reduction, pcgi worse,withdrwan due to worsening, serious adverse reactions
white, 2011;cbt;tau;NA;NA;depr;msd;hads-d;follow up;120;self-report;8,3;8;3,7;3,9;6,2;7,2;3,7;4,7;143;151;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;white_2011_msd_hads-d_followup_120.0_self-report_cbt_tau_NA_NA;-0,235063249;0,11708962;NA;NA;primary;low;low;low;high;low;high;ISRCTN Registry, ISRCTN54285094, A randomised controlled trial of adaptive pacing, cognitive behaviour therapy, and graded exercise, as supplements to standardised specialist medical care versus standardised specialist medical care alone for patients with the chronic fatigue syndrome/myalgic encephalomyelitis or encephalopathy, https://www.isrctn.com/ISRCTN54285094;gb;clinical;no;NA;adults;yes;NA;mixed;individual;NA;no;15;NA;900;NA;36;NA;0,42;NA;60;NA;NA;NA;NA;NA;NA;39;37;12;11;NA;NA;NA;NA;161;160;321;158;159;317;NA;NA;NA;NA;NA;NA;combined;cfs/me;4,6;4,7;1,8;1,7;NA;NA;NA;NA;yes;we excluded patients who were younger than 18 years or at significant risk of self-harm, unable to attend hospital appointments, unable to speak and read English, had medical needs that made participation inappropriate, had previously received a trial treatment for their present illness at a pace trial clinic (we initially excluded anyone whohadreceivedatrialtreatment,butfoundthenatureof treatment given elsewhere hard to establish).10;yes;at 52 weeks, participants rated satisfaction with treatment received on a 7-point scale, condensed into three categories to aid interpretation (satisfied, neutral, or dissatisfied).;yes;table 4, measured serious deterioation, physical functioning reduction, pcgi worse,withdrwan due to worsening, serious adverse reactions
white, 2011;cbt;tau;NA;NA;anx;msd;hads-a;follow up;120;self-report;8,1;7,9;4,3;4,3;6,8;8;4,2;4,4;143;151;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;white_2011_msd_hads-a_followup_120.0_self-report_cbt_tau_NA_NA;-0,278100086;0,117250725;NA;NA;primary;low;low;low;high;low;high;ISRCTN Registry, ISRCTN54285094, A randomised controlled trial of adaptive pacing, cognitive behaviour therapy, and graded exercise, as supplements to standardised specialist medical care versus standardised specialist medical care alone for patients with the chronic fatigue syndrome/myalgic encephalomyelitis or encephalopathy, https://www.isrctn.com/ISRCTN54285094;gb;clinical;no;NA;adults;yes;NA;mixed;individual;NA;no;15;NA;900;NA;36;NA;0,42;NA;60;NA;NA;NA;NA;NA;NA;39;37;12;11;NA;NA;NA;NA;161;160;321;158;159;317;NA;NA;NA;NA;NA;NA;combined;cfs/me;4,6;4,7;1,8;1,7;NA;NA;NA;NA;yes;we excluded patients who were younger than 18 years or at significant risk of self-harm, unable to attend hospital appointments, unable to speak and read English, had medical needs that made participation inappropriate, had previously received a trial treatment for their present illness at a pace trial clinic (we initially excluded anyone whohadreceivedatrialtreatment,butfoundthenatureof treatment given elsewhere hard to establish).10;yes;at 52 weeks, participants rated satisfaction with treatment received on a 7-point scale, condensed into three categories to aid interpretation (satisfied, neutral, or dissatisfied).;yes;table 4, measured serious deterioation, physical functioning reduction, pcgi worse,withdrwan due to worsening, serious adverse reactions
white, 2011;cbt;tau;NA;NA;phs;msd;sf-36 physical functioning;post;24;self-report;39;39,2;15,3;15,4;54,2;48,4;21,6;23,1;155;157;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;white_2011_msd_sf-36physicalfunctioning_post_24.0_self-report_cbt_tau_NA_NA;0,258677912;0,11370486;NA;NA;primary;low;low;low;high;low;high;ISRCTN Registry, ISRCTN54285094, A randomised controlled trial of adaptive pacing, cognitive behaviour therapy, and graded exercise, as supplements to standardised specialist medical care versus standardised specialist medical care alone for patients with the chronic fatigue syndrome/myalgic encephalomyelitis or encephalopathy, https://www.isrctn.com/ISRCTN54285094;gb;clinical;no;NA;adults;yes;NA;mixed;individual;NA;no;15;NA;900;NA;36;NA;0,42;NA;60;NA;NA;NA;NA;NA;NA;39;37;12;11;NA;NA;NA;NA;161;160;321;158;159;317;NA;NA;NA;NA;NA;NA;combined;cfs/me;4,6;4,7;1,8;1,7;NA;NA;NA;NA;yes;we excluded patients who were younger than 18 years or at significant risk of self-harm, unable to attend hospital appointments, unable to speak and read English, had medical needs that made participation inappropriate, had previously received a trial treatment for their present illness at a pace trial clinic (we initially excluded anyone whohadreceivedatrialtreatment,butfoundthenatureof treatment given elsewhere hard to establish).10;yes;at 52 weeks, participants rated satisfaction with treatment received on a 7-point scale, condensed into three categories to aid interpretation (satisfied, neutral, or dissatisfied).;yes;table 4, measured serious deterioation, physical functioning reduction, pcgi worse,withdrwan due to worsening, serious adverse reactions
white, 2011;cbt;tau;NA;NA;phs;msd;sf-36 physical functioning;follow up;120;self-report;39;39,2;15,3;15,4;62,2;57,4;27,2;27,9;118;115;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;white_2011_msd_sf-36physicalfunctioning_followup_120.0_self-report_cbt_tau_NA_NA;0,173677025;0,131283587;NA;NA;primary;low;low;low;high;low;high;ISRCTN Registry, ISRCTN54285094, A randomised controlled trial of adaptive pacing, cognitive behaviour therapy, and graded exercise, as supplements to standardised specialist medical care versus standardised specialist medical care alone for patients with the chronic fatigue syndrome/myalgic encephalomyelitis or encephalopathy, https://www.isrctn.com/ISRCTN54285094;gb;clinical;no;NA;adults;yes;NA;mixed;individual;NA;no;15;NA;900;NA;36;NA;0,42;NA;60;NA;NA;NA;NA;NA;NA;39;37;12;11;NA;NA;NA;NA;161;160;321;158;159;317;NA;NA;NA;NA;NA;NA;combined;cfs/me;4,6;4,7;1,8;1,7;NA;NA;NA;NA;yes;we excluded patients who were younger than 18 years or at significant risk of self-harm, unable to attend hospital appointments, unable to speak and read English, had medical needs that made participation inappropriate, had previously received a trial treatment for their present illness at a pace trial clinic (we initially excluded anyone whohadreceivedatrialtreatment,butfoundthenatureof treatment given elsewhere hard to establish).10;yes;at 52 weeks, participants rated satisfaction with treatment received on a 7-point scale, condensed into three categories to aid interpretation (satisfied, neutral, or dissatisfied).;yes;table 4, measured serious deterioation, physical functioning reduction, pcgi worse,withdrwan due to worsening, serious adverse reactions
wiborg, 2015;cbt;wl;NA;NA;som;msd;cis;post;48;self-report;50,9;49,9;4,7;4,8;33,5;46,6;13,6;8,5;136;88;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;wiborg_2015_msd_cis_post_48.0_self-report_cbt_wl_NA_NA;-1,100307935;0,146415013;NA;NA;primary;some concerns;low;low;high;some concerns;high;NA;nl;clinical;no;NA;adults;no;NA;mixed;group;NA;no;14;NA;1680;NA;24;NA;0,58;NA;120;NA;NA;NA;NA;NA;NA;38,1;37,3;11,5;10,8;101;56;157;0,77;136;68;204;53;68;121;NA;NA;NA;NA;NA;In the intervention group, 4 patients had less than 4 additional symptoms at the baseline assessment, 2 pa- tients were diagnosed with a medical condition during the trial accounting for the complaints and received ad- ditional therapy tailored to their needs, 2 patients dis- closed a dispute over a disability pension, and 1 patient received individual CBT for CFS;combined;cfs/me;6,9;7,04;1,9;2;97,2;120;115,2;127,2;yes;patients who were in dispute over a disability pension were temporarily excluded from the trial;no;NA;no;NA
wiborg, 2015;cbt;wl;NA;NA;phs;msd;sf-36 physical functioning;post;48;self-report;55,4;60;18,8;20;74,4;63,3;22;21,1;136;88;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;wiborg_2015_msd_sf-36physicalfunctioning_post_48.0_self-report_cbt_wl_NA_NA;0,510926597;0,138936068;NA;NA;primary;some concerns;low;low;high;some concerns;high;NA;nl;clinical;no;NA;adults;no;NA;mixed;group;NA;no;14;NA;1680;NA;24;NA;0,58;NA;120;NA;NA;NA;NA;NA;NA;38,1;37,3;11,5;10,8;101;56;157;0,77;136;68;204;53;68;121;NA;NA;NA;NA;NA;In the intervention group, 4 patients had less than 4 additional symptoms at the baseline assessment, 2 pa- tients were diagnosed with a medical condition during the trial accounting for the complaints and received ad- ditional therapy tailored to their needs, 2 patients dis- closed a dispute over a disability pension, and 1 patient received individual CBT for CFS;combined;cfs/me;6,9;7,04;1,9;2;97,2;120;115,2;127,2;yes;patients who were in dispute over a disability pension were temporarily excluded from the trial;no;NA;no;NA
williams, 2010;cbt;tau;NA;NA;som;msd;bpi-severity;post;24;self-report;5,1;4,9;1,4;1,4;4,3;4,9;1,6;1,5;59;59;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;williams_2010_msd_bpi-severity_post_24.0_self-report_cbt_tau_NA_NA;-0,384388646;0,18582943;NA;NA;primary;low;low;low;high;some concerns;high;NA;us;clinical;no;NA;adults;yes;living well with fibromyalgia;self-guided;individual;NA;internet;13;NA;NA;NA;24;NA;0,54;NA;NA;NA;NA;NA;NA;NA;NA;50,17;50,75;12,34;10,58;NA;NA;NA;NA;59;59;118;59;59;118;NA;NA;NA;NA;NA;NA;clinical interview;fm;NA;NA;NA;NA;113,4;112,08;82,2;73,2;yes;subjects were excluded from participation if they had any of following: (1) A severe physical impairment that precluded receiving/using the website or using the self-management skills contained on the website, (2) co-morbid medical illnesses capable of causing a worsening of physical functional status independent of fm (e.g., cardiopulmonary disorders, uncontrolled endocrine or allergic disorders, malignancy within 2 years, (3) Any present psychiatric disorder involving a history of psychosis, current suicide risk or attempt within 2 years of the study, or substance abuse within 2 years, (4) Prior CBT for pain management, and (5) a pending status associated with disability compensation or the receipt of disability compensation for less than 2 years.;yes;Items from the client satisfaction questionnaire (csq-12), were modified for FM and used to assess treatment satisfaction within the two treatment arms of the study. in order to verify that the web-sm arm in fact received and utilized a content that differed from the standard care, several questions were added to the csq-12 as a manipulation check of the study design.;no;NA
williams, 2010;cbt;tau;NA;NA;depr;msd;ces-d;post;24;self-report;15,1;17,1;10,1;11,5;16,4;17,5;11,9;11,5;59;59;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;williams_2010_msd_ces-d_post_24.0_self-report_cbt_tau_NA_NA;-0,093394268;0,18421658;NA;NA;primary;low;low;low;high;some concerns;high;NA;us;clinical;no;NA;adults;yes;living well with fibromyalgia;self-guided;individual;NA;internet;13;NA;NA;NA;24;NA;0,54;NA;NA;NA;NA;NA;NA;NA;NA;50,17;50,75;12,34;10,58;NA;NA;NA;NA;59;59;118;59;59;118;NA;NA;NA;NA;NA;NA;clinical interview;fm;NA;NA;NA;NA;113,4;112,08;82,2;73,2;yes;subjects were excluded from participation if they had any of following: (1) A severe physical impairment that precluded receiving/using the website or using the self-management skills contained on the website, (2) co-morbid medical illnesses capable of causing a worsening of physical functional status independent of fm (e.g., cardiopulmonary disorders, uncontrolled endocrine or allergic disorders, malignancy within 2 years, (3) Any present psychiatric disorder involving a history of psychosis, current suicide risk or attempt within 2 years of the study, or substance abuse within 2 years, (4) Prior CBT for pain management, and (5) a pending status associated with disability compensation or the receipt of disability compensation for less than 2 years.;yes;Items from the client satisfaction questionnaire (csq-12), were modified for FM and used to assess treatment satisfaction within the two treatment arms of the study. in order to verify that the web-sm arm in fact received and utilized a content that differed from the standard care, several questions were added to the csq-12 as a manipulation check of the study design.;no;NA
williams, 2010;cbt;tau;NA;NA;anx;msd;stpi-state;post;24;self-report;17,1;16,9;6;6,3;18,1;18,4;7,1;5,9;59;59;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;williams_2010_msd_stpi-state_post_24.0_self-report_cbt_tau_NA_NA;-0,045660675;0,184139227;NA;NA;primary;low;low;low;high;some concerns;high;NA;us;clinical;no;NA;adults;yes;living well with fibromyalgia;self-guided;individual;NA;internet;13;NA;NA;NA;24;NA;0,54;NA;NA;NA;NA;NA;NA;NA;NA;50,17;50,75;12,34;10,58;NA;NA;NA;NA;59;59;118;59;59;118;NA;NA;NA;NA;NA;NA;clinical interview;fm;NA;NA;NA;NA;113,4;112,08;82,2;73,2;yes;subjects were excluded from participation if they had any of following: (1) A severe physical impairment that precluded receiving/using the website or using the self-management skills contained on the website, (2) co-morbid medical illnesses capable of causing a worsening of physical functional status independent of fm (e.g., cardiopulmonary disorders, uncontrolled endocrine or allergic disorders, malignancy within 2 years, (3) Any present psychiatric disorder involving a history of psychosis, current suicide risk or attempt within 2 years of the study, or substance abuse within 2 years, (4) Prior CBT for pain management, and (5) a pending status associated with disability compensation or the receipt of disability compensation for less than 2 years.;yes;Items from the client satisfaction questionnaire (csq-12), were modified for FM and used to assess treatment satisfaction within the two treatment arms of the study. in order to verify that the web-sm arm in fact received and utilized a content that differed from the standard care, several questions were added to the csq-12 as a manipulation check of the study design.;no;NA
williams, 2010;cbt;tau;NA;NA;phs;msd;sf-36 physical functioning;post;24;self-report;38,9;38,9;8,6;9,5;41,1;38,9;8,7;8,6;59;59;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;williams_2010_msd_sf-36physicalfunctioning_post_24.0_self-report_cbt_tau_NA_NA;0,252683078;0,184857759;NA;NA;primary;low;low;low;high;some concerns;high;NA;us;clinical;no;NA;adults;yes;living well with fibromyalgia;self-guided;individual;NA;internet;13;NA;NA;NA;24;NA;0,54;NA;NA;NA;NA;NA;NA;NA;NA;50,17;50,75;12,34;10,58;NA;NA;NA;NA;59;59;118;59;59;118;NA;NA;NA;NA;NA;NA;clinical interview;fm;NA;NA;NA;NA;113,4;112,08;82,2;73,2;yes;subjects were excluded from participation if they had any of following: (1) A severe physical impairment that precluded receiving/using the website or using the self-management skills contained on the website, (2) co-morbid medical illnesses capable of causing a worsening of physical functional status independent of fm (e.g., cardiopulmonary disorders, uncontrolled endocrine or allergic disorders, malignancy within 2 years, (3) Any present psychiatric disorder involving a history of psychosis, current suicide risk or attempt within 2 years of the study, or substance abuse within 2 years, (4) Prior CBT for pain management, and (5) a pending status associated with disability compensation or the receipt of disability compensation for less than 2 years.;yes;Items from the client satisfaction questionnaire (csq-12), were modified for FM and used to assess treatment satisfaction within the two treatment arms of the study. in order to verify that the web-sm arm in fact received and utilized a content that differed from the standard care, several questions were added to the csq-12 as a manipulation check of the study design.;no;NA
yang, 2022;cbt;tau;NA;NA;som;msd;ibs-sss;post;4;self-report;320,5;312,52;63,18;60,56;193,03;325,5;71,64;46,12;29;30;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;yang_2022_msd_ibs-sss_post_4.0_self-report_cbt_tau_NA_NA;-2,177653946;0,330284273;NA;NA;primary;low;high;low;high;some concerns;high;NA;kr;community;no;NA;students;yes;cbt-i;psy;group;NA;no;4;NA;360;NA;4;NA;1;NA;90;NA;NA;NA;NA;NA;NA;20,5;20,42;3,31;2,31;26;26;52;0,87;30;30;60;30;30;60;29;30;59;schedule conflict with his/her part-time job;NA;NA;clinical interview;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;"any GI tract disorders such as inflammatory bowel disorders, lactose malabsorption and obstructive bowel disorders; history of surgeries in the digestive system; sleep apnea and shift work disorder";no;NA;no;NA
yang, 2022;cbt;tau;NA;NA;phs;msd;ibs-qol;post;4;self-report;126,48;134,73;25,95;21,7;151,28;132,63;15,33;23,51;29;30;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;yang_2022_msd_ibs-qol_post_4.0_self-report_cbt_tau_NA_NA;0,924052145;0,274312638;NA;NA;primary;low;high;low;high;some concerns;high;NA;kr;community;no;NA;students;yes;cbt-i;psy;group;NA;no;4;NA;360;NA;4;NA;1;NA;90;NA;NA;NA;NA;NA;NA;20,5;20,42;3,31;2,31;26;26;52;0,87;30;30;60;30;30;60;29;30;59;schedule conflict with his/her part-time job;NA;NA;clinical interview;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;"any GI tract disorders such as inflammatory bowel disorders, lactose malabsorption and obstructive bowel disorders; history of surgeries in the digestive system; sleep apnea and shift work disorder";no;NA;no;NA
yang, 2022;cbt;tau;NA;NA;som;msd;ibs-sss;follow up;16;self-report;320,5;312,52;63,18;60,56;147,31;299,27;89,89;85,57;29;30;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;yang_2022_msd_ibs-sss_followup_16.0_self-report_cbt_tau_NA_NA;-1,709461338;0,305366629;NA;NA;primary;low;high;low;high;some concerns;high;NA;kr;community;no;NA;students;yes;cbt-i;psy;group;NA;no;4;NA;360;NA;4;NA;1;NA;90;NA;NA;NA;NA;NA;NA;20,5;20,42;3,31;2,31;26;26;52;0,87;30;30;60;30;30;60;29;30;59;schedule conflict with his/her part-time job;NA;NA;clinical interview;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;"any GI tract disorders such as inflammatory bowel disorders, lactose malabsorption and obstructive bowel disorders; history of surgeries in the digestive system; sleep apnea and shift work disorder";no;NA;no;NA
yang, 2022;cbt;tau;NA;NA;phs;msd;ibs-qol;follow up;16;self-report;126,48;134,72;25,95;21,7;161,55;121,8;7,1;27,19;29;30;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;yang_2022_msd_ibs-qol_followup_16.0_self-report_cbt_tau_NA_NA;1,959040801;0,318146478;NA;NA;primary;low;high;low;high;some concerns;high;NA;kr;community;no;NA;students;yes;cbt-i;psy;group;NA;no;4;NA;360;NA;4;NA;1;NA;90;NA;NA;NA;NA;NA;NA;20,5;20,42;3,31;2,31;26;26;52;0,87;30;30;60;30;30;60;29;30;59;schedule conflict with his/her part-time job;NA;NA;clinical interview;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;"any GI tract disorders such as inflammatory bowel disorders, lactose malabsorption and obstructive bowel disorders; history of surgeries in the digestive system; sleep apnea and shift work disorder";no;NA;no;NA
zernicke, 2013;ambt;tau;NA;NA;som;msd;ibs-sss;post;8;self-report;248,6;249;108,9;107,6;169,4;230;125,9;117,9;43;47;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;zernicke_2013_msd_ibs-sss_post_8.0_self-report_ambt_tau_NA_NA;-0,493350298;0,214261559;NA;NA;primary;low;low;low;high;some concerns;high;NA;ca;clinical;no;NA;adults;yes;based on the manual by kabat-zinn (university of messachusetts medical center);para;group;NA;no;9;NA;900;NA;8;NA;1,13;NA;100;NA;6;NA;NA;NA;NA;45;44;12,4;12,6;40;41;81;0,9;43;47;90;39;NA;NA;NA;36;NA;NA;NA;NA;clinical interview;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;concurrent self-reported diagnosis of a dsm-iv axis i mood, anxiety, or psychotic disorder;no;NA;no;NA
zernicke, 2013;ambt;tau;NA;NA;phs;msd;ibs-qol;post;8;self-report;65,3;61,6;23,6;23,3;75;63,1;24,9;23,3;43;47;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;zernicke_2013_msd_ibs-qol_post_8.0_self-report_ambt_tau_NA_NA;0,490025252;0,21421843;NA;NA;primary;low;low;low;high;some concerns;high;NA;ca;clinical;no;NA;adults;yes;based on the manual by kabat-zinn (university of messachusetts medical center);para;group;NA;no;9;NA;900;NA;8;NA;1,13;NA;100;NA;6;NA;NA;NA;NA;45;44;12,4;12,6;40;41;81;0,9;43;47;90;39;NA;NA;NA;36;NA;NA;NA;NA;clinical interview;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;concurrent self-reported diagnosis of a dsm-iv axis i mood, anxiety, or psychotic disorder;no;NA;no;NA
zernicke, 2013;ambt;tau;NA;NA;som;msd;ibs-sss;follow up;32;self-report;248,6;249;108,9;107,6;193,6;213,8;128,5;119,3;43;47;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;zernicke_2013_msd_ibs-sss_followup_32.0_self-report_ambt_tau_NA_NA;-0,161802868;0,211377325;NA;NA;primary;low;low;low;high;some concerns;high;NA;ca;clinical;no;NA;adults;yes;based on the manual by kabat-zinn (university of messachusetts medical center);para;group;NA;no;9;NA;900;NA;8;NA;1,13;NA;100;NA;6;NA;NA;NA;NA;45;44;12,4;12,6;40;41;81;0,9;43;47;90;39;NA;NA;NA;36;NA;NA;NA;NA;clinical interview;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;concurrent self-reported diagnosis of a dsm-iv axis i mood, anxiety, or psychotic disorder;no;NA;no;NA
zernicke, 2013;ambt;tau;NA;NA;phs;msd;ibs-qol;follow up;32;self-report;65,3;61,6;23,6;23,3;74,3;66,5;26,9;24;43;47;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;zernicke_2013_msd_ibs-qol_followup_32.0_self-report_ambt_tau_NA_NA;0,304157958;0,212262256;NA;NA;primary;low;low;low;high;some concerns;high;NA;ca;clinical;no;NA;adults;yes;based on the manual by kabat-zinn (university of messachusetts medical center);para;group;NA;no;9;NA;900;NA;8;NA;1,13;NA;100;NA;6;NA;NA;NA;NA;45;44;12,4;12,6;40;41;81;0,9;43;47;90;39;NA;NA;NA;36;NA;NA;NA;NA;clinical interview;ibs;NA;NA;NA;NA;NA;NA;NA;NA;yes;concurrent self-reported diagnosis of a dsm-iv axis i mood, anxiety, or psychotic disorder;no;NA;no;NA
zonneveld, 2012;cbt;wl;NA;NA;som;msd;scl-90-som;post;13;self-report;29,61;28,67;8,29;9,53;25,96;27,97;5,86;5,84;61;72;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;zonneveld_2012_msd_scl-90-som_post_13.0_self-report_cbt_wl_NA_NA;-0,341667412;0,175289102;NA;NA;primary;low;low;low;high;some concerns;high;NTR1609 (TrialRegister.nl);nl;clinical;no;NA;adults;yes;coping with the consequences of unexplained physical symptoms;psy;group;NA;no;13;NA;1560;NA;13;NA;1;NA;120;NA;11,23;NA;1,73;NA;NA;46;44;NA;NA;67;64;131;0,81;84;78;162;53;65;118;65;72;137;NA;NA;NA;clinical interview;usd (dsm-iv);NA;NA;NA;NA;108;117,96;117,72;126,84;yes;cognitive impairment;no;NA;yes;after the training, one patient reported rumination about possible death of beloved people, which tired her out.
zonneveld, 2012;cbt;wl;NA;NA;depr;msd;scl-90-depression;post;13;self-report;32,94;30,19;11,92;12,03;28,61;30,22;7,42;7,47;61;72;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;zonneveld_2012_msd_scl-90-depression_post_13.0_self-report_cbt_wl_NA_NA;-0,214950253;0,174522317;NA;NA;primary;low;high;low;high;some concerns;high;NTR1609 (TrialRegister.nl);nl;clinical;no;NA;adults;yes;coping with the consequences of unexplained physical symptoms;psy;group;NA;no;13;NA;1560;NA;13;NA;1;NA;120;NA;11,23;NA;1,73;NA;NA;46;44;NA;NA;67;64;131;0,81;84;78;162;53;65;118;65;72;137;NA;NA;NA;clinical interview;usd (dsm-iv);NA;NA;NA;NA;108;117,96;117,72;126,84;yes;cognitive impairment;no;NA;yes;after the training, one patient reported rumination about possible death of beloved people, which tired her out.
zonneveld, 2012;cbt;wl;NA;NA;anx;msd;scl-90-anx;post;13;self-report;18,52;17,33;8,01;7,54;17,41;17,1;4,76;4,75;61;72;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;zonneveld_2012_msd_scl-90-anx_post_13.0_self-report_cbt_wl_NA_NA;0,064826256;0,174064106;NA;NA;primary;low;high;low;high;some concerns;high;NTR1609 (TrialRegister.nl);nl;clinical;no;NA;adults;yes;coping with the consequences of unexplained physical symptoms;psy;group;NA;no;13;NA;1560;NA;13;NA;1;NA;120;NA;11,23;NA;1,73;NA;NA;46;44;NA;NA;67;64;131;0,81;84;78;162;53;65;118;65;72;137;NA;NA;NA;clinical interview;usd (dsm-iv);NA;NA;NA;NA;108;117,96;117,72;126,84;yes;cognitive impairment;no;NA;yes;after the training, one patient reported rumination about possible death of beloved people, which tired her out.
zonneveld, 2012;cbt;wl;NA;NA;phs;msd;sf-36 physical compnent;post;13;self-report;29,34;29,05;9,65;8,24;34,54;30,98;6,44;6,45;56;65;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;zonneveld_2012_msd_sf-36physicalcompnent_post_13.0_self-report_cbt_wl_NA_NA;0,54884518;0,185748184;NA;NA;primary;low;high;low;high;some concerns;high;NTR1609 (TrialRegister.nl);nl;clinical;no;NA;adults;yes;coping with the consequences of unexplained physical symptoms;psy;group;NA;no;13;NA;1560;NA;13;NA;1;NA;120;NA;11,23;NA;1,73;NA;NA;46;44;NA;NA;67;64;131;0,81;84;78;162;53;65;118;65;72;137;NA;NA;NA;clinical interview;usd (dsm-iv);NA;NA;NA;NA;108;117,96;117,72;126,84;yes;cognitive impairment;no;NA;yes;after the training, one patient reported rumination about possible death of beloved people, which tired her out.